

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 August 2009 (13.08.2009)

PCT

(10) International Publication Number
WO 2009/100029 A1

(51) International Patent Classification:
C12Q 1/68 (2006.01)

(21) International Application Number:
PCT/US2009/032881

(22) International Filing Date:
2 February 2009 (02.02.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/025,536 1 February 2008 (01.02.2008) US
61/100,293 26 September 2008 (26.09.2008) US

(71) Applicant (for all designated States except US): **THE GENERAL HOSPITAL CORPORATION** [US/US]; 55 Fruit Street, Boston, MA 02114 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SKOG, Johan** [SE/US]; 218 Thorndike Street, Cambridge, Massachusetts 02141 (US). **BREAKEYFIELD, Xandra O.** [US/US]; 127 Homer Street, Newton, Massachusetts 02459 (US). **BROWN, Dennis** [GB/US]; 3 Walnut Avenue, Natick, Massachusetts 01760 (US). **MIRANDA, Kevin C.** [AU/US]; 22 Bigelow Street, Apt. 3A, Cambridge, Massachusetts 02139 (US). **RUSSO, Leileata M.** [AU/US]; 1 Oak Grove Avenue, Apt. 227, Melrose, Massachusetts 02176 (US).

(74) Agent: **RESNICK, David**; Nixon Peabody Llp, 100 Summer Street, Boston, Massachusetts 02110-2131 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF MICROVESICLES IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF MEDICAL DISEASES AND CONDITIONS

(57) Abstract: The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a subject by detecting a biomarker in microvesicles isolated from a biological sample from the subject. Moreover, disclosed subject matter is directed to methods of diagnosis, monitoring a disease by determining the concentration of microvesicles within a biological sample; methods of delivering a nucleic acid or protein to a target all by administering microvesicles that contain said nucleic acid or protein; methods for performing a body fluid transfusion by introducing a microvesicle-free or microvesicle enriched fluid fraction into a patient.



WO 2009/100029 A1

USE OF MICROVESICLES IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF MEDICAL DISEASES AND CONDITIONS

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to US provisional applications 61/025,536, filed February 1, 2008 and 61/100,293, filed September 26, 2008, each of which is incorporated herein by reference in its entirety.

GOVERNMENTAL SUPPORT

[0002] This invention was made with Government support under grants NCI CA86355 and NCI CA69246 awarded by the National Cancer Institute. The Government has certain rights in the invention.

FIELD OF THE INVENTION

[0003] The present invention relates to the fields of medical diagnosis, patient monitoring, treatment efficacy evaluation, nucleic acid and protein delivery, and blood transfusion.

BACKGROUND OF THE INVENTION

[0004] Glioblastomas are highly malignant brain tumors with a poor prognosis despite intensive research and clinical efforts (Louis et al., 2007). The invasive nature of this tumor makes complete surgical resection impossible and the median survival time is only about 15 months (Stupp et al., 2005). Glioblastoma cells as well as many other tumor cells have a remarkable ability to mold their stromal environment to their own advantage. Tumor cells directly alter surrounding normal cells to facilitate tumor cell growth, invasion, chemo-resistance, immune-evasion and metastasis (Mazzocca et al., 2005; Muerkoster et al., 2004; Singer et al., 2007). The tumor cells also hijack the normal vasculature and stimulate rapid formation of new blood vessels to supply the tumor with nutrition (Carmeliet and Jain, 2000). Although the immune system can initially suppress tumor growth, it is often progressively blunted by tumor activation of immunosuppressive pathways (Gabilovich, 2007).

[0005] Small microvesicles shed by cells are known as exosomes (Thery et al., 2002). Exosomes are reported as having a diameter of approximately 30-100 nm and are shed from many different cell types under both normal and pathological conditions (Thery et al., 2002). These microvesicles were first described as a mechanism to discard transferrin-receptors

from the cell surface of maturing reticulocytes (Pan and Johnstone, 1983). Exosomes are formed through inward budding of endosomal membranes giving rise to intracellular multivesicular bodies (MVB) that later fuse with the plasma membrane, releasing the exosomes to the exterior (Thery et al., 2002). However, there is now evidence for a more direct release of exosomes. Certain cells, such as Jurkat T-cells, are said to shed exosomes directly by outward budding of the plasma membrane (Booth et al., 2006). All membrane vesicles shed by cells are referred to herein collectively as microvesicles.

[0006] Microvesicles in *Drosophila melanogaster*, so called argosomes, are said to contain morphogens such as Wingless protein and to move over large distances through the imaginal disc epithelium in developing *Drosophila melanogaster* embryos (Greco et al., 2001). Microvesicles found in semen, known as prostasomes, are stated to have a wide range of functions including the promotion of sperm motility, the stabilization of the acrosome reaction, the facilitation of immunosuppression and the inhibition of angiogenesis (Delves et al., 2007). On the other hand, prostasomes released by malignant prostate cells are said to promote angiogenesis. Microvesicles are said to transfer proteins (Mack et al., 2000) and recent studies state that microvesicles isolated from different cell lines can also contain messenger RNA (mRNA) and microRNA (miRNA) and can transfer mRNA to other cell types (Baj-Krzyworzeka et al., 2006; Valadi et al., 2007).

[0007] Microvesicles derived from B-cells and dendritic cells are stated to have potent immuno-stimulatory and antitumor effects *in vivo* and have been used as antitumor vaccines (Chaput et al., 2005). Dendritic cell-derived microvesicles are stated to contain the co-stimulatory proteins necessary for T-cell activation, whereas most tumor cell-derived microvesicles do not (Wieckowski and Whiteside, 2006). Microvesicles isolated from tumor cells may act to suppress the immune response and accelerate tumor growth (Clayton et al., 2007; Liu et al., 2006a). Breast cancer microvesicles may stimulate angiogenesis, and platelet-derived microvesicles may promote tumor progression and metastasis of lung cancer cells (Janowska-Wieczorek et al., 2005; Millimaggi et al., 2007).

[0008] Cancers arise through accumulation of genetic alterations that promote unrestricted cell growth. It has been stated that each tumor harbors, on average, around 50-80 mutations that are absent in non-tumor cells (Jones et al., 2008; Parsons et al., 2008; Wood et al., 2007). Current techniques to detect these mutation profiles include the analysis of biopsy samples and the non-invasive analysis of mutant tumor DNA fragments circulating in bodily fluids such as blood (Diehl et al., 2008). The former method is invasive, complicated and

possibly harmful to subjects. The latter method inherently lacks sensitivity due to the extremely low copy number of mutant cancer DNA in bodily fluid (Gormally et al., 2007). Therefore, one challenge facing cancer diagnosis is to develop a diagnostic method that can detect tumor cells at different stages non-invasively, yet with high sensitivity and specificity. It has also been stated that gene expression profiles (encoding mRNA or microRNA) can distinguish cancerous and non-cancerous tissue (Jones et al., 2008; Parsons et al., 2008; Schetter et al., 2008). However, current diagnostic techniques to detect gene expression profiles require intrusive biopsy of tissues. Some biopsy procedures cause high risk and are potentially harmful. Moreover, in a biopsy procedure, tissue samples are taken from a limited area and may give false positives or false negatives, especially in tumors which are heterogeneous and/or dispersed within normal tissue. Therefore, a non-intrusive and sensitive diagnostic method for detecting biomarkers would be highly desirable.

SUMMARY OF THE INVENTION

[0009] In general, the invention is a novel method for detecting in a subject the presence or absence of a variety of biomarkers contained in microvesicles, thereby aiding the diagnosis, monitoring and evaluation of diseases, other medical conditions, and treatment efficacy associated with microvesicle biomarkers.

[0010] One aspect of the invention are methods for aiding in the diagnosis or monitoring of a disease or other medical condition in a subject, comprising the steps of: a) isolating a microvesicle fraction from a biological sample from the subject; and b) detecting the presence or absence of a biomarker within the microvesicle fraction, wherein the biomarker is associated with the disease or other medical condition. The methods may further comprise the step or steps of comparing the result of the detection step to a control (e.g., comparing the amount of one or more biomarkers detected in the sample to one or more control levels), wherein the subject is diagnosed as having the disease or other medical condition (e.g., cancer) if there is a measurable difference in the result of the detection step as compared to a control.

[0011] Another aspect of the invention is a method for aiding in the evaluation of treatment efficacy in a subject, comprising the steps of: a) isolating a microvesicle fraction from a biological sample from the subject; and b) detecting the presence or absence of a biomarker within the microvesicle fraction, wherein the biomarker is associated with the treatment efficacy for a disease or other medical condition. The method may further

comprise the step of providing a series of a biological samples over a period of time from the subject. Additionally, the method may further comprise the step or steps of determining any measurable change in the results of the detection step (e.g., the amount of one or more detected biomarkers) in each of the biological samples from the series to thereby evaluate treatment efficacy for the disease or other medical condition.

[0012] In certain preferred embodiments of the foregoing aspects of the invention, the biological sample from the subject is a sample of bodily fluid. Particularly preferred body fluids are blood and urine.

[0013] In certain preferred embodiments of the foregoing aspects of the invention, the methods further comprise the isolation of a selective microvesicle fraction derived from cells of a specific type (e.g., cancer or tumor cells). Additionally, the selective microvesicle fraction may consist essentially of urinary microvesicles.

[0014] In certain embodiments of the foregoing aspects of the invention, the biomarker associated with a disease or other medical condition is i) a species of nucleic acid; ii) a level of expression of one or more nucleic acids; iii) a nucleic acid variant; or iv) a combination of any of the foregoing. Preferred embodiments of such biomarkers include messenger RNA, microRNA, DNA, single stranded DNA, complementary DNA and noncoding DNA.

[0015] In certain embodiments of the foregoing aspects of the invention, the disease or other medical condition is a neoplastic disease or condition (e.g., glioblastoma, pancreatic cancer, breast cancer, melanoma and colorectal cancer), a metabolic disease or condition (e.g., diabetes, inflammation, perinatal conditions or a disease or condition associated with iron metabolism), a post transplantation condition, or a fetal condition.

[0016] Another aspect of the invention is a method for aiding in the diagnosis or monitoring of a disease or other medical condition in a subject, comprising the steps of a) obtaining a biological sample from the subject; and b) determining the concentration of microvesicles within the biological sample.

[0017] Yet another aspect of this invention is a method for delivering a nucleic acid or protein to a target cell in an individual comprising the steps of administering microvesicles which contain the nucleic acid or protein, or one or more cells that produce such microvesicles, to the individual such that the microvesicles enter the target cell of the individual. In a preferred embodiment of this aspect of the invention, microvesicles are delivered to brain cells.

[0018] A further aspect of this invention is a method for performing bodily fluid transfusion (e.g., blood, serum or plasma), comprising the steps of obtaining a fraction of donor body fluid free of all or substantially all microvesicles, or free of all or substantially all microvesicles from a particular cell type (e.g., tumor cells), and introducing the microvesicle-free fraction to a patient. A related aspect of this invention is a composition of matter comprising a sample of body fluid (e.g., blood, serum or plasma) free of all or substantially all microvesicles, or free of all or substantially all microvesicles from a particular cell type.

[0019] Another aspect of this invention is a method for performing bodily fluid transfusion (e.g., blood, serum or plasma), comprising the steps of obtaining a microvesicle-enriched fraction of donor body fluid and introducing the microvesicle-enriched fraction to a patient. In a preferred embodiment, the fraction is enriched with microvesicles derived from a particular cell type. A related aspect of this invention is a composition of matter comprising a sample of bodily fluid (e.g., blood, serum or plasma) enriched with microvesicles.

[0020] A further aspect of this invention is a method for aiding in the identification of new biomarkers associated with a disease or other medical condition, comprising the steps of obtaining a biological sample from a subject; isolating a microvesicle fraction from the sample; and detecting within the microvesicle fraction species of nucleic acid; their respective expression levels or concentrations; nucleic acid variants; or combinations thereof.

[0021] Various aspects and embodiments of the invention will now be described in detail. It will be appreciated that modification of the details may be made without departing from the scope of the invention. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0022] All patents, patent applications, and publications identified are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representations as to the contents of these documents are based on the information available to the applicants and do not constitute any admission as to the correctness of the dates or contents of these documents.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1. Glioblastoma cells produce microvesicles containing RNA.

(a) Scanning electron microscopy image of a primary glioblastoma cell (bar = 10 μm). (b) Higher magnification showing the microvesicles on the cell surface. The vesicles vary in size with diameters between around 50 nm and around 500 nm (bar = 1 μm). (c) Graph showing the amount of total RNA extracted from microvesicles that were either treated or not treated with RNase A. The amounts are indicated as the absorption (Abs, y-axis) of 260nm wavelength (x-axis). The experiments were repeated 5 times and a representative graph is shown. (d) Bioanalyzer data showing the size distribution of total RNA extracted from primary glioblastoma cells and (e) Bioanalyzer data showing the size distribution of total RNA extracted from microvesicles isolated from primary glioblastoma cells. The 25 nt peak represents an internal standard. The two prominent peaks in (d) (arrows) represent 18S (left arrow) and 28S (right arrow) ribosomal RNA. The ribosomal peaks are absent from RNA extracted from microvesicles (e). (f) Transmission electron microscopy image of microvesicles secreted by primary glioblastoma cells (bar = 100 nm).

FIGURE 2. Analysis of microvesicle RNA. FIGS. 2 (a) and 2 (b) are scatter plots of mRNA levels in microvesicles and mRNA levels in donor glioblastoma cells from two different experiments. Linear regressions show that mRNA levels in donor cells versus microvesicles were not well correlated. FIGS. 2 (c) and 2 (d) are mRNA levels in two different donor cells or two different microvesicle preparations. In contrast to FIGS. 2 (a) and 2 (b), linear regressions show that mRNA levels between donor cells FIG 2 (c) or between microvesicles FIG 2 (d) were closely correlated.

FIGURE 3. Analysis of microvesicle DNA.

a) GAPDH gene amplification with DNA templates from exosomes treated with DNase prior to nucleic acid extraction. The lanes are identified as follows:

1. 100bp MW ladder
2. Negative control
3. Genomic DNA control from GBM 20/3 cells
4. DNA from normal serum exosomes (tumor cell-free control)
5. Exosome DNA from normal human fibroblasts (NHF19)
6. Exosome DNA from primary medulloblastoma cells (D425)

b) GAPDH gene amplification with DNA templates from exosomes without prior DNase treatment. The lanes are identified as follows:

1. 100bp MW ladder
2. DNA from primary melanoma cell 0105
3. Exosome DNA from melanoma 0105
4. Negative Control
5. cDNA from primary GBM 20/3 (positive control)

c) Human Endogenous Retrovirus K gene amplification. The lanes are identified as follows:

1. 100 bp MW ladder
2. Exosome DNA from medulloblastoma D425 a
3. Exosome DNA from medulloblastoma D425 b
4. Exosome DNA from normal human fibroblasts (NHF19)
5. Exosome DNA from normal human serum
6. Genomic DNA from GBM 20/3.
7. Negative Control

d) Tenascin C gene amplification. The lanes are listed identified follows:

1. 100bp MW ladder
2. Exosomes from normal human fibroblasts (NHF19)
3. Exosomes from serum (tumor cell free individual A)
4. Exosomes from serum (tumor cell free individual B)
5. Exosomes from primary medulloblastoma cell D425

e) Transposable Line 1 element amplification. The lanes are identified as follows:

1. 100bp MW ladder.
2. Exosome DNA from normal human serum.
3. Exosome DNA from normal human fibroblasts
4. Exosome DNA from medulloblastoma D425 a

5. Exosome DNA from medulloblastoma D425 b

f) DNA is present in exosomes from D425 medulloblastoma cell. The lanes are identified as follows:

1. 100bp marker
2. D425 no DNase
3. D425 with DNase
4. 1kb marker

g) Single stranded nucleic acid analysis using a RNA pico chip. Upper panel: purified DNA was not treated with DNase; lower panel: purified DNA was treated with DNase. The arrow in the upper panel refers to the detected nucleic acids. The peak at 25 nt is an internal standard.

h) Analysis of nucleic acids contained in exosomes from primary medulloblastoma D425. Upper panel: single stranded nucleic acids detected by a RNA pico chip. Lower panel: double stranded nucleic acids detected by a DNA 1000 chip. The arrow in the upper panel refers to the detected nucleic acids. The two peaks (15 and 1500 bp) are internal standards.

i) Analysis of exosome DNA from different origins using a RNA pico chip. Upper panel: DNA was extracted from exosomes from glioblastoma cells. Lower panel: DNA was extracted from exosomes from normal human fibroblasts.

FIGURE 4. Extracellular RNA extraction from serum is more efficient when a serum exosome isolation step is included. a) Exosome RNA from serum. b) Direct whole serum extraction. c) Empty well. Arrows refer to the detected RNA in the samples.

FIGURE 5. Comparison of gene expression levels between microvesicles and cells of origin. 3426 genes were found to be more than 5-fold differentially distributed in the microvesicles as compared to the cells from which they were derived (p-value <0.01).

FIGURE 6. Ontological analysis of microvesicular RNAs. (a) Pie chart displays the biological process ontology of the 500 most abundant mRNA species in the microvesicles. (b) Graph showing the intensity of microvesicle RNAs belonging to ontologies related to tumor growth. The x-axis represents the number of mRNA transcripts present in the ontology. The median intensity levels on the arrays were 182.

FIGURE 7. Clustering diagram of mRNA levels. Microarray data on the mRNA expression profiles in cell lines and exosomes isolated from the culture media of these cell lines were analyzed and clusters of expression profiles were generated. The labels of the RNA species are as follows:

20/3C-1: Glioblastoma 20/3 Cell RNA, array replicate 1

20/3C-2: Glioblastoma 20/3 Cell RNA, array replicate 2

11/5C: Glioblastoma 11/5 Cell RNA

0105C: Melanoma 0105 Cell RNA

0664C: Melanoma 0664 Cell RNA

0664 E-1: Melanoma 0664 exosome RNA, array replicate 1

0664 E-2: Melanoma 0664 exosome RNA, array replicate 2

0105E: Melanoma 0105 Exosome RNA

20/3E: Glioblastoma 20/3 Exosome RNA

11/5E-1: Glioblastoma 11/5 Exosomes, array replicate 1

11/5E-2: Glioblastoma 11/5 Exosomes, array replicate 2

GBM: glioblastoma. The scale refers to the distance between clusters.

FIGURE 8. Microvesicles from serum contain microRNAs. Levels of mature miRNAs extracted from microvesicles and from glioblastoma cells from two different patients (GBM1 and GBM2) were analysed using quantitative miRNA RT-PCR. The cycle threshold (Ct) value is presented as the mean \pm SEM (n = 4).

FIGURE 9. Clustering diagram of microRNA levels. Microarray data on the microRNA expression profiles in cell lines and exosomes isolated from the culture media of these cell lines were analyzed and clusters of expression profiles were generated. The labels of the RNA species are as follows:

0664C-1: Melanoma 0664 Cell RNA, array replicate 1

0664C-2: Melanoma 0664 Cell RNA, array replicate 2

0105C-1: Melanoma 0105 Cell RNA, array replicate 1

0105C-2: Melanoma 0105 Cell RNA, array replicate 2

20/3C-1: Glioblastoma 20/3 Cell RNA, array replicate 1
20/3C-2: Glioblastoma 20/3 Cell RNA, array replicate 2
11/5C-1: Glioblastoma 11/5 Cell RNA, array replicate 1
11/5C-2: Glioblastoma 11/5 Cell RNA, array replicate 2
11/5E-1: Glioblastoma 11/5 Exosomes, array replicate 1
11/5E-2: Glioblastoma 11/5 Exosomes, array replicate 2
20/3E-1: Glioblastoma 20/3 Exosome RNA, array replicate 1
20/3E-2: Glioblastoma 20/3 Exosome RNA, array replicate 2
0664 E: Melanoma 0664 exosome RNA
0105E-1: Melanoma 0105 Exosome RNA, array replicate 1
0105E-2: Melanoma 0105 Exosome RNA, array replicate 2

GBM: Glioblastoma. The scale refers to the distance between clusters.

FIGURE 10. The expression level of microRNA-21 in serum microvesicles is associated with glioma. Shown is a bar graph, normal control serum on the left, glioma serum on the right. Quantitative RT-PCR was used to measure the levels of microRNA-21 (miR-21) in exosomes from serum of glioblastoma patients as well as normal patient controls. Glioblastoma serum showed a 5.4 reduction of the Ct-value, corresponding to an approximately 40 ($2^{\Delta Ct}$)-fold increase of miR21. The miR21 levels were normalized to GAPDH in each sample (n=3).

FIGURE 11. Nested RT-PCR was used to detect EGFRvIII mRNA in tumor samples and corresponding serum exosomes. The wild type EGFR PCR product appears as a band at 1153 bp and the EGFRvIII PCR product appears as a band at 352 bp. RT PCR of GAPDH mRNA was included as a positive control (226 bp). Samples considered as positive for EGFRvIII are indicated with an asterisk. Patients 11, 12 and 14 showed only a weak amplification of EGFRvIII in the tumor sample, but it was evident when more samples were loaded.

FIGURE 12. Nested RT PCR of EGFRvIII was performed on microvesicles from 52 normal control serums. EGFRvIII (352 bp) was never found in the normal control serums. PCR of GAPDH (226 bp) was included as a control.

FIGURE 13. Hepcidin mRNA can be detected within exosomes from human serum. A) Pseudo-gel generated by an Agilent Bioanalyzer. B) Raw plot generated by an Agilent Bioanalyser for the positive control (Sample 1). C) Raw plot generated by an Agilent Bioanalyser for the negative control (Sample 2). D) Raw plot generated by an Agilent Bioanalyser for the exosomes (Sample 3).

FIGURE 14. Urinary exosome isolation and nucleic acid identification within urinary exosomes. (a) Electron microscopy image of a multivesicular body (MVB) containing many small “exosomes” in a kidney tubule cell. (b) Electron microscopy image of isolated urinary exosomes. (c) Analysis of RNA transcripts contained within urinary exosomes by an Agilent Bioanalyzer. A broad range of RNA species were identified but both 18S and 28S ribosomal RNAs were absent. (d) Identification of various RNA transcripts in urinary exosomes by PCR. The transcripts thus identified were: Aquaporin 1 (AQP1); Aquaporin 2 (AQP2); Cubulin (CUBN); Megalin (LRP2); Arginine Vasopressin Receptor 2 (AVPR2); Sodium/Hydrogen Exchanger 3 (SLC9A3); V-ATPase B1 subunit (ATP6V1B1); Nephtrin (NPHS1); Podocin (NPHS2); and Chloride Channel 3 (CLCN3). From top to bottom, the five bands in the molecular weight (MW) lane correspond to 1000, 850, 650, 500, 400, 300 base pair fragments. (e) Bioanalyzer diagrams of exosomal nucleic acids from urine samples. The numbers refer to the numbering of human individuals. (f) Pseudogels depicting PCR products generated with different primer pairs using the nucleic acid extracts described in (e). House refers to actin gene and the actin primers were from Ambion (TX, USA). The +ve control refers to PCRs using human kidney cDNA from Ambion (TX, USA) as templates and the -ve control refers to PCRs without nucleic acid templates. (g) Pseudo-gel picture showing positive identification of actin gene cDNA via PCR with and without the DNase treatment of exosomes prior to nucleic acid extraction. (h) Bioanalyzer diagrams showing the amount of nucleic acids isolated from human urinary exosomes.

FIGURE 15. Analysis of prostate cancer biomarkers in urinary exosomes. (a) Gel pictures showing PCR products of the *TMPRSS2-ERG* gene and digested fragments of the PCR products. P1 and P2 refer to urine samples from patient 1 and patient 2, respectively. For each sample, the undigested product is in the left lane and the digested product is in the right lane. MWM indicates lanes with MW markers. The sizes of the bands (both undigested and digested) are indicated on the right of the panel. (b) Gel pictures showing PCR products of the *PCA3* gene and digested fragments of the PCR products. P1, P2, P3 and P4 refer to urine samples from patient 1, patient 2, patient 3 and patient 4, respectively. For each

sample, the undigested product is in the left lane and the digested product is in the right lane. MWM indicates lanes with MW markers. The sizes of the bands (both undigested and digested) are indicated on the right of the panel. (c) A summary of the information of the patients and the data presented in (a) and (b). TMERG refers to the *TMPRSS2-ERG* fusion gene.

FIGURE 16. BRAF mRNA is contained within microvesicles shed by melanoma cells. (a) An electrophoresis gel picture showing RT-PCR products of BRAF gene amplification. (b) An electrophoresis gel picture showing RT-PCR products of GAPDH gene amplification. The lanes and their corresponding samples are as follows: Lane #1 - 100 bp Molecular Weight marker; Lane #2 - YUMEL-01-06 exo; Lane # 3 - YUMEL-01-06 cell; Lane # 4 YUMEL-06-64 exo; Lane # 5. YUMEL-06-64 cell; Lane # 6. M34 exo; Lane # 7 - M34 cell; Lane # 8 - Fibroblast cell; Lane # 9 - Negative control. The reference term “exo” means that the RNA was extracted from exosomes in the culture media. The reference term “cell” means that the RNA was extracted from the cultured cells. The numbers following YUMEL refers to the identification of a specific batch of YUMEL cell line. (c) Sequencing results of PCR products from YUMEL-01-06 exo. The results from YUMEL-01-06 cell, YUMEL-06-64 exo and YUMEL-06-64 cell are the same as those from YUMEL-01-06 exo. (d) Sequencing results of PCR products from M34 exo. The results from M34 cell are the same as those from M34 exo.

FIGURE 17. Glioblastoma microvesicles can deliver functional RNA to HBMVECs. (a) Purified microvesicles were labelled with membrane dye PKH67 (green) and added to HBMVECs. The microvesicles were internalised into endosome-like structures within an hour. (b) Microvesicles were isolated from glioblastoma cells stably expressing Gluc. RNA extraction and RT-PCR of Gluc and GAPDH mRNAs showed that both were incorporated into microvesicles. (c) Microvesicles were then added to HBMVECs and incubated for 24 hours. The Gluc activity was measured in the medium at 0, 15 and 24 hours after microvesicle addition and normalized to Gluc activity in microvesicles. The results are presented as the mean \pm SEM (n = 4).

FIGURE 18. Glioblastoma microvesicles stimulate angiogenesis *in vitro* and contain angiogenic proteins. (a) HBMVECs were cultured on Matrigel™ in basal medium (EBM) alone, or supplemented with GBM microvesicles (EBM+MV) or angiogenic factors (EGM). Tubule formation was measured after 16 hours as average tubule length \pm SEM compared to cells grown in EBM (n = 6). (b) Total protein from primary glioblastoma cells and

microvesicles (MV) from these cells (1 mg each) were analysed on a human angiogenesis antibody array. (c) The arrays were scanned and the intensities analysed with the Image J software (n = 4).

FIGURE 19. Microvesicles isolated from primary glioblastoma cells promote proliferation of the U87 glioblastoma cell line. 100,000 U87 cells were seeded in wells of a 24 well plate and allowed to grow for three days in (a) normal growth medium (DMEM-5% FBS) or (b) normal growth medium supplemented with 125 µg microvesicles. (c) After three days, the non-supplemented cells had expanded to 480,000 cells, whereas the microvesicle-supplemented cells had expanded to 810,000 cells. NC refers to cells grown in normal control medium and MV refers to cells grown in medium supplemented with microvesicles. The result is presented as the mean ± SEM (n=6).

DETAILED DESCRIPTION OF THE INVENTION

[0023] Microvesicles are shed by eukaryotic cells, or budded off of the plasma membrane, to the exterior of the cell. These membrane vesicles are heterogeneous in size with diameters ranging from about 10nm to about 5000 nm. The small microvesicles (approximately 10 to 1000nm, and more often 30 to 200 nm in diameter) that are released by exocytosis of intracellular multivesicular bodies are referred to in the art as “exosomes”. The methods and compositions described herein are equally applicable to microvesicles of all sizes; preferably 30 to 800 nm; and more preferably 30 to 200 nm.

[0024] In some of the literature, the term “exosome” also refers to protein complexes containing exoribonucleases which are involved in mRNA degradation and the processing of small nucleolar RNAs (snoRNAs), small nuclear RNAs (snRNAs) and ribosomal RNAs (rRNA) (Liu et al., 2006b; van Dijk et al., 2007). Such protein complexes do not have membranes and are not “microvesicles” or “exosomes” as those terms are used here in.

Exosomes As Diagnostic And/Or Prognostic Tools

[0025] Certain aspects of the present invention are based on the surprising finding that glioblastoma derived microvesicles can be isolated from the serum of glioblastoma patients. This is the first discovery of microvesicles derived from cells in the brain, present in a bodily fluid of a subject. Prior to this discovery it was not known whether glioblastoma cells produced microvesicles or whether such microvesicles could cross the blood brain barrier into the rest of the body. These microvesicles were found to contain mutant mRNA associated with tumor cells. The microvesicles also contained microRNAs (miRNAs) which

were found to be abundant in glioblastomas. Glioblastoma-derived microvesicles were also found to potentially promote angiogenic features in primary human brain microvascular endothelial cells (HBMVEC) in culture. This angiogenic effect was mediated at least in part through angiogenic proteins present in the microvesicles. The nucleic acids found within these microvesicles, as well as other contents of the microvesicles such as angiogenic proteins, can be used as valuable biomarkers for tumor diagnosis, characterization and prognosis by providing a genetic profile. Contents within these microvesicles can also be used to monitor tumor progression over time by analyzing if other mutations are acquired during tumor progression as well as if the levels of certain mutations are becoming increased or decreased over time or over a course of treatment

[0026] Certain aspects of the present invention are based on the finding that microvesicles are secreted by tumor cells and circulating in bodily fluids. The number of microvesicles increases as the tumor grows. The concentration of the microvesicles in bodily fluids is proportional to the corresponding tumor load. The bigger the tumor load, the higher the concentration of microvesicles in bodily fluids.

[0027] Certain aspects of the present invention are based on another surprising finding that most of the extracellular RNAs in bodily fluid of a subject are contained within microvesicles and thus protected from degradation by ribonucleases. As shown in Example 3, more than 90% of extracellular RNA in total serum can be recovered in microvesicles.

[0028] One aspect of the present invention relates to methods for detecting, diagnosing, monitoring, treating or evaluating a disease or other medical condition in a subject by determining the concentration of microvesicles in a biological sample. The determination may be performed using the biological sample without first isolating the microvesicles or by isolating the microvesicles first.

[0029] Another aspect of the present invention relates to methods for detecting, diagnosing, monitoring, treating or evaluating a disease or other medical condition in a subject comprising the steps of, isolating exosomes from a bodily fluid of a subject, and analyzing one or more nucleic acids contained within the exosomes. The nucleic acids are analyzed qualitatively and/or quantitatively, and the results are compared to results expected or obtained for one or more other subjects who have or do not have the disease or other medical condition. The presence of a difference in microvesicular nucleic acid content of the subject, as compared to that of one or more other individuals, can indicate the presence or

absence of, the progression of (e.g., changes of tumor size and tumor malignancy), or the susceptibility to a disease or other medical condition in the subject.

[0030] Indeed, the isolation methods and techniques described herein provide the following heretofore unrealized advantages: 1) the opportunity to selectively analyze disease- or tumor-specific nucleic acids, which may be realized by isolating disease- or tumor-specific microvesicles apart from other microvesicles within the fluid sample; 2) significantly higher yield of nucleic acid species with higher sequence integrity as compared to the yield/integrity obtained by extracting nucleic acids directly from the fluid sample; 3) scalability, e.g. to detect nucleic acids expressed at low levels, the sensitivity can be increased by pelleting more microvesicles from a larger volume of serum; 4) purer nucleic acids in that protein and lipids, debris from dead cells, and other potential contaminants and PCR inhibitors are excluded from the microvesicle pellets before the nucleic acid extraction step; and 5) more choices in nucleic acid extraction methods as microvesicle pellets are of much smaller volume than that of the starting serum, making it possible to extract nucleic acids from these microvesicle pellets using small volume column filters.

[0031] The microvesicles are preferably isolated from a sample taken of a bodily fluid from a subject. As used herein, a “bodily fluid” refers to a sample of fluid isolated from anywhere in the body of the subject, preferably a peripheral location, including but not limited to, for example, blood, plasma, serum, urine, sputum, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, fluid of the respiratory, intestinal, and genitourinary tracts, tear fluid, saliva, breast milk, fluid from the lymphatic system, semen, cerebrospinal fluid, intra-organ system fluid, ascitic fluid, tumor cyst fluid, amniotic fluid and combinations thereof.

[0032] The term “subject” is intended to include all animals shown to or expected to have microvesicles. In particular embodiments, the subject is a mammal, a human or nonhuman primate, a dog, a cat, a horse, a cow, other farm animals, or a rodent (e.g. mice, rats, guinea pig, etc.). The term “subject” and “individual” are used interchangeably herein.

[0033] Methods of isolating microvesicles from a biological sample are known in the art. For example, a method of differential centrifugation is described in a paper by Raposo et al. (Raposo et al., 1996) , and similar methods are detailed in the Examples section herein. Methods of anion exchange and/or gel permeation chromatography are described in US Patent Nos. 6,899,863 and 6,812,023. Methods of sucrose density gradients or organelle electrophoresis are described in U.S. Patent No. 7,198,923. A method of magnetic activated

cell sorting (MACS) is described in (Taylor and Gercel-Taylor, 2008). A method of nanomembrane ultrafiltration concentrator is described in (Cheruvanky et al., 2007). Preferably, microvesicles can be identified and isolated from bodily fluid of a subject by a newly developed microchip technology that uses a unique microfluidic platform to efficiently and selectively separate tumor derived microvesicles. This technology, as described in a paper by Nagrath et al. (Nagrath et al., 2007), can be adapted to identify and separate microvesicles using similar principles of capture and separation as taught in the paper. Each of the foregoing references is incorporated by reference herein for its teaching of these methods.

[0034] In one embodiment, the microvesicles isolated from a bodily fluid are enriched for those originating from a specific cell type, for example, lung, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colorectal, breast, prostate, brain, esophagus, liver, placenta, fetus cells. Because the microvesicles often carry surface molecules such as antigens from their donor cells, surface molecules may be used to identify, isolate and/or enrich for microvesicles from a specific donor cell type (Al-Nedawi et al., 2008; Taylor and Gercel-Taylor, 2008). In this way, microvesicles originating from distinct cell populations can be analyzed for their nucleic acid content. For example, tumor (malignant and non-malignant) microvesicles carry tumor-associated surface antigens and may be detected, isolated and/or enriched via these specific tumor-associated surface antigens. In one example, the surface antigen is epithelial-cell-adhesion-molecule (EpCAM), which is specific to microvesicles from carcinomas of lung, colorectal, breast, prostate, head and neck, and hepatic origin, but not of hematological cell origin (Balzar et al., 1999; Went et al., 2004). In another example, the surface antigen is CD24, which is a glycoprotein specific to urine microvesicles (Keller et al., 2007). In yet another example, the surface antigen is selected from a group of molecules CD70, carcinoembryonic antigen (CEA), EGFR, EGFRvIII and other variants, Fas ligand, TRAIL, transferrin receptor, p38.5, p97 and HSP72. Additionally, tumor specific microvesicles may be characterized by the lack of surface markers, such as CD80 and CD86.

[0035] The isolation of microvesicles from specific cell types can be accomplished, for example, by using antibodies, aptamers, aptamer analogs or molecularly imprinted polymers specific for a desired surface antigen. In one embodiment, the surface antigen is specific for a cancer type. In another embodiment, the surface antigen is specific for a cell type which is not necessarily cancerous. One example of a method of microvesicle separation based on cell

surface antigen is provided in U.S. Patent No. 7,198,923. As described in, e.g., U.S. Patent Nos. 5,840,867 and 5,582,981, WO/2003/050290 and a publication by Johnson et al. (Johnson et al., 2008), aptamers and their analogs specifically bind surface molecules and can be used as a separation tool for retrieving cell type-specific microvesicles. Molecularly imprinted polymers also specifically recognize surface molecules as described in, e.g., US Patent Nos. 6,525,154, 7,332,553 and 7,384,589 and a publication by Bossi et al. (Bossi et al., 2007) and are a tool for retrieving and isolating cell type-specific microvesicles. Each of the foregoing reference is incorporated herein for its teaching of these methods.

[0036] It may be beneficial or otherwise desirable to extract the nucleic acid from the exosomes prior to the analysis. Nucleic acid molecules can be isolated from a microvesicle using any number of procedures, which are well-known in the art, the particular isolation procedure chosen being appropriate for the particular biological sample. Examples of methods for extraction are provided in the Examples section herein. In some instances, with some techniques, it may also be possible to analyze the nucleic acid without extraction from the microvesicle.

[0037] In one embodiment, the extracted nucleic acids, including DNA and/or RNA, are analyzed directly without an amplification step. Direct analysis may be performed with different methods including, but not limited to, the nanostring technology. NanoString technology enables identification and quantification of individual target molecules in a biological sample by attaching a color coded fluorescent reporter to each target molecule. This approach is similar to the concept of measuring inventory by scanning barcodes. Reporters can be made with hundreds or even thousands of different codes allowing for highly multiplexed analysis. The technology is described in a publication by Geiss et al. (Geiss et al., 2008) and is incorporated herein by reference for this teaching.

[0038] In another embodiment, it may be beneficial or otherwise desirable to amplify the nucleic acid of the microvesicle prior to analyzing it. Methods of nucleic acid amplification are commonly used and generally known in the art, many examples of which are described herein. If desired, the amplification can be performed such that it is quantitative. Quantitative amplification will allow quantitative determination of relative amounts of the various nucleic acids, to generate a profile as described below.

[0039] In one embodiment, the extracted nucleic acid is RNA. RNAs are then preferably reverse-transcribed into complementary DNAs before further amplification. Such

reverse transcription may be performed alone or in combination with an amplification step. One example of a method combining reverse transcription and amplification steps is reverse transcription polymerase chain reaction (RT-PCR), which may be further modified to be quantitative, e.g., quantitative RT-PCR as described in US Patent No. 5,639,606, which is incorporated herein by reference for this teaching.

[0040] Nucleic acid amplification methods include, without limitation, polymerase chain reaction (PCR) (US Patent No. 5,219,727) and its variants such as in situ polymerase chain reaction (US Patent No. 5,538,871), quantitative polymerase chain reaction (US Patent No. 5,219,727), nested polymerase chain reaction (US Patent No. 5,556,773), self sustained sequence replication and its variants (Guatelli et al., 1990), transcriptional amplification system and its variants (Kwoh et al., 1989), Qb Replicase and its variants (Miele et al., 1983), cold-PCR (Li et al., 2008) or any other nucleic acid amplification methods, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. Especially useful are those detection schemes designed for the detection of nucleic acid molecules if such molecules are present in very low numbers. The foregoing references are incorporated herein for their teachings of these methods.

[0041] The analysis of nucleic acids present in the microvesicles is quantitative and/or qualitative. For quantitative analysis, the amounts (expression levels), either relative or absolute, of specific nucleic acids of interest within the microvesicles are measured with methods known in the art (described below). For qualitative analysis, the species of specific nucleic acids of interest within the microvesicles, whether wild type or variants, are identified with methods known in the art (described below).

[0042] “Genetic aberrations” is used herein to refer to the nucleic acid amounts as well as nucleic acid variants within the microvesicles. Specifically, genetic aberrations include, without limitation, over-expression of a gene (e.g., oncogenes) or a panel of genes, under-expression of a gene (e.g., tumor suppressor genes such as p53 or RB) or a panel of genes, alternative production of splice variants of a gene or a panel of genes, gene copy number variants (CNV) (e.g. DNA double minutes) (Hahn, 1993), nucleic acid modifications (e.g., methylation, acetylation and phosphorylations), single nucleotide polymorphisms (SNPs), chromosomal rearrangements (e.g., inversions, deletions and duplications), and mutations (insertions, deletions, duplications, missense, nonsense, synonymous or any other nucleotide changes) of a gene or a panel of genes, which mutations, in many cases, ultimately affect the

activity and function of the gene products, lead to alternative transcriptional splicing variants and/or changes of gene expression level.

[0043] The determination of such genetic aberrations can be performed by a variety of techniques known to the skilled practitioner. For example, expression levels of nucleic acids, alternative splicing variants, chromosome rearrangement and gene copy numbers can be determined by microarray analysis (US Patent Nos. 6,913,879, 7,364,848, 7,378,245, 6,893,837 and 6,004,755) and quantitative PCR. Particularly, copy number changes may be detected with the Illumina Infinium II whole genome genotyping assay or Agilent Human Genome CGH Microarray (Steemers et al., 2006). Nucleic acid modifications can be assayed by methods described in, e.g., US Patent No. 7,186,512 and patent publication WO/2003/023065. Particularly, methylation profiles may be determined by Illumina DNA Methylation OMA003 Cancer Panel. SNPs and mutations can be detected by hybridization with allele-specific probes, enzymatic mutation detection, chemical cleavage of mismatched heteroduplex (Cotton et al., 1988), ribonuclease cleavage of mismatched bases (Myers et al., 1985), mass spectrometry (US Patent Nos. 6,994,960, 7,074,563, and 7,198,893), nucleic acid sequencing, single strand conformation polymorphism (SSCP) (Orita et al., 1989), denaturing gradient gel electrophoresis (DGGE)(Fischer and Lerman, 1979a; Fischer and Lerman, 1979b), temperature gradient gel electrophoresis (TGGE) (Fischer and Lerman, 1979a; Fischer and Lerman, 1979b), restriction fragment length polymorphisms (RFLP) (Kan and Dozy, 1978a; Kan and Dozy, 1978b), oligonucleotide ligation assay (OLA), allele-specific PCR (ASPCR) (US Patent No. 5,639,611), ligation chain reaction (LCR) and its variants (Abravaya et al., 1995; Landegren et al., 1988; Nakazawa et al., 1994), flow-cytometric heteroduplex analysis (WO/2006/113590) and combinations/modifications thereof. Notably, gene expression levels may be determined by the serial analysis of gene expression (SAGE) technique (Velculescu et al., 1995). In general, the methods for analyzing genetic aberrations are reported in numerous publications, not limited to those cited herein, and are available to skilled practitioners. The appropriate method of analysis will depend upon the specific goals of the analysis, the condition/history of the patient, and the specific cancer(s), diseases or other medical conditions to be detected, monitored or treated. The forgoing references are incorporated herein for their teachings of these methods.

[0044] A variety of genetic aberrations have been identified to occur and/or contribute to the initial generation or progression of cancer. Examples of genes which are commonly up-regulated (i.e. over-expressed) in cancer are provided in Table 4 (cancers of different

types) and Table 6 (pancreatic cancer). Examples of microRNAs which are up-regulated in brain tumor are provided in Table 8. In one embodiment of the invention, there is an increase in the nucleic acid expression level of a gene listed in Table 4 and/or Table 6 and/or of a microRNA listed in Table 8. Examples of genes which are commonly down-regulated (e.g. under-expressed) in cancer are provided in Table 5 (cancers of different types) and Table 7 (pancreatic cancer). Examples of microRNAs which are down-regulated in brain tumor are provided in Table 9. In one embodiment of the invention, there is a decrease in the nucleic acid expression level of a gene listed in Table 5 and/or Table 7 and/or a microRNA listed in Table 9. Examples of genes which are commonly under expressed, or over expressed in brain tumors are reviewed in (Furnari et al., 2007) , and this subject matter is incorporated herein by reference. With respect to the development of brain tumors, RB and p53 are often down-regulated to otherwise decrease their tumor suppressive activity. Therefore, in these embodiments, the presence or absence of an increase or decrease in the nucleic acid expression level of a gene(s) and/or a microRNA(s) whose disregulated expression level is specific to a type of cancer can be used to indicate the presence or absence of the type of cancer in the subject.

[0045] Likewise, nucleic acid variants, e.g., DNA or RNA modifications, single nucleotide polymorphisms (SNPs) and mutations (e.g., missense, nonsense, insertions, deletions, duplications) may also be analyzed within microvesicles from bodily fluid of a subject, including pregnant females where microvesicles derived from the fetus may be in serum as well as amniotic fluid. Non-limiting examples are provided in Table 3. In yet a further embodiment, the nucleotide variant is in the EGFR gene. In a still further embodiment, the nucleotide variant is the EGFRvIII mutation/variant. The terms “EGFR”, “epidermal growth factor receptor” and “ErbB1” are used interchangeably in the art, for example as described in a paper by Carpenter (Carpenter, 1987). With respect to the development of brain tumors, RB, PTEN, p16, p21 and p53 are often mutated to otherwise decrease their tumor suppressive activity. Examples of specific mutations in specific forms of brain tumors are discussed in a paper by Furnari et al. (Furnari et al., 2007), and this subject matter is incorporated herein by reference.

[0046] In addition, more genetic aberrations associated with cancers have been identified recently in a few ongoing research projects. For example, the Cancer Genome Atlas (TCGA) program is exploring a spectrum of genomic changes involved in human cancers. The results of this project and other similar research efforts are published and

incorporated herein by reference (Jones et al., 2008; McLendon et al., 2008; Parsons et al., 2008; Wood et al., 2007). Specifically, these research projects have identified genetic aberrations, such as mutations (e.g., missense, nonsense, insertions, deletions and duplications), gene expression level variations (mRNA or microRNA), copy number variations and nucleic acid modification (e.g. methylation), in human glioblastoma, pancreatic cancer, breast cancer and/or colorectal cancer. The genes most frequently mutated in these cancers are listed in Table 11 and Table 12 (glioblastoma), Table 13 (pancreatic cancer), Table 14 (breast cancer) and Table 15 (colorectal cancer). The genetic aberrations in these genes, and in fact any genes which contain any genetic aberrations in a cancer, are targets that may be selected for use in diagnosing and/or monitoring cancer by the methods described herein.

[0047] Detection of one or more nucleotide variants can be accomplished by performing a nucleotide variant screen on the nucleic acids within the microvesicles. Such a screen can be as wide or narrow as determined necessary or desirable by the skilled practitioner. It can be a wide screen (set up to detect all possible nucleotide variants in genes known to be associated with one or more cancers or disease states). Where one specific cancer or disease is suspected or known to exist, the screen can be specific to that cancer or disease. One example is a brain tumor/brain cancer screen (e.g., set up to detect all possible nucleotide variants in genes associated with various clinically distinct subtypes of brain cancer or known drug-resistant or drug-sensitive mutations of that cancer).

[0048] In one embodiment, the analysis is of a profile of the amounts (levels) of specific nucleic acids present in the microvesicle, herein referred to as a “quantitative nucleic acid profile” of the microvesicles. In another embodiment, the analysis is of a profile of the species of specific nucleic acids present in the microvesicles (both wild type as well as variants), herein referred to as a “nucleic acid species profile.” A term used herein to refer to a combination of these types of profiles is “genetic profile” which refers to the determination of the presence or absence of nucleotide species, variants and also increases or decreases in nucleic acid levels.

[0049] Once generated, these genetic profiles of the microvesicles are compared to those expected in, or otherwise derived from a healthy normal individual. A profile can be a genome wide profile (set up to detect all possible expressed genes or DNA sequences). It can be narrower as well, such as a cancer wide profile (set up to detect all possible genes or nucleic acids derived therefrom, or known to be associated with one or more cancers).

Where one specific cancer is suspected or known to exist, the profile can be specific to that cancer (e.g., set up to detect all possible genes or nucleic acids derived therefrom, associated with various clinically distinct subtypes of that cancer or known drug-resistant or sensitive mutations of that cancer).

[0050] Which nucleic acids are to be amplified and/or analyzed can be selected by the skilled practitioner. The entire nucleic acid content of the exosomes or only a subset of specific nucleic acids which are likely or suspected of being influenced by the presence of a disease or other medical condition such as cancer, can be amplified and/or analyzed. The identification of a nucleic acid aberration(s) in the analyzed microvesicle nucleic acid can be used to diagnose the subject for the presence of a disease such as cancer, hereditary diseases or viral infection with which that aberration(s) is associated. For instance, analysis for the presence or absence of one or more nucleic acid variants of a gene specific to a cancer (e.g. the EGFRvIII mutation) can indicate the cancer's presence in the individual. Alternatively, or in addition, analysis of nucleic acids for an increase or decrease in nucleic acid levels specific to a cancer can indicate the presence of the cancer in the individual (e.g., a relative increase in EGFR nucleic acid, or a relative decrease in a tumor suppressor gene such as p53).

[0051] In one embodiment, mutations of a gene which is associated with a disease such as cancer (e.g. via nucleotide variants, over-expression or under-expression) are detected by analysis of nucleic acids in microvesicles, which nucleic acids are derived from the genome itself in the cell of origin or exogenous genes introduced through viruses. The nucleic acid sequences may be complete or partial, as both are expected to yield useful information in diagnosis and prognosis of a disease. The sequences may be sense or anti-sense to the actual gene or transcribed sequences. The skilled practitioner will be able to devise detection methods for a nucleotide variance from either the sense or anti-sense nucleic acids which may be present in a microvesicle. Many such methods involve the use of probes which are specific for the nucleotide sequences which directly flank, or contain the nucleotide variances. Such probes can be designed by the skilled practitioner given the knowledge of the gene sequences and the location of the nucleic acid variants within the gene. Such probes can be used to isolate, amplify, and/or actually hybridize to detect the nucleic acid variants, as described in the art and herein.

[0052] Determining the presence or absence of a particular nucleotide variant or plurality of variants in the nucleic acid within microvesicles from a subject can be performed

in a variety of ways. A variety of methods are available for such analysis, including, but not limited to, PCR, hybridization with allele-specific probes, enzymatic mutation detection, chemical cleavage of mismatches, mass spectrometry or DNA sequencing, including minisequencing. In particular embodiments, hybridization with allele specific probes can be conducted in two formats: 1) allele specific oligonucleotides bound to a solid phase (glass, silicon, nylon membranes) and the labeled sample in solution, as in many DNA chip applications, or 2) bound sample (often cloned DNA or PCR amplified DNA) and labeled oligonucleotides in solution (either allele specific or short so as to allow sequencing by hybridization). Diagnostic tests may involve a panel of variances, often on a solid support, which enables the simultaneous determination of more than one variance. In another embodiment, determining the presence of at least one nucleic acid variance in the microvesicle nucleic acid entails a haplotyping test. Methods of determining haplotypes are known to those of skill in the art, as for example, in WO 00/04194.

[0053] In one embodiment, the determination of the presence or absence of a nucleic acid variant(s) involves determining the sequence of the variant site or sites (the exact location within the sequence where the nucleic acid variation from the norm occurs) by methods such as polymerase chain reaction (PCR), chain terminating DNA sequencing (US Patent No. 5547859), minisequencing (Fiorentino et al., 2003), oligonucleotide hybridization, pyrosequencing, Illumina genome analyzer, deep sequencing, mass spectrometry or other nucleic acid sequence detection methods. Methods for detecting nucleic acid variants are well known in the art and disclosed in WO 00/04194, incorporated herein by reference. In an exemplary method, the diagnostic test comprises amplifying a segment of DNA or RNA (generally after converting the RNA to complementary DNA) spanning one or more known variants in the desired gene sequence. This amplified segment is then sequenced and/or subjected to electrophoresis in order to identify nucleotide variants in the amplified segment.

[0054] In one embodiment, the invention provides a method of screening for nucleotide variants in the nucleic acid of microvesicles isolated as described herein. This can be achieved, for example, by PCR or, alternatively, in a ligation chain reaction (LCR) (Abravaya et al., 1995; Landegren et al., 1988; Nakazawa et al., 1994). LCR can be particularly useful for detecting point mutations in a gene of interest (Abravaya et al., 1995). The LCR method comprises the steps of designing degenerate primers for amplifying the target sequence, the primers corresponding to one or more conserved regions of the nucleic acid corresponding to the gene of interest, amplifying PCR products with the primers using, as a template, a nucleic

acid obtained from a microvesicle, and analyzing the PCR products. Comparison of the PCR products of the microvesicle nucleic acid to a control sample (either having the nucleotide variant or not) indicates variants in the microvesicle nucleic acid. The change can be either an absence or presence of a nucleotide variant in the microvesicle nucleic acid, depending upon the control.

[0055] Analysis of amplification products can be performed using any method capable of separating the amplification products according to their size, including automated and manual gel electrophoresis, mass spectrometry, and the like.

[0056] Alternatively, the amplification products can be analyzed based on sequence differences, using SSCP, DGGE, TGGE, chemical cleavage, OLA, restriction fragment length polymorphisms as well as hybridization, for example, nucleic acid microarrays.

[0057] The methods of nucleic acid isolation, amplification and analysis are routine for one skilled in the art and examples of protocols can be found, for example, in *Molecular Cloning: A Laboratory Manual* (3-Volume Set) Ed. Joseph Sambrook, David W. Russel, and Joe Sambrook, Cold Spring Harbor Laboratory, 3rd edition (January 15, 2001), ISBN: 0879695773. A particular useful protocol source for methods used in PCR amplification is *PCR Basics: From Background to Bench* by Springer Verlag; 1st edition (October 15, 2000), ISBN: 0387916008.

[0058] Many methods of diagnosis performed on a tumor biopsy sample can be performed with microvesicles since tumor cells, as well as some normal cells are known to shed microvesicles into bodily fluid and the genetic aberrations within these microvesicles reflect those within tumor cells as demonstrated herein. Furthermore, methods of diagnosis using microvesicles have characteristics that are absent in methods of diagnosis performed directly on a tumor biopsy sample. For example, one particular advantage of the analysis of microvesicular nucleic acids, as opposed to other forms of sampling of tumor/cancer nucleic acid, is the availability for analysis of tumor/cancer nucleic acids derived from all foci of a tumor or genetically heterogeneous tumors present in an individual. Biopsy samples are limited in that they provide information only about the specific focus of the tumor from which the biopsy is obtained. Different tumorous/cancerous foci found within the body, or even within a single tumor often have different genetic profiles and are not analyzed in a standard biopsy. However, analysis of the microvesicular nucleic acids from an individual presumably provides a sampling of all foci within an individual. This provides valuable

information with respect to recommended treatments, treatment effectiveness, disease prognosis, and analysis of disease recurrence, which cannot be provided by a simple biopsy.

[0059] Identification of genetic aberrations associated with specific diseases and/or medical conditions by the methods described herein can also be used for prognosis and treatment decisions of an individual diagnosed with a disease or other medical condition such as cancer. Identification of the genetic basis of a disease and/or medical condition provides useful information guiding the treatment of the disease and/or medical condition. For example, many forms of chemotherapy have been shown to be more effective on cancers with specific genetic abnormalities/aberrations. One example is the effectiveness of EGFR-targeting treatments with medicines, such as the kinase inhibitors gefitinib and erlotinib. Such treatment have been shown to be more effective on cancer cells whose EGFR gene harbors specific nucleotide mutations in the kinase domain of EGFR protein (U.S. Patent publication 20060147959). In other words, the presence of at least one of the identified nucleotide variants in the kinase domain of EGFR nucleic acid message indicates that a patient will likely benefit from treatment with the EGFR-targeting compound gefitinib or erlotinib. Such nucleotide variants can be identified in nucleic acids present in microvesicles by the methods described herein, as it has been demonstrated that EGFR transcripts of tumor origin are isolated from microvesicles in bodily fluid.

[0060] Genetic aberrations in other genes have also been found to influence the effectiveness of treatments. As disclosed in the publication by Furnari et al. (Furnari et al., 2007), mutations in a variety of genes affect the effectiveness of specific medicines used in chemotherapy for treating brain tumors. The identification of these genetic aberrations in the nucleic acids within microvesicles will guide the selection of proper treatment plans.

[0061] As such, aspects of the present invention relate to a method for monitoring disease (e.g. cancer) progression in a subject, and also to a method for monitoring disease recurrence in an individual. These methods comprise the steps of isolating microvesicles from a bodily fluid of an individual, as discussed herein, and analyzing nucleic acid within the microvesicles as discussed herein (e.g. to create a genetic profile of the microvesicles). The presence/absence of a certain genetic aberration/profile is used to indicate the presence/absence of the disease (e.g. cancer) in the subject as discussed herein. The process is performed periodically over time, and the results reviewed, to monitor the progression or regression of the disease, or to determine recurrence of the disease. Put another way, a change in the genetic profile indicates a change in the disease state in the subject. The period

of time to elapse between sampling of microvesicles from the subject, for performance of the isolation and analysis of the microvesicle, will depend upon the circumstances of the subject, and is to be determined by the skilled practitioner. Such a method would prove extremely beneficial when analyzing a nucleic acid from a gene that is associated with the therapy undergone by the subject. For example, a gene which is targeted by the therapy can be monitored for the development of mutations which make it resistant to the therapy, upon which time the therapy can be modified accordingly. The monitored gene may also be one which indicates specific responsiveness to a specific therapy.

[0062] Aspects of the present invention also relate to the fact that a variety of non-cancer diseases and/or medical conditions also have genetic links and/or causes, and such diseases and/or medical conditions can likewise be diagnosed and/or monitored by the methods described herein. Many such diseases are metabolic, infectious or degenerative in nature. One such disease is diabetes (e.g. diabetes insipidus) in which the vasopressin type 2 receptor (V2R) is modified. Another such disease is kidney fibrosis in which the genetic profiles for the genes of collagens, fibronectin and TGF- β are changed. Changes in the genetic profile due to substance abuse (e.g. a steroid or drug use), viral and/or bacterial infection, and hereditary disease states can likewise be detected by the methods described herein.

[0063] Diseases or other medical conditions for which the inventions described herein are applicable include, but are not limited to, nephropathy, diabetes insipidus, diabetes type I, diabetes II, renal disease glomerulonephritis, bacterial or viral glomerulonephritides, IgA nephropathy, Henoch-Schonlein Purpura, membranoproliferative glomerulonephritis, membranous nephropathy, Sjogren's syndrome, nephrotic syndrome minimal change disease, focal glomerulosclerosis and related disorders, acute renal failure, acute tubulointerstitial nephritis, pyelonephritis, GU tract inflammatory disease, Pre-clampsia, renal graft rejection, leprosy, reflux nephropathy, nephrolithiasis, genetic renal disease, medullary cystic, medullary sponge, polycystic kidney disease, autosomal dominant polycystic kidney disease, autosomal recessive polycystic kidney disease, tuberous sclerosis, von Hippel-Lindau disease, familial thin-glomerular basement membrane disease, collagen III glomerulopathy, fibronectin glomerulopathy, Alport's syndrome, Fabry's disease, Nail-Patella Syndrome, congenital urologic anomalies, monoclonal gammopathies, multiple myeloma, amyloidosis and related disorders, febrile illness, familial Mediterranean fever, HIV infection-AIDS, inflammatory disease, systemic vasculitides, polyarteritis nodosa, Wegener's granulomatosis, polyarteritis,

necrotizing and crescentic glomerulonephritis, polymyositis-dermatomyositis, pancreatitis, rheumatoid arthritis, systemic lupus erythematosus, gout, blood disorders, sickle cell disease, thrombotic thrombocytopenia purpura, Fanconi's syndrome, transplantation, acute kidney injury, irritable bowel syndrome, hemolytic-uremic syndrome, acute cortical necrosis, renal thromboembolism, trauma and surgery, extensive injury, burns, abdominal and vascular surgery, induction of anesthesia, side effect of use of drugs or drug abuse, circulatory disease myocardial infarction, cardiac failure, peripheral vascular disease, hypertension, coronary heart disease, non-atherosclerotic cardiovascular disease, atherosclerotic cardiovascular disease, skin disease, psoriasis, systemic sclerosis, respiratory disease, COPD, obstructive sleep apnea, hypoxia at high altitude or endocrine disease, acromegaly, diabetes mellitus, or diabetes insipidus.

[0064] Selection of an individual from whom the microvesicles are isolated is performed by the skilled practitioner based upon analysis of one or more of a variety of factors. Such factors for consideration are whether the subject has a family history of a specific disease (e.g. a cancer), has a genetic predisposition for such a disease, has an increased risk for such a disease due to family history, genetic predisposition, other disease or physical symptoms which indicate a predisposition, or environmental reasons. Environmental reasons include lifestyle, exposure to agents which cause or contribute to the disease such as in the air, land, water or diet. In addition, having previously had the disease, being currently diagnosed with the disease prior to therapy or after therapy, being currently treated for the disease (undergoing therapy), being in remission or recovery from the disease, are other reasons to select an individual for performing the methods.

[0065] The methods described herein are optionally performed with the additional step of selecting a gene or nucleic acid for analysis, prior to the analysis step. This selection can be based on any predispositions of the subject, or any previous exposures or diagnosis, or therapeutic treatments experienced or concurrently undergone by the subject.

[0066] The cancer diagnosed, monitored or otherwise profiled, can be any kind of cancer. This includes, without limitation, epithelial cell cancers such as lung, ovarian, cervical, endometrial, breast, brain, colon and prostate cancers. Also included are gastrointestinal cancer, head and neck cancer, non-small cell lung cancer, cancer of the nervous system, kidney cancer, retina cancer, skin cancer, liver cancer, pancreatic cancer, genital-urinary cancer and bladder cancer, melanoma, and leukemia. In addition, the methods and compositions of the present invention are equally applicable to detection, diagnosis and

prognosis of non-malignant tumors in an individual (e.g. neurofibromas, meningiomas and schwannomas).

[0067] In one embodiment, the cancer is brain cancer. Types of brain tumors and cancer are well known in the art. Glioma is a general name for tumors that arise from the glial (supportive) tissue of the brain. Gliomas are the most common primary brain tumors. Astrocytomas, ependymomas, oligodendrogliomas, and tumors with mixtures of two or more cell types, called mixed gliomas, are the most common gliomas. The following are other common types of brain tumors: Acoustic Neuroma (Neurilemmoma, Schwannoma, Neurinoma), Adenoma, Astracytoma, Low-Grade Astrocytoma, giant cell astrocytomas, Mid- and High-Grade Astrocytoma, Recurrent tumors, Brain Stem Glioma, Chordoma, Choroid Plexus Papilloma, CNS Lymphoma (Primary Malignant Lymphoma), Cysts, Dermoid cysts, Epidermoid cysts, Craniopharyngioma, Ependymoma Anaplastic ependymoma, Gangliocytoma (Ganglioneuroma), Ganglioglioma, Glioblastoma Multiforme (GBM), Malignant Astracytoma, Glioma, Hemangioblastoma, Inoperable Brain Tumors, Lymphoma, Medulloblastoma (MDL), Meningioma, Metastatic Brain Tumors, Mixed Glioma, Neurofibromatosis, Oligodendroglioma. Optic Nerve Glioma, Pineal Region Tumors, Pituitary Adenoma, PNET (Primitive Neuroectodermal Tumor), Spinal Tumors, Subependymoma, and Tuberous Sclerosis (Bourneville's Disease).

[0068] In addition to identifying previously known nucleic acid aberrations (as associated with diseases), the methods of the present invention can be used to identify previously unidentified nucleic acid sequences/modifications (e.g. post transcriptional modifications) whose aberrations are associated with a certain disease and/or medical condition. This is accomplished, for example, by analysis of the nucleic acid within microvesicles from a bodily fluid of one or more subjects with a given disease/medical condition (e.g. a clinical type or subtype of cancer) and comparison to the nucleic acid within microvesicles of one or more subjects without the given disease/medical condition, to identify differences in their nucleic acid content. The differences may be any genetic aberrations including, without limitation, expression level of the nucleic acid, alternative splice variants, gene copy number variants (CNV), modifications of the nucleic acid, single nucleotide polymorphisms (SNPs), and mutations (insertions, deletions or single nucleotide changes) of the nucleic acid. Once a difference in a genetic parameter of a particular nucleic acid is identified for a certain disease, further studies involving a clinically and statistically significant number of subjects may be carried out to establish the correlation between the

genetic aberration of the particular nucleic acid and the disease. The analysis of genetic aberrations can be done by one or more methods described herein, as determined appropriate by the skilled practitioner.

Exosomes As Delivery Vehicles

[0069] Aspects of the present invention also relate to the actual microvesicles described herein. In one embodiment, the invention is an isolated microvesicle as described herein, isolated from an individual. In one embodiment, the microvesicle is produced by a cell within the brain of the individual (e.g. a tumor or non-tumor cell). In another embodiment, the microvesicle is isolated from a bodily fluid of an individual, as described herein. Methods of isolation are described herein.

[0070] Another aspect of the invention relates to the finding that isolated microvesicles from human glioblastoma cells contain mRNAs, miRNAs and angiogenic proteins. Such glioblastoma microvesicles were taken up by primary human brain endothelial cells, likely via an endocytotic mechanism, and a reporter protein mRNA incorporated into the microvesicles was translated in those cells. This indicates that messages delivered by microvesicles can change the genetic and/or translational profile of a target cell (a cell which takes up a microvesicle). The microvesicles also contained miRNAs which are known to be abundant in glioblastomas (Krichevsky et al, manuscript in preparation). Thus microvesicles derived from glioblastoma tumors function as delivery vehicles for mRNA, miRNA and proteins which can change the translational state of other cells via delivery of specific mRNA species, promote angiogenesis of endothelial cells, and stimulate tumor growth.

[0071] In one embodiment, microvesicles are depleted from a bodily fluid from a donor subject before said bodily fluid is delivered to a recipient subject. The donor subject may be a subject with an undetectable tumor and the microvesicles in the bodily fluid are derived from the tumor. The tumor microvesicles in the donor bodily fluid, if unremoved, would be harmful since the genetic materials and proteins in the microvesicle may promote unrestricted growth of cells in the recipient subject.

[0072] As such, another aspect of the invention is the use of the microvesicles identified herein to deliver a nucleic acid to a cell. In one embodiment, the cell is within the body of an individual. The method comprises administering a microvesicle(s) which contains the nucleic acid, or a cell that produces such microvesicles, to the individual such that the

microvesicles contacts and/or enters the cell of the individual. The cell to which the nucleic acid gets delivered is referred to as the target cell.

[0073] The microvesicle can be engineered to contain a nucleic acid that it would not naturally contain (i.e. which is exogenous to the normal content of the microvesicle). This can be accomplished by physically inserting the nucleic acid into the microvesicles. Alternatively, a cell (e.g. grown in culture) can be engineered to target one or more specific nucleic acid into the exosome, and the exosome can be isolated from the cell. Alternatively, the engineered cell itself can be administered to the individual.

[0074] In one embodiment, the cell which produces the exosome for administration is of the same or similar origin or location in the body as the target cell. That is to say, for delivery of a microvesicle to a brain cell, the cell which produces the microvesicle would be a brain cell (e.g. a primary cell grown in culture). In another embodiment, the cell which produces the exosome is of a different cell type than the target cell. In one embodiment, the cell which produces the exosome is a type that is located proximally in the body to the target cell.

[0075] A nucleic acid sequence which can be delivered to a cell via an exosome can be RNA or DNA, and can be single or double stranded, and can be selected from a group comprising: nucleic acid encoding a protein of interest, oligonucleotides, nucleic acid analogues, for example peptide-nucleic acid (PNA), pseudo-complementary PNA (pc-PNA), locked nucleic acid (LNA) etc. Such nucleic acid sequences include, for example, but are not limited to, nucleic acid sequences encoding proteins, for example that act as transcriptional repressors, antisense molecules, ribozymes, small inhibitory nucleic acid sequences, for example but are not limited to RNAi, shRNA, siRNA, miRNA, antisense oligonucleotides, and combinations thereof.

[0076] Microvesicles isolated from a cell type are delivered to a recipient subject. Said microvesicles may benefit the recipient subject medically. For example, the angiogenesis and pro-proliferation effects of tumor exosomes may help the regeneration of injured tissues in the recipient subject. In one embodiment, the delivery means is by bodily fluid transfusion wherein microvesicles are added into a bodily fluid from a donor subject before said bodily fluid is delivered to a recipient subject.

[0077] In another embodiment, the microvesicle is an ingredient (e.g. the active ingredient in a pharmaceutically acceptable formulation suitable for administration to the

subject (e.g. in the methods described herein). Generally this comprises a pharmaceutically acceptable carrier for the active ingredient. The specific carrier will depend upon a number of factors (e.g., the route of administration).

[0078] The “pharmaceutically acceptable carrier” means any pharmaceutically acceptable means to mix and/or deliver the targeted delivery composition to a subject. This includes a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in carrying or transporting the subject agents from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and is compatible with administration to a subject, for example a human.

[0079] Administration to the subject can be either systemic or localized. This includes, without limitation, dispensing, delivering or applying an active compound (e.g. in a pharmaceutical formulation) to the subject by any suitable route for delivery of the active compound to the desired location in the subject, including delivery by either the parenteral or oral route, intramuscular injection, subcutaneous/intradermal injection, intravenous injection, buccal administration, transdermal delivery and administration by the rectal, colonic, vaginal, intranasal or respiratory tract route.

[0080] It should be understood that this invention is not limited to the particular methodologies, protocols and reagents, described herein and as such may vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present invention, which is defined solely by the claims.

[0081] In one respect, the present invention relates to the herein described compositions, methods, and respective components thereof, as essential to the invention, yet open to the inclusion of unspecified elements, essential or not (“comprising”). In some embodiments, other elements to be included in the description of the composition, method or respective component thereof are limited to those that do not materially affect the basic and novel characteristic(s) of the invention (“consisting essentially of”). This applies equally to steps within a described method as well as compositions and components therein. In other embodiments, the inventions, compositions, methods, and respective components thereof, described herein are intended to be exclusive of any element not deemed an essential element to the component, composition or method (“consisting of”).

EXAMPLES

Examples 1-7. Tumor cells shed microvesicles, which contain RNAs, including mRNAs and microRNAs, and that microvesicles contain more than 90% of the extracellular RNA in bodily fluids.

Example 1: Microvesicles are shed from primary human glioblastoma cells.

[0082] Glioblastoma tissue was obtained from surgical resections and tumor cells were dissociated and cultured as monolayers. Specifically, brain tumor specimens from patients diagnosed by a neuropathologist as glioblastoma multiforme were taken directly from surgery and placed in cold sterile Neurobasal media (Invitrogen, Carlsbad, CA, USA). The specimens were dissociated into single cells within 1 hr from the time of surgery using a Neural Tissue Dissociation Kit (Miltenyi Biotech, Berich Gladbach, Germany) and plated in DMEM 5% dFBS supplemented with penicillin-streptomycin (10 IU ml⁻¹ and 10 µg ml⁻¹, respectively, Sigma-Aldrich, St Louis, MO, USA). Because microvesicles can be found in the fetal bovine serum (FBS) traditionally used to cultivate cells, and these microvesicles contain substantial amounts of mRNA and miRNA, it was important to grow the tumor cells in media containing microvesicle-depleted FBS (dFBS). Cultured primary cells obtained from three glioblastoma tumors were found to produce microvesicles at both early and later passages (a passage is a cellular generation defined by the splitting of cells, which is a common cell culture technique and is necessary to keep the cells alive). The microvesicles were able to be detected by scanning electronmicroscopy (FIGS 1a and 1b) and transmission electronmicroscopy (FIG 1f). Briefly, human glioblastoma cells were placed on ornithine-coated cover-slips, fixed in 0.5x Karnovskys fixative and then washed 2x5min (2 times with 5 min each) with PBS. The cells were dehydrated in 35% EtOH 10 min, 50% EtOH 2x 10 min, 70% EtOH 2x 10 min, 95% EtOH 2x 10 min, and 100% EtOH 4 x 10 min. The cells were then transferred to critical point drying in a Tousimis SAMDR1-795 semi-automatic Critical Point Dryer followed by coating with chromium in a GATAN Model 681 High Resolution Ion Beam Coater. As shown in FIGS. 1a and 1b, tumor cells were covered with microvesicles varying in size from about 50 - 500 nm.

Example 2: Glioblastoma microvesicles contain RNA.

[0083] To isolate microvesicles, glioblastoma cells at passage 1-15 were cultured in microvesicle-free media (DMEM containing 5% dFBS prepared by ultracentrifugation at 110,000 x g for 16 hours to remove bovine microvesicles). The conditioned medium from 40

million cells was harvested after 48 hours. The microvesicles were purified by differential centrifugation. Specifically, glioblastoma conditioned medium was centrifuged for 10 min at 300 x g to eliminate any cell contamination. Supernatants were further centrifuged for 20 min at 16,500 x g and filtered through a 0.22 μm filter. Microvesicles were then pelleted by ultracentrifugation at 110,000 x g for 70 min. The microvesicle pellets were washed in 13 ml PBS, pelleted again and resuspended in PBS.

[0084] Isolated microvesicles were measured for their total protein content using DC Protein Assay (Bio-Rad, Hercules, CA, USA).

[0085] For the extraction of RNA from microvesicles, RNase A (Fermentas, Glen Burnie, MD, USA) at a final concentration of 100 $\mu\text{g/ml}$ was added to suspensions of microvesicles and incubated for 15 min at 37°C to get rid of RNA outside of the microvesicles and thus ensure that the extracted RNA would come from inside the microvesicles. Total RNA was then extracted from the microvesicles using the MirVana RNA isolation kit (Ambion, Austin TX, USA) according to the manufacturer's protocol. After treatment with DNase according to the manufacturer's protocol, the total RNA was quantified using a nanodrop ND-1000 instrument (Thermo Fischer Scientific, Wilmington, DE, USA).

[0086] Glioblastoma microvesicles were found to contain RNA and protein in a ratio of approximately 1:80 (μg RNA: μg protein). The average yield of proteins and RNAs isolated from microvesicles over a 48-hour period in culture was around 4 μg protein and 50 ng RNA/million cells.

[0087] To confirm that the RNA was contained inside the microvesicles, microvesicles were either exposed to RNase A or mock treatment before RNA extraction (FIG. 1c). There was never more than a 7% decrease in RNA content following RNase treatment. Thus, it appears that almost all of the extracellular RNA from the media is contained within the microvesicles and is thereby protected from external RNases by the surrounding vesicular membrane.

[0088] Total RNA from microvesicles and their donor cells were analyzed with a Bioanalyzer, showing that the microvesicles contain a broad range of RNA sizes consistent with a variety of mRNAs and miRNAs, but lack 18S and 28S the ribosomal RNA peaks characteristic of cellular RNA (FIGS. 1d and 1e).

Example 3: Microvesicles contain DNA.

[0089] To test if microvesicles also contain DNA, exosomes were isolated as mentioned in Example 2 and then treated with DNase before being lysed to release contents. The DNase treatment step was to remove DNA outside of the exosomes so that only DNA residing inside the exosomes was extracted. Specifically, the DNase treatment was performed using the DNA-free kit from Ambion according to manufacturer's recommendations (Catalog#AM1906). For the DNA purification step, an aliquot of isolated exosomes was lysed in 300µl lysis buffer that was part of the MirVana RNA isolation kit (Ambion) and the DNAs were purified from the lysed mixture using a DNA purification kit (Qiagen) according to the manufacturer's recommendation.

[0090] To examine whether the extracted DNA contains common genes, PCRs were performed using primer pairs specific to GAPDH, Human endogenous retrovirus K, Tenascin-c and Line-1. For the GAPDH gene, the following primers were used: Forw3GAPDHnew (SEQ ID NO: 1) and Rev3GAPDHnew (SEQ ID NO: 2). The primer pair amplifies a 112bp amplicon if the template is a spliced GAPDH cDNA and a 216bp amplicon if the template is an un-spliced genomic GAPDH DNA. In one experiment, isolated exosomes were treated with DNase before being lysed for DNA extraction (FIG. 3a). The 112bp fragments were amplified as expected from the exosomes from the tumor serum (See Lane 4 in FIG. 3a) and the primary tumor cells (See Lane 6 in FIG. 3a) but not from the exosomes from normal human fibroblasts (See Lane 5 in FIG. 3a). The 216bp fragment could not be amplified from exosomes of all three origins. However, fragments of both 112bp and 216bp were amplified when the genomic DNA isolated from the glioblastoma cell was used as templates (See Lane 3 in FIG. 3a). Thus, spliced GAPDH DNA exists within exosomes isolated from tumor cells but not within exosomes isolated from normal fibroblast cells.

[0091] In contrast, in another experiment, isolated exosomes were not treated with DNase before being lysed for DNA extraction (FIG. 3b). Not only the 112bp fragments but also the 216bp fragments were amplified from exosomes isolated from primary melanoma cells (See Lane 3 in FIG. 3b), suggesting that non-spliced GAPDH DNA or partially spliced cDNA that has been reverse transcribed exists outside of the exosomes.

[0092] For the Human Endogenous Retrovirus K (HERV-K) gene, the following primers were used: HERVK_6Forw (SEQ ID NO: 3) and HERVK_6Rev (SEQ ID NO: 4). The primer pair amplifies a 172bp amplicon. DNA was extracted from exosomes that were isolated and treated with DNase, and used as the template for PCR amplification. As shown

in FIG. 3c, 172bp fragments were amplified in all tumor and normal human serum exosomes but not in exosomes from normal human fibroblasts. These data suggest that unlike exosomes from normal human fibroblasts, tumor and normal human serum exosomes contain endogenous retrovirus DNA sequences. To examine if tumor exosomes also contain transposable elements, the following LINE-1 specific primers were used for PCR amplifications: Line1_Forw (SEQ ID NO: 5) and Line1_Rev (SEQ ID NO: 6). These two primers are designed to detect LINE-1 in all species since each primer contains equal amounts of two different oligos. For the Line1_Forw primer, one oligo contains a C and the other oligo contains a G at the position designated with "s". For the Line1_Rev primer, one oligo contains an A and the other oligo contains a G at the position designated with "r". The primer pair amplifies a 290bp amplicon. The template was the DNA extracted from exosomes that were treated with DNase (as described above). As shown in FIG. 3e, 290bp LINE-1 fragments could be amplified from the exosomes from tumor cells and normal human serum but not from exosomes from the normal human fibroblasts.

[0093] To test if exosomes also contain Tenascin-C DNA, the following primer pair was used to perform PCR: Tenascin C Forw (SEQ ID NO: 7) and Tenascin C Rev (SEQ ID NO: 8). The primer pair amplifies a 197bp amplicon. The template was the DNA extracted from exosomes that were isolated and then treated with DNase before lysis. As shown in FIG. 3d, 197bp Tenascin C fragments were amplified in exosomes from tumor cells or normal human serum but not in exosomes from normal human fibroblasts. Thus, Tenascin-C DNA exists in tumor and normal human serum exosomes but not in exosomes from normal human fibroblasts.

[0094] To further confirm the presence of DNA in exosomes, exosomal DNA was extracted from D425 medulloblastoma cells using the method described above. Specifically, the exosomes were isolated and treated with DNase before lysis. Equal volumes of the final DNA extract were either treated with DNase or not treated with DNase before being visualized by Ethidium Bromide staining in 1% agarose gel. Ethidium Bromide is a dye that specifically stains nucleic acids and can be visualized under ultraviolet light. As shown in FIG. 3f, Ethidium Bromide staining disappeared after DNase treatment (See Lane 3 in FIG. 3f) while strong staining could be visualized in the un-treated aliquot (See Lane 2 in FIG. 3f). The DNase treated and non-treated extracts were also analyzed on a RNA pico chip (Agilent Technologies). As shown in FIG. 3g, single stranded DNA could be readily detected in the

DNase-non-treated extract (See upper panel in FIG. 3g) but could barely be detected in the DNase-treated extract (See lower panel in FIG. 3g).

[0095] To test whether the extracted DNA was single-stranded, nucleic acids were extracted from the treated exosomes as described in the previous paragraph and further treated with RNase to eliminate any RNA contamination. The treated nucleic acids were then analyzed on a RNA pico Bioanalyzer chip and in a DNA 1000 chip. The RNA pico chip only detects single stranded nucleic acids. The DNA 1000 chip detected double stranded nucleic acids. As shown in FIG. 3h, single stranded nucleic acids were detected (See upper panel) but double stranded nucleic acids were not detected (See lower panel). Thus, the DNA contained within tumor exosomes are mostly single stranded.

[0096] To demonstrate that single stranded DNA exists in tumor cells but not in normal human fibroblasts, nucleic acids were extracted from exosomes from either glioblastoma patient serum or normal human fibroblasts. The exosomes were treated with DNase before lysis and the purified nucleic acids were treated with RNase before analysis. As shown in FIG. 3i, exosomal nucleic acids extracted from glioblastoma patient serum could be detected by a RNA pico chip. In contrast, only a very small amount of single stranded DNA was extracted from normal human fibroblasts.

[0097] Accordingly, exosomes from tumor cells and normal human serum were found to contain contain single-stranded DNA. The single-stranded DNA is a reverse transcription product since the amplification products do not contain introns (FIG. 3a and FIG. 3b). It is known that tumor cells as well as normal progenitor cells/stem cells have active reverse transcriptase (RT) activity although the activity in normal progenitor cells/stem cells is relatively much lower. This RT activity makes it plausible that RNA transcripts in the cell can be reverse transcribed and packaged into exosomes as cDNA. Interestingly, exosomes from tumor cells contain more cDNAs corresponding to tumor-specific gene transcripts since tumor cells usually have up-regulated reverse transcriptase activity. Therefore, tumor specific cDNA in exosomes may be used as biomarkers for the diagnosis or prognosis of different tumor types. The use of cDNAs as biomarkers would skip the step of reverse transcription compared to the used of mRNA as biomarkers for tumors. In addition, the use of exosomal cDNA is advantageous over the use of whole serum/plasma DNA because serum/plasma contains genomic DNA released from dying cells. When testing amplified whole serum/plasma DNA, there will be more background.

Example 4: Most extracellular RNA in human serum is contained within exosomes.

[0098] To determine the amount of RNA circulating in serum as “free RNA”/RNA-protein complex versus the amount of RNA contained within the exosomes, we isolated serum from a healthy human subject, and evenly split the serum into two samples with equal volume. For sample 1, the serum was ultracentrifuged to remove most microvesicles. Then the serum supernatant was collected and RNA left in the supernatant was extracted using Trizol LS. For sample 2, the serum was not ultracentrifuged and total RNA was extracted from the serum using Trizol LS. The amount of RNA in the sample 1 supernatant and sample 2 serum was measured. As a result, it was found that the amount of free RNA in sample 1 supernatant was less than 10% of the amount of total RNA isolated from the serum sample 2. Therefore, a majority of the RNA in serum is associated with the exosomes.

Example 5: High efficiency of serum extracellular nucleic acid extraction is achieved by incorporating a serum exosome isolation step.

[0099] Whole serum and plasma contain large amounts of circulating DNA and possibly also RNA protected in protein complexes, while free RNA have a half-life of a few minutes in serum. Extracellular nucleic acid profiles in serum vary between normal and diseased mammals and thus may be biomarkers for certain diseases. To examine the profiles, nucleic acids need to be extracted. However, direct extraction of nucleic acids from serum and plasma is not practical, especially from large serum/plasma volumes. In this case, large volumes of Trizol LS (a RNA extraction reagent) are used to instantly inactivate all serum nucleases before extracting the exosomal nucleic acids. Subsequently, contaminants precipitate into the sample and affect subsequent analyses. As shown in Example 4, most extracellular RNAs in serum are contained in serum exosomes. Therefore, we tested whether it is more efficient to isolate extracellular nucleic acids by isolating the serum exosomes before nucleic acid extraction.

[00100] Four milliliter (ml) blood serum from a patient was split into 2 aliquots of 2 ml each. Serum exosomes from one aliquot were isolated prior to RNA extraction. The methods of exosome isolation and RNA extraction are the same as mentioned in Example 2. For the other aliquot, RNA was extracted directly using Trizol LS according to manufacturer’s recommendation. The nucleic acids from these two extractions were analyzed on a Bioanalyzer RNA chip (Agilent Technologies). As shown in Figure 4, the amount of RNA extracted with the former method is significantly more than that obtained from the latter

method. Further, the quality of RNA extracted with the latter method is relatively poor compared to that with the former method. Thus, the step of exosome isolation contributes to the efficiency of extracellular RNA extraction from serum.

Example 6: Microarray analysis of mRNA.

[00101] Microarray analysis of the mRNA population in glioblastoma cells and microvesicles derived from them was performed by Miltenyi Biotech (Auburn, CA, USA) using the Agilent Whole Human Genome Microarray, 4x44K, two color array. The microarray analysis was performed on two different RNA preparations from primary glioblastoma cells and their corresponding microvesicles RNA preparations prepared as described in Examples 1 and 2. The data was analyzed using the GeneSifter software (Vizxlabs, Seattle, WA, USA). The Intersector software (Vizxlabs) was used to extract the genes readily detected on both arrays. The microarray data have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO series accession number GSE13470.

[00102] We found approximately 22,000 gene transcripts in the cells and 27,000 gene transcripts in the microvesicles that were detected well above background levels (99% confidence interval) on both arrays. Approximately 4,700 different mRNAs were detected exclusively in microvesicles on both arrays, indicating a selective enrichment process within the microvesicles. Consistent with this, there was a poor overall correlation in levels of mRNAs in the microvesicles as compared to their cells of origin from two tumor cell preparations (FIGS. 2a and 2b). In contrast, there was a good correlation in levels of mRNA from one cell culture (A) versus the second cell culture (B) (FIG. 2c) and a similar correlation in levels of mRNA from the corresponding microvesicles (A) and (B) (FIG. 2d). Accordingly, there is a consistency of mRNA distribution within the tumor cells and microvesicles. In comparing the ratio of transcripts in the microvesicles versus their cells of origin, we found 3,426 transcripts differentially distributed more than 5-fold (p-value <0.01). Of these, 2,238 transcripts were enriched (up to 380 fold) and 1,188 transcripts were less abundant (up to 90 fold) than in the cells (FIG. 5). The intensities and ratios of all gene transcripts were documented. The ontologies of mRNA transcripts enriched or reduced more than 10-fold were recorded and reviewed.

[00103] The mRNA transcripts that were highly enriched in the microvesicles were not always the ones that were most abundant in the microvesicles. The most abundant transcripts

would be more likely to generate an effect in the recipient cell upon delivery, and therefore the 500 most abundant mRNA transcripts present in microvesicles were divided into different biological processes based on their ontology descriptions (FIG. 6a). Of the various ontologies, angiogenesis, cell proliferation, immune response, cell migration and histone modification were selected for further study as they represent specific functions that could be involved in remodeling the tumor stroma and enhancing tumor growth. Glioblastoma microvesicle mRNAs belonging to these five ontologies were plotted to compare their levels and contribution to the mRNA spectrum (FIG. 6b). All five ontologies contained mRNAs with very high expression levels compared to the median signal intensity level of the array.

[00104] A thorough analysis of mRNAs that are enriched in the microvesicles versus donor cells, suggests that there may be a cellular mechanism for localizing these messages into microvesicles, possibly via a “zip code” in the 3'UTR as described for mRNAs translated in specific cellular locations, such as that for beta actin (Kislauskis et al., 1994). The conformation of the mRNAs in the microvesicles is not known, but they may be present as ribonuclear particles (RNPs) (Mallardo et al., 2003) which would then prevent degradation and premature translation in the donor cell.

[00105] Microarray analysis of the mRNA populations in glioblastoma cells and microvesicles derived from glioblastoma cells, melanoma cells, and microvesicles derived from melanoma cells was performed by Illumina Inc. (San Diego, CA, USA) using the Whole-Genome cDNA-mediated Annealing, Selection, Extension, and Ligation (DASL) Assay. The Whole-Genome DASL Assay combines the PCR and labeling steps of Illumina's DASL Assay with the gene-based hybridization and whole-genome probe set of Illumina's HumanRef-8 BeadChip. This BeadChip covers more than 24,000 annotated genes derived from RefSeq (Build 36.2, Release 22). The microarray analysis was performed on two different RNA preparations from primary glioblastoma cells, microvesicles from glioblastomas cells (derived with the method as described in Examples 1 and 2), melanoma cells, and microvesicles from melanoma cells (derived with the method as described in Examples 1 and 2).

[00106] The expression data for each RNA preparation were pooled together and used to generate a cluster diagram. As shown in FIG. 7, mRNA expression profiles for glioblastoma cells, microvesicles from glioblastomas cells, melanoma cells, and microvesicles from melanoma cells are clustered together, respectively. Expression profiles of the two primary glioblastoma cell lines 20/3C and 11/5c are clustered with a distance of about 0.06.

Expression profiles of the two primary melanoma cell lines 0105C and 0664C are clustered with a distance of about 0.09. Expression profiles of exosomes from the two primary melanoma cell lines 0105C and 0664C are clustered together with a distance of around 0.15. Expression profiles of exosomes from the two primary glioblastomas cell lines 20/3C and 11/5c are clustered together with a distance of around 0.098. Thus, exosomes from glioblastoma and melanoma have distinctive mRNA expression signatures and the gene expression signature of exosomes differs from that of their original cells. These data demonstrate that mRNA expression profiles from microvesicles may be used in the methods described herein for the diagnosis and prognosis of cancers.

Example 7: Glioblastoma microvesicles contain miRNA

[00107] Mature miRNA from microvesicles and from donor cells was detected using a quantitative miRNA reverse transcription PCR. Specifically, total RNA was isolated from microvesicles and from donor cells using the mirVana RNA isolation kit (Applied Biosystems, Foster City, CA, USA). Using the TaqMan® MicroRNA Assay kits (Applied Biosystems, Foster City, CA, USA), 30 ng total RNA was converted into cDNA using specific miR-primers and further amplified according to the manufacturer's protocol.

[00108] A subset of 11 miRNAs among those known to be up-regulated and abundant in gliomas was analyzed in microvesicles purified from two different primary glioblastomas (GBM 1 and GBM 2). These subset contained let-7a, miR-15b, miR-16, miR-19b, miR-21, miR-26a, miR-27a, miR-92, miR-93, miR-320 and miR-20. All of these miRNA were readily detected in donor cells and in microvesicles (FIG. 8). The levels were generally lower in microvesicles per µg total RNA than in parental cells (10%, corresponding to approximately 3 Ct-values), but the levels were well correlated, indicating that these 11 miRNA species are not enriched in microvesicles.

[00109] Microarray analysis of the microRNA populations in glioblastoma cells and microvesicles derived from glioblastoma cells, melanoma cells, and microvesicles derived from melanoma cells was performed by Illumina Inc. (San Diego, CA, USA) using the MicroRNA Expression Profiling Panel, powered by the DASL Assay. The human MicroRNA Panels include 1146 microRNA species. The microarray analysis was performed on two different RNA preparations from primary glioblastoma cells, microvesicles from glioblastomas cells (derived using the method described in Examples 1 and 2), melanoma

cells, and microvesicles from melanoma cells (derived using the method described in Examples 1 and 2).

[00110] The expression data for each RNA preparation were pooled together and used to generate a cluster diagram. As shown in FIG. 9, microRNA expression profiles for glioblastoma cells, microvesicles from glioblastomas cells, melanoma cells, and microvesicles from melanoma cells are clustered together, respectively. Expression profiles of the two primary melanoma cell lines 0105C and 0664C are clustered with a distance of about 0.13. Expression profiles of the two primary glioblastomas cell lines 20/3C and 11/5c are clustered with a distance of about 0.12. Expression profiles of exosomes from the two primary glioblastomas cell lines 20/3C and 11/5c are clustered together with a distance of around 0.12. Expression profiles of exosomes from the two primary melanoma cell lines 0105C and 0664C are clustered together with a distance of around 0.17. Thus, exosomes from glioblastoma and melanoma have distinctive microRNA expression signatures and that the gene expression signature of exosomes differs from that of their original cells. Furthermore, as demonstrated herein, microRNA expression profiles from microvesicles may be used in the methods described herein for the diagnosis and prognosis of cancers.

[00111] The finding of miRNAs in microvesicles suggests that tumor-derived microvesicles can modify the surrounding normal cells by changing their transcriptional/translational profiles. Furthermore, as demonstrated herein, miRNA expression profile from microvesicles may be used in the methods described herein for the diagnosis and prognosis of cancers, including but not limited to glioblastoma.

Examples 8-15. These examples show that nucleic acids within exosomes from bodily fluids can be used as biomarkers for diseases or other medical conditions.

Example 8: Expression profiles of miRNAs in microvesicles can be used as sensitive biomarkers for glioblastoma.

[00112] To determine if microRNAs within exosomes may be used as biomarkers for a disease and/or medical condition, we examined the existence of a correlation between the expression level of microRNA and disease status. Since microRNA-21 is expressed at high levels in glioblastoma cells and is readily detectable in exosomes isolated from serum of glioblastoma patients, we measured quantitatively microRNA-21 copy numbers within exosomes from the sera of glioblastoma patients by quantitative RT-PCR. Specifically, exosomes were isolated from 4 ml serum samples from 9 normal human subjects and 9

glioblastoma patients. The RNA extraction procedure was similar to the RNA extraction procedure as described in Example 2. The level of miR-21 was analyzed using singleplex qPCR (Applied Biosystems) and normalized to GAPDH expression level.

[00113] As shown in FIG. 10, the average Ct-value was 5.98 lower in the glioblastoma serum sample, suggesting that the exosomal miRNA-21 expression level in glioblastoma patients is approximately 63 fold higher than that in a normal human subject. The difference is statistically significant with a p value of 0.01. Therefore, there is a correlation between microRNA-21 expression level and glioblastoma disease status, which demonstrates that validity and applicability of the non-invasive diagnostic methods disclosed herein. For example, in one aspect, the method comprised the steps of isolating exosomes from the bodily fluid of a subject and analyzing microRNA-21 expression levels within the exosomes by measuring the copy number of microRNA-21 and comparing the number to that within exosomes from a normal subject or to a standard number generated by analyzing microRNA-21 contents within exosomes from a group of normal subjects. An increased copy number indicates the existence of glioblastoma in the subject; while the absence of an increased copy number indicates the absence of glioblastoma in the subject. This basic method may be extrapolated to diagnose/monitor other diseases and/or medical conditions associated with other species of microRNAs.

Example 9: mRNAs in microvesicles can be used as sensitive biomarkers for diagnosis

[00114] Nucleic acids are of high value as biomarkers because of their ability to be detected with high sensitivity by PCR methods. Accordingly, the following tests were designed and carried out to determine whether the mRNA in microvesicles could be used as biomarkers for a medical disease or condition, in this case glioblastoma tumors. The epidermal growth factor receptor (EGFR) mRNA was selected because the expression of the EGFRvIII mutation is specific to some tumors and defines a clinically distinct subtype of glioma (Pelloski et al., 2007). In addition, EGFRvIII mutations traditionally cannot be detected using tissues other than the lesion tissues since these mutations are somatic mutations but not germ line mutations. Therefore, a biopsy from lesion tissues such as glioma tumor is conventionally required for detecting EGFRvIII mutations. As detailed below, nested RT-PCR was used to identify EGFRvIII mRNA in glioma tumor biopsy samples and the results compared with the mRNA species found in microvesicles purified from a serum sample from the same patient.

[00115] Microvesicles were purified from primary human glioblastoma cells followed by RNA extraction from both the microvesicles and donor cells (biopsy). The samples were coded and the PCRs were performed in a blind fashion. Gli-36EGFRvIII (human glioma cell stably expressing EGFRvIII) was included as a positive control. The microvesicles from 0.5-2 ml of frozen serum samples were pelleted as described in Example 2 and the RNA was extracted using the MirVana Microvesicles RNA isolation kit. Nested RT-PCR was then used to amplify both the wild type EGFR (1153 bp) and EGFRvIII (352 bp) transcripts from both the microvesicles and donor cells using the same set of primers. Specifically, the RNA was converted to cDNA using the Omniscript RT kit (Qiagen Inc, Valencia, CA, USA) according to the manufacturer's recommended protocol. GAPDH primers were GAPDH Forward (SEQ ID NO: 9) and GAPDH Reverse (SEQ ID NO: 10). The EGFR/EGFRvIII PCR1 primers were SEQ ID NO: 11 and SEQ ID NO: 12. The EGFR/EGFRvIII PCR2 primers were SEQ ID NO: 13 and SEQ ID NO: 14. The PCR cycling protocol was 94 °C for 3 minutes; 94 °C for 45 seconds, 60 °C for 45 seconds, 72 °C for 2 minutes for 35 cycles; and a final step 72 °C for 7 minutes.

[00116] We analyzed the biopsy sample to determine whether the EGFRvIII mRNA was present and compared the result with RNA extracted from exosomes purified from a frozen serum sample from the same patient. Fourteen of the 30 tumor samples (47%) contained the EGFRvIII transcript, which is consistent with the percentage of glioblastomas found to contain this mutation in other studies (Nishikawa et al., 2004). EGFRvIII could be amplified from exosomes in seven of the 25 patients (28%) from whom serum was drawn around the time of surgery (FIG. 11 and Table 1). When a new pair of primers EGFR/EGFRvIII PCR3: SEQ ID NO: 15 and SEQ ID NO: 16, were used as the second primer pair for the above nested PCR amplification, more individuals were found to harbor EGFRvIII mutations (Table 1). EGFRvIII could be amplified from exosomes in the six patients who was identified as negatives with the old pair of primers EGFRvIII PCR2: SEQ ID NO: 13 AND SEQ ID NO: 14. Notably, exosomes from individual 13, whose biopsy did not show EGFRvIII mutation, was shown to contain EGFRvIII mutation, suggesting an increased sensitivity of EGFRvIII mutation detection using exosomes technology. From the exosomes isolated from 52 normal control serum samples, EGFRvIII could not be amplified (FIG. 12). Interestingly, two patients with an EGFRvIII negative tumor sample turned out to be EGFRvIII positive in the serum exosomes, supporting heterogeneous foci of EGFRvIII expression in the glioma tumor. Furthermore, our data also showed that intact RNAs in microvesicles were, unexpectedly,

able to be isolated from frozen bodily serum of glioblastoma patients. These blind serum samples from confirmed glioblastoma patients were obtained from the Cancer Research Center (VU medical center, Amsterdam, the Netherlands) and were kept at -80°C until use. The identification of tumor specific RNAs in serum microvesicles allows the detection of somatic mutations which are present in the tumor cells. Such technology should result in improved diagnosis and therapeutic decisions.

[00117] The RNA found in the microvesicles contains a “snapshot” of a substantial array of the cellular gene expression profile at a given time. Among the mRNA found in glioblastoma-derived microvesicles, the EGFR mRNA is of special interest since the EGFRvIII splice variant is specifically associated with glioblastomas (Nishikawa et al., 2004). Here it is demonstrated that brain tumors release microvesicles into the bloodstream across the blood-brain-barrier (BBB), which has not been shown before. It is further demonstrated that mRNA variants, such as EGFRvIII in brain tumors, are able to be detected by a method comprising the steps of isolating exosomes from a small amount of patient serum and analyzing the RNA in said microvesicles.

[00118] Knowledge of the EGFRvIII mutation in tumors is important in choosing an optimal treatment regimen. EGFRvIII-positive gliomas are over 50 times more likely to respond to treatment with EGFR-inhibitors like erlotinib or gefitinib (Mellinghoff et al., 2005).

Example 10: Diagnosis of iron metabolism disorders

[00119] The exosome diagnostics method can be adapted for other purposes as shown by the following example.

[00120] Heparin, an antimicrobial peptide, is the master hormonal regulator of iron metabolism. This peptide is produced mainly in mammalian liver and is controlled by the erythropoietic activity of the bone-marrow, the amount of circulating and stored body iron, and inflammation. Upon stimulation, heparin is secreted into the circulation or urine where it may act on target ferroportin-expressing cells. Ferroportin is the sole iron exporter identified to date and when bound to heparin, it is internalized and degraded. The resulting destruction of ferroportin leads to iron retention in ferroportin expressing cells such as macrophages and enterocytes. This pathophysiological mechanism underlies anemia of chronic diseases. More specifically, inappropriately high levels of heparin and elevated iron content within the reticuloendothelial system characterize anemia. Indeed, anemia may be

associated with many diseases and/or medical conditions such as infections (acute and chronic), cancer, autoimmune, chronic rejection after solid-organ transplantation, and chronic kidney disease and inflammation (Weiss and Goodnough, 2005). On the other hand, in a genetic iron overload disease such as hereditary hemochromatosis, inappropriately low expression levels of hepcidin encourage a potentially fatal excessive efflux of iron from within the reticuloendothelial system. So, hepcidin is up-regulated in anemia associated with chronic disease, but down-regulated in hemochromatosis.

[00121] Currently, there is no suitable assay to quantitatively measure hepcidin levels in circulation or urine (Kemna et al., 2008) except time-of-flight mass spectrometry (TOF MS), which needs highly specialized equipment, and therefore is not readily accessible. Recently, the method of Enzyme Linked ImmunoSorbent Assay (ELISA) has been proposed to quantitatively measure hepcidin hormone levels but this method is not consistent because of the lack of clear correlations with hepcidin (Kemna et al., 2005; Kemna et al., 2007) and other iron related parameters (Brookes et al., 2005; Roe et al., 2007).

[00122] Hepcidin mRNA was detected in exosomes from human serum, as follows. Exosomes were first isolated from human serum and their mRNA contents extracted before conversion to cDNA and PCR amplification. PCR primers were designed to amplify a 129 nucleotide fragment of human Hepcidin. The sequences of the primers are SEQ ID NO: 57 and SEQ ID NO: 58. A hepcidin transcript of 129 nucleotides (the middle peak in FIG. 13D) was readily detected by Bioanalyzer. As a positive control (FIG. 13B), RNA from a human hepatoma cell line Huh-7 was extracted and converted to cDNA. The negative control (FIG. 13C) is without mRNA. These Bioanalyzer data are also shown in the pseudogel in FIG. 13A.

[00123] Hepcidin mRNA in microvesicles in circulation correlates with hepcidin mRNA in liver cells. Hence, measuring hepcidin mRNA within microvesicles in a bodily fluid sample would allow one to diagnose or monitor anemia or hemochromatosis in the subject.

[00124] Thus, it is possible to diagnose and/or monitor anemia and hemochromatosis in a subject by isolating microvesicles from a bodily fluid and comparing the hepcidin mRNA in said microvesicles with the mRNA from from a normal subject. With an anemic subject, the copy number of mRNA is increased over the normal, non-anemic level. In a subject suffering from hemochromatosis, the copy number is decreased relative to the mRNA in a normal subject.

Example 11: Non-invasive transcriptional profiling of exosomes for diabetic nephropathy diagnosis

[00125] Diabetic nephropathy (DN) is a life threatening complication that currently lacks specific treatments. Thus, there is a need to develop sensitive diagnostics to identify patients developing or at risk of developing DN, enabling early intervention and monitoring.

[00126] Urine analysis provides a way to examine kidney function without having to take a biopsy. To date, this analysis has been limited to the study of protein in the urine. This Example sets forth a method to obtain from urine transcriptional profiles derived from cells that normally could only be obtained by kidney biopsy. Specifically, the method comprises the steps of isolating urine exosomes and analyzing the RNAs within said exosomes to obtain transcriptional profiles, which can be used to examine molecular changes being made by kidney cells in diabetic individuals and provide a 'snap shot' of any new proteins being made by the kidney. State-of-the-art technologies to obtain exosomal transcription profiles include, but are not limited to, contemporary hybridization arrays, PCR based technologies, and next generation sequencing methods. Since direct sequencing does not require pre-designed primers or spotted DNA oligos, it will provide a non-biased description of exosomal RNA profiles. An example of next generation sequencing technology is provided by the Illumina Genome Analyzer, which utilizes massively parallel sequencing technology which allows it to sequence the equivalent of 1/3 a human genome per run. The data obtainable from this analysis would enable one to rapidly and comprehensively examine the urinary exosomal transcriptional profile and allow comparison to the whole kidney. Using such a method, one could obtain much needed information regarding the transcription profile of urinary exosomes. A comparison of transcripts in control versus diabetes-derived urinary exosomes could further provide one with a comprehensive list of both predicted and new biomarkers for diabetic nephropathy.

[00127] In order to prove the feasibility of the diagnostic method described above, an experiment was designed and carried out to isolate urinary exosomes and to confirm the presence of renal specific biomarkers within these exosomes. In this experiment, a fresh morning urine sample of 220 ml was collected from a 28-year old healthy male subject and processed via differential centrifugation to isolate urinary exosomes. Specifically, urine was first spun at 300 x g spin for 10 minutes to remove any cells from the sample. The supernatant was collected and then underwent a 20-minute 16,500 x g spin to bring down any cell debris or protein aggregates. The supernatant was then passed through a 0.22 μ M

membrane filter to remove debris with diameters larger than 0.22 μ M. Finally, the sample underwent ultra-centrifugation at 100,000 x g for 1 hour to pellet the exosomes (They et al., 2006). The pellet was gently washed in phosphate buffered saline (PBS) and RNA was extracted using a Qiagen RNeasy kit pursuant to the manufacturer's instructions. The isolated RNA was converted to cDNA using the Omniscript RT kit (Qiagen) followed by PCR amplification of renal specific genes.

[00128] The renal specific genes examined and their corresponding renal area where the gene is expressed are as follows: AQP1 – proximal tubules; AQP2 – distal tubule (principal cells); CUBN – proximal tubules; LRP2 – proximal tubules; AVPR2 – proximal and distal tubules; SLC9A3 (NHE-3) - Proximal tubule; ATP6V1B1 – distal tubule (intercalated cells); NPHS1 – glomerulus (podocyte cells); NPHS2 – glomerulus (podocyte cells); and CLCN3 – Type B intercalated cells of collecting ducts. The sequences of the primers designed to amplify each gene are AQP1-F (SEQ ID NO: 17) and AQP1-R (SEQ ID NO: 18); AQP2-F (SEQ ID NO: 19) and AQP2-R (SEQ ID NO: 20); CUBN-F (SEQ ID NO: 21) and CUBN-R (SEQ ID NO: 22); LRP2-F (SEQ ID NO: 23) and LRP2-R (SEQ ID NO: 24); AVPR2-F (SEQ ID NO: 25) and AVPR2-R (SEQ ID NO: 26); SLC9A3-F (SEQ ID NO: 27) and SLC9A3-R (SEQ ID NO: 28); ATP6V1B1-F (SEQ ID NO: 29) and ATP6V1B1-R (SEQ ID NO: 30); NPHS1-F (SEQ ID NO: 31) and NPHS1-R (SEQ ID NO: 32); NPHS2-F (SEQ ID NO: 33) and NPHS2-R (SEQ ID NO: 34); CLCN5-F (SEQ ID NO: 35) and CLCN5-R (SEQ ID NO: 36).

[00129] The expected sizes of the PCR products for each gene are AQP1-226bp, AQP2-208bp, CUBN-285bp, LRP2-220bp, AVPR2-290bp, SLC9A3-200bp, ATP6V1B1-226bp, NPHS1-201bp, NPHS2-266bp and CLCN5-204bp. The PCR cycling protocol was 95 °C for 8 minutes; 95 °C for 30 seconds, 60 °C for 30 seconds, 72 °C for 45 seconds for 30 cycles; and a final step 72 °C for 10 minutes.

[00130] As shown in FIG. 14a, kidney tubule cells contain multivesicular bodies, which is an intermediate step during exosome generation. Exosomes isolated from these cells can be identified by electron microscopy (FIG. 14b). Analysis of total RNA extracted from urinary exosomes indicates the presence of RNA species with a broad range of sizes (FIG. 14c). 18S and 28S ribosomal RNAs were not found. PCR analysis confirmed the presence of renal specific transcripts within urinary exosomes (FIG. 14d). These data show that kidney cells shed exosomes into urine and these urinary exosomes contain transcripts of renal

origin, and that the exosome method can detect renal biomarkers associated with certain renal diseases and/or other medical conditions.

[00131] To further confirm the presence of renal specific mRNA transcripts in urinary exosomes, an independent set of experiments were performed using urine samples from six individuals. Exosomal nucleic acids were extracted from 200ml morning urine samples from each individual following a procedure as mentioned above. Specifically, urine samples underwent differential centrifugation starting with a 1000 ×g centrifugation to spin down whole cells and cell debris. The supernatant was carefully removed and centrifuged at 16,500 ×g for 20 minutes. The follow-on supernatant was then removed and filtered through a 0.8µm filter to remove residual debris from the exosome containing supernatant. The final supernatant then underwent ultracentrifugation at 100,000 ×g for 1hr 10min. The pellet was washed in nuclease free PBS and re-centrifuged at 100,000 ×g for 1hr 10min to obtain the exosomes pellet which is ready for nucleic acid extraction. Nucleic acids were extracted from the pelleted exosomes using the Arcturus PicoPure RNA Isolation kit and the nucleic acid concentration and integrity was analyzed using a Bioanalyzer (Agilent) Pico chip. As shown in FIG. 14e, nucleic acids isolated from urinary exosomes vary from individual to individual. To test whether the presence of renal biomarkers also varies from individual to individual, PCR amplifications were carried out for Aquaporin1, Aquaporin2 and Cubilin gene using a new set of primer pairs: AQP1 new primer pair: SEQ ID NO: 37 and SEQ ID NO: 38; AQP2 new primer pair: SEQ ID NO: 39 and SEQ ID NO: 40; CUBN new primer pair: SEQ ID NO: 41 and SEQ ID NO: 42. These primer pairs were designed specifically to amplify the spliced and reverse transcribed cDNA fragments. Reverse transcription was performed using the Qiagen Sensiscript kit. As shown in FIG. 14f, no amplification was seen in individual 1, probably due to failed nucleic acid extraction. AQP1 was amplified only in individual 2. CUBN was amplified in individual 2 and 3. And AQP2 was amplified in individual 2, 3, 4 and 5. In comparison actin gene (indicated by “House” in FIG. 14f) was amplified in individual 2, 3, 4, 5 and 6. These data provide more evidence that urinary exosomes contain renal specific mRNA transcripts although the expression levels are different between different individuals.

[00132] To test the presence of cDNAs in urinary exosomes, a 200ml human urine sample was split into two 100ml urine samples. Urinary exosomes were isolated from each sample. Exosomes from one sample were treated with DNase and those from the other sample were mock treated. Exosomes from each sample were then lysed for nucleic acid

extraction using PicoPure RNA isolation kit (Acturus). The nucleic acids were used as templates for nested-PCR amplification (PCR protocols described in Example 9) without prior reverse transcription. The primer pairs to amplify the actin gene were Actin-FOR (SEQ ID NO: 43) and Actin-REV (SEQ ID NO: 44); Actin-nest-FOR (SEQ ID NO: 45) and Actin-nest-REV (SEQ ID NO: 46) with an expected final amplicon of 100bp based on the actin gene cDNA sequence. As shown in FIG. 14g, the 100bp fragments were present in the positive control (human kidney cDNA as templates), DNase treated and non-treated exosomes, but absent in the negative control lane (without templates). Accordingly, actin cDNA is present in both the DNase treated and non-treated urinary exosomes.

[00133] To test whether most nucleic acids extracted using the method were present within exosomes, the nucleic acids extracted from the DNase treated and non-treated exosomes were dissolved in equal volumes and analyzed using a RNA Pico chip (Agilent Technologies). As shown in FIG. 14h, the concentration of the isolated nucleic acids from the DNase treated sample was 1,131 pg/ul and that from the non-treated sample was 1,378 pg/ul. Thus, more than 80% nucleic acids extracted from urinary exosomes using the above method were from inside exosomes.

[00134] To identify the content of urinary exosomes systematically, nucleic acids were extracted from urinary exosomes and submitted to the Broad Institute for sequencing. Approximately 14 million sequence reads were generated, each 76 nucleotides in length. These sequence reads correspond to fragments of DNA/RNA transcripts present within urinary exosomes. Using an extremely strict alignment parameter (100% identity over full length sequence), approximately 15% of the reads were aligned to the human genome. This percentage would likely increase if less stringent alignment criteria was used. A majority of these 15% reads did not align with protein coding genes but rather with non-coding genomic elements such as transposons and various LINE & SINE repeat elements. Notably, for those reads that are not aligned to the human genome, many are aligned to viral sequences. To the extent that the compositions and levels of nucleic acids contained in urinary exosomes change with respect to a disease status, profiles of the nucleic acids could be used according to the present methods as biomarkers for disease diagnosis.

[00135] This example demonstrates that the exosome method of analyzing urine exosomes can be used to determine cellular changes in the kidney in diabetes-related kidney disease without having to take a high-risk, invasive renal biopsy. The method provides a new and sensitive diagnostic tool using exosomes for early detection of kidney diseases such as

diabetic nephropathy. This will allow immediate intervention and treatment. In sum, the exosome diagnostic method and technology described herein provides a means of much-needed diagnostics for diabetic nephropathy and other diseases which are associated with certain profiles of nucleic acids contained in urinary exosomes.

Example 12: Prostate cancer diagnosis and urinary exosomes

[00136] Prostate cancer is the most common cancer in men today. The risk of prostate cancer is approximately 16%. More than 218,000 men in the United States were diagnosed in 2008. The earlier prostate cancer is detected, the greater are the chances of successful treatment. According to the American Cancer Society, if prostate cancers are found while they are still in the prostate itself or nearby areas, the five-year relative survival rate is over 98%.

[00137] One established diagnostic method is carried out by measuring the level of prostate specific antigen (PSA) in the blood, combined with a digital rectal examination. However, both the sensitivity and specificity of the PSA test requires significant improvement. This low specificity results in a high number of false positives, which generate numerous unnecessary and expensive biopsies. Other diagnostic methods are carried out by detecting the genetic profiles of newly identified biomarkers including, but not limited to, prostate cancer gene 3 (PCA3) (Groskopf et al., 2006; Nakanishi et al., 2008), a fusion gene between transmembrane protease serine 2 and ETS-related gene (TMPRSS2-ERG) (Tomlins et al., 2005), glutathione S-transferase pi (Goessl et al., 2000; Gonzalzo et al., 2004), and alpha-methylacyl CoA racemase (AMACR) (Zehentner et al., 2006; Zielie et al., 2004) in prostate cancer cells found in bodily fluids such as serum and urine (Groskopf et al., 2006; Wright and Lange, 2007). Although these biomarkers may give increased specificity due to overexpression in prostate cancer cells (e.g., PCA3 expression is increased 60- to 100-fold in prostate cancer cells), a digital rectal examination is required to milk prostate cells into the urine just before specimen collection (Nakanishi et al., 2008). Such rectal examinations have inherent disadvantages such as the bias on collecting those cancer cells that are easily milked into urine and the involvement of medical doctors which is costly and time consuming.

[00138] Here, a new method of detecting the genetic profiles of these biomarkers is proposed to overcome the limitation mentioned above. The method comprises the steps of isolating exosomes from a bodily fluid and analyzing the nucleic acid from said exosomes. The procedures of the method are similar to those detailed in Example 9. In this example, the

urine samples were from four diagnosed prostate cancer patients. As shown in FIG. 15c, the cancer stages were characterized in terms of grade, Gleason stage and PSA levels. In addition, the nucleic acids analyzed by nested-RT-PCR as detailed in Example 7 were TMPRSS2-ERG and PCA3, two of the newly identified biomarkers of prostate cancer. For amplification of TMPRSS2-ERG, the primer pair for the first amplification step was TMPRSS2-ERG F1 (SEQ ID NO: 47) and TMPRSS2-ERG R1 (SEQ ID NO: 48); and the primer pair for the second amplification step was TMPRSS2-ERG F2 (SEQ ID NO: 49) and TMPRSS2-ERG R2 (SEQ ID NO: 50). The expected amplicon is 122 base pairs (bp) and gives two fragments (one is 68 bp, the other is 54 bp) after digestion with the restriction enzyme HaeII. For amplification of PCA3, the primer pair for the first amplification step was PCA3 F1 (SEQ ID NO: 51) and PCA3 R1 (SEQ ID NO: 52); and the primer pair for the second amplification step was PCA3 F2 (SEQ ID NO: 53) and PCA3 R2 (SEQ ID NO: 54). The expected amplicon is 152 bp in length and gives two fragments (one is 90 bp, the other is 62 bp) after digestion with the restriction enzyme ScaI.

[00139] As shown in FIG. 15a, in both patient 1 and 2, but not in patient 3 and 4, the expected amplicon of TMPRSS2-ERG could be detected and digested into two fragments of expected sizes. As shown in FIG. 15b, in all four patients, the expected amplicon of PCA3 could be detected and digested into two fragments of expected sizes. Therefore, PCA3 expression could be detected in urine samples from all four patients, while TMPRSS2-ERG expression could only be detected in urine samples from patient 1 and 2 (FIG. 15c). These data, although not conclusive due to the small sample size, demonstrate the applicability of the new method in detecting biomarkers of prostate cancer. Further, the exosome method is not limited to diagnosis but can be employed for prognosis and/or monitoring other medical conditions related to prostate cancer.

Example 13: Microvesicles in non-invasive prenatal diagnosis

[00140] Prenatal diagnosis is now part of established obstetric practice all over the world. Conventional methods of obtaining fetal tissues for genetic analysis includes amniocentesis and chorionic villus sampling, both of which are invasive and confer risk to the unborn fetus. There is a long-felt need in clinical genetics to develop methods of non-invasive diagnosis. One approach that has been investigated extensively is based on the discovery of circulating fetal cells in maternal plasma. However, there are a number of barriers that hinder its application in clinical settings. Such barriers include the scarcity of fetal cells (only 1.2 cells/ml maternal blood), which requires relatively large volume blood

samples, and the long half life of residual fetal cells from previous pregnancy, which may cause false positives. Another approach is based on the discovery of fetal DNA in maternal plasma. Sufficient fetal DNA amounts and short clearance time overcome the barriers associated with the fetal cell method. Nevertheless, DNA only confers inheritable genetic and some epigenetic information, both of which may not represent the dynamic gene expression profiles that are linked to fetal medical conditions. The discovery of circulating fetal RNA in maternal plasma (Ng et al., 2003b; Wong et al., 2005) may be the method of choice for non-invasive prenatal diagnosis.

[00141] Several studies suggest that fetal RNAs are of high diagnostic value. For example, elevated expression of fetal corticotropin-releasing hormone (CRH) transcript is associated with pre-eclampsia (a clinical condition manifested by hypertension, edema and proteinuria) during pregnancy (Ng et al., 2003a). In addition, the placenta-specific 4 (PLAC4) mRNA in maternal plasma was successfully used in a non-invasive test for aneuploid pregnancy (such as trisomy 21, Down syndrome) (Lo et al., 2007). Furthermore, fetal human chorionic gonadotropin (hCG) transcript in maternal plasma may be a marker of gestational trophoblastic diseases (GTDs), which is a tumorous growth of fetal tissues in a maternal host. Circulating fetal RNAs are mainly of placenta origin (Ng et al., 2003b). These fetal RNAs can be detected as early as the 4th week of gestation and such RNA is cleared rapidly postpartum.

[00142] Prenatal diagnosis using circulating fetal RNAs in maternal plasma, nevertheless, has several limitations. The first limitation is that circulating fetal RNA is mixed with circulating maternal RNA and is not effectively separable. Currently, fetal transcripts are identified, based on an assumption, as those that are detected in pregnant women antepartum as well as in their infant's cord blood, yet are significantly reduced or absent in maternal blood within 24 or 36 hours postpartum (Maron et al., 2007). The second limitation is that no method is established to enrich the circulating fetal RNA for enhanced diagnostic sensitivity since it is still unknown how fetal RNA is packaged and released. The way to overcome these limitations may lie in the isolation of microvesicles and the analysis of the fetal RNAs therein.

[00143] Several facts suggest that microvesicles, which are shed by eukaryotic cells, are the vehicles for circulating fetal RNAs in maternal plasma. First, circulating RNAs within microvesicles are protected from RNase degradation. Second, circulating fetal RNAs have been shown to remain in the non-cellular fraction of maternal plasma, which is consistent

with the notion that microvesicles encompassing these fetal RNAs are able to be filtered through 0.22 um membrane. Third, similar to tumorous tissues which are know to shed microvesicles, placental cells, which are a pseudo-malignant fetal tissue, are most likely capable of shedding microvesicles. Thus, a novel method of non-invasive prenatal diagnosis is comprised of isolating fetal microvesicles from maternal blood plasma and then analyzing the nucleic acids within the microvesicles for any genetic variants associated with certain diseases and/or other medical conditions.

[00144] A hypothetical case of non-invasive prenatal diagnosis is as follows: peripheral blood samples are collected from pregnant women and undergo magnetic activated cell sorting (MACS) or other affinity purification to isolate and enrich fetus-specific microvesicles. The microvesicular pellet is resuspended in PBS and used immediately or stored at -20°C for further processing. RNA is extracted from the isolated microvesicles using the Qiagen RNA extraction kit as per the manufacturer's instructions. RNA content is analyzed for the expression level of fetal human chorionic gonadotropin (hCG) transcript. An increased expression level of hCG compared to the standard range points to the development of gestational trophoblastic diseases (GTDs) and entail further the need for clinical treatment for this abnormal growth in the fetus. The sensitivity of microvesicle technology makes it possible to detect the GTDs at a very early stage before any symptomatic manifestation or structural changes become detectable under ultrasonic examination. The standard range of hCG transcript levels may be determined by examining a statistically significant number of circulating fetal RNA samples from normal pregnancies.

[00145] This prenatal diagnostic method may be extrapolated to the prenatal diagnosis and/or monitoring of other diseases or medical conditions by examining those transcripts associated with these diseases or medical conditions. For example, extraction and analysis of anaplastic lymphoma kinase (ALK) nucleic acid from microvesicles of fetus origin from maternal blood is a non-invasive prenatal diagnosis of neuroblastoma, which is closely associated with mutations within the kinase domain or elevated expression of *ALK* (Mosse et al., 2008). Accordingly, the microvesicle methods and technology described herein may lead to a new era of much-needed, non-invasive prenatal genetic diagnosis.

Example 14: Melanoma diagnosis

[00146] Melanoma is a malignant tumor of melanocytes (pigment cells) and is found predominantly in skin. It is a serious form of skin cancer and accounts for 75 percent of all deaths associated with skin cancer. Somatic activating mutations (e.g. V600E) of BRAF are the earliest and most common genetic abnormality detected in the genesis of human melanoma. Activated BRAF promotes melanoma cell cycle progression and/or survival.

[00147] Currently, the diagnosis of melanoma is made on the basis of physical examination and excisional biopsy. However, a biopsy can sample only a limited number of foci within the lesion and may give false positives or false negatives. The exosome method provides a more accurate means for diagnosing melanoma. As discussed above, the method is comprised of the steps of isolating exosomes from a bodily fluid of a subject and analyzing the nucleic acid from said exosomes.

[00148] To determine whether exosomes shed by melanoma cells contain BRAF mRNA, we cultured primary melanoma cells in DMEM media supplemented with exosome-depleted FBS and harvested the exosomes in the media using a similar procedure as detailed in Example 2. The primary cell lines were Yumel and M34. The Yumel cells do not have the V600E mutation in BRAF, while M34 cells have the V600E mutation in BRAF. RNAs were extracted from the exosomes and then analyzed for the presence of BRAF mRNA by RT-PCR. The primers used for PCR amplification were: BRAF forward (SEQ ID NO: 55) and BRAF reverse (SEQ ID NO: 56). The amplicon is 118 base pairs (bp) long and covers the part of BRAF cDNA sequence where the V600E mutation is located. As shown in FIG. 16a, a band of 118 bp was detected in exosomes from primary melanoma cells (Yumel and M34 cells), but not in exosomes from human fibroblast cells or negative controls. The negative detection of a band of 118 bp PCR product is not due to a mistaken RNA extraction since GAPDH transcripts could be detected in exosomes from both melanoma cell and human fibroblast cells (FIG. 16b). The 118 bp PCR products were further sequenced to detect the V600E mutation. As shown in FIGS. 16c and 16d, PCR products from YUMEL cells, as expected, contain wild type BRAF mRNA. In contrast, PCR products from M34 cells, as expected, contain mutant BRAF mRNA with a T-A point mutation, which causes the amino acid Valine (V) to be replaced by Glutamic acid (E) at the amino acid position 600 of the BRAF protein. Furthermore, BRAF mRNA cannot be detected in exosomes from normal human fibroblast cells, suggesting the BRAF mRNA is not contained in exosomes of all tissue origins.

[00149] These data suggest that melanoma cells shed exosomes into the blood circulation and thus melanoma can be diagnosed by isolating these exosomes from blood serum and analyzing the nucleic acid therefrom for the presence or absence of mutations (e.g., V600E) in BRAF. The method described above can also be employed to diagnose melanomas that are associated with other BRAF mutations and mutations in other genes. The method can also be employed to diagnose melanomas that are associated with the expression profiles of BRAF and other nucleic acids.

Example 15: Detection of MMP levels from exosomes to monitor post transplantation conditions.

[00150] Organ transplants are usually effective treatments for organ failures. Kidney failure, heart disease, end-stage lung disease and cirrhosis of the liver are all conditions that can be effectively treated by a transplant. However, organ rejections caused by post-transplantation complications are major obstacles for long-term survival of the allograft recipients. For example, in lung transplantations, bronchiolitis obliterans syndrome is a severe complication affecting survival rates. In kidney transplants, chronic allograft nephropathy remains one of the major causes of renal allograft failure. Ischemia-reperfusion injury damages the donor heart after heart transplantation, as well as the donor liver after orthotopic liver transplantation. These post-transplantation complications may be ameliorated once detected at early stages. Therefore, it is essential to monitor post-transplantation conditions in order to alleviate adverse complications.

[00151] Alterations in the extracellular matrix contribute to the interstitial remodeling in post-transplantation complications. Matrix metalloproteinases (MMPs) are involved in both the turnover and degradation of extracellular matrix (ECM) proteins. MMPs are a family of proteolytic, zinc-dependent enzymes, with 27 members described to date, displaying multidomain structures and substrate specificities, and functioning in the processing, activation, or deactivation of a variety of soluble factors. Serum MMP levels may indicate the status of post-transplantation conditions. Indeed, circulating MMP-2 is associated with cystatin C, post-transplant duration, and diabetes mellitus in kidney transplant recipients (Chang et al., 2008). Disproportional expression of MMP-9 is linked to the development of bronchiolitis obliterans syndrome after lung transplantation (Hubner et al., 2005).

[00152] MMP mRNAs (MMP1, 8, 12, 15, 20, 21, 24, 26 and 27) can be detected in exosomes shed by glioblastoma cells as shown in Example 4 and Table 10. The present

exosome method, isolating exosomes from a bodily fluid and analyzing nucleic acids from said exosomes, can be used to monitor transplantation conditions. The exosome isolation procedure is similar to that detailed in Example 2. The present procedures to analyze nucleic acid contained within exosomes are detailed in Example 9. A significant increase in the expression level of MMP-2 after kidney transplantation will indicate the onset and/or deterioration of post-transplantation complications. Similarly, a significantly elevated level of MMP-9 after lung transplantation, suggests the onset and/or deterioration of bronchiolitis obliterans syndrome.

[00153] Therefore, the exosome method can be used to monitor post-transplantation conditions by determining the expression levels of MMP proteins associated with post-transplantation complications. It is also expected that the method can be extrapolated to monitor post-transplantation conditions by determining the expression of other marker genes as well as monitor other medical conditions by determining the genetic profile of nucleic acids associated with these medical conditions.

Examples 16-18. Microvesicles can be therapeutic agents or delivery vehicles of therapeutic agents.

Example 16: Microvesicle proteins induce angiogenesis in vitro.

[00154] A study was designed and carried out to demonstrate glioblastoma microvesicles contribute to angiogenesis. HBMVECs (30,000 cells), a brain endothelial cell line, (Cell Systems, Catalogue #ACBRI-376, Kirkland, WA, USA) were cultured on Matrigel-coated wells in a 24-well plate in basal medium only (EBM) (Lonza Biologics Inc., Portsmouth, NH, USA), basal medium supplemented with glioblastoma microvesicles (EBM+ MV) (7 µg/well), or basal medium supplemented with a cocktail of angiogenic factors (EGM; hydrocortisone, EGF, FGF, VEGF, IGF, ascorbic acid, FBS, and heparin; Singlequots (EBM positive control). Tubule formation was measured after 16 hours and analyzed with the Image J software. HBMVECs cultured in the presence of glioblastoma microvesicles demonstrated a doubling of tubule length within 16 hours. The result was comparable to the result obtained with HBMCECs cultured in the presence of angiogenic factors (FIG. 18a). These results show that glioblastoma-derived microvesicles play a role in initiating angiogenesis in brain endothelial cells.

[00155] Levels of angiogenic proteins in microvesicles were also analyzed and compared with levels in glioblastoma donor cells. Using a human angiogenesis antibody

array, we were able to detect 19 proteins involved in angiogenesis. Specifically, total protein from either primary glioblastoma cells or purified microvesicles isolated from said cells were lysed in lysis buffer (Promega, Madison, WI, USA) and added to the human angiogenesis antibody array (Panomics, Fremont CA, USA) according to manufacturer's recommendations. The arrays were scanned and analyzed with the Image J software. As shown in FIG. 18b, of the seven of the 19 angiogenic proteins were readily detected in the microvesicles, 6 (angiogenin, IL-6, IL-8, TIMP-I, VEGF and TIMP-2) were present at higher levels on a total protein basis as compared to the glioblastoma cells (FIG. 18c). The three angiogenic proteins most enriched in microvesicles compared to tumor cells were angiogenin, IL-6 and IL-8, all of which have been implicated in glioma angiogenesis with higher levels associated with increased malignancy (25-27).

[00156] Microvesicles isolated from primary glioblastoma cells were also found to promote proliferation of a human U87 glioma cell line. In these studies, 100 000 U87 cells were seeded in wells of a 24-well plate and allowed to grow for three days (DMEM-5%FBS) or DMEM-5%FBS supplemented with 125 μ g microvesicles isolated from primary glioblastoma cells. After three days, untreated U87 cells (FIG. 19a) were found to be fewer in number as determined using a Burker chamber, than those supplemented with microvesicles (FIG. 19b). Both non-supplemented and supplemented U87 cells had increased 5-and 8-fold in number over this period, respectively (FIG. 19c). Thus, glioblastoma microvesicles appear to stimulate proliferation of other glioma cells.

Example 17: Glioblastoma microvesicles are taken up by HBMVECs.

[00157] To demonstrate that glioblastoma microvesicles are able to be taken up by human brain microvesicular endothelial cells (HBMVECs), purified glioblastoma microvesicles were labeled with PKH67 Green Fluorescent labeling kit (Sigma-Aldrich, St Louis, MO, USA). The labeled microvesicles were incubated with HBMVEC in culture (5 μ g/50,000 cells) for 20 min at 4°C. The cells were washed and incubated at 37°C for 1 hour. Within 30 min the PKH67-labeled microvesicles were internalized into endosome-like structures within the HBMVECs (FIG. 17a). These results show that glioblastoma microvesicles can be internalized by brain endothelial cells.

[00158] Similar results were obtained when adding the fluorescently labeled microvesicles to primary glioblastoma cells.

Example 18: mRNA delivered by glioblastoma microvesicles can be translated in recipient cells.

[00159] To determine whether glioblastoma-derived microvesicles mRNA could be delivered to and expressed in recipient cells, primary human glioblastoma cells were infected with a self-inactivating lentivirus vector expressing secreted Gaussia luciferase (*Gluc*) using a CMV promoter at an infection efficiency of >95%. The cells were stably transduced and generated microvesicles during the subsequent passages (2-10 passages were analyzed). Microvesicles were isolated from the cells and purified as described above. RT-PCR analysis showed that the mRNA for *Gluc* (555 bp) as well as GAPDH (226 bp) were present in the microvesicles (FIG. 17b). The level of *Gluc* mRNA was even higher than that for GAPDH as evaluated with quantitative RT-PCR.

[00160] Fifty micrograms of the purified microvesicles were added to 50,000 HBMVE cells and incubated for 24 hrs. The *Gluc* activity in the supernatant was measured directly after microvesicle addition (0 hrs), and after 15 hrs and 24 hrs. The *Gluc* activity in the supernatant was normalized to the *Gluc* protein activity associated with the microvesicles. The results are presented as the mean \pm SEM (n=4). Specifically, the activity in the recipient HBMVE cells demonstrated a continual translation of the microvesicular *Gluc* mRNA. Thus, mRNA incorporated into the tumor microvesicles can be delivered into recipient cells and generate a functional protein.

[00161] The statistical analyses in all examples were performed using the Student's t-test.

References

1. Abnavaya, K., J.J. Carrino, S. Muldoon, and H.H. Lee. 1995. Detection of point mutations with a modified ligase chain reaction (Gap-LCR). *Nucleic Acids Res.* 23:675-82.
2. Al-Nedawi, K., B. Meehan, J. Micallef, V. Lhotak, L. May, A. Guha, and J. Rak. 2008. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nat Cell Biol.* 10:619-24.
3. Baj-Krzyworzeka, M., R. Szatanek, K. Weglarczyk, J. Baran, B. Urbanowicz, P. Branski, M.Z. Ratajczak, and M. Zembala. 2006. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. *Cancer Immunol Immunother.* 55:808-18.

4. Balzar, M., M.J. Winter, C.J. de Boer, and S.V. Litvinov. 1999. The biology of the 17-1A antigen (Ep-CAM). *J Mol Med.* 77:699-712.
5. Booth, A.M., Y. Fang, J.K. Fallon, J.M. Yang, J.E. Hildreth, and S.J. Gould. 2006. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. *J Cell Biol.* 172:923-35.
6. Bossi, A., F. Bonini, A.P. Turner, and S.A. Piletsky. 2007. Molecularly imprinted polymers for the recognition of proteins: the state of the art. *Biosens Bioelectron.* 22:1131-7.
7. Brookes, M.J., N.K. Sharma, C. Tselepis, and T.H. Iqbal. 2005. Serum pro-hepcidin: measuring active hepcidin or a non-functional precursor? *Gut.* 54:169-70.
8. Carmeliet, P., and R.K. Jain. 2000. Angiogenesis in cancer and other diseases. *Nature.* 407:249-57.
9. Carpenter, G. 1987. Receptors for epidermal growth factor and other polypeptide mitogens. *Annu Rev Biochem.* 56:881-914.
10. Chang, H.R., W.H. Kuo, Y.S. Hsieh, S.F. Yang, C.C. Lin, M.L. Lee, J.D. Lian, and S.C. Chu. 2008. Circulating matrix metalloproteinase-2 is associated with cystatin C level, posttransplant duration, and diabetes mellitus in kidney transplant recipients. *Transl Res.* 151:217-23.
11. Chaput, N., J. Taieb, F. Andre, and L. Zitvogel. 2005. The potential of exosomes in immunotherapy. *Expert Opin Biol Ther.* 5:737-47.
12. Cheruvanky, A., H. Zhou, T. Pisitkun, J.B. Kopp, M.A. Knepper, P.S. Yuen, and R.A. Star. 2007. Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. *Am J Physiol Renal Physiol.* 292:F1657-61.
13. Clayton, A., J.P. Mitchell, J. Court, M.D. Mason, and Z. Tabi. 2007. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. *Cancer Res.* 67:7458-66.
14. Cotton, R.G., N.R. Rodrigues, and R.D. Campbell. 1988. Reactivity of cytosine and thymine in single-base-pair mismatches with hydroxylamine and osmium tetroxide and its application to the study of mutations. *Proc Natl Acad Sci U S A.* 85:4397-401.

15. Delves, G.H., A.B. Stewart, A.J. Cooper, and B.A. Lwaleed. 2007. Prostatomes, angiogenesis, and tissue factor. *Semin Thromb Hemost.* 33:75-9.
16. Diehl, F., K. Schmidt, M.A. Choti, K. Romans, S. Goodman, M. Li, K. Thornton, N. Agrawal, L. Sokoll, S.A. Szabo, K.W. Kinzler, B. Vogelstein, and L.A. Diaz, Jr. 2008. Circulating mutant DNA to assess tumor dynamics. *Nat Med.* 14:985-90.
17. Fiorentino, F., M.C. Magli, D. Podini, A.P. Ferraretti, A. Nuccitelli, N. Vitale, M. Baldi, and L. Gianaroli. 2003. The minisequencing method: an alternative strategy for preimplantation genetic diagnosis of single gene disorders. *Mol Hum Reprod.* 9:399-410.
18. Fischer, S.G., and L.S. Lerman. 1979a. Length-independent separation of DNA restriction fragments in two-dimensional gel electrophoresis. *Cell.* 16:191-200.
19. Fischer, S.G., and L.S. Lerman. 1979b. Two-dimensional electrophoretic separation of restriction enzyme fragments of DNA. *Methods Enzymol.* 68:183-91.
20. Furnari, F.B., T. Fenton, R.M. Bachoo, A. Mukasa, J.M. Stommel, A. Stegh, W.C. Hahn, K.L. Ligon, D.N. Louis, C. Brennan, L. Chin, R.A. DePinho, and W.K. Cavenee. 2007. Malignant astrocytic glioma: genetics, biology, and paths to treatment. *Genes Dev.* 21:2683-710.
21. Gabrilovich, D.I. 2007. Molecular mechanisms and therapeutic reversal of immune suppression in cancer. *Curr Cancer Drug Targets.* 7:1.
22. Geiss, G.K., R.E. Bumgarner, B. Birditt, T. Dahl, N. Dowidar, D.L. Dunaway, H.P. Fell, S. Ferree, R.D. George, T. Grogan, J.J. James, M. Maysuria, J.D. Mitton, P. Oliveri, J.L. Osborn, T. Peng, A.L. Ratcliffe, P.J. Webster, E.H. Davidson, and L. Hood. 2008. Direct multiplexed measurement of gene expression with color-coded probe pairs. *Nat Biotechnol.* 26:317-25.
23. Goessl, C., H. Krause, M. Muller, R. Heicappell, M. Schrader, J. Sachsinger, and K. Miller. 2000. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. *Cancer Res.* 60:5941-5.
24. Gonzalgo, M.L., M. Nakayama, S.M. Lee, A.M. De Marzo, and W.G. Nelson. 2004. Detection of GSTP1 methylation in prostatic secretions using combinatorial MSP analysis. *Urology.* 63:414-8.

25. Gormally, E., E. Caboux, P. Vineis, and P. Hainaut. 2007. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. *Mutat Res.* 635:105-17.
26. Greco, V., M. Hannus, and S. Eaton. 2001. Argosomes: a potential vehicle for the spread of morphogens through epithelia. *Cell.* 106:633-45.
27. Groskopf, J., S.M. Aubin, I.L. Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, J. Mathis, J. Pham, T. Meyer, M. Cass, P. Hodge, M.L. Macairan, L.S. Marks, and H. Rittenhouse. 2006. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. *Clin Chem.* 52:1089-95.
28. Guatelli, J.C., K.M. Whitfield, D.Y. Kwoh, K.J. Barringer, D.D. Richman, and T.R. Gingeras. 1990. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. *Proc Natl Acad Sci U S A.* 87:1874-8.
29. Hahn, P.J. 1993. Molecular biology of double-minute chromosomes. *Bioessays.* 15:477-84.
30. Hubner, R.H., S. Meffert, U. Mundt, H. Bottcher, S. Freitag, N.E. El Mokhtari, T. Pufe, S. Hirt, U.R. Folsch, and B. Bewig. 2005. Matrix metalloproteinase-9 in bronchiolitis obliterans syndrome after lung transplantation. *Eur Respir J.* 25:494-501.
31. Janowska-Wieczorek, A., M. Wysoczynski, J. Kijowski, L. Marquez-Curtis, B. Machalinski, J. Ratajczak, and M.Z. Ratajczak. 2005. Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. *Int J Cancer.* 113:752-60.
32. Johnson, S., D. Evans, S. Laurensen, D. Paul, A.G. Davies, P.K. Ferrigno, and C. Walti. 2008. Surface-immobilized peptide aptamers as probe molecules for protein detection. *Anal Chem.* 80:978-83.
33. Jones, S., X. Zhang, D.W. Parsons, J.C. Lin, R.J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, S.M. Hong, B. Fu, M.T. Lin, E.S. Calhoun, M. Kamiyama, K. Walter, T. Nikolskaya, Y. Nikolsky, J. Hartigan, D.R. Smith, M. Hidalgo, S.D. Leach, A.P. Klein, E.M. Jaffee, M. Goggins, A. Maitra, C. Iacobuzio-Donahue, J.R. Eshleman, S.E. Kern, R.H. Hruban, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V.E. Velculescu, and K.W. Kinzler. 2008. Core Signaling

- Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. *Science*.
34. Kan, Y.W., and A.M. Dozy. 1978a. Antenatal diagnosis of sickle-cell anaemia by D.N.A. analysis of amniotic-fluid cells. *Lancet*. 2:910-2.
 35. Kan, Y.W., and A.M. Dozy. 1978b. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. *Proc Natl Acad Sci U S A*. 75:5631-5.
 36. Keller, S., C. Rupp, A. Stoeck, S. Runz, M. Fogel, S. Lugert, H.D. Hager, M.S. Abdel-Bakky, P. Gutwein, and P. Altevogt. 2007. CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int*. 72:1095-102.
 37. Kemna, E., P. Pickkers, E. Nemeth, H. van der Hoeven, and D. Swinkels. 2005. Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. *Blood*. 106:1864-6.
 38. Kemna, E.H., H. Tjalsma, V.N. Podust, and D.W. Swinkels. 2007. Mass spectrometry-based hepcidin measurements in serum and urine: analytical aspects and clinical implications. *Clin Chem*. 53:620-8.
 39. Kemna, E.H., H. Tjalsma, H.L. Willems, and D.W. Swinkels. 2008. Hepcidin: from discovery to differential diagnosis. *Haematologica*. 93:90-7.
 40. Kislauskis, E.H., X. Zhu, and R.H. Singer. 1994. Sequences responsible for intracellular localization of beta-actin messenger RNA also affect cell phenotype. *J Cell Biol*. 127:441-51.
 41. Kwoh, D.Y., G.R. Davis, K.M. Whitfield, H.L. Chappelle, L.J. DiMichele, and T.R. Gingeras. 1989. Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. *Proc Natl Acad Sci U S A*. 86:1173-7.
 42. Landegren, U., R. Kaiser, J. Sanders, and L. Hood. 1988. A ligase-mediated gene detection technique. *Science*. 241:1077-80.
 43. Li, J., L. Wang, H. Mamon, M.H. Kulke, R. Berbeco, and G.M. Makrigiorgos. 2008. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. *Nat Med*. 14:579-84.

44. Liu, C., S. Yu, K. Zinn, J. Wang, L. Zhang, Y. Jia, J.C. Kappes, S. Barnes, R.P. Kimberly, W.E. Grizzle, and H.G. Zhang. 2006a. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. *J Immunol.* 176:1375-85.
45. Liu, Q., J.C. Greimann, and C.D. Lima. 2006b. Reconstitution, activities, and structure of the eukaryotic RNA exosome. *Cell.* 127:1223-37.
46. Lo, Y.M., N.B. Tsui, R.W. Chiu, T.K. Lau, T.N. Leung, M.M. Heung, A. Gerovassili, Y. Jin, K.H. Nicolaidis, C.R. Cantor, and C. Ding. 2007. Plasma placental RNA allelic ratio permits noninvasive prenatal chromosomal aneuploidy detection. *Nat Med.* 13:218-23.
47. Louis, D.N., H. Ohgaki, O.D. Wiestler, W.K. Cavenee, P.C. Burger, A. Jouvett, B.W. Scheithauer, and P. Kleihues. 2007. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 114:97-109.
48. Mack, M., A. Kleinschmidt, H. Bruhl, C. Klier, P.J. Nelson, J. Cihak, J. Plachy, M. Stangassinger, V. Erfle, and D. Schlondorff. 2000. Transfer of the chemokine receptor CCR5 between cells by membrane-derived microparticles: a mechanism for cellular human immunodeficiency virus 1 infection. *Nat Med.* 6:769-75.
49. Mallardo, M., A. Deitinghoff, J. Muller, B. Goetze, P. Macchi, C. Peters, and M.A. Kiebler. 2003. Isolation and characterization of Staufen-containing ribonucleoprotein particles from rat brain. *Proc Natl Acad Sci U S A.* 100:2100-5.
50. Maron, J.L., K.L. Johnson, D. Slonim, C.Q. Lai, M. Ramoni, G. Alterovitz, Z. Jarrah, Z. Yang, and D.W. Bianchi. 2007. Gene expression analysis in pregnant women and their infants identifies unique fetal biomarkers that circulate in maternal blood. *J Clin Invest.* 117:3007-19.
51. Mazzocca, A., R. Coppari, R. De Franco, J.Y. Cho, T.A. Libermann, M. Pinzani, and A. Toker. 2005. A secreted form of ADAM9 promotes carcinoma invasion through tumor-stromal interactions. *Cancer Res.* 65:4728-38.
52. McLendon, R., A. Friedman, D. Bigner, E.G. Van Meir, D.J. Brat, G. Marie Mastrogiannakis, J.J. Olson, T. Mikkelsen, N. Lehman, K. Aldape, W.K. Alfred Yung, O. Bogler, S. Vandenberg, M. Berger, M. Prados, D. Muzny, M. Morgan, S. Scherer, A. Sabo, L. Nazareth, L. Lewis, O. Hall, Y. Zhu, Y. Ren, O. Alvi, J. Yao, A. Hawes,

- S. Jhangiani, G. Fowler, A. San Lucas, C. Kovar, A. Cree, H. Dinh, J. Santibanez, V. Joshi, M.L. Gonzalez-Garay, C.A. Miller, A. Milosavljevic, L. Donehower, D.A. Wheeler, R.A. Gibbs, K. Cibulskis, C. Sougnez, T. Fennell, S. Mahan, J. Wilkinson, L. Ziaugra, R. Onofrio, T. Bloom, R. Nicol, K. Ardlie, J. Baldwin, S. Gabriel, E.S. Lander, L. Ding, R.S. Fulton, M.D. McLellan, J. Wallis, D.E. Larson, X. Shi, R. Abbott, L. Fulton, K. Chen, D.C. Koboldt, M.C. Wendl, R. Meyer, Y. Tang, L. Lin, J.R. Osborne, B.H. Dunford-Shore, T.L. Miner, K. Delehaunty, C. Markovic, G. Swift, W. Courtney, C. Pohl, S. Abbott, A. Hawkins, S. Leong, C. Haipek, H. Schmidt, M. Wiechert, T. Vickery, S. Scott, D.J. Dooling, A. Chinwalla, G.M. Weinstock, E.R. Mardis, R.K. Wilson, G. Getz, W. Winckler, R.G. Verhaak, M.S. Lawrence, M. O'Kelly, J. Robinson, G. Alexe, R. Beroukhim, S. Carter, D. Chiang, J. Gould, et al. 2008. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature*.
53. Mellinshoff, I.K., M.Y. Wang, I. Vivanco, D.A. Haas-Kogan, S. Zhu, E.Q. Dia, K.V. Lu, K. Yoshimoto, J.H. Huang, D.J. Chute, B.L. Riggs, S. Horvath, L.M. Liau, W.K. Cavenee, P.N. Rao, R. Beroukhim, T.C. Peck, J.C. Lee, W.R. Sellers, D. Stokoe, M. Prados, T.F. Cloughesy, C.L. Sawyers, and P.S. Mischel. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. *N Engl J Med*. 353:2012-24.
54. Miele, E.A., D.R. Mills, and F.R. Kramer. 1983. Autocatalytic replication of a recombinant RNA. *J Mol Biol*. 171:281-95.
55. Millimaggi, D., M. Mari, S. D'Ascenzo, E. Carosa, E.A. Jannini, S. Zucker, G. Carta, A. Pavan, and V. Dolo. 2007. Tumor vesicle-associated CD147 modulates the angiogenic capability of endothelial cells. *Neoplasia*. 9:349-57.
56. Mosse, Y.P., M. Laudenslager, L. Longo, K.A. Cole, A. Wood, E.F. Attiyeh, M.J. Laquaglia, R. Sennett, J.E. Lynch, P. Perri, G. Laureys, F. Speleman, C. Kim, C. Hou, H. Hakonarson, A. Torkamani, N.J. Schork, G.M. Brodeur, G.P. Tonini, E. Rappaport, M. Devoto, and J.M. Maris. 2008. Identification of ALK as a major familial neuroblastoma predisposition gene. *Nature*.
57. Muerkoster, S., K. Wegehenkel, A. Arlt, M. Witt, B. Sipos, M.L. Kruse, T. Sebens, G. Kloppel, H. Kalthoff, U.R. Folsch, and H. Schafer. 2004. Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased

- secretion and paracrine effects of nitric oxide and interleukin-1beta. *Cancer Res.* 64:1331-7.
58. Myers, R.M., Z. Larin, and T. Maniatis. 1985. Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes. *Science.* 230:1242-6.
59. Nagrath, S., L.V. Sequist, S. Maheswaran, D.W. Bell, D. Irimia, L. Ulkus, M.R. Smith, E.L. Kwak, S. Digumarthy, A. Muzikansky, P. Ryan, U.J. Balis, R.G. Tompkins, D.A. Haber, and M. Toner. 2007. Isolation of rare circulating tumour cells in cancer patients by microchip technology. *Nature.* 450:1235-9.
60. Nakanishi, H., J. Groskopf, H.A. Fritsche, V. Bhadkamkar, A. Blase, S.V. Kumar, J.W. Davis, P. Troncoso, H. Rittenhouse, and R.J. Babaian. 2008. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. *J Urol.* 179:1804-9; discussion 1809-10.
61. Nakazawa, H., D. English, P.L. Randell, K. Nakazawa, N. Martel, B.K. Armstrong, and H. Yamasaki. 1994. UV and skin cancer: specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. *Proc Natl Acad Sci U S A.* 91:360-4.
62. Ng, E.K., T.N. Leung, N.B. Tsui, T.K. Lau, N.S. Panesar, R.W. Chiu, and Y.M. Lo. 2003a. The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia. *Clin Chem.* 49:727-31.
63. Ng, E.K., N.B. Tsui, T.K. Lau, T.N. Leung, R.W. Chiu, N.S. Panesar, L.C. Lit, K.W. Chan, and Y.M. Lo. 2003b. mRNA of placental origin is readily detectable in maternal plasma. *Proc Natl Acad Sci U S A.* 100:4748-53.
64. Nishikawa, R., T. Sugiyama, Y. Narita, F. Furnari, W.K. Cavenee, and M. Matsutani. 2004. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. *Brain Tumor Pathol.* 21:53-6.
65. Orita, M., H. Iwahana, H. Kanazawa, K. Hayashi, and T. Sekiya. 1989. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. *Proc Natl Acad Sci U S A.* 86:2766-70.
66. Pan, B.T., and R.M. Johnstone. 1983. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. *Cell.* 33:967-78.

67. Parsons, D.W., S. Jones, X. Zhang, J.C. Lin, R.J. Leary, P. Angenendt, P. Mankoo, H. Carter, I.M. Siu, G.L. Gallia, A. Olivi, R. McLendon, B.A. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D.A. Busam, H. Tekleab, L.A. Diaz, Jr., J. Hartigan, D.R. Smith, R.L. Strausberg, S.K. Marie, S.M. Shinjo, H. Yan, G.J. Riggins, D.D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V.E. Velculescu, and K.W. Kinzler. 2008. An Integrated Genomic Analysis of Human Glioblastoma Multiforme. *Science*.
68. Pelloski, C.E., K.V. Ballman, A.F. Furth, L. Zhang, E. Lin, E.P. Sulman, K. Bhat, J.M. McDonald, W.K. Yung, H. Colman, S.Y. Woo, A.B. Heimberger, D. Suki, M.D. Prados, S.M. Chang, F.G. Barker, 2nd, J.C. Buckner, C.D. James, and K. Aldape. 2007. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. *J Clin Oncol*. 25:2288-94.
69. Raposo, G., H.W. Nijman, W. Stoorvogel, R. Liejendekker, C.V. Harding, C.J. Melief, and H.J. Geuze. 1996. B lymphocytes secrete antigen-presenting vesicles. *J Exp Med*. 183:1161-72.
70. Roe, M.A., C. Spinks, A.L. Heath, L.J. Harvey, R. Foxall, J. Wimperis, C. Wolf, and S.J. Fairweather-Tait. 2007. Serum prohepcidin concentration: no association with iron absorption in healthy men; and no relationship with iron status in men carrying HFE mutations, hereditary haemochromatosis patients undergoing phlebotomy treatment, or pregnant women. *Br J Nutr*. 97:544-9.
71. Schetter, A.J., S.Y. Leung, J.J. Sohn, K.A. Zanetti, E.D. Bowman, N. Yanaihara, S.T. Yuen, T.L. Chan, D.L. Kwong, G.K. Au, C.G. Liu, G.A. Calin, C.M. Croce, and C.C. Harris. 2008. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA*. 299:425-36.
72. Singer, C.F., D. Gschwantler-Kaulich, A. Fink-Retter, C. Haas, G. Hudelist, K. Czerwenka, and E. Kubista. 2007. Differential gene expression profile in breast cancer-derived stromal fibroblasts. *Breast Cancer Res Treat*.
73. Steemers, F.J., W. Chang, G. Lee, D.L. Barker, R. Shen, and K.L. Gunderson. 2006. Whole-genome genotyping with the single-base extension assay. *Nat Methods*. 3:31-3.
74. Stupp, R., W.P. Mason, M.J. van den Bent, M. Weller, B. Fisher, M.J. Taphoorn, K. Belanger, A.A. Brandes, C. Marosi, U. Bogdahn, J. Curschmann, R.C. Janzer, S.K.

- Ludwin, T. Gorlia, A. Allgeier, D. Lacombe, J.G. Cairncross, E. Eisenhauer, and R.O. Mirimanoff. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med.* 352:987-96.
75. Taylor, D.D., and C. Gercel-Taylor. 2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol.* 110:13-21.
76. They, C., S. Amigorena, G. Raposo, and A. Clayton. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. *Curr Protoc Cell Biol.* Chapter 3:Unit 3 22.
77. They, C., L. Zitvogel, and S. Amigorena. 2002. Exosomes: composition, biogenesis and function. *Nat Rev Immunol.* 2:569-79.
78. Tomlins, S.A., D.R. Rhodes, S. Perner, S.M. Dhanasekaran, R. Mehra, X.W. Sun, S. Varambally, X. Cao, J. Tchinda, R. Kuefer, C. Lee, J.E. Montie, R.B. Shah, K.J. Pienta, M.A. Rubin, and A.M. Chinnaiyan. 2005. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. *Science.* 310:644-8.
79. Valadi, H., K. Ekstrom, A. Bossios, M. Sjostrand, J.J. Lee, and J.O. Lotvall. 2007. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 9:654-9.
80. van Dijk, E.L., G. Schilders, and G.J. Pruijn. 2007. Human cell growth requires a functional cytoplasmic exosome, which is involved in various mRNA decay pathways. *RNA.* 13:1027-35.
81. Velculescu, V.E., L. Zhang, B. Vogelstein, and K.W. Kinzler. 1995. Serial analysis of gene expression. *Science.* 270:484-7.
82. Weiss, G., and L.T. Goodnough. 2005. Anemia of chronic disease. *N Engl J Med.* 352:1011-23.
83. Went, P.T., A. Lugli, S. Meier, M. Bundi, M. Mirlacher, G. Sauter, and S. Dirnhofer. 2004. Frequent EpCam protein expression in human carcinomas. *Hum Pathol.* 35:122-8.
84. Wieckowski, E., and T.L. Whiteside. 2006. Human tumor-derived vs dendritic cell-derived exosomes have distinct biologic roles and molecular profiles. *Immunol Res.* 36:247-54.

85. Wong, B.C., R.W. Chiu, N.B. Tsui, K.C. Chan, L.W. Chan, T.K. Lau, T.N. Leung, and Y.M. Lo. 2005. Circulating placental RNA in maternal plasma is associated with a preponderance of 5' mRNA fragments: implications for noninvasive prenatal diagnosis and monitoring. *Clin Chem.* 51:1786-95.
86. Wood, L.D., D.W. Parsons, S. Jones, J. Lin, T. Sjoblom, R.J. Leary, D. Shen, S.M. Boca, T. Barber, J. Ptak, N. Silliman, S. Szabo, Z. Dezso, V. Ustyanksky, T. Nikolskaya, Y. Nikolsky, R. Karchin, P.A. Wilson, J.S. Kaminker, Z. Zhang, R. Croshaw, J. Willis, D. Dawson, M. Shipitsin, J.K. Willson, S. Sukumar, K. Polyak, B.H. Park, C.L. Pethiyagoda, P.V. Pant, D.G. Ballinger, A.B. Sparks, J. Hartigan, D.R. Smith, E. Suh, N. Papadopoulos, P. Buckhaults, S.D. Markowitz, G. Parmigiani, K.W. Kinzler, V.E. Velculescu, and B. Vogelstein. 2007. The genomic landscapes of human breast and colorectal cancers. *Science.* 318:1108-13.
87. Wright, J.L., and P.H. Lange. 2007. Newer potential biomarkers in prostate cancer. *Rev Urol.* 9:207-13.
88. Zehentner, B.K., H. Secrist, X. Zhang, D.C. Hayes, R. Ostenson, G. Goodman, J. Xu, M. Kiviat, N. Kiviat, D.H. Persing, and R.L. Houghton. 2006. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients. *Mol Diagn Ther.* 10:397-403.
89. Zielie, P.J., J.A. Mobley, R.G. Ebb, Z. Jiang, R.D. Blute, and S.M. Ho. 2004. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. *J Urol.* 172:1130-3.

Table 1. RNA in glioblastoma microvesicles can be used as sensitive biomarkers.

Nested RT-PCR was used to monitor EGFRvIII mRNA in glioma biopsy tissue as well as exosomes purified from a frozen serum sample from the same patient. Samples from 30 patients were analysed in a blinded fashion and PCR reactions were repeated at least three times for each sample. No EGFRvIII mRNA was found in serum microvesicles from 30 normal controls. PP1 refers to primer pair composed of SEQ ID NOs: 13 and 14. PP2 refers to primer pair composed of SEQ ID NOS: 15 and 16. “-“ refers to “not available”.

Patient#	Time of serum collection*	Serum volume	Biopsy EGFRvIII	Serum exosome EGFRvIII(PP1)	Serum exosome EGFRvIII(PP2)
1	0	3 ml	Yes	Yes	-
2	0	2 ml	No	No	-
3	0	2.5 ml	No	No	-
4	0	1 ml	Yes	No	Yes
5	0	1 ml	Yes	No	Yes
6	0	1 ml	No	No	-
7	0	0.6 ml	Yes	Yes	-
8	0	1 ml	No	No	-
9	0	1 ml	Yes	Yes	-
10	0	1 ml	No	Yes	-
11	0	2 ml	Yes	No	Yes
12	0	2 ml	Yes	Yes	-
13	0	2 ml	No	Yes	-
14	0	2 ml	Yes	Yes	-
15	0	2 ml	No	No	-
16	0	2 ml	No	No	-
17	0	1 ml	Yes	No	-
18	0	0.8 ml	Yes	No	-
19	0	1 ml	No	No	-
20	0	1 ml	No	No	-
21	0	1 ml	No	No	-
22	0	1 ml	No	No	-
23	0	1 ml	No	No	-
24	0	1 ml	No	No	-
25	0	1 ml	No	No	-
26	14	0.6 ml	Yes	No	Yes
27	14	1.2 ml	No	No	No
28	14	0.8 ml	Yes	No	Yes
29	14	0.9 ml	Yes	No	No
30	14	0.6 ml	Yes	No	Yes

*Days post-surgery of tumor removal

Table 2 Abbreviations used in Table 3.

Abbreviation	Term
A	amplification
AEL	acute eosinophilic leukemia
AL	acute leukemia
ALCL	anaplastic large-cell lymphoma
ALL	acute lymphocytic leukemia
AML	acute myelogenous leukemia
AML*	acute myelogenous leukemia (primarily treatment associated)
APL	acute promyelocytic leukemia
B-ALL	B-cell acute lymphocyte leukemia
B-CLL	B-cell Lymphocytic leukemia
B-NHL	B-cell Non-Hodgkin Lymphoma
CLL	chronic lymphatic leukemia
CML	chronic myeloid leukemia
CMML	chronic myelomonocytic leukemia
CNS	central nervous system
D	large deletion
DFSP	dermatofibrosarcoma protuberans
DLBL	diffuse large B-cell lymphoma
DLCL	diffuse large-cell lymphoma
Dom	dominant
E	epithelial
F	frames
GIST	gastrointestinal stromal tumour
JMML	juvenile myelomonocytic leukemia
L	leukaemia/lymphoma
M	mesenchymal
MALT	mucosa-associated lymphoid tissue lymphoma
MDS	myelodysplastic syndrome
Mis	Missense
MLCLS	mediastinal large cell lymphoma with sclerosis
MM	multiple myeloma
MPD	Myeloproliferative disorder
N	nonsense
NHL	non-Hodgkin lymphoma
NK/T	natural killer T cell
NSCLC	non small cell lung cancer
O	other
PMBL	primary mediastinal B-cell lymphoma
pre-B All	pre-B-cell acute lymphoblastic leukaemia
Rec	recessive
S	splice site
T	translocation
T-ALL	T-cell acute lymphoblastic leukemia
T-CLL	T-cell chronic lymphocytic leukaemia
TGCT	testicular germ cell tumour
T-PLL	T cell prolymphocytic leukaemia

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>ABL1</i>	25	P00519	9q34.1	CML, ALL	-	-	L	Dom	T	<i>BCR, ETV6</i>
<i>ABL2</i>	27	P42684	1q24-q25	AML	-	-	L	Dom	T	<i>ETV6</i>
<i>AF15Q14</i>	57082	NP_06511	15q14	AML	-	-	L	Dom	T	<i>MLL</i>
<i>AF1Q</i>	10962	Q13015	1q21	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>AF3p21</i>	51517	Q9NZQ3	3p21	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>AF3q31</i>	27125	NP_05523	5q31	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>AKT2</i>	208	P31751	19q13.1-q13.2	Ovarian, pancreatic	-	-	E	Dom	A	<i>NPM1, TPM3, TFG, TPM4, ATIC, CLTC, MSN, ALO17</i>
<i>ALK</i>	238	Q9UM73	2p23	ALCL	-	-	L	Dom	T	-
<i>ALO17</i>	57714	XP_29076	17q25.3	ALCL	-	-	L	Dom	T	<i>ALK</i>
<i>APC</i>	324	P25054	5q21	Colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS	Colorectal, pancreatic, desmoid, hepatoblastoma, glioma, other CNS	Adenomatous polyposis coli; Turcot syndrome	E, M, O	Rec	D ⁺ , Mts, N, F, S	-
<i>ARHGEF1</i>	23365	NP_05612	11q23.3	AML	-	-	L	Dom	T	<i>MLL</i>
<i>ARHH</i>	399	Q15669	4p13	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>ARNT</i>	405	P27540	1q21	AML	-	-	L	Dom	T	<i>ETV6</i>
<i>ASPSCRI</i>	79058	NP_07698	17q25	Alveolar soft part sarcoma	-	-	M	Dom	T	<i>TFE3</i>
<i>ATF1</i>	466	P18846	12q13	Malignant melanoma of soft parts, angiomatoid fibrous histiocytoma	-	-	E, M	Dom	T	<i>EWSR1</i>
<i>ATTC</i>	471	P31939	2q35	ALCL	-	-	L	Dom	T	<i>ALK</i>
<i>ATM</i>	472	Q13315	11q22.3	T-PLL	Leukaemia, lymphoma, medulloblastoma, glioma	Ataxia telangiectasia	L, O	Rec	D, Mts, N, F, S	-
<i>BCL10</i>	8915	O95999	1p22	MAIT	-	-	L	Dom	T	<i>IGHa</i>
<i>BCL11A</i>	53335	NP_06048	2p13	B-CLL	-	-	L	Dom	T	<i>IGHa</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>BCL11B</i>	64919	NP_61280	14q32.1	T-ALL	-	-	L	Dom	T	<i>TLX3</i>
<i>BCL2</i>	596	P10415	18q21.3	NHL, CLL	-	-	L	Dom	T	<i>IGHa</i>
<i>BCL3</i>	602	P20749	19q13	CLL	-	-	L	Dom	T	<i>IGHa</i>
<i>BCL5</i>	603	I52586	17q22	CLL	-	-	L	Dom	T	<i>MYC</i>
<i>BCL6</i>	604	P41182	3q27	NHL, CLL	-	-	L	Dom	T, Mis	<i>IG loci, ZNFN1A1, LCP1, PM1, TERC, MHC2TA, NACA, HSPCB, HSPCA, HISTH4L, IL21R, POU2AF1, ARHG, EIF4A2, MYC</i>
<i>BCL7A</i>	605	NP_06627	12q24.1	B-NHL	-	-	L	Dom	T	<i>MYC</i>
<i>BCL9</i>	607	O00512	1q21	B-ALL	-	-	L	Dom	T	<i>IGHa, IGLa</i>
<i>BCR</i>	613	P11274	22q11.21	CML, ALL	-	-	L	Dom	T	<i>ABL1, FGFR1</i>
<i>BHD</i>	201163	NP_65943	17p11.2	-	Renal, fibrofolliculomas, trichodiscomas	Birt-Hogg-Dube syndrome	E, M	Rec?	Mis, N, F	-
<i>BIRC3</i>	330	Q13489	11q22-q23	MALT	-	-	L	Dom	T	<i>MALT1</i>
<i>BLM</i>	641	P54132	15q26.1	-	Leukaemia, lymphoma, skin squamous cell, other cancers	Bloom Syndrome	L, E	Rec	Mis, N, F	-
<i>BMPRIA</i>	657	P36894	10q22.3	-	Gastrointestinal polyps	Juvenile polyposis	E	Rec	Mis, N, F	-
<i>BRAP</i>	673	P15056	7q34	-	-	-	E	Dom	M	-
<i>BRCA1</i>	672	P38398	17q21	Ovarian	Breast, ovarian	Hereditary breast/ovarian	E	Rec	D, Mis, N, F, S	-
<i>BRCA2</i>	675	P51587	13q12	Breast, ovarian, pancreatic	Breast, ovarian, pancreatic, leukaemia (FANCB)	Hereditary breast/ovarian	L, E, ovarian	Rec	D, Mis, N, F, S	-F, S

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>BRD4</i>	23476	O60885	19p13.1	Lethal midline carcinoma of young people	FANCD1)	-	E	Dom	T	<i>NUT</i>
<i>BTG1</i>	694	P31607	12q22	BCLL	-	-	L	Dom	T	<i>MYC</i>
<i>CBLA2T1</i>	862	Q06455	8q22	AML	-	-	L	Dom	T	<i>MLL, RUNX1</i>
<i>CBLA2T3</i>	863	NP_005178	16q24	AML	-	-	L	Dom	T	<i>RUNX1</i>
<i>CBFB</i>	865	Q13951	16q22	AML	-	-	L	Dom	T	<i>MYH11</i>
<i>CBL</i>	867	P22681	11q23.3	AML	-	-	L	Dom	T	<i>MLL</i>
<i>CCND1</i>	595	P24385	11q13	CLL, B-ALL, breast	-	-	L, E	Dom	T	<i>IGHa, FSTL3</i>
<i>CDH1</i>	999	P12830	16q22.1	Lobular breast, gastric	Gastric	Familial gastric carcinoma	E	Rec	Mis, N, F, S	-
<i>CDK4</i>	1019	P11802	12q14	-	Melanoma	Familial malignant melanoma	E	Dom	Mis	-
<i>CDKN2A-p14^{ARF}</i>	1029	NP_478102	9p21	Melanoma, multiple other	Melanoma, pancreatic	Familial malignant melanoma	L, E, M, O	Rec	D, S	-
<i>CDKN2A-p16^{INK4A}</i>	1029	P42771	9p21	Melanoma, multiple other	Melanoma, pancreatic	Familial malignant melanoma	L, E, M, O	Rec	D, Mis, N, F, S	-
<i>CDY2</i>	1045	Q99636	13q12.3	AML	-	-	L	Dom	T	<i>ETV6</i>
<i>CEBPA</i>	1050	NP_004355	11p15.5	AML, MDS	-	-	L	Dom	Mis, N, F	-
<i>CEP1</i>	11064	NP_008949	9q33	MPPD/NHL	-	-	L	Dom	T	<i>FGFR1</i>
<i>CHC2</i>	26511	NP_036242	4q11-q12	AML	-	-	L	Dom	T	<i>ETV6</i>
<i>CHN1</i>	1123	P15882	2q31-q32.1	Extraskelatal myxoid chondrosarcoma	-	-	M	Dom	T	<i>TAF15</i>
<i>CLTC</i>	1213	Q00610	17q11-qter	ALCL	-	-	L	Dom	T	<i>ALK</i>
<i>COL1A1</i>	1277	P02452	17q21.31-q22	Dermatofibrosarcoma protuberans	-	-	M	Dom	T	<i>PDGFB</i>
<i>COPB2</i>	1316	Q99612	10p15	Prostatic, glioma	-	-	E, O	Rec	Mis, N	-

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>COX6C</i>	1345	P09669	8q22-q23	Uterine leiomyoma	-	-	M	Dom	T	<i>HMGGA2</i>
<i>CRBBP</i>	1387	Q92793	16p13.3	AL, AML	-	-	L	Dom	T	<i>MLL, MORF, RUNXBP2</i>
<i>CTNNB1</i>	1499	P35222	3p22-p21.3	Colorectal, ovarian, hepatoblastoma, others	-	-	E, M, O	Dom	H, Mis	-
<i>CYLD</i>	1540	NP_05606	16q12-q13	Cylindroma	Cylindroma	Familial cylindromatosis	E	Rec	Mis, N, F, S	-
<i>D10S170</i>	8030	NP_00542	10q21	Papillary thyroid, CML	-	-	E	Dom	T	<i>RET, PDGFRB</i>
<i>DDB2</i>	1643	Q92466	11p12	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum E	E	Rec	M, N	-
<i>DDIT3</i>	1649	P35638	12q13.1-q13.2	Liposarcoma	-	-	M	Dom	T	<i>FUS</i>
<i>DDX10</i>	1662	Q13206	11q22-q23	AMEL5	-	-	L	Dom	T	<i>NUP98</i>
<i>DEK</i>	7913	P35659	6p23	AML	-	-	L	Dom	T	<i>NUM214</i>
<i>EGFR</i>	1956	P00533	7p12.3-p12.1	Glioma	-	-	O	Dom	A, O ^{II}	-
<i>EIF4A2</i>	1974	Q14240	3q27.3	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>ELKS</i>	23085	NP_05587	9	Papillary thyroid	-	-	E	Dom	T	<i>RET</i>
<i>ELL</i>	8178	P55199	19p13.1	AL	-	-	L	Dom	T	<i>MLL</i>
<i>EP300</i>	2033	Q09472	22q13	Colorectal, breast, pancreatic, AML	-	-	L, E	Rec	T	<i>MLL, RUNXBP2</i>
<i>EP315</i>	2060	P42366	1p32	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>ERBB2</i>	2064	P04626	17q21.1	Breast, ovarian, other tumour types	-	-	E	Dom	A	-
<i>ERCC2</i>	2068	P18074	19q13.2-q13.3	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum D	E	Rec	M, N, F, S	-
<i>ERCC3</i>	2071	P19447	2q21	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum B	E	Rec	M, S	-
<i>ERCC4</i>	2072	Q92889	16p13.3	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum F	E	Rec	M, N, F	-
<i>ERCC5</i>	2073	P28715	13q33	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum G	E	Rec	M, N, F	-
<i>ERG</i>	2078	P11308	21q22.3	Ewing's sarcoma	-	-	M	Dom	T	<i>EWSR1</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>ETV1</i>	2115	P50549	7p22	Ewing's sarcoma	-	-	M	Dom	T	<i>EW/SRI</i>
<i>ETV4</i>	2118	P43268	17q21	Ewing's sarcoma	-	-	M	Dom	T	<i>EW/SRI</i>
<i>ETV6</i>	2120	P41212	12p13	Congenital fibrosarcoma, multiple leukaemia and lymphoma, secretory breast	-	-	L, E, M	Dom	T	<i>NTRK3, RUNX1, PDGFRB, ABL1, MNL, ABL2, FAC16, CHIC2, ARNT, JAK2, ETV1, CDX2, STL, RUNX1, ETV6</i>
<i>EVI1</i>	2122	Q003112	3q26	AML, CMML	-	-	L	Dom	T	<i>FLI1, ERG, ZNF278, NR4A3, TEC, FEV, ATF1, ETV1, ETV4, WT1, ZNF384</i>
<i>EW/SRI</i>	2130	NP_00523	22q12	Ewing's sarcoma, desmoplastic small round cell, ALL	-	-	L, M	Dom	T	-
<i>EXT1</i>	2131	NP_00011	8q24.11-q24.13	-	Exostoses, osteosarcoma	Multiple exostoses type 1	M	Rec	Miss, N, F, S	-
<i>EXT2</i>	2132	Q93063	11p12-p11	-	Exostoses, osteosarcoma	Multiple exostoses type 2	M	Rec	Miss, N, F, S	-
<i>FAC16</i>	23305	NP_05607	5q31	AML, AEL	-	-	L	Dom	T	<i>ETV6</i>
<i>FANCA</i>	2175	NP_00012	16q24.3	-	AML, leukaemia	Fanconi anaemia A	L	Rec	D, Miss, N, F, S	-
<i>FANCC</i>	2176	Q00597	9q22.3	-	AML, leukaemia	Fanconi anaemia C	L	Rec	D, Miss, N, F, S	-
<i>FANCD2</i>	2177	NP_14907	3p26	-	AML, leukaemia	Fanconi anaemia D2	L	Rec	D, Miss, N, F	-
<i>FANCE</i>	2178	NP_06874	6p21-p22	-	AML, leukaemia	Fanconi anaemia E	L	Rec	N, F, S	-
<i>FANCF</i>	2188	Q9NP18	11p15	-	AML, leukaemia	Fanconi anaemia F	L	Rec	N, F	-
<i>FANCG</i>	2189	Q15287	9p13	-	AML, leukaemia	Fanconi anaemia G	L	Rec	Miss, N, F, S	-
<i>FEV</i>	54738	NP_05999	2q36	Ewing's sarcoma	-	-	M	Dom	T	<i>EW/SRI</i>
<i>FGFR1</i>	2260	P11362	8p11.2-p11.1	MPD/NHL	-	-	L	Dom	T	<i>BCR, FOP, ZNF198, CEP1</i>
<i>FGFR1OP</i>	11116	NP_00897	6q27	MPD/NHL	-	-	L	Dom	T	<i>FGFR1</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>FGFR2</i>	2263	P21802	10q26	Gastric	-	-	E	Dom	Miss	-
<i>FGFR3</i>	2261	P22607	4p16.3	Bladder, MM	-	-	L, E	Dom	Miss, T	<i>IGHa</i>
<i>FH</i>	2271	P07954	1q42.1	-	Leiomyomatosis, renal	Hereditary leiomyomatosis and renal-cell cancer	E, M	Rec	Miss, N, F	-
<i>FP1L1</i>	81608	NP_11217	4q12	Idiopathic hyperparathyroidic syndrome	-	-	L	Dom	T	<i>PDGFRa</i>
<i>FLI1</i>	2313	Q01543	11q24	Ewing's sarcoma	-	-	M	Dom	T	<i>EWSR1</i>
<i>FLT3</i>	2322	P36888	13q12	AML, ALL	-	-	L	Dom	Miss, O	-
<i>FLT4</i>	2324	P35916	5q35.3	Angiosarcoma	-	-	M	Dom	Miss	-
<i>FNBP1</i>	23048	XP_05266	9q23	AML	-	-	L	Dom	T	<i>MLL</i>
<i>FOXO1A</i>	2308	Q12778	13q14.1	Alveolar rhabdomyosarcoma	-	-	M	Dom	T	<i>PAX3</i>
<i>FOXO3A</i>	2309	Q43524	6q21	AML	-	-	L	Dom	T	<i>MLL</i>
<i>FSTL3</i>	10272	O95633	19p13	B-CLL	-	-	L	Dom	T	<i>CCND1</i>
<i>FUS</i>	2521	P35637	16p11.2	Liposarcoma	-	-	M	Dom	T	<i>DDIT3</i>
<i>GAS7</i>	8522	O60861	17p	AML ^s	-	-	L	Dom	T	<i>MLL</i>
<i>GATA1</i>	2623	P15976	Xp11.23	Megakaryoblastic leukaemia	-	-	L	Dom	Miss, F	-
<i>GMP5</i>	8833	P49915	3q24	AML	-	-	L	Dom	T	<i>MLL</i>
<i>GNAS</i>	2778	P04895	20q13.2	Pituitary adenoma	-	-	E	Dom	Miss	-
<i>GOLGA5</i>	9950	NP_00510	14q	Papillary thyroid	-	-	E	Dom	T	<i>RET</i>
<i>GPC3</i>	2719	P51654	Xq26.1	-	Wilms tumour	Stimpson-Golabi-Behnzel O syndrome	O	Rec	T, D, Miss, N, F, S	-
<i>GPHN</i>	10243	Q9N0X3	14q24	AL	-	-	L	Dom	T	<i>MLL</i>
<i>GRAF</i>	23092	NP_05588	5q31	AML, MDS	-	-	L	Dom	T, F, S	<i>MLL</i>
<i>HEI10</i>	57820	NP_06700	14q11.1	Uterine leiomyoma	-	-	M	Dom	T	<i>HMGGA2</i>
<i>HPI</i>	3092	O00291	7q11.23	CMMML	-	-	L	Dom	T	<i>PDGFRB</i>
<i>HIST1H4</i>	8294	NP_00348	6p21.3	NHL	-	-	L	Dom	T	<i>BCL6</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>HLE</i>	3131	Q16534	17q22	ALL	-	-	L	Dom	T	<i>TCF3</i>
<i>HMGGA2</i>	8091	P52926	12q15	Lipoma	-	-	M	Dom	T	<i>LHFP</i> , <i>RAD51L1</i> , <i>LPP</i> , <i>HEI10</i> , <i>COX6C</i>
<i>HOXA11</i>	3207	P31270	7p15-p14.2	CML	-	-	L	Dom	T	<i>NUP98</i>
<i>HOXA13</i>	3209	P31271	7p15-p14.2	AML	-	-	L	Dom	T	<i>NUP98</i>
<i>HOXA9</i>	3205	P31269	7p15-p14.2	AML [§]	-	-	L	Dom	T	<i>NUP98</i>
<i>HOXC13</i>	3229	P31276	12q13.3	AML	-	-	L	Dom	T	<i>NUP98</i>
<i>HOXD11</i>	3237	P31277	2q31-q32	AML	-	-	L	Dom	T	<i>NUP98</i>
<i>HOXD13</i>	3239	P35453	2q31-q32	AML [§]	-	-	L	Dom	T	<i>NUP98</i>
<i>HRAS</i>	3265	P01112	11p15.5	Infrrequent sarcomas, rare other types	-	-	L, M	Dom	Miss	-
<i>HRPT2</i>	3279	NP_01352	1q21-q31	Parathyroid adenoma	Parathyroid adenoma, multiple ossifying jaw fibroma	Hyperpara-thyroidism jaw tumour syndrome	E, M	Rec	Miss, N, F	-
<i>HSPCA</i>	3320	P07900	1q21.2-q22	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>HSPCB</i>	3326	P08238	6p12	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>IGHa</i>	3492	-	14q32.33	MM, NHL, Burkitt's lymphoma, CLL, MALT	-	-	L	Dom	T	<i>MYC</i> , <i>IGFR3</i> , <i>PAX5</i> , <i>IRTA1</i> , <i>IRF4</i> , <i>CCND1</i> , <i>BCL9</i> , <i>BCL6</i> , <i>BCL8</i> , <i>BCL2</i> , <i>BCL3</i> , <i>BCL10</i> , <i>BCL11A</i> , <i>LHX4</i>
<i>IGKa</i>	50802	-	2p12	Burkitt's lymphoma	-	-	L	Dom	T	<i>MYC</i>
<i>IGLa</i>	3535	-	22q11.1-q11.2	Burkitt's lymphoma	-	-	L	Dom	T	<i>BCL9</i> , <i>MYC</i>
<i>IL21R</i>	50615	Q9HBE5	16p11	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>IRF4</i>	3662	Q15306	6p25-p23	MM	-	-	L	Dom	T	<i>IGHa</i>
<i>IRTA1</i>	83417	NP_11257	1q21	B-NHL	-	-	L	Dom	T	<i>IGHa</i>
<i>JAK2</i>	3717	O60674	9p24	ALL, AML	-	-	L	Dom	T	<i>ETV6</i>
<i>KIT</i>	3815	P10721	4q12	GISt, AML, TGCT	GISt, epithelioma	Familial gastrointestinal stromal	L, M, O	Dom	Miss, O	-
<i>KRAS2</i>	3845	NP_00497	12p12.1	Pancreatic, colorectal, thyroid, AML	-	-	L, E, M, O	Dom	Miss	-

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>IAF4</i>	3899	P51826	2q11.2-q12	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>LASP1</i>	3927	Q14847	17q11-q21.3	AML	-	-	L	Dom	T	<i>MLL</i>
<i>LCK</i>	3932	NP_00534	1p35-p34.3	T-ALL	-	-	L	Dom	T	<i>TRBc</i>
<i>ICP1</i>	3936	P13796	13q14.1-q14.3	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>LCX</i>	80312	XP_16761	10q21	AML	-	-	L	Dom	T	<i>MLL</i>
<i>LHFP</i>	10186	NP_00577	13q12	Lipoma	-	-	M	Dom	T	<i>HMGGA2</i>
<i>LMO1</i>	4004	P25800	11p15	T-ALL	-	-	L	Dom	T	<i>TRDc</i>
<i>LMO2</i>	4005	P25791	11p13	T-ALL	-	-	L	Dom	T	<i>TRDc</i>
<i>LPP</i>	4026	NP_00556	3q28	Lipoma, leukaemia	-	-	L, M	Dom	T	<i>HMGGA2, MLL</i>
<i>LYL1</i>	4066	P12980	19p13.2-p13.1	T-ALL	-	-	L	Dom	T	<i>TRBc</i>
<i>MADH4</i>	4089	Q13485	18q21.1	Colorectal, pancreatic, small intestine	Gastrointestinal polyps	Juvenile polyposis	E	Rec	D, Mis, N, F	-
<i>MALTI</i>	10892	Q9UDY8	18q21	MALT	-	-	L	Dom	T	<i>BIRC3</i>
<i>MAML2</i>	84441	XP_04571	11q22-q23	Salivary-gland mucocypidermoid	-	-	E	Dom	T	<i>MECT1</i>
<i>MAP2K4</i>	6416	P45985	17p11.2	Pancreatic, breast, colorectal	-	-	E	Rec	D, Mis, N	-
<i>MDS1</i>	4197	Q13465	3q26	MDS, AML	-	-	L	Dom	T	<i>RUNX1</i>
<i>MECT1</i>	94159	AAK9383	19p13	Salivary-gland mucocypidermoid	-	-	E	Dom	T	<i>MAML2</i>
<i>MEN1</i>	4221	O00255	11q13	Parathyroid	Parathyroid adenoma, pituitary adenoma, pancreatic islet cell, carcinoid	Multiple endocrine neoplasia type 1	E	Rec	D, Mis, N, F, S	-
<i>MET</i>	4233	P08381	7q31	Papillary renal, head-neck squamous cell	Papillary renal	Familial papillary renal	E	Dom	Mis	-
<i>MHC2TA</i>	4261	P33076	16p13	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>MLL1</i>	4291	P58340	3q25.1	AML	-	-	L	Dom	T	<i>NPML</i>
<i>MLH1</i>	4292	P40692	3p21.3	Colorectal, endometrial, ovarian, CNS	Colorectal, endometrial, ovarian, CNS	Hereditary non-polyposis colorectal, Turcot syndrome	E, O	Rec	D, Mis, N, F, S	-

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>MLL</i>	4297	Q03164	11q23	AML, ALL	-	-	L	Dom	T, O	<i>MLL, MLLT1, MLLT2, MLLT3, MLLT4, MLLT7, MLLT10, MLLT6, ELL, EP315, AF1Q, CREBBP, SH3GL1, FNBPI, PNOTT1, MSF, GPHN, GMP5, SSH3BP1, ARHGEF12, GAST, FOXO3A, LAF4, LCX, SEPT6, LPP, CBF2T1, GRAF, EP300, PICAM</i>
<i>MLL1</i>	4298	Q03111	19p13.3	AL	-	-	L	Dom	T	<i>MLL</i>
<i>MLL10</i>	8028	P51197	10p12	AL	-	-	L	Dom	T	<i>MLL, PICAM</i>
<i>MLL12</i>	4299	P51825	4q21	AL	-	-	L	Dom	T	<i>MLL</i>
<i>MLL13</i>	4300	P42568	9p22	ALL	-	-	L	Dom	T	<i>MLL</i>
<i>MLL14</i>	4301	P55196	6q27	AL	-	-	L	Dom	T	<i>MLL</i>
<i>MLL16</i>	4302	P55198	17q21	AL	-	-	L	Dom	T	<i>MLL</i>
<i>MLL17</i>	4303	NP_00592	Xq13.1	AL	-	-	L	Dom	T	<i>MLL</i>
<i>MNI</i>	4330	Q10571	22q13	AML, meningioma	-	-	L, O	Dom	T	<i>ETV6</i>
<i>MSF</i>	10801	NP_00663	17q25	AML ^s	-	-	L	Dom	T	<i>MLL</i>
<i>MSH2</i>	4436	P43246	2p22-p21	Colorectal, endometrial, ovarian	Colorectal, endometrial, ovarian	Hereditary non-polyposis colorectal	E	Rec	D, Mfs, N, F, S	-
<i>MSH6</i>	2956	P52701	2p16	Colorectal	Colorectal, endometrial, ovarian	Hereditary non-polyposis colorectal	E	Rec	Mfs, N, F, S	-
<i>MSN</i>	4478	P26038	Xq11.2-q12	ALCL	-	-	L	Dom	T	<i>ALK</i>
<i>MUTYH</i>	4595	NP_03635	1p34.3-1p32.1	-	Colorectal	Adenomatous polyposis coli	E	Rec	Mfs, N, F, S	-

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>MYC</i>	4609	P01106	8q24.12-q24.13	Burkitt's lymphoma, amplified in other cancers, B-CLL	-	-	L, E	Dom	A, T	<i>IGKα, BCL5, BCL2A, BTG1, TRAc, IGHα</i>
<i>MYCL1</i>	4610	P12524	1p34.3	Small cell lung	-	-	E	Dom	A	-
<i>MYCN</i>	4613	P04198	2p24.1	Neuroblastoma	-	-	O	Dom	A	-
<i>MYH11</i>	4629	P35749	16p13.13-p13.12	AML	-	-	L	Dom	T	<i>CBFB</i>
<i>MYH9</i>	4627	P35579	22q13.1	ALCL	-	-	L	Dom	T	<i>ALK</i>
<i>MYS74</i>	23522	NP_03646	10q22	AML	-	-	L	Dom	T	<i>CREBBP</i>
<i>MACA</i>	4666	NP_00558	12q23-q24.1	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>NBS1</i>	4683	NP_00247	8q21	-	NHL, glioma, medulloblastoma, rhabdomyosarcoma	Nijmegen breakage syndrome	L, E, M, O	Rec	Ms, N, F	-
<i>NC042</i>	10499	Q15596	8q13.1	AML	-	-	L	Dom	T	<i>RUNXBP2</i>
<i>NC044</i>	8031	Q13772	10q11.2	Papillary thyroid	-	-	E	Dom	T	<i>RET</i>
<i>NF1</i>	4763	P21359	17q12	Neurofibroma, glioma	Neurofibroma, glioma	Neurofibromatosis type 1	O	Rec	D, Ms, N, F, S, O	-
<i>NF2</i>	4771	P35240	22q12.2	Meningioma, acoustic neuroma	Meningioma, acoustic neuroma	Neurofibromatosis type 2	O	Rec	D, Ms, N, F, S, O	-
<i>NOTCH1</i>	4851	P46531	9q34.3	T-ALL	-	-	L	Dom	T	<i>TRBα</i>
<i>NPM1</i>	4869	P06748	5q35	NHL, APL, AML	-	-	L	Dom	T	<i>ALK, RARA, MLL1</i>
<i>NR4A3</i>	8013	Q92570	9q22	Extraskelatal myxoid chondrosarcoma	-	-	M	Dom	T	<i>EWSR1</i>
<i>NRAS</i>	4893	P01111	1p13.2	Melanoma, MM, AML, thyroid	-	-	L, E	Dom	Ms	-
<i>NSD1</i>	64324	NP_07190	5q35	AML	-	-	L	Dom	T	<i>NUP98</i>
<i>NTRK1</i>	4914	P04629	1q21-q22	Papillary thyroid	-	-	E	Dom	T	<i>TPM3, TPR, TRG</i>
<i>NTRK3</i>	4916	Q16288	15q25	Congenital fibrosarcoma, secretory breast	-	-	E, M	Dom	T	<i>ETV6</i>
<i>NUMA1</i>	4926	NP_00617	11q13	APL	-	-	L	Dom	T	<i>RARA</i>
<i>NUP214</i>	8021	P35658	9q34.1	AML	-	-	L	Dom	T	<i>DEK, SET</i>
<i>NUP98</i>	4928	P52948	11p15	AML	-	-	L	Dom	T	<i>HOXA9, NSD1,</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>NOT</i>	2566+46	XP_17172	15q13	Lethal midline carcinoma of young people	-	-	E	Dom	T	<i>BRD4</i>
<i>OLIG2</i>	10215	Q13516	21q22.11	T-ALL	-	-	L	Dom	T	<i>IRAd</i>
<i>PAX3</i>	5077	P23760	2q35	Alveolar rhabdomyosarcoma	-	-	M	Dom	T	<i>FOXO1A</i>
<i>PAX5</i>	5079	Q02548	9p13	NHL	-	-	L	Dom	T	<i>IGHd</i>
<i>PAX7</i>	5081	P23759	1p36.2-p36.12	Alveolar rhabdomyosarcoma	-	-	M	Dom	T	<i>FOXO1A</i>
<i>PAX8</i>	7849	Q06710	2q12-q14	Follicular thyroid	-	-	E	Dom	T	<i>PPARG</i>
<i>PBX1</i>	5087	NP_00257	1q23	Pre-B-ALL	-	-	L	Dom	T	<i>TCF3</i>
<i>PCML</i>	5108	NP_00618	8p22-p21.3	Papillary thyroid	-	-	E	Dom	T	<i>RET</i>
<i>PDGFB</i>	5155	P01127	22q12.3-q13.1	DFSP	-	-	M	Dom	T	<i>COL1A1</i>
<i>PDGFRA</i>	5156	P16234	4q11-q13	GISST	-	-	M, O	Dom	Mis, O	-
<i>PDGFRB</i>	5159	NP_00260	5q31-q32	MPP, AMML, CML	-	-	L	Dom	T	<i>ETV6, TRP11, HIP1, RAB5EP, H4</i>
<i>PIC1M</i>	8301	Q13492	11q14	T-ALL, AML	-	-	L	Dom	T	<i>MLLT10, MLL</i>
<i>PLM1</i>	5292	P11309	6p21.2	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>PML</i>	5371	P29590	15q22	APL	-	-	L	Dom	T	<i>RARA</i>
<i>PMS1</i>	5378	P54277	2q31-q33	-	Colorectal, endometrial, ovarian	Hereditary non-polyposis colorectal cancer	E	Rec	Mis, N	-
<i>PMS2</i>	5395	P54278	7p22	-	Colorectal, endometrial, ovarian, medulloblastoma, glioma	Hereditary non-polyposis colorectal cancer, Turcot syndrome	E	Rec	Mis, N, F	-
<i>PMSX1</i>	5396	P54821	1q24	AML	-	-	L	Dom	T	<i>NUP98</i>
<i>PNUIT1</i>	5413	NP_00267	22q11.2	AML	-	-	L	Dom	T	<i>MLL</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>POU2AF1</i>	5450	Q16633	11q23.1	NHL	–	–	L	Dom	T	<i>BCL6</i>
<i>PPARG</i>	5468	P37231	3p25	Follicular thyroid	–	–	E	Dom	T	<i>PAX8</i>
<i>PRCC</i>	5546	Q92733	1q21.1	Papillary renal	–	–	E	Dom	T	<i>TFEB3</i>
<i>PRKARIA</i>	5573	P10644	17q23-q24	Papillary thyroid	Myxoma, endocrine, papillary thyroid	Carney complex	E, M	Dom, Rec	T, Mis, N, F, S	<i>RET</i>
<i>PRO1073</i>	29005	Q9UHZ2	11q31.1	Renal-cell carcinoma (childhood epitheloid)	–	–	E	Dom	T	<i>TFEB</i>
<i>PSIP2</i>	11168	NP_15009	9p22.2	AML	–	–	L	Dom	T	<i>NUP98</i>
<i>PTCH</i>	5727	Q13635	9q22.3	Skin basal cell, medulloblastoma	Skin basal cell, medulloblastoma	Nevoid basal-cell carcinoma syndrome	E, M	Rec	Mis, N, F, S	–
<i>PTEN</i>	5728	O00633	10q23.3	Glioma, prostatic, endometrial	Hamartoma, glioma, prostatic, endometrial	Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome	L, E, M, O	Rec	D, Mis, N, F, S	–
<i>PTPN11</i>	5781	Q06124	12q24.1	JMML, MDS	–	–	L	Dom	Mis	–
<i>RAB5EP</i>	9135	NP_00469	17p13	CMML	–	–	L	Dom	T	<i>PDGFRB</i>
<i>RAD51L1</i>	5890	NP_00286	14q23-q24.2	Lipoma, leiomyoma	–	–	M	Dom	T	<i>HMGGA2</i>
<i>RAP1GDS1</i>	5910	P52306	4q21-q25	T-ALL	–	–	L	Dom	T	<i>NUP98</i>
<i>RARA</i>	5914	P10276	17q12	APL	–	–	L	Dom	T	<i>PML, ZNF145, TTF1, NUMA1, NPM1</i>
<i>RBI</i>	5925	P06400	13q14	Retinoblastoma, sarcoma, breast, small-cell lung	Retinoblastoma, sarcoma, breast, small-cell lung	Familial retinoblastoma	L, E, M, O	Rec	D, Mis, N, F, S	–
<i>RECQL4</i>	9401	Q94761	8q24.3	–	Osteosarcoma, skin basal and squamous cell	Rothmund-Thompson syndrome	M	Rec	N, F, S	–
<i>REL</i>	5966	Q04864	2p13-p12	Hodgkin	–	–	L	Dom	A	–
<i>RET</i>	5979	P07949	10q11.2	Medullary thyroid, Lymphoma	Medullary thyroid,	Multiple	E, O	Dom	T, Mis, N,	<i>H4, PRKARIA</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>RPL22</i>	6146	P35268	3q26	AML, CMML	papillary thyroid, pheochromocytoma	endocrine	L	Dom	T	<i>NCOA4, PCML, GOLGA5, TRIM33</i>
<i>RUNX1</i>	861	Q01196	21q22.3	AML, pre-B-ALL	papillary thyroid, pheochromocytoma	2A/2B	L	Dom	T	<i>RUNX1, RPL22, MDS1, EVI1, CBF A2T3, CBF A2T1, ETV6</i>
<i>RUNXBP2</i>	799	NP_00675	8p11	AML	AML, MDS	Schwachman-Diamond syndrome	L	Dom	T	<i>CREBBP, NCOA2, EP300</i>
<i>SBDS</i>	51119	Q9Y3A5	7q11	AML, pre-B-ALL	AML, MDS	Schwachman-Diamond syndrome	L	Rec	Gene conversion	–
<i>SDHB</i>	6390	P21912	1p36.1-p35	–	Paraganglioma, pheochromocytoma	Familial paraganglioma	O	Rec	Mis, N, F	–
<i>SDHC</i>	6391	O75609	1q21	–	Paraganglioma, pheochromocytoma	Familial paraganglioma	O	Rec	Mis, N, F	–
<i>SDHD</i>	6392	O14521	11q23	–	Paraganglioma, pheochromocytoma	Familial paraganglioma	O	Rec	Mis, N, F, S	–
<i>SEPT6</i>	23157	NP_05594	Xq24	AML	–	–	L	Dom	T	<i>MLL</i>
<i>SET</i>	6418	Q01105	9q34	AML	–	–	L	Dom	T	<i>NUP214</i>
<i>SFPQ</i>	6421	P23246	1p34.3	Papillary renal cell	–	–	E	Dom	T	<i>TFE3</i>
<i>SH3GL1</i>	6455	Q99961	19p13.3	AL	–	–	L	Dom	T	<i>MLL</i>
<i>SMARCB1</i>	6598	Q12824	22q11	Malignant thalidoid	Malignant thalidoid	Rhabdoid predisposition syndrome	M	Rec	D, N, F, S	–
<i>SMO</i>	6608	Q99835	7q31-q32	Skin basal cell	–	–	E	Dom	Mis	–
<i>SS18</i>	6760	Q15552	18q11.2	Synovial sarcoma	–	–	M	Dom	T	<i>SSX1, SSX2</i>
<i>SS18L1</i>	26039	O75177	20q13.3	Synovial sarcoma	–	–	M	Dom	T	<i>SSX1</i>
<i>SSH3BP1</i>	10006	NP_00546	10p11.2	AML	–	–	L	Dom	T	<i>MLL</i>
<i>SSX1</i>	6756	Q16384	Xp11.23-p11.22	Synovial sarcoma	–	–	M	Dom	T	<i>SS18</i>
<i>SSX2</i>	6757	Q16385	Xp11.23-p11.22	Synovial sarcoma	–	–	M	Dom	T	<i>SS18</i>
<i>SSX4</i>	6759	O60224	Xp11.23	Synovial sarcoma	–	–	M	Dom	T	<i>SS18</i>
<i>STK11</i>	6794	Q15831	19p13.3	NSCLC	Jejunal hamartoma, ovarian, testicular, pancreatic	Peutz-Jeghers syndrome	E, M, O	Rec	D, Mis, N,	–
<i>STL</i>	7955	NP0K01	6q23	B-ALL	–	–	L	Dom	T	<i>ETV6</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>SUFU</i>	51684	EIN NP_05725	10q24.32	Medulloblastoma	Medulloblastoma	Medulloblastoma a predisposition	O	Rec	D, F, S	-
<i>TAF15</i>	8148	Q92804	17q11.1-q11.2	Extracerebral myxoid chondrosarcomas, ALL	-	-	L, M	Dom	T	<i>TEC, CHN1, ZNF384</i>
<i>TAL1</i>	6886	P17542	1p32	Lymphoblastic leukaemia/ biphasic T-ALL	-	-	L	Dom	T	<i>TRDα</i>
<i>TAL2</i>	6887	Q16559	9q31	T-ALL	-	-	L	Dom	T	<i>TRBα</i>
<i>TCF1</i>	6927	P20823	12q24.2	Hepatic adenoma, hepatocellular carcinoma	Hepatic adenoma, hepatocellular carcinoma	Familial hepatic adenoma	E	Rec	Mis, F	-
<i>TCF12</i>	6938	Q99081	15q21	Extracerebral myxoid chondrosarcoma	-	-	M	Dom	T	<i>TEC</i>
<i>TCF3</i>	6929	P15923	19p13.3	Extracerebral myxoid chondrosarcoma	-	-	L	Dom	T	<i>PBX1, HLF, TFP1</i>
<i>TCL1A</i>	8115	NP_06880	14q32.1	T-CLL	-	-	L	Dom	T	<i>TRAb</i>
<i>TEC</i>	7006	P42680	4p12	Extracerebral myxoid chondrosarcoma	-	-	M	Dom	T	<i>EMSR1, TAF15, TCF12</i>
<i>TEF3</i>	7030	P19532	Xp11.22	Papillary renal, alveolar soft part sarcoma	-	-	E	Dom	T	<i>SFPQ, ASPSCR1, PRC1</i>
<i>TEB</i>	7942	P19484	6p21	Renal (childhood epithelioid) Papillary thyroid, ALCL	-	-	E, M	Dom	T	<i>ALPHA</i>
<i>TFG</i>	10342	NP_00606	3q11-q12	Papillary thyroid, ALCL	-	-	E, L	Dom	T	<i>NTRK1, ALK</i>
<i>TFPT</i>	29844	NP_03747	19q13	Pre-B-ALL	-	-	L	Dom	T	<i>TCF3</i>
<i>TFRC</i>	7037	P02786	3q29	NHL	-	-	L	Dom	T	<i>BCL6</i>
<i>TFPI</i>	8805	O15164	7q32-q34	APL	-	-	L	Dom	T	<i>RARA</i>
<i>TIAX1</i>	3195	P31314	10q24	T-ALL	-	-	L	Dom	T	<i>TRBα, TRDα</i>
<i>TIAX3</i>	30012	O43711	5q35.1	T-ALL	-	-	L	Dom	T	<i>BCL11B</i>
<i>INFRS16</i>	355	P25445	10q24.1	TGCT, nasal NK/T lymphoma, skin squamous-cell carcinoma (burn-	-	-	L, E, O	Rec	Mis	-

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
<i>TOP1</i>	7150	P11387	20q12-q13.1	AML ^s AML ^s	–	–	L	Dom	T	<i>NUP98</i>
<i>TP53</i>	7157	P04637	17p13	Breast, colorectal, lung, sarcoma, adrenocortical, glioma, multiple other types	Breast, sarcoma, adrenocortical carcinoma, glioma, multiple other types	L1-Fraumeni syndrome	L, E, M, O	Rec	Mis, N, F	–
<i>TPM3</i>	7170	P06753	1q22-q23	Papillary thyroid, ALCL	–	–	E, L	Dom	T	<i>NTRK1, ALK</i>
<i>TPM4</i>	7171	P07226	19p13.1	ALCL	–	–	L	Dom	T	<i>ALK</i>
<i>TPR</i>	7175	P12270	1q25	Papillary thyroid	–	–	E	Dom	T	<i>NTRK1</i>
<i>TRAA</i>	6955	–	14q11.2	T-ALL	–	–	L	Dom	T	<i>ATL, OIG2, MYC, TCL1A</i>
<i>TRBA</i>	6957	–	7q35	T-ALL	–	–	L	Dom	T	<i>HOX11, ICK, NOTCH1, TAL2, IY11</i>
<i>TRDA</i>	6964	–	14q11	T-cell leukaemia	–	–	L	Dom	T	<i>TAL1, HOX11, TTX1, LMO1, LMO2</i>
<i>TRIM33</i>	51592	Q9UCN9	1p13	Papillary thyroid	–	–	E	Dom	T	<i>RET</i>
<i>TRIP11</i>	9321	NP_00423	14q31-q32	AML	–	–	L	Dom	T	<i>PDGFRB</i>
<i>TSCI</i>	7248	Q92574	9q34	–	Hamartoma, renal cell	Tuberous sclerosis 1	E, O	Rec	D, Mis, N, F, S	–
<i>TSC2</i>	7249	P49815	16p13.3	–	Hamartoma, renal cell	Tuberous sclerosis 2	E, O	Rec	D, Mis, N, F, S	–
<i>TSHR</i>	7253	P16473	14q31	Toxic thyroid adenoma	Thyroid adenoma	–	E	Dom	Mis	–
<i>VHL</i>	7428	P40337	3p25	Renal, hemangioma, pheochromocytoma	Renal, hemangioma, pheochromocytoma	von Hippel-Lindau syndrome	E, M, O	Rec	D, Mis, N, F, S	–
<i>WAS</i>	7454	P42768	Xp11.23-p11.22	–	Lymphoma	Wiskott-Aldrich syndrome	L	Rec	Mis, N, F, S	–
<i>WHSC1L1</i>	54904	NP_06024	8p12	AML	–	–	L	Dom	T	<i>NUP98</i>
<i>WRN</i>	7486	Q14191	8p12-p11.2	–	Osteosarcoma, meningioma, others	Werner syndrome	L, E, M, O	Rec	Mis, N, F, S	–
<i>WT1</i>	7490	NP_00036	11p13	Wilms', desmoplastic small round cell	Wilms' tumor	Dens-Drash syndrome, Frasier	O	Rec	D, Mis, N, F, S	<i>EWSR1</i>

Table 3: Genes Commonly Mutated in Cancers

Symbol	Locustlink ID	Protein ID*	Chromosome band	Tumour types (somatic)	Tumour types (germline)	Cancer syndrome	Tissue type	Cancer molecular genetics	Mutation type	Translocation partner
XP4	7507	P23025	9q22.3	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum A	E	Rec	Mis, N, F, S	-
XP2	7508	Q01831	3p25	-	Skin basal cell, skin squamous cell, melanoma	Xeroderma pigmentosum C	E	Rec	Mis, N, F, S	-
ZNF145	7704	Q05516	11q23.1	APL	-	-	L	Dom	T	RARA
ZNF198	7750	Q9UBW7	13q11-q12	MPD/NHL	-	-	L	Dom	T	FGFR1
ZNF278	23598	NP_05513	22q12-q14	Ewing's sarcoma	-	-	M	Dom	T	EWSR1
ZNF384	171017	NP_59773	12p13	ALL	-	-	L	Dom	T	EWSR1, TAF15
ZNFN1A1	10320	NP_00605	7p12	ALL, DLBCL	-	-	L	Dom	T	BCL6

*From Swiss-Prot/Refseq; #D (large deletion) covers the abnormalities that result in allele loss/loss of heterozygosity at many recessive cancer genes; \$Refers to cases of acute myeloid leukaemia that are associated with treatment; ||O (other) in the 'mutation type' column refers primarily to small in-frame deletions/insertions as found in KIT/PDGFR/A, and larger duplications/insertions as found in FLT3 and EGFR. Note that where an inversion/large deletion has been shown to result in a fusions protein, these have been listed under translocations. The Wellcome Trust Sanger Institute web version of the cancer-gene set can be found at <http://www.sanger.ac.uk/genetics/CPG/Census/>. A, amplification; AEL, acute eosinophilic leukaemia; AL, acute leukaemia; ALCL, anaplastic large-cell lymphoma; ALL, acute lymphocytic leukaemia; AML, acute myelogenous leukaemia; APL, acute promyelocytic leukaemia; B-ALL, B-cell acute lymphocytic leukaemia; B-CLL, B-cell lymphocytic leukaemia; B-NHL, B-cell non-Hodgkin's lymphoma; CLL, chronic lymphatic leukaemia; CML, chronic myeloid leukaemia; CMML, chronic myelomonocytic leukaemia; CNS, central nervous system; D, large deletion; DHSF, dermatofibrosarcoma protuberans; DLBCL, diffuse large B-cell lymphoma; Dom, dominant; E, epithelial; F, frameshift; GST, gastrointestinal stromal tumour; JMML, juvenile myelomonocytic leukaemia; L, leukaemia/lymphoma; M, mesenchymal; MALT, mucosa-associated lymphoid tissue; MDS, myelodysplastic syndrome; MM, multiple myeloma; Mis, missense; N, nonsense; NHL, non-Hodgkin's lymphoma; NK/T, natural killer T cell; NSCLC, non-small-cell lung cancer; O, other; pre-B-ALL, pre-B-cell acute lymphoblastic leukaemia; Rec, recessive; S, splice site; T, translocation; T-ALL, T-cell acute lymphoblastic leukaemia; T-CLL, T-cell chronic lymphocytic leukaemia; TGCT, testicular germ-cell tumour; T-PLL, T-cell prolymphocytic leukaemia.

Table 4: Commonly Upregulated Genes in Cancers

UniGene	Gene symbol	N	Up #	Down #	UniGene	Gene symbol	N	Up #	Down #
Hs. 159430	FNDC3B	11	10	0	Hs. 239388	PAQR8	8	5	1
Hs. 518201	DTX3L	8	7	0	Hs. 592827	RBAK	8	5	1
Hs. 530899	LOC162073	8	7	0	Hs. 525157	TNFSF13B	8	5	1
Hs. 15159	CKLF	11	9	1	Hs. 126774	DTL	13	8	0
Hs. 474150	BID	16	13	0	Hs. 385913	ANP32E	13	8	1
Hs. 7753	CALU	15	12	0	Hs. 532968	DKFP762E1312	13	8	1
Hs. 418795	GLT2SDI	10	8	0	Hs. 372429	PDIA6	13	8	1
Hs. 435556	BFAR	12	9	0	Hs. 233952	PSMA7	13	8	1
Hs. 459362	PACI	12	9	1	Hs. 533770	SLC38A1	13	8	1
Hs. 521800	Cborf76	8	6	0	Hs. 489284	ARPC18	18	11	0
Hs. 209561	KIAA1715	8	6	0	Hs. 497788	EPRS	18	11	0
Hs. 585011	Clorf96	8	6	1	Hs. 79110	NCL	18	11	0
Hs. 403933	FBX032	8	6	1	Hs. 251531	PSMA4	18	11	0
Hs. 368853	AYTL2	15	11	1	Hs. 429180	EIF2S2	18	11	1
Hs. 511093	NUSAP1	11	8	0	Hs. 468885	ILF3	18	11	1
Hs. 370895	RPN2	14	10	0	Hs. 169840	TTK	18	11	1
Hs. 180062	PSMBB	17	12	0	Hs. 489365	APIST	15	9	1
Hs. 444600	BOLAZ	10	7	0	Hs. 256639	PPIH	15	9	1
Hs. 445890	CHIH4	13	9	0	Hs. 14559	CEP55	10	6	1
Hs. 534392	KDELR3	13	9	0	Hs. 308613	MTERFD1	10	6	1
Hs. 632 191	XTP3TPA	13	9	0	Hs. 21331	ZWILCH	10	6	1
Hs. 387567	ACLV	19	13	1	Hs. 524599	NAPIL1	17	10	1
Hs. 533282	NONO	18	12	0	Hs. 78171	PGKI	17	10	2
Hs. 83753	SNRPB	18	12	0	Hs. 512380	PLEKHB2	12	7	1
Hs. 471441	PSMBZ	18	12	1	Hs. 352018	TAP1	19	11	1
Hs. 482497	TNPOI	18	12	1	Hs. 194698	CCNB2	14	8	1
Hs. 370937	TAPBP	15	10	0	Hs. 153357	PLOD3	14	8	1
Hs. 126941	FAM49B	12	8	0	Hs. 471200	NRP2	14	8	2
Hs. 408629	KDELICI	12	8	0	Hs. 250822	AURKA	16	9	1
Hs. 497384	IPO9	12	8	1	Hs. 75528	GNI2	16	9	1
Hs. 8752	TMEM4	12	8	1	Hs. 1197	HSPEI	16	9	1
Hs. 195642	C17orf27	9	6	0	Hs. 202672	DNMT1	18	10	1
Hs. 358997	TTL	9	6	0	Hs. 433670	FIL	18	10	1
Hs. 1600	CCT5	20	13	0	Hs. 519972	HLA-F	18	10	1
Hs. 269408	E2F3	17	11	0	HS. 520210	KDELR2	18	10	1
Hs. 234027	ZBTB12	17	11	1	Hs. 40515.1	CARD-4	11	6	1
Hs. 520205	EIF2AK1	14	9	0	Hs. 477700	DBRI	11	6	1
Hs. 89545	PSMB4	14	9	0	Hs. I4468	FLJ11286	11	6	1
Hs. 449415	EIF2C2	14	9	1	Hs. 516077	FLJ14668	11	6	1
Hs. 409065	FEN1	14	9	1	HS. 494337	GOLPH2	11	6	1
Hs. 313	SPP1	14	9	2	Hs. 371036	NOX4	11	6	1
Hs. 525135	FARP1	14	9	2	Hs. 438683	SLAMF8	11	6	1
Hs. 524390	K-ALPHA-1	11	7	0	Hs. 520714	SNXIO	11	6	1
Hs. 432360	SCNM1	11	7	0	Hs. 159428	BAX	13	7	1
Hs. 172028	ADAM10	19	12	0	Hs. 311609	DDX39	13	7	1
Hs. 381189	CBX3	19	12	0	Hs. 463035	FKBP10	13	7	1
Hs. 522257	HNRPK	19	12	0	Hs. 438695	FKBP11	13	7	1
Hs. 470943	STAT1	19	12	0	Hs. 515255	LSM4	13	7	1
Hs. 118638	NME1	19	12	1	Hs. 55285	MORC2	13	7	1
Hs. 519452	NPM1	19	12	1	Hs. 43666	PTP4A3	13	7	1
Hs. 506748	HDGF	16	10	0	Hs. 369440	SFXN1	13	7	1
Hs. 386283	ADAM12	16	10	2	Hs. 517155	TMEPAI	13	7	1
Hs. 474740	APOL2	8	5	0	Hs. 631580	UBA2	13	7	1
Hs. 552608	C1orf58	8	5	0	Hs. 46346S	UTP16	13	7	1
Hs. 470654	CDCA7	8	5	0	Hs. 492974	WISP1	13	7	1
Hs. 179'B8	FMNL3	8	5	0	Hs. 113876	WHSC1	13	7	1
Hs. 143618	GEMIN6	8	5	0	Hs. 494614	BAT2D1	15	8	2
Hs. 6459	GPRI72A	8	5	0	Hs. 166463	HNRPU	19	10	2
Hs. 133294	IQGAP3	8	5	0					

No number of studies (types of cancer) which have available expression data on a test gene.

Up # or down # number of cancer types whose expression of the tested gene is up or down -regulated.

All these genes are significantly consistently up-regulated ($P < 10$) in a large majority of cancer types.

doi: 10.1377/journal.pone.0001149.001

Atty. Docket No. 030258-61532

Table 5: Commonly Downregulated Genes in Cancers

UniGene	Gene symbol	N	Up #	Down #	UniGene	Gene symbol	N	Up #	Down #
Hs. 401835	TCEAL2	10	0	8	Hs. 306083	LOC91689	8	0	5
Hs. 58351	ABCA8	13	0	10	Hs. 160953	PS3AIP1	8	0	5
Hs. 525205	NDRG2	12	0	9	Hs. 2112252	SLC24A3	8	0	5
Hs. 524085	USP2	12	0	9	Hs. 163079	TUBAL3	8	0	5
Hs. 172755	BRP44L	11	0	8	Hs. 389171	PINK1	13	0	8
Hs. 22242	ECHDC3	11	0	8	Hs. 470887	GULP1	13	1	8
Hs. 196952	HLF	19	1	13	Hs. 490981	MSRA	13	1	8
Hs. 496587	CHRDLL1	12	0	8	Hs. 476092	CLEC3B	18	0	11
Hs. 476319	ECHDC2	12	0	8	Hs. 386502	FMO4	18	0	11
Hs. 409352	FLJ20701	12	0	8	Hs. 137367	ANK2	18	1	11
Hs. 103253	PLIN	12	0	8	Hs. 212088	EPHX2	18	1	11
Hs. 293970	ALDH6A1	18	1	12	Hs. 157818	KCNAB1	18	1	11
Hs. 390729	ERBB4	17	0	11	Hs. 163924	NR3C2	18	1	11
Hs. 553502	RORA	17	0	11	Hs. 269128	PPP2R1B	18	1	11
Hs. 388918	RECK	14	0	9	Hs. 40582	CDC148	15	1	9
Hs. 216226	SYNGR1	14	0	9	Hs. 438867	FL20489	10	1	6
Hs. 506357	fam107a	14	1	9	Hs. 224008	FEZ1	17	1	10
Hs. 476454	ABHD6	11	0	7	Hs. 443789	C6orf60	12	1	7
Hs. 519694	Csor4	11	0	7	Hs. 475319	LRRFIP2	12	1	7
Hs. 528385	DHR54	11	0	7	Hs. 514713	MPPE1	12	1	7
Hs. 477288	TRPM3	1	0	7	Hs. 183153	ARL4D	19	1	11
Hs. 420830	HIF3A	11	1	7	Hs. 642660	C10orf116	19	1	11
Hs. 511265	SEMA6D	11	1	7	Hs. 495912	DMD	19	1	11
Hs. 436657	CLU	19	1	12	Hs. 503126	SHANK2	14	1	8
Hs. 78482	PALM	16	0	10	Hs. 481342	SORBS2	14	1	8
Hs. 82318	WASF3	16	0	10	Hs. 169441	MAGI1	16	1	9
Hs. 268869	ADHFE1	8	0	5	Hs. 75652	GSTM5	18	1	10
Hs. 34494	AGXT2	8	0	5	Hs. 405156	PPAP28	18	1	10
Hs. 249129	CIDEA	8	0	5	Hs. 271771	SNCA	18	1	10
Hs. 302754	EFCBP1	8	0	5	Hs. 181855	CASC5	9	1	5
Hs. 521953	EFHC2	8	0	5	Hs. 506458	ANKS1B	11	1	6
Hs. 200100	Ells1	8	0	5	Hs. 445885	KIAA1217	11	1	6
Hs. 479703	FL21511	8	0	5	Hs. 643583	DKFZp667G2110	13	1	7
Hs. 500750	HPSE2	8	0	5	Hs. 406787	FBX03	13	1	7
Hs. 380929	LDHD	8	0	5	Hs. 431498	FOXP1	13	1	7

All these genes are significantly consistently down-regulated ($P < 10^{-5}$) in a large majority of cancer types.
doi:10.1371/journal.pone.0001149.t002

Table 6: Commonly Upregulated Genes in Pancreatic Cancer

Accession	Gene Symbol	Gene Name	FC
NM_006475	POSTN	periostin, osteoblast specific factor	13.28
NM_005980	S100P	S100 calcium binding protein P	12.36
NM_004385	CSPG2	chondroitin sulfate proteoglycan 2 (versican)	10.57
NM_003118	SPARC	secreted protein, acidic cysteine-rich (osteonectin)	10.46
NM_003225	TFF1	trefoil factor 1 (breast cancer, estrogen-inducible sequence expressed in)	8.13
NM_002026	FN1	fibronectin 1	7.93
NM_006142	SFN	stratifin	7.81
NM_000393	COL5A2	collagen, type V, alpha 2	7.22
NM_005940	MMP11	matrix metalloproteinase 11 (stromelysin 3)	7.17
NM_000088	COL1A1	collagen, type I, alpha 1	6.50
NM_000930	PLAT	plasminogen activator, tissue	6.46
NM_003064	SLPI	secretory leukocyte protease inhibitor (antileukoproteinase)	6.01
NM_006516	SLC2A1	solute carrier family 2 (facilitated glucose transporter), member 1	5.39
NM_003226	TFF3	trefoil factor 3 (intestinal)	5.28
NM_004460	FAP	fibroblast activation protein alpha	5.20
NM_003467	CXCR4	chemokine (C-X-C motif) receptor 4	5.18
NM_003247	THBS2	thrombospondin 2	5.04
NM_012101	TRIM29	tripartite motif-containing	4.91
NM_033664	CDH11	cadherin 11, type 2, OB-cadherin (osteoblast)	4.52
NM_006169	NNMT	nicotinamide N-methyltransferase	4.51
NM_004425	ECM1	extracellular matrix protein 1	4.39
NM_003358	UGCG	UDP-glucose ceramide glucosyltransferase	4.36
NM_000700	ANXA1	annexin A1	4.31
NM_004772	C5orf13	chromosome 5 open reading frame 13	4.29
NM_182470	PKM2	pyruvate kinase, muscle	4.28
NM_004994	MMP9	matrix metalloproteinase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase)	4.19
NM_006868	RAB31	RAB31, member RAS oncogene family	4.18
NM_001932	MPP3	membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 3)	4.16
AF200348	D2S448	Melanoma associated gene	4.14
NM_000574	DAF	decay accelerating factor for complement (CD55, Cromer blood group system)	4.11
NM_000213	ITGB4	integrin beta	4.11
NM_001645	APOC1	apolipoprotein C-I	3.86
NM_198129	LAMA3	laminin, alpha 3	3.86
NM_002997	SDC1	syndecan 1	3.80
NM_001769	CD9	CD9 antigen (p24)	3.78
BC004376	ANXA8	annexin A8	3.74
NM_005620	S100A11	S100 calcium binding protein A11 (calgizzatin)	3.72
NM_002659	PLAUR	plasminogen activator urokinase receptor	3.70
NM_002966	S100A10	S100 calcium binding protein A10 (annexin II ligand, calpactin I, light polypeptide (p11))	3.67
NM_004898	CLOCK	clock homolog (mouse)	3.65
NM_002345	LUM	lumican	3.59
NM_006097	MYL9	myosin light polypeptide 9, regulatory	3.44
NM_004120	GBP2	guanylate binding protein 2, interferon-inducible	3.44
AK056875	LOC91316	similar to bK246H3.1 (immunoglobulin lambda-like polypeptide 1, pre-B-cell specific)	3.40
NM_001827	CKS2	CDC28 protein kinase regulator subunit 2	3.36
NM_002203	ITGA2	integrin alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor)	3.35
NM_000599	IGFBP5	insulin-like growth factor binding protein 5	3.33
NM_004530	MMP2	matrix metalloproteinase 2 (gelatinase A, 72kDa gelatinase, 72kDa type IV collagenase)	3.33
NM_004335	BST2	bone marrow stromal cell antigen	3.30
NM_000593	TAP1	transporter 1, ATP-binding cassette, sub-family B (MDR/TAP)	3.29
NM_004915	ABCG1	ATP-binding cassette sub-family G (WHITE), member	3.27
NM_001235	SERPINH 1	serine (or cysteine) proteinase inhibitor, clade H (heat shock protein 47), member 1 (collagen binding protein 1)	3.25
NM_001165	BIRC3	baculoviral IAP repeat-containing 3	3.23
NM_002658	PLAU	plasminogen activator, urokinase	3.20
NM_021103	TMSB10	thymosin, beta 10	3.18
NM_000304	PMP22	peripheral myelin protein 22	3.15
XM_371541	KIAA1641	KIAA1641 protein	3.11
NM_012329	MMD	monocyte to macrophage differentiation-associated	3.07
NM_182744	NBL1	neuroblastoma suppression of tumorigenicity 1	3.06
NM_002245	KCNK1	potassium channel, subfamily K, member 1	3.03
NM_000627	LTBP1	latent transforming growth factor beta binding protein 1	3.02
NM_000063	C2	complement component 2	3.01
NM_000100	CSTB	cystatin B (stefin B)	2.99
NM_000396	CTSK	cathepsin K (pseudodeficiency)	2.98

NM 016816	OAS1	2' 5'-oligoadenylate synthetase 1, 40/46kDa	2.98
NM 004240	TRIP10	thyroid hormone receptor interactor 10	2.95
NM 000138	FBN1	fibrillin 1 (Marfan syndrome)	2.94
NM 002318	LOXL2	lysyl oxidase-like 2	2.92
NM 002053	GBP1	guanylate binding orotein 1 interferon-inducible, lysyl 67kDa	2.90
NM 005564	LCN2	lipocalin 2 (oncogene 24p3)	2.88
NM 153490	KRT13	keratin 13	2.85
NM 004723	ARHGEF 2	rho/rac guanine nucleotide exchange factor (GEF) 2	2.80
NM 004146	NDUFB7	NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 18kDa	2.79
NM 003937	KYNU	kynureninase (L-kynurenine hvdrolase)	2.77
NM 002574	PRDX1	Peroxiredoxin 1	2.77
NM 002444	MSN	moesin	2.73
NM 002901	RCN1	reticulocalbin 1, EF-hand calcium binding domain	2.73
NM 005165	ALDOC	aldolase C, fructose-bisphosphate	2.72
NM 002204	ITGA3	integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)	2.72
NM 033138	CALD1	caldesmon 1	2.71
NM 003816	ADAM9	a disintegrin and metalloproteinase domain 9 (meltrin gamma)	2.69
NM 173843	IL1RN	interleukin 1 receptor antagonist	2.66
NM 000602	SERPINE 1	serine (or cysteine) proteinase inhibitor, clade E (nexin, plasminggen activator inhibitor type 1), member 1	2.65
NM 002213	ITGB5	integrin, beta 5	2.64
NM 004447	EPS8	epidermal growth factor receptor pathway substrate 8	2.64
NM 002928	RGS16	regulator of G-protein singalling 16	2.62
NM 001288	CLIC1	chloride intracellular channel 1	2.61
NM 015996	TAGLN	transgelin	2.57
NM 002087	GRN	granulin	2.55
NM 001183	ATP6AP1	ATPase, H+ transporting, lysosomal accessory protein 1	2.54
NM 001730	KLF5	Kruppel-like factor 5 (intestinal)	2.51
NM 003516	HIST2H2 AA	histone 2, H2aa	2.50
NM 014736	KIAA0101	KIAA0101 gene product	2.49
NM 002290	LAMA4	laminin, alpha 4	2.49
NM 001826	CKS1B	CDC28 protein kinase reaulatory subunit 1B	2.48
NM 001814	CTSC	cathepsin C	2.45
NM 176825	SULT1C1	sulfotransferase family cytosolic, 1C, member 1	2.43
NM 002862	PYGB	phosphorylase, glycogen; brain	2.41
NM 000917	P4HA1	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4- hydroxylase), alpha polypeptideI	2.41
NM 001428	ENO1	enolase 1 (alpha)	2.40
NM 001425	EMP3	epithelial membrane protein 3	2.40
NM 019111	HLA-DRA	maior histocompatibility complex, class II, DR alpha	2.38
NM 001387	DPYSL3	dihydropyrimidinase-like 3	2.36
NM 006471	MRCL3	myosin regulatory light chain MRCL3	2.34
NM 006332	IFI30	interferon gamma-inducible protein 30	2.34
NM 001312	CRIP2	cysteine-rich protein 2	2.33
NM 002224	ITPR3	inositol 1 4 5-triphosphate receptor tvpe 3	2.31
NM 053025	MYLK	myosin light peptide kinase	2.29
NM 002785	PSG11	pregnancy specific beta-1-glycoprotein 11	2.27
NM 000900	MGP	matrix Gla protein	2.26
NM 000962	PTGS1	prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	2.25
NM 005915	MCM6	minichromosome maintenance deficient 6 (MIS5 homolog, S. pombe) (S. cerevisiae)	2.24
NM 001067	TOP2A	topoisomerase (DNA) II alpha 170kDa	2.23
NM 001878	CRABP2	cellular retinoic acid binding protein 2	2.23
NM 006745	SC4MOL	sterol-C4-methyl oxidase-like	2.22
NM 003528	HIST2H2	histone 2, H2be	2.22
BF347579		Transcribed sequence with strong similarity to protein pir:I38500 (H.sapiens) I38500 interferon gamma receptor accessory factor-1 precursor - human	2.21
NM 005261	GEM	GTP binding protein overexpressed in skeletal muscle	2.19
NM 021874	CDC25B	cell division cycle 25B	2.18
NM 022550	XRCC4	X-ray repair complementing defective repair in Chinese hamster cells 4	2.17
NM 020250	GSN	gelsolin (amyloidosis, Finnish type)	2.17
NM 002916	RFC4	replication factor C (activator 1) 4, 37kDa	2.16
NM 005606	LGMN	legumain	2.14
NM 006762	LAPTM5	Lysosomal-associated multispinning membrane protein-5	2.14
NM 002727	PRG1	proteoglycan 1, secretory granule	2.14
NM 002609	PDGFRB	platelet-derived growth factor receptor, beta polypeptide	2.14
NM 001424	EMP2	epithelial membrane protein 2	2.12
NM_005022	PFN1	profilin 1	2.12
NM_001657	AREG	amphiregulin amphireaulin (schwannoma-derived growth factor)	2.11
NM_005100	AKAP12	A kinase (PRKA) anchor protein (gravin) 12	2.11
NM_000860	HPGD	hydroxyprostaglandin dehydrogenase 15 (NAD)	2.10

NM_007115	TNFAIP6	tumor necrosis factor alpha-induced protein 6	2.09
NM_021638	AFAP	actin filament associated protein	2.08
NM_001946	DUSP6	dual specificity phosphatase 6	2.05
NM_181802	UBE2C	ubiquitin-conjugating enzyme E2C	2.04
NM_002593	PCOLCE	procollagen C-endopeptidase enhancer	2.02
NM_033292	CASP1	caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase)	2.02
NM_003870	IQGAP1	IQ motif containing GTPase activating protein 1	2.02
NM_005563	STMN1	stathmin 1/oncoprotein 18	2.01
NM_005558	LAD1	ladinin 1	2.01
NM_001776	ENTPD1	ectonucleoside triphosphate diphosphohydrolase 1	2.00
NM_001299	CNN1	calponin 1, basic, smooth muscle	2.00
AK055128	PSMD14	proteasome (prosome, macropain) 26S subunit, non-ATPase, 14	2.00
NM_006304	SHFM1	split hand/foot malformation (ectrodactyly) type 1	1.98
NM_004024	ATF3	activating transcription factor 3	1.98
NM_000291	PGK1	phosphoglycerate kinase 1	1.98
NM_006520	TCTE1L	t-complex-associated-testis-expressed 1-like	1.97
NM_201380	PLEC1	plectin 1 intermediate filament binding protein 500kDa	1.97
NM_002838	PTPRC	protein tyrosine phosphatase, receptor type, C	1.97
NM_000211	ITGB2	integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit)	1.97
NM_002577	PAK2	p21 (CDKN1A)-activated kinase 2	1.96
NM_000295	SERPINA 1	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1	1.96
NM_183001	SHC1	SHC (Src homology 2 domain containing) transforming protein 1	1.96
NM_005019	PDE1A	phosphodiesterase 1A, calmodulin-dependent	1.95
NM_002298	LCP1	lymphocyte cytosolic protein 1 (L-plastin)	1.95
NM_006769	LMO4	LIM domain only 4	1.94
NM_001465	FYB	FYN binding protein (FYB-120/130)	1.93
NM_183422	TSC22	transforming growth factor beta-stimulated protein TSC-22	1.92
NM_001777	CD47	CD47 antigen (Rh-related antigen, integrin-associated signal transducer)	1.92
NM_001755	CBFB	core-binding factor, beta subunit	1.90
NM_005544	IRS1	insulin receptor substrate 1	1.88
NM_000698	ALOX5	arachidonate 5-lipoxygenase	1.88
NM_006096	NRG1	N-myc downstream regulated gene 1	1.88
NM_001105	ACVR1	activin A receptor, type 1	1.87
NM_003105	SORL1	sortilin-related receptor, L(DLR class) A repeats-containing	1.85
NM_001998	FBLN2	fibulin 2	1.85
NM_014791	MELK	maternal embryonic leucine zipper kinase	1.85
NM_003092	SNRPB2	small nuclear ribonucleoprotein polypeptide B	1.84
NM_001120	TETRAN	tetracycline transporter-like protein	1.84
NM_182943	PLOD2	procollagen-lysine, 2-oxoglutarate 5-dioxygenase (lysine hydroxylase) 2	1.83
NM_181862	BACH	brain acyl-CoA hydrolase	1.82
NM_021102	SPINT2	serine protease inhibitor, Kunitz type, 2	1.82
NM_004419	DUSP5	dual specificity phosphatase 5	1.81
NM_006482	DYRK2	dual specificity tyrosine-(Y)-phosphorylation regulated kinase 2	1.81
NM_145690	YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide	1.81
NM_000714	BZRP	benzodiazapine receptor (peripheral)	1.81
NM_013995	LAMP2	lysosomal-associated membrane protein 2	1.80
CA450153	ACYP1	acylphosphatase 1, erythrocyte (common) type	1.80
NM_000405	GM2A	GM2 ganglioside activator protein	1.79
NM_139275	AKAP1	A kinase (PRKA) anchor protein 1	1.79
NM_001679	ATP1B3	ATPase, Na+/K+ transporting, beta 3 polypeptide	1.79
NM_016343	CENPF	centromere protein F, 350/400ka (mitosin)	1.79
NM_002201	ISG20	interferon stimulated gene 20kDa	1.79
NM_002463	MX2	myxovirus (influenza virus) resistance 2 (mouse)	1.79
NM_006820	C1orf29	chromosome 1 open reading frame 29	1.79
NM_201397	GPX1	glutathione peroxidase 1	1.79
NM_005738	ARL4	ADP-ribosylation factor-like 4	1.78
NM_001038	SCNN1A	sodium channel nonvoltage-gated 1 alpha	1.78
NM_002863	PYGL	phosphorylase, glycogen; liver (Hers disease, glycogen storage disease type VI)	1.78
NM_001281	CKAP1	cytoskeleton associated protein 1	1.77
NM_003879	CFLAR	CASP8 and FADD-like apoptosis regulator	1.76
NM_182948	PRKACB	protein kinase, cAMP-dependent catalytic, beta	1.75
NM_006009	TUBA3	tubulin, alpha 3	1.75
NM_201444	DGKA	diacylglycerol kinase, alpha 80kDa	1.74
NM_005471	GNPDA1	glucosamine-6-phosphate deaminase 1	1.74
NM_001451	FOXF1	forkhead box F1	1.74
NM_001988	EVPL	envoplakin	1.73
NM_021724	NR1D1	nuclear receptor subfamily 1, group D member 1	1.73
NM_006364	SEC23A	Sec23 homolog A (S. cerevisiae)	1.72
NM_002129	HMGB2	high-mobility group box 2	1.72

NM_004172	SLC1A3	solute carrier family 1 (glial high affinity glutamate transporter), member 3	1.71
NM_001421	ELF4	E74-like factor 4 (ets domain transcription factor)	1.71
NM_005566	LDHA	lactate dehydrogenase A	1.70
NM_000270	NP	nucleoside phosphorylase	1.69
NM_153425	TRADD	TNFRSF1A-associated via death domain	1.67
NM_004762	PSCD1	pleckstrin homology, Sec7 and coiled-coil domains (cytohesin 1)	1.67
NM_001985	ETFB	electron-transfer-flavoprotein, beta polypeptide	1.67
NM_016587	CBX3	chromobox homolog 3 (HP1 gamma homolog, Drosophila)	1.66
NM_002085	GPX4	glutathione peroxidase 4 (phospholipid hydroperoxidase)	1.66
NM_002795	PSMB3	proteasome (prosome, macropain) subunit, beta type, 3	1.65
NM_000963	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	1.65
NM_001642	APLP2	amyloid beta (A4) precursor-like protein 2	1.65
NM_000569	FCGR3A	Fc fragment of IgG low affinity iiiia receptor for (CD16)	1.64
NM_000362	TIMP3	tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)	1.63
NM_002417	MKI67	antigen identified by monoclonal antibody Ki-67	1.63
NM_000175	GPI	glucose phosphatase isomerase	1.63
AF179995	SEPT8	septin 8	1.62
NM_004121	GGTLA1	gamma-glutamyltransferase-like activity 1	1.62
NM_002690	POLB	polymerase (DNA directed), beta	1.62
NM_004334	BST1	bone marrow stromal cell antigen 1	1.61
NM_001892	CSNK1A1	casein kinase 1, alpha 1	1.61
NM_014670	BZW1	basic leucine zipper and W2 domains 1	1.60
NM_001110	ADAM10	a disintegrin and metalloproteinase domain 10	1.60
NM_005792	MPHOSP H6	M-phase phosphoprotein 6	1.60
NM_001126	ADSS	adenylosuccinate synthase	1.59
XM 376059	SERTAD2	SERTA domain containing 2	1.59
NM_001664	ARHA	ras homolog gene family, member A	1.59
NM_002475	MLC1SA	myosin light chain 1 slow a	1.59
NM_014498	GOLPH4	golgi phosphoprotein 4	1.59
NM_005964	MYH10	myosin heavy polypeptide 10 non-muscle	1.59
NM_003330	TXNRD1	thioredoxin reductase 1	1.59
NM_001757	CBR1	carbonyl reductase 1	1.58
NM_003130	SRI	sorcin	1.57
NM_006765	TUSC3	tumor suppressor candidate 3	1.57
NM_183047	PRKCBP 1	protein kinase C binding protein 1	1.57
NM_005333	HCCS	holocytochrome c synthase (cytochrome c heme-lyase)	1.57
NM_001444	FABP5	fatty acid binding protein 5 (psoriasis-associated)	1.57
NM_001799	CDK7	cyclin-dependent kinase 7 (M015 homolog, Xenopus laevis, cdk-activating kinase)	1.57
NM_001539	DNAJA1	DnaJ (Hsp40) homolog subfamily A member 1	1.57
NM_004475	FLOT2	flotillin 2	1.57
NM_004308	ARHGAP 1	Rho GTPase activating protein 1	1.56
NM_002388	MCM3	MCM3 minichromosome maintenance deficient 3 (S. cerevisiae)	1.56
NM_006435	IFITM2	interferon induced transmembrane protein 2 (1-8D)	1.56
NM_000454	SOD1	superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))	1.56
NM_015161	ARL6IP	ADP-ribosylation factor-like 6 interacting protein	1.56
NM_078480	SLAHBP1	fuse-binding protein-interacting repressor	1.56
NM_025207	PP591	FAD-synthetase	1.56
NM_002833	PTPN9	protein tyrosine phosphatase non-receptor type 9	1.55
NM_001753	CAV1	caveolin 1 caveolae protein 22kDa	1.55
NM_003286	TOP1	topoisomerase (DNA) I	1.55
BU739663		Transcribed sequence with moderate similarity to protein sp:P13196 (H.sapiens) HEM1_HUMAN 5-aminolevulinic acid synthase, nonspecific mitochondrial precursor	1.55
NM_006788	RALBP1	ralA binding protein 1	1.54
NM_000944	PPP3CA	protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform (calcineurin A alpha)	1.54
NM_003374	VDAC1	voltage-dependent anion channel 1	1.54
NM_000560	CD53	CD53 antigen	1.54
NM_002037	FYN	FYN oncogene related to SRC FGR, YES	1.54
NM_002885	RAP1GA1	RAP1 GTPase activating protein 1	1.53
NM_018979	PRKWINK 1	lprotein kinase, lysine deficient 1	1.53
NM_002835	PTPN12	protein tyrosine phosphatase, non-receptor type 12	1.53
NM_007315	STAT1	signal transducer and activator of transcription 1, 91kDa	1.52
NM_014846	KIAA0196	KIAA0196 gene product	1.52
NM_001237	CCNA2	cyclin A2	1.52
NM_004596	SNRPA	small nuclear ribonucleoprotein polypeptide A	1.52
NM_002790	PSMA5	proteasome (prosome, macropain) subunit, alpha type, 5	1.52
NM_015361	R3HDM	R3H domain (binds single-stranded nucleic acids) containing	1.52
NM_001665	ARHG	ras homolog gene family, member G (rho G)	1.51
NM_002788	PSMA3	proteasome (prosome macropain) subunit, alpha type, 3	1.50
NM_006904	PRKDC	protein kinase, DNA-activated, catalytic polypeptide	1.50
NM_003400	XPO1	exportin 1 (CRM1 homolog, yeast)	1.50

NM_178014	OK/SW-cl.56	beta 5-tubulin	1.50
NM_002634	PHB	prohibitin	1.49
NM_004792	PPIG	peptidyl-prolyl isomerase G (cyclophilin G)	1.49
NM_002508	NID	nidogen (enactin)	1.49
NM_001765	CD1C	CD1C antigen, c polypeptide	1.48
NM_000311	PRNP	prion protein (p27-30) (Creutzfeld-Jakob disease, Gerstmann-Strausler-Scheinker syndrome, fatal familial insomnia)	1.48
NM_006437	ADPRTL1	ADP-ribosyltransferase (NAD+; poly (ADP-ribose) polymerase)-like 1	1.48
NM_002759	PRKR	protein kinase, interferon-inducible double stranded RNA dependent	1.48
NM_014669	KIAA0095	KIAA0095 gene product	1.47
NM_003391	WNT2	wingless-type MMTV integration site family member 2	1.47
NM_004309	ARHGDI A	Rho GDP dissociation inhibitor (GDI) alpha	1.47
NM_000418	IL4R	interleukin 4 receptor	1.46
NM_003352	UBL1	ubiquitin-like 1 (sentrin)	1.46
NM_006290	TNFAIP3	tumor necrosis factor alpha-induced protein 3	1.45
NM_004763	ITGB1BP1	integrin beta 1 binding protein 1	1.45
NM_005754	G3BP	Ras-GTPase-activating protein SH3-domain-binding protein	1.45
NM_021990	GABRE	gamma-aminobutyric acid (GABA) A receptor, epsilon	1.44
NM_001379	DNMT1	DNA (cytosine-5-)-methyltransferase 1	1.44
NM_001154	ANXA5	annexin A5	1.44
NM_004354	CCNG2	cyclin G2	1.44
NM_005002	NDUFA9	NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa	1.43
NM_001931	DLAT	dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex)	1.43
NM_005902	MADH3	MAD mothers against decapentaplegic homolog 3 (Drosophila)	1.43
NM_000110	DPYD	dihydropyrimidine dehydrogenase	1.43
NM_001316	CSE1L	CSE1 chromosome segregation 1-like (yeast)	1.43
NM_000167	GK	glycerol kinase	1.43
NM_001924	GADD45 A	growth arrest and DNA-damage-inducible, alpha	1.42
NM_014225	PPP2R1A	protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), alpha isoform	1.42
NM_001233	CAV2	caveolin 2	1.42
NM_176863	PSME3	proteasome (prosome, macropain) activator subunit 3 (PA28 gamma; Ki)	1.42
NM_001905	CTPS	CTP synthase	1.41
NM_005653	TFCP2	transcription factor CP2	1.41
NM_003405	YWHAH	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta polypeptide	1.41
NM_003392	WNT5A	wingless-type MMTV integration site family, member 5A	1.40
NM_002375	MAP4	microtubule-associated protein 4	1.40
NM_006353	HMGN4	high mobility group nucleosomal binding domain 4	1.39
NM_006527	SLBP	stem-loop (histone) binding protein	1.39
NM_000517	HBA2	hemoglobin alpha 2	1.38
NM_002661	PLCG2	phospholipase C, gamma 2 (phosphatidylinositol-specific)	1.38
NM_001493	GDI1	GDP dissociation inhibitor 1	1.38
NM_181430	FOXP2	forkhead box K2	1.38
NM_002086	GRB2	growth factor receptor-bound protein 2	1.38
NM_002868	RAB5B	RAB5B, member RAS oncogene family	1.37
NM_002768	PCOLN3	procollagen (type III) N-endopeptidase	1.37
NM_014742	TM9SF4	transmembrane 9 superfamily protein member 4	1.37
NM_004344	CETN2	centrin, EF-hand protein, 2	1.37
NM_002881	RALB	v-ral simian leukemia viral oncogene homolog B (ras related; GTP binding protein)	1.36
NM_004099	STOM	stomatin	1.36
NM_031844	HNRPU	heterogeneous nuclear ribonucleoprotein U (scaffold attachment factor A)	1.36
NM_000480	AMPD3	adenosine monophosphate deaminase (isoform E)	1.35
NM_006561	CUGBP2	CUG triplet repeat RNA binding protein 2	1.35
NM_152879	DGKD	diacylglycerol kinase delta 130kDa	1.35
NM_138558	PPP1R8	protein phosphatase 1 regulatory (inhibitor) subunit 8	1.35
NM_004941	DHX8	DEAH (Asp-Glu-Ala-His) box polypeptide 8	1.34
NM_021079	NMT1	N-myristoyltransferase 1	1.33
NM_004622	TSN	translin	1.33
NM_002473	MYH9	myosin, heavy polypeptide 9, non-muscle	1.33
NM_006889	CD86	CD86 antigen (CD28 antigen ligand 2, B7-2 antigen)	1.33
NM_004383	CSK	c-src tyrosine kinase	1.33
NM_004317	ASNA1	arsA arsenite translocator ATP-binding homolog 1 (bacterial)	1.33
NM_024298	LENG4	leukocyte receptor cluster (LRC) member 4	1.32
NM_001912	CTSL	cathepsin L	1.32
NM_001357	DHX9	DEAH (Asp-Glu-Ala-His) box polypeptide 9	1.32
NM_006849	PDIP	protein disulfide isomerase, pancreatic	1.32
NM_018457	DKFZP564J157	DKFZ, 0564J157 protein	1.31
NM_024880	TCF7L2	transcription factor 7-like 2 (T-cell specific, HMG-box)	1.31
NM_002081	GPC1	glypican 1	1.31
NM_004235	KLF4	Kruppel-like factor 4 (gut)	1.31

NM_005565	LCP2	lymphocyte cytosolic protein 2 (SH2 domain containing leukocyte protein of 76kDa)	1.30
NM_002667	PLN	phospholamban	1.30
NM_004946	DOCK2	dedicator of cytokinesis 2	1.30
NM_002035	FVT1	follicular lymphoma variant translocation 1	1.29
NM_002865	RAB2	RAB2 member RAS oncogene family	1.29
NM_002806	PSMC6	proteasome (prosome macropain) 26S subunit ATPase 6	1.29
NM_004240	TRIP10	thyroid hormone receptor interactor 10	1.28
NM_003760	EIF4G3	eukaryotic translation initiation factor 4 gamma, 3	1.28
NM_005151	USP14	ubiquitin specific protease 14 (tRNA quanine transglycosylase)	1.28
NM_015922	H105E3	NAD(P) deoendent steroid dehydrogenase-like	1.27
NM_033306	CASP4	caspase 4 apoptosis-related cysteine protease	1.27
NM_198189	COPS8	COP9 constitutive photomorphogenic homolog subunit 8 (Arabidopsis)	1.27
NM_001933	DLST	dihydrolipoamide S-succinyltransferase (E2 component of 2-oxo-glutarate complex)	1.27
NM_015004	KIAA0116	KIAA0116 protein	1.27
NM_033362	MRPS12	mitochondrial ribosomal protein S12	1.27
NM_004180	TANK	TRAF family member-associated NFKB activator	1.26
NM_014734	KIAA0247	KIAA0247	1.26
NM_005271	GLUD1	glutamate dehydrogenase 1	1.25
NM_003009	SEPW1	selenoprotein W, 1	1.25
NM_182641	FALZ	fetal Alzheimer antigen	1.24
NM_007362	NCBP2	nuclear cap binding protein subunit 2 20kDa	1.24
NM_004292	RIN1	Ras and Rab interactor 1	1.24
NM_014608	CYFIP1	cytoplasmic FMR1 interacting protein 1	1.23
NM_022333	TIAL1	TIA1 cytotoxic granule-associated RNA binding protein-like 1	1.23
NM_003126	SPTA1	spectrin alpha erythrocytic 1 (elliptocytosis 2)	1.22
NM_014602	PIK3R4	phosphoinositide-3-kinase regulatory subunit 4, p150	1.18
NM_002194	INPP1	inositol polyphosphate-1-phosphatase	1.16

Note: Accession IDs "NM_XXXX" are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucore>).

Table 7: Commonly Downregulated Genes in Pancreatic Cancer

Accession	Gene Symbol	Gene Name	FC
NM_006499	LGALS8	galactosite-binding, soluble, 8 (galectin 8)	0.87
NM_000466	PEX1	peroxisome biogenesis factor 1	0.81
NM_002766	PRPSAP1	phosphoribosyl pyrophosphate synthetase-associated protein 1	0.81
NM_147131	GALT	galactose-1-phosphate uridylyltransferase	0.80
NM_002101	GYPC	glycophorin C (Gerbich blood group)	0.80
NM_002880	RAF1	v-raf-1 murine leukemia viral oncogene homolog 1	0.80
NM_004649	C218f33	chromosome 21 open reading frame 33	0.80
NM_003262	TLOC1	translocation protein 1	0.79
NM_147223	NCOA1	nuclear receptor coactivator 1	0.79
NM_007062	PWP1	nuclear phosphoprotein similar to <i>S. cerevisiae</i> PWP1	0.79
NM_005561	LAMP1	lysosomal-associated membrane protein 1	0.79
NM_006810	PDIR	for protein disulfide isomerase-related	0.78
NM_033360	KRAS2	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog	0.77
NM_001513	GSTZ1	glutathione transferase zeta 1 (maleylacetoacetate isomerase)	0.77
NM_006184	NUCB1	nucleobindin 1	0.77
NM_001634	AMD1	adenosylmethionine decarboxylase 1	0.76
NM_006749	SLC20A2	solute carrier family 20 (phosphate transporter), member 2	0.76
NM_003144	SSR1	signal sequence receptor alpha (translocon-associated protein alpha)	0.76
NM_004606	TAF1	TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor 250kDa	0.75
BX648788		MRNA; cDNA DKFZP686M12165 (from clone DKFZP686M12165)	0.75
NM_004035	ACOX1	acyl-Coenzyme A oxidase 1 palmitoyl	0.74
NM_000287	PEX6	peroxisomal biogenesis factor 6	0.73
NM_003884	PCAF	p300/CBP-associated factor	0.73
NM_006870	DSTN	destrin (actin depolymerizing factor)	0.73
NM_001604	PAX6	paired box gene 6 (aniridia keratitis)	0.72
NM_000722	CACNA2 D1	calcium channel voltage-dependent alpha 2/delta subunit 1	0.72
NM_033022	RPS24	ribosomal protein S24	0.72
NM_004563	PCK2	phosphoenolpyruvate carboxykinase 2 (mitochondrial)	0.72
NM_002602	PDE6G	phosphodiesterase 6G cGMP-specific, rod, gamma	0.72
NM_001889	CRYZ	crystalline, zeta (quinone reductase)	0.72
NM_002339	LSP1	lymphocyte-specific protein 1	0.72
NM_016848	SHC3	src homology 2 domain containing transforming protein C3	0.71
NM_002906	RDX	radixin	0.71
NM_007014	WWP2	Nedd-4-like ubiquitin-protein ligase	0.71
NM_000414	HSD17B4	hydroxysteroid (17-beta) dehydrogenase 4	0.71
NM_001127	AP1B1	adaptor-related protein complex 1, beta 1 subunit	0.71
NM_002402	MEST	mesoderm specific transcript homolog (mouse)	0.70
NM_033251	RPL13	ribosomal protein L13	0.70
NM_139069	MAPK9	mitogen-activated protein kinase 9	0.70
NM_002913	RFC1	replication factor C (activator 1) 1, 145kDa	0.70
NM_000487	ARSA	arylsulfatase A	0.70
NM_006973	ZNF32	zinc finger protein 32 (KOX 30)	0.70
NM_005310	GRB7	growth factor receptor-bound protein 7	0.70
NM_005962	MXI1	MAX interacting protein 1	0.69
NM_005359	MADH4	MAD, mothers against decapentaplegic homolog 4 (Drosophila)	0.69
NM_002340	LSS	lanosterol synthase (2 3-oxidosqualene-lanosterol cyclase)	0.69
NM_003684	MKNK1	MAP kinase-interacting serine/threonine kinase 1	0.68
NM_005671	D8S2298 E	reproduction 8	0.68
NM_000309	PPOX	protoporphyrinogen oxidase	0.68
NM_000994	RPL32	ribosomal protein L32	0.68
NM_000972	RPL7A	ribosomal protein L7a	0.68
NM_005101	GIP2	interferon, alpha-inducible protein (clone IFI-15K)	0.67
NM_001129	AEBP1	AE binding protein 1	0.67
NM_001011	RPS7	ribosomal protein S7	0.67
NM_001153	ANXA4	annexin A4	0.67
NM_012335	MYO1F	myosin IF	0.66
NM_005007	NFKBIL1	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-like 1	0.66
NM_001870	CPA3	carboxypeptidase A3 (mast cell)	0.66
NM_181826	NF2	neurofibromin 2 (bilateral acoustic neuroma)	0.66
NM_000285	PEPD	peptidase D	0.66
NM_006180	NTRK2	neurotrophic tyrosine kinase, receptor type 2	0.66
NM_000543	SMPD1	sphingomyelin phosphodiesterase 1, acid lysosomal (acid sphingomyelinase)	0.66
NM_001459	FLT3LG	fms-related tyrosine kinase 3 ligand	0.65
NM_003750	EIF3S10	eukaryotic translation initiation factor 3, subunit 10 theta, 150/170kDa	0.65

NM_005570	LMAN1	lectin mannose-binding, 1	0.65
NM_004409	DMPK	dystrophia myotonica-protein kinase	0.65
NM_172159	KCNAB1	potassium voltage-gated channel, shaker-related subfamily, beta member 1	0.65
XM 352750	COL14A1	collagen, type XIV, alpha 1 (undulin)	0.65
NM_001731	BTG1	B-cell translocation gene 1, anti-proliferative	0.65
NM_000884	IMPDH2	IMP (inosine monophosphate) dehydrogenase 2	0.64
NM_001885	CRYAB	crystallin, alpha B	0.64
NM_000240	MAOA	monoamine oxidase A	0.64
NM_003136	SRP54	signal recognition particle 54kDa	0.63
NM_000281	PCBD	6-pyruvoyl-tetrahydropterin synthase/dimerization cofactor of hepatocyte nuclear factor 1 alpha (TCF1)	0.63
NM_005729	PPIF	peptidylprolyl isomerase F (cyclophilin F)	0.63
NM_006481	TCF2	transcription factor 2, hepatic; LF-B3' variant hepatic nuclear factor	0.63
NM_002089	CXCL2	chemokine (C-X-C motif) liqand 2	0.63
NM_001961	EEF2	eukaryotic translation elongation factor 2	0.63
NM_001801	CDO1	cysteine dioxygenase type I	0.63
NM_006389	HYOU1	hypoxia up-regulated 1	0.63
XM 167711	ITGA8	integrin, alpha 8	0.62
NM_014765	TOMM20	translocase of outer mitochondrial membrane 20 homolog (yeast)	0.62
NM_006714	SMPDL3 A	sphingomyelin phosphodiesterase, acid-like 3A	0.62
NM_000016	ACAOM	acyl-Coenzyme A dehydrogenase C-4 to C-12 straight chain	0.62
NM_003924	PHOX2B	paired-like homeobox 2b	0.62
NM_002078	GOLGA4	golgi autoantigen, golgin subfamily a 4	0.62
NM_002736	PRKAR2 B	protein kinase cAMP-dependent, regulatory, type II beta	0.62
BQ217469	K1AA0114	K1AA0114 gene product	0.61
NM_006307	SRPX	sushi-repeat-containing protein X-linked	0.61
NM_002184	IL6ST	interleukin 6 signal transducer (gp130 oncostatin M receptor)	0.61
NM_153186	ANKR015	ankyrin repeat domain 15	0.61
NM_003038	SIC1A4	solute carrier family 1 (glutamate/neutral amino acid transporter), member 4	0.60
NM_006195	PBX3	pre-B-cell leukemia transcription factor 3	0.60
NM_000327	ROM1	retinal outer segment membrane protein 1	0.60
NM_003463	PTP4A1	protein tyrosine phosphatase type IVA, member 1	0.60
NM_001520	GTF3C1	general transcription factor iiiC polypeptide 1 alpha 220kDa	0.60
NM_006277	ITSN2	intersectin 2	0.59
NM_000985	RPL17	ribosomal protein L17	0.59
NM_000909	NPY1R	neuropeptide Y receptor Y1	0.59
NM_001014	RPS10	ribosomal protein S10	0.59
NM_022307	ICA1	islet cell autoantigen 1 69kDa	0.58
NM_002567	PBP	prostatic binding protein	0.58
NM_012324	MAPK8IP 2	mitogen-activated protein kinase 8 interacting protein 2	0.58
NM_004490	GRB14	growth factor receptor-bound protein 14	0.58
NM_004733	SLC33A1	solute carrier family 33 (acetyl-CoA transporter), member 1	0.57
NM_002197	AC01	aconitase 1, soluble	0.57
NM_000505	F12	coagulation factor Xii (Hageman factor)	0.57
NM_005010	NRCAM	neuronal cell adhesion molecule	0.56
NM_006963	ZNF22	zinc finger protein 22 (KOX 15)	0.56
NM_006827	TMP21	transmembrane trafficking protein	0.55
NM_004394	DAP	death-associated protein	0.54
NM_001089	ABCA3	ATP-binding cassette, sub-family A (ABC), member 3	0.54
NM_004470	FKBP2	FK506 binding protein 2, 13kDa	0.53
NM_005749	TOB1	transducer of ERBB2, 1	0.53
NM_001355	DDT	D-dopachrome tautomerase	0.53
NM_002111	HD	huntington (Huntington disease)	0.53
NM_002635	SIC25A3	solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3	0.53
NM_005596	NFIB	nuclear factor I/B	0.53
NM_006273	CCL7	chemokine (C-C motif) liqand 7	0.53
NM_001013	RPS9	ribosomal protein S9	0.52
NM_001551	IGBP1	immunoglobulin (CD79A) binding protein 1	0.52
NM_004498	ONECUT 1	one cut domain, family member 1	0.52
NM_004484	GPC3	glypican 3	0.52
NM_130797	DPP6	dipeptidylpeptidase 6	0.52
NM_000746	CHRNA7	cholinergic receptor, nicotinic, alpha polypeptide 7	0.51
NM_001756	SERPINA 6	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase antitrypsin), member 6	0.51
NM_001327	CTAG1	cancer/testis antigen 1	0.51
NM_003651	CSDA	cold shock domain protein A	0.50
NM_005848	IRLB	c-myc promoter-binding protein	0.50
BC040073	H19	H19, imprinted maternally expressed untranslated mRNA	0.50
NM_002228	JUN	v-jun sarcoma virus 17 oncogene homolog (avian)	0.49
NM_000795	DRD2	dopamine receptor D2	0.48
NM_002084	GPX3	glutathione peroxidase 3 (plasma)	0.48

NM_002716	PPP2R1B	protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta isoform	0.48
NM_005166	APLP1	amyloid beta (A4) precursor-like protein 1	0.48
NM_005911	MAT2A	methionine adenosyltransferase II, alpha	0.47
NM_000208	INSR	insulin receptor	0.47
NM_170736	KCNJ15	potassium inwardly-rectifying channel, subfamily J, member 15	0.47
NM_001190	BCAT2	branched chain aminotransferase 2, mitochondrial	0.47
NM_005336	HDLBP	high density lipoprotein binding protein (viquilin)	0.46
NM_001076	UGT2B15	UDP glycosyltransferase 2 family, polypeptide B15	0.46
NM_001152	SLC25A5	solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator, member 5)	0.46
NM_002729	HHEX	hematopoietically expressed homeobox	0.46
NM_002847	PTPRN2	protein tyrosine phosphatase, receptor type, N polypeptide 2	0.44
NM_000447	PSEN2	presenilin 2 (Alzheimer disease 4)	0.44
NM_152868	KCNJ4	potassium inwardly-rectifying channel, subfamily J, member 4	0.44
NM_001759	CCND2	cyclin D2	0.44
NM_000316	PTHRI	parathyroid hormone receptor 1	0.44
NM_001612	ACRV1	acrosomal vesicle protein 1	0.43
NM_002467	MYC	v-mc myelocytomatosis viral oncogene homolog (avian)	0.43
NM_004454	ETV5	ets variant gene 5 (ets-related molecule)	0.43
NM_002846	PTPRN	protein tyrosine phosphatase, receptor type N	0.43
NM_005622	SAH	SA hypertension-associated homolog (rat)	0.42
NM_001989	EVX1	eve, even-skipped homeo box homolog 1 (Drosophila)	0.42
NM_000166	GJB1	gap junction protein, beta 1, 32kDa (connexin 32, Charcot-Marie-Tooth neuropathy, X-linked)	0.42
NM_014685	HERPUD1	homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1	0.42
NM_001735	C5	complement component 5	0.41
NM_005504	BCAT1	branched chain aminotransferase 1, cytosolic	0.41
NM_006808	SEC61B	Sec61 beta subunit	0.40
NM_006751	SSFA02	sperm specific antigen 2	0.39
NM_005947	MT1B	metallothionein 1B (functional)	0.38
NM_005576	LOXL1	lysyl oxidase-like 1	0.37
NM_005627	SGK	serum/glucocorticoid regulated kinase	0.36
NM_004683	RGN	regucalcin (senescence marker protein-30)	0.36
NM_00918	P4HB	procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), beta polypeptide (protein disulfide isomerase; thyroid hormone binding protein p55)	0.36
BC044862		Macrophage stimulating 1 (hepatocyte growth factor-like), mRNA (cDNA clone IMAGE:4821945), with apparent retained intron	0.35
NM_005952	MT1X	metallothionein 1X	0.35
NM_000429	MAT1A	methionine adenosyltransferase 1, alpha	0.35
NM_004010	DMD	dystrophin (muscular dystrophy, Duchenne and Becker types)	0.34
NM_000689	ALDH1A1	aldehyde dehydrogenase 1 family, member A1	0.34
NM_002889	RARRES2	retinoic acid receptor responder (tazarotene induced) 2	0.33
NM_006280	SSRA	signal sequence receptor, delta (translocon-associated protein delta)	0.33
NM_003819	PABPC4	poly(A) binding protein, cytoplasmic 4 (inducible form)	0.32
NM_000755	CRAT	carnitine acetyltransferase	0.32
NM_015684	ATP5S	ATP synthase, H+ transporting, mitochondrial F0 complex, subunit s (factor B)	.030
NM_033200	BC002942	hypothetical protein BC002942	0.30
BCG986717		Transcribed sequences	0.29
NM_148923	CYB5	cytochrome b-5	0.29
NM_000609	CXCL12	chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1)	0.29
NM_001979	EPHX2	epoxide hydrolase 2, cytoplasmic	0.28
NM_001332	CTNND2	catenin (caherin-associated protein), delta 2 (neural plakophilin-related arm-repeat protein)	0.27
NM_001831	CLU	clusterin (complement lysis inhibitor, SP-40, 40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)	0.27
NM_005080	XBP1	X-box binding protein 1	0.27
NM_000156	GAMT	guanidinoacetate N-methyltransferase	0.27
NM_182848	CLDN10	claudin 10	0.26
NM_000065	C6	complement component 6	0.26
NM_000128	F11	coagulation factor XI (plasma thromboplasin antecedent)	0.24
NM_003822	MR5A2	nuclear receptor subfamily 5, group A, member 2	0.24
NM_006406	PRDX4	peroxiredoxin 4	0.21
BM799844	BNIP3	BCL2/adenovirus E1B 19kDa interacting protein 3	0.21
NM_018646	TRPV6	transient receptor potential cation channel, subfamily V, member 6	0.21
NM_005013	NUCB2	nucleobindin 2	0.21
NM_000624	SERPINA3	serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3	0.19
NM_005065	SEL1L	sel-1 suppressor of lin-12-like (C. elegans)	0.18
NM_198235	RNASE1	ribonuclease, RNase A family, 1 (pancreatic)	0.17
NM_006498	LGALS2	lectin, galactoside-binding, soluble, 2 (galectin 2)	0.16
NM_002899	RBP1	retinol binding protein 1, cellular	0.12
NM_004413	DPEP1	dipeptidase 1 (renal)	0.12
NM_021603	FXYD2	FXYD domain containing ion transport regulator 2	0.09
NM_138938	PAP	pancreatitis-associated protein	0.08

NM 201553	FGL	fibrinogen-like 1	0.07
NM 001482	GATM	glycerine amidinotransferase (L-arginine: glycine amidinotransferase)	0.04
NM 033240	ELA2A	elastase 2 ^a	0.02
NM 000101	CYBA	cytochrome b-245, alpha polypeptide	0.02

Note: Accession IDs "NM_XXXX" are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide>).

Table 8. microRNAs that are up-regulated in glioblastoma cells.

Fold change	microRNA
Up 10X	miR-10b, miR-10a, miR-96
Up 2-10X	miR-182, miR-199b, miR-21, miR124, miR-199a, miR-199-s, miR-199a, miR-106b, miR-15b, miR-188, miR-148a, miR-104, miR-224, miR-368, miR-23a, miR-210N, miR-183, miR-25, miR-200cN, miR-373, miR-17-5p, let-7a, miR-16, miR-19b, miR-26a, miR-27a, miR-92, miR-93, miR-320 and miR-20
Up 1-2 X	miR-143, miR-186. miR-337, miR-30a-3p, miR-355, miR-324-3p etc.

Table 9. microRNAs that are down-regulated in glioblastoma cells.

Fold change	microRNA
Down 10X	miR-218, miR-124a, miR-124b, miR-137, miR-184, miR-129, miR-33, miR-139, miR-128b, miR-128a, miR-330, miR-133a, miR-203, miR-153, miR-326, miR-105, miR-338, miR-133b, miR-132, miR-154, miR-29bN
Down 2-10X	miR-7N, miR-323, miR-219, miR-328, miR-149, miR-122a, miR-321, miR-107, miR-190, miR-29cN, miR-95, miR-154, miR-221, miR-299, miR-31, miR-370, miR-331, miR-342, miR-340

Table 10. MMP genes contained within microvesicles isolated from glioblastoma cell line.

Gene Symbol	Accession ID	Gene Description
MMP1	AK097805	Homo sapiens cDNA FLJ40486 fis, clone TESTI2043866. [AK097805]
MMP8	NM_002424	Homo sapiens matrix metalloproteinase 8 (neutrophil collagenase) (MMP8), mRNA [NM_002424]
MMP12	NM_002426	Homo sapiens matrix metalloproteinase 12 (macrophage elastase) (MMP12), mRNA [NM_002426]
MMP15	NM_002428	Homo sapiens matrix metalloproteinase 15 (membrane-inserted) (MMP15), mRNA [NM_002428]
MMP20	NM_004771	Homo sapiens matrix metalloproteinase 20 (enamelysin) (MMP20), mRNA [NM_004771]
MMP21	NM_147191	Homo sapiens matrix metalloproteinase 21 (MMP21), mRNA [NM_147191]
MMP24	NM_006690	Homo sapiens matrix metalloproteinase 24 (membrane-inserted) (MMP24), mRNA [NM_006690]
MMP26	NM_021801	Homo sapiens matrix metalloproteinase 26 (MMP26), mRNA [NM_021801]
MMP27	NM_022122	Homo sapiens matrix metalloproteinase 27 (MMP27), mRNA [NM_022122]

Note: Gene symbols are standard symbols assigned by Entrez Gene (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene>). Accession IDs are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide>).

Table 11. Genes containing somatic mutations in glioblastoma adapted from the result of TCGA project (McLendon et al., 2008).

Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id
A2M	2	BCL11A	53335	CHEK2	11200
A2M	2	BCL11A	53335	CHEK2	11200
A2M	2	BCL11A	53335	CHEK2	11200
ABCA3	21	BCL11A	53335	CHEK2	11200
ABCC4	10257	BCL11A	53335	CHEK2	11200
ABCC4	10257	BCL2L13	23786	CHEK2	11200
ABCC4	10257	BCR	613	CHEK2	11200
ADAM12	8038	BMPR1A	657	CHEK2	11200
ADAM15	8751	BRCA1	672	CHEK2	11200
ADAMTSL3	57188	BRCA2	675	CHEK2	11200
ADAMTSL3	57188	BRCA2	675	CHEK2	11200
ADM	133	BRCA2	675	CHI3L2	1117
AIFM1	9131	BTK	695	CHIC2	26511
AKAP2	11217	C18orf25	147339	CHL1	10752
AKAP2	11217	C20orf160	140706	CHL1	10752
ALK	238	C20orf160	140706	CMTM3	123920
ANK2	287	C22orf24	25775	CNTFR	1271
ANK2	287	C6orf60	79632	COL11A1	1301
ANK2	287	C6orf60	79632	COL1A1	1277
ANK2	287	C9orf72	203228	COL1A1	1277
ANK2	287	CAND1	55832	COL1A1	1277
ANK2	287	CASP9	842	COL1A1	1277
ANXA1	301	CAST	831	COL1A2	1278
ANXA7	310	CAST	831	COL1A2	1278
AOC3	8639	CAST	831	COL3A1	1281
AOC3	8639	CBL	867	COL3A1	1281
APBB1IP	54518	CBL	867	COL3A1	1281
APC	324	CCR5	1234	COL3A1	1281
ARNT	405	CD46	4179	COL5A1	1289
ASPM	259266	CDC123	8872	COL6A2	1292
ASPM	259266	CDKL5	6792	COL6A2	1292
ASXL1	171023	CDKN2A	1029	COL6A2	1292
ASXL1	171023	CDKN2A	1029	CRLF1	9244
ATM	472	CDKN2A	1029	CSF3R	1441
ATM	472	CENPF	1063	CSF3R	1441
ATM	472	CENPF	1063	CSMD3	114788
ATP6V1E1	529	CENTG1	116986	CSMD3	114788
ATR	545	CENTG1	116986	CSNK1E	1454
AVIL	10677	CES3	23491	CTNNB1	1499
AXL	558	CES3	23491	CTSH	1512
BAI3	577	CHAT	1103	CTSH	1512
BAI3	577	CHAT	1103	CYLD	1540
BAI3	577	CHD5	26038	CYP27B1	1594
BAMBI	25805	CHEK1	1111	CYP27B1	1594
BCAR1	9564	CHEK1	1111	CYP3A4	1576
BCAR1	9564	CHEK1	1111	DCX	1641
BCL11A	53335	CHEK1	1111	DDIT3	1649
		CHEK2	11200	DDR2	4921
		CHEK2	11200	DDR2	4921
		CHEK2	11200	DDR2	4921
		CHEK2	11200	DES	1674
		CHEK2	11200	DES	1674

Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id
DGKD	8527	EPHA4	2043	FN1	2335
DGKG	1608	EPHA4	2043	FOXO3	2309
DHTKD1	55526	EPHA6	285220	FOXO3	2309
DMBT1	1755	EPHA7	2045	FOXO3	2309
DMRT3	58524	EPHA7	2045	FRAP1	2475
DOCK1	1793	EPHA8	2046	FURIN	5045
DOCK1	1793	EPHA8	2046	FURIN	5045
DOCK1	1793	EPHB1	2047	FURIN	5045
DOCK8	81704	ERBB2	2064	GARNL3	84253
DOCK8	81704	ERBB2	2064	GATA3	2625
DPYSL4	10570	ERBB2	2064	GATA3	2625
DPYSL4	10570	ERBB2	2064	GCLC	2729
DST	667	ERBB2	2064	GDF10	2662
DST	667	ERBB2	2064	GLI1	2735
DST	667	ERBB2	2064	GLI3	2737
DST	667	ERBB2	2064	GLTSCR2	29997
DST	667	ERBB2	2064	GNAI1	2770
DST	667	ERBB2	2064	GNAS	2778
DST	667	ERBB2	2064	GNAS	2778
DST	667	ERBB3	2065	GPR78	27201
DTX3	196403	ESR1	2099	GRIA2	2891
EGFR	1956	ETNK2	55224	GRLF1	2909
EGFR	1956	EYA1	2138	GRN	2896
EGFR	1956	EYA1	2138	GRN	2896
EGFR	1956	F13A1	2162	GSTM5	2949
EGFR	1956	FBXW7	55294	GSTM5	2949
EGFR	1956	FBXW7	55294	GSTM5	2949
EGFR	1956	FGFR1	2260	GSTM5	2949
EGFR	1956	FGFR1	2260	GSTM5	2949
EGFR	1956	FGFR2	2263	GSTM5	2949
EGFR	1956	FGFR3	2261	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
EGFR	1956	FKBP9	11328	GSTM5	2949
ELAVL2	1993	FLI1	2313	HSPA8	3312
EP300	2033	FLI1	2313	HSPA8	3312
EP300	2033	FLT1	2321	HSPA8	3312
EP400	57634	FLT4	2324	HSPA8	3312
EP400	57634	FN1	2335	HSPA8	3312
EP400	56734	FN1	2335	HSPA8	3312
EPHA2	1969	FN1	2335	HSPA8	3312
EPHA3	2042	FN1	2335	HSPA8	3312
EPHA3	2042	FN1	2335	ID3	3399
		FN1	2335	IFITM3	10410

Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id
IFITM3	10410	LRRN2	10446	NF1	4763
IFITM3	10410	LTF	4057	NF1	4763
IFITM3	10410	LTF	4057	NF1	4763
IFITM3	10410	LYN	4067	NF1	4763
IFITM3	10410	MAG	4099	NF1	4763
IFITM3	10410	MAP3K6	9064	NF1	4763
IL1RL1	9173	MAPK13	5603	NF1	4763
IL31	386653	MAPK7	5598	NF1	4763
ILK	3611	MAPK8IP2	23542	NF1	4763
ING4	51147	MAPK8IP3	23162	NF1	4763
ING4	51147	MAPK9	5601	NF1	4763
ING4	51147	MAPK9	5601	NF1	4763
INHBE	83729	MARK1	4139	NF1	4763
IQGAP1	8826	MARK1	4139	NF1	4763
IRAK3	11213	MDM2	4193	NMBR	4829
IRS1	3667	MDM4	4194	NMBR	4829
IRS1	3667	MEOX2	4223	NOS3	4846
ISL1	3670	MET	4233	NOS3	4846
ITGAL	3683	MET	4233	NOTCH1	4851
ITGB2	3689	MET	4233	NOTCH1	4851
ITGB2	3689	MLH1	4292	NRXN3	9369
ITGB2	3689	MLH1	4292	NTRK3	4916
ITGB3	3690	MLH1	4292	NUMA1	4926
ITGB3	3690	MLL4	9757	NUP214	8021
ITGB3	3690	MLL4	9757	ONECUT2	9480
ITGB3	3690	MLL4	9757	OR5P2	120065
ITGB3	3690	MLLT7	4303	PAX5	5079
JAG1	182	MMD2	221938	PDGFRA	5156
KIAA1632	57724	MN1	4330	PDGFRA	5156
KIF3B	9371	MSH2	4436	PDGFRA	5156
KIT	3815	MSH2	4436	PDGFRB	5159
KIT	3815	MSH6	2956	PDGFRB	5159
KIT	3815	MSH6	2956	PDK2	5164
KLF4	9314	MSH6	2956	PDPK1	5170
KLF4	9314	MSH6	2956	PDZD2	23037
KLF6	1316	MSI1	4440	PDZD2	23037
KLF6	1316	MSI1	4440	PHLPP	23239
KLK8	11202	MTAP	4507	PI15	51050
KPNA2	3838	MUSK	4593	PI15	51050
KPNA2	3838	MYCN	4613	PIK3C2A	5286
KRAS	3845	MYCN	4613	PIK3C2B	5287
KSR2	283455	MYLK2	85366	PIK3C2G	5288
KSR2	283455	MYO3A	53904	PIK3C2G	5288
KTN1	3895	MYST4	23522	PIK3C2G	5288
LAMP1	3916	MYST4	23522	PIK3C2G	5288
LAMP1	3916	MYST4	23522	PIK3C2G	5288
LAX1	54900	MYST4	23522	PIK3CA	5290
LCK	3932	NBN	4683	PIK3CA	5290
LDHA	3939	NDUFA10	4705	PIK3CA	5290
LDHA	3939	NEK10	152110	PIK3CA	5290
LGALS3BP	3959	NELL2	4753	PIK3CA	5290
LGALS3BP	3959	NF1	4763	PIK3R1	5295
LGALS3BP	3959	NF1	4763	PIK3R1	5295

Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id
PIK3R1	5295	PTEN	5728	SLIT2	9353
PIK3R1	5295	PTEN	5728	SMAD2	4087
PIK3R1	5295	PTEN	5728	SMAD4	4089
PIK3R1	5295	PTEN	5728	SNF1LK2	23235
PIM1	5292	PTEN	5728	SNF1LK2	23235
PLAG1	5324	PTEN	5728	SNX13	23161
PML	5371	PTEN	5728	SOCS1	8651
PMS2	5395	PTEN	5728	SOX11	6664
POU2F1	5451	PTEN	5728	SOX11	6664
PPP2R5D	5528	PTEN	5728	SPARC	6678
PRKCA	5578	PTEN	5728	SPDEF	25803
PRKCA	5578	PTEN	5728	SPN	6693
PRKCB1	5579	PTEN	5728	SPRED3	399473
PRKCB1	5579	PTK2B	2185	SRPK2	6733
PRKCD	5580	PTPN11	5781	ST7	7982
PRKCD	5580	PTPN11	5781	STAT1	6772
PRKCD	5580	RADIL	55698	STAT3	6774
PRKCD	5580	RADIL	55698	STK32B	55351
PRKCD	5580	RB1	5925	STK36	27148
PRKCD	5580	RB1	5925	SYP	6855
PRKCD	5580	RB1	5925	TAF1	6872
PRKCD	5580	RB1	5925	TAF1	6872
PRKCZ	5590	RB1	5925	TAOK3	51347
PRKCZ	5590	RB1	5925	TAS1R1	80835
PRKD2	25865	RB1	5925	TBK1	29110
PRKD2	25865	RB1	5925	TBK1	29110
PRKDC	5591	RB1	5925	TCF12	6938
PRKDC	5591	RB1	5925	TCF12	6938
PRKDC	5591	RB1	5925	TCF12	6938
PROX1	5629	RINT1	60561	TERT	7015
PSMD13	5719	RIPK4	54101	TERT	7015
PSMD13	5719	RNF38	152006	TGFBR2	7048
PSMD13	5719	ROR2	4920	TIMP2	7077
PTCH1	5727	ROR2	4920	TNC	3371
PTCH1	5727	ROS1	6098	TNC	3371
PTEN	5728	ROS1	6098	TNC	3371
PTEN	5728	RPN1	6184	TNFRSF11B	4982
PTEN	5728	RPS6KA3	6197	TNK2	10188
PTEN	5728	RTN1	6252	TNK2	10188
PTEN	5728	RUNX1T1	862	TNK2	10188
PTEN	5728	RYR3	6263	TOP1	7150
PTEN	5728	RYR3	6263	TP53	7157
PTEN	5728	SAC	55811	TP53	7157
PTEN	5728	SAC	55811	TP53	7157
PTEN	5728	SEMA3B	7869	TP53	7157
PTEN	5728	SERPINA3	12	TP53	7157
PTEN	5728	SERPINE1	5054	TP53	7157
PTEN	5728	SHH	6469	TP53	7157
PTEN	5728	SLC12A6	9990	TP53	7157
PTEN	5728	SLC12A6	9990	TP53	7157
PTEN	5728	SLC25A13	10165	TP53	7157
PTEN	5728	SLC25A13	10165	TP53	7157
PTEN	5728	SLC2A2	6514	TP53	7157
PTEN	5728	SLIT2	9353	TP53	7157
PTEN	5728	SLIT2	9353	TP53	7157

Hugo Gene Symbol	Entrez_Gene_Id	Hugo Gene Symbol	Entrez_Gene_Id	
TP53	7157	TSC2	7249	
TP53	7157	TSC2	7249	
TP53	7157	TSC2	7249	
TP53	7157	UNG	7374	
TP53	7157	UPF2	26019	
TP53	7157	UPF2	26019	
TP53	7157	VAV2	7410	
TP53	7157	VLDLR	7436	
TP53	7157	WNT2	7472	
TP53	7157	ZEB1	6935	
TP53	7157	ZEB1	6935	
TP53	7157	ZNF384	171017	
TP53	7157	ZNF384	171017	
TP53	7157	<p>Note: Hugo Gene Symbols are assigned to individual genes by HUGO Gene Nomenclature Committee (http://www.genenames.org/). Entrez_Gene_Ids are assigned to individual genes by Entrez Gene (http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene).</p>		
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TP53	7157			
TPBG	7162			
TRIM24	8805			
TRIM3	10612			
TRIM33	51592			
TRIP6	7205			
TRRAP	8295			
TRRAP	8295			
TSC1	7248			

Table 12. Genes containing somatic mutations in glioblastoma adapted from the paper by Parsons et. al. (Parsons et al., 2008)

Gene symbol	Accession ID
A2M	NM_000014
A4GALT	CCDS14041.1
A4GNT	CCDS3097.1
AACS	CCDS9263.1
ABCA10	CCDS11684.1
ABCA12	NM_015657
ABCA13	NM_152701
ABCA4	CCDS747.1
ABCA5	CCDS11685.1
ABCA7	CCDS12055.1
ABCA9	CCDS11681.1
ABCB1	CCDS5608.1
ABCB6	CCDS2436.1
ABCC10	CCDS4896.1
ABCC11	CCDS10732.1
ABCC3	NM_003786
ABCC5	NM_005688
ABCD2	CCDS8734.1
ABCF2	CCDS5922.1
ABCG2	CCDS3628.1
ABHD3	NM_138340
ABHD4	CCDS9572.1
ABHD7	CCDS736.1
ABL2	NM_007314
ABTB2	CCDS7890.1
ACAD9	CCDS3053.1
ACADS	CCDS9207.1
ACADSB	CCDS7634.1
ACAT2	CCDS5268.1
ACCN1	CCDS11276.1
ACCN3	CCDS5914.1
ACF	CCDS7241.1
ACLY	CCDS11412.1
ACOX3	CCDS3401.1
ACP5	CCDS12265.1
ACRBP	CCDS8554.1
ACTG1	CCDS11782.1
ACTN1	CCDS9792.1
ACTR10	NM_018477
ACTR1A	CCDS7536.1
ACTR8	CCDS2875.1
ACTRT1	CCDS14611.1
ADAM12	CCDS7653.1
ADAM15	CCDS1084.1
ADAM18	CCDS6113.1
ADAM28	NM_014265

Gene symbol	Accession ID	Gene symbol	Accession ID
ADAM29	CCDS3823.1	APOB	CCDS1703.1
ADAMTS1	NM_006988	APOBEC3G	CCDS13984.1
ADAMTS13	CCDS6970.1	APRG1	NM_178339
ADAMTS17	CCDS10383.1	AQP10	CCDS1065.1
ADAMTS20	NM_175851	AR	CCDS14387.1
ADAMTS4	CCDS1223.1	ARD1B	ENST00000286794
ADAMTS8	NM_007037	ARHGAP4	CCDS14736.1
ADAR	CCDS1071.1	ARHGAP5	NM_001173
ADARB2	CCDS7058.1	ARHGAP8	CCDS14058.1
ADCY1	NM_021116	ARHGDIG	CCDS10404.1
ADCY8	CCDS6363.1	ARHGEF9	NM_015185
ADRBK2	CCDS13832.1	ARID1A	CCDS285.1
AGC1	NM_001135	ARL1	NM_001177
AGL	CCDS759.1	ARNT2	NM_014862
AGPAT1	CCDS4744.1	ARPI0	CCDS13985.1
AGPS	CCDS2275.1	ARSE	CCDS14122.1
AGRN	NM_198576	ASB4	CCDS5641.1
AHDC1	NM_001029882	ASCL4	NM_203436
AHI1	NM_017651	ASCL5	ENST00000344317
AIMIL	NM_017977	ASGR1	CCDS11089.1
AKAP11	CCDS9383.1	ASHIL	CCDS1113.1
AKAP13	NM_007200	ASIP	CCDS13232.1
AKAP4	CCDS14329.1	ASTN	CCDS1319.1
AKAP9	CCDS5622.1	ATAD2B	ENST00000295142
AKNA	CCDS6805.1	ATP10B	ENST00000327245
AKR7A2	CCDS194.1	ATP12A	NM_001676
ALDH18A1	CCDS7443.1	ATP13A1	NM_020410
ALDH1A2	CCDS10163.1	ATP13A2	CCDS175.1
ALDH1L1	CCDS3034.1	ATP1A2	CCDS1196.1
ALDH2	CCDS9155.1	ATP2A1	CCDS10643.1
ALLC	NM_018436	ATP2A3	CCDS11041.1
ALOX12	CCDS11084.1	ATP2B1	CCDS9035.1
ALOXE3	CCDS11130.1	ATP2B2	CCDS2601.1
ALPI	CCDS2492.1	ATP6V1G3	CCDS1396.1
ALPK2	CCDS11966.1	ATP7B	NM_000053
ALPK3	CCDS10333.1	ATP8A1	CCDS3466.1
ALPL	CCDS217.1	ATP8B1	CCDS11965.1
ALS2CL	CCDS2743.1	ATRNL1	CCDS7592.1
ALS2CR12	CCDS2346.1	ATXN1	NM_000332
AMACO	CCDS7589.1	AUTS2	CCDS5539.1
AMID	CCDS7297.1	AXIN2	CCDS11662.1
ANK2	CCDS3702.1	AZII	NM_001009811
ANK3	CCDS7258.1	B3Gn-T6	NM_138706
ANKMY1	CCDS2536.1	BAD	CCDS8065.1
ANKRD10	CCDS9520.1	BAI2	CCDS346.1
ANKRD11	NM_013275	BAMBI	CCDS7162.1
ANKRD12	CCDS11843.1	BAT2D1	CCDS1296.1
ANKRD15	CCDS6441.1	BAZ1A	CCDS9651.1
ANKRD28	NM_015199	BCAR3	CCDS745.1
ANP32D	NM_012404	BCL2L1	CCDS13188.1
AP3B1	CCDS4041.1	BCL2L12	CCDS12776.1
APG7L	CCDS2605.1	BCL2L2	CCDS9591.1
API5	NM_006595	BCL6	CCDS3289.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
BCOR	CCDS14250.1	C1orf147	NM_001025592	CACNG4	CCDS11667.1
BFSP1	CCDS13126.1	C1orf151	NM_001032363	CADPS	CCDS2898.1
BIN1	CCDS2137.1	C1orf16	CCDS1355.1	CADPS2	NM_017954
BIRC1	CCDS4009.1	C1orf173	NM_001002912	CALM1	CCDS9892.1
BIRC6	NM_016252	C1orf84	NM_015284	CAMSAP1	NM_015447
BMP3	CCDS3588.1	C1QDC1	CCDS8720.1	CAPN12	CCDS12519.1
BMPER	CCDS5442.1	C2orf10	CCDS13352.1	CAPN3	CCDS10084.1
BNC2	CCDS6482.1	C2orf102	CCDS13299.1	CAPN3	CCDS10084.1
BOC	CCDS2971.1	C2orf114	CCDS13218.1	CAPZA3	CCDS8681.1
BPY2IP1	NM_018174	C2orf23	CCDS13122.1	CARD11	CCDS5336.1
BRAF	CCDS5863.1	C2orf78	ENST00000278779	CART1	CCDS9028.1
BRF1	CCDS10001.1	C21orf29	CCDS13712.1	CASC5	NM_170589
BRP44L	CCDS5293.1	C21orf5	CCDS13643.1	CASQ1	CCDS1198.1
BRPF1	CCDS2575.1	C21orf69	NM_058189	CCDC15	NM_025004
BSN	CCDS2800.1	C2orf17	CCDS2434.1	CCNF	CCDS10467.1
BST1	CCDS3416.1	C2orf29	CCDS2050.1	CCNL2	ENST00000321423
BTAF1	CCDS7419.1	C2orf3	CCDS1961.1	CCNYL1	ENST00000339882
BTBD1	CCDS10322.1	C3orf14	CCDS2896.1	CD19	CCDS10644.1
BTBD3	CCDS13113.1	C4orf7	CCDS3537.1	CD84	CCDS1206.1
BTC	CCDS3566.1	C5AR1	NM_001736	CD96	CCDS2958.1
BTK	CCDS14482.1	C6	CCDS3936.1	CDA08	CCDS10728.1
BTNL2	CCDS4749.1	C6orf103	ENST00000326929	CDC2L6	CCDS5085.1
BTNL9	CCDS4460.1	C6orf150	CCDS4978.1	CDC7	CCDS734.1
BUCS1	CCDS10587.1	C6orf163	NM_001010868	CDCA8	CCDS424.1
C10orf18	ENST00000263123	C6orf165	CCDS5009.1	CDH23	NM_022124
C10orf26	CCDS7540.1	C6orf168	NM_032511	CDH24	CCDS9585.1
C10orf33	CCDS7474.1	C6orf170	NM_152730	CDH26	CCDS13485.1
C10orf47	CCDS7085.1	C6orf21	NM_001003693	CDH5	CCDS10804.1
C10orf64	ENST00000265453	C6orf213	NM_001010852	CDK5	NM_004935
C10orf71	ENST00000323868	C6orf29	CCDS4724.1	CDK6	CCDS5628.1
C10orf80	NM_001008723	C6orf4	CCDS5092.1	CDT1	NM_030928
C10orf81	CCDS7583.1	C6orf68	CCDS5118.1	CDX1	CCDS4304.1
C11orf11	NM_006133	C7orf16	CCDS5436.1	CDYL2	NM_152342
C11ORF4	CCDS8066.1	C8A	CCDS606.1	CEACAM1	CCDS12609.1
C12orf11	CCDS8708.1	C8B	NM_000066	CELSR3	CCDS2775.1
C12orf42	NM_198521	C8orf77	NM_001039382	CENPF	NM_016343
C14orf115	CCDS9830.1	C8ORFK23	NM_001039112	CENTG3	NM_031946
C14orf131	NM_018335	C9orf126	NM_173690	CEP135	NM_025009
C14orf133	CCDS9862.1	C9orf19	CCDS6598.1	Cep164	NM_014956
C14orf145	NM_152446	C9orf5	NM_032012	CEP2	CCDS13255.1
C14orf155	CCDS9679.1	C9orf50	NM_199350	CETP	CCDS10772.1
C14orf159	NM_024952	CA2	CCDS6239.1	CFTR	CCDS5773.1
C14orf31	CCDS9704.1	CAB39	CCDS2478.1	CGI-38	CCDS10835.1
C14orf43	CCDS9819.1	CABIN1	CCDS13823.1	CGI-96	CCDS14036.1
C14orf49	CCDS9935.1	CABP1	CCDS9204.1	CGNL1	CCDS10161.1
C15orf2	CCDS10015.1	CACNA1A	NM_000068	CHAD	CCDS11568.1
C15orf42	ENST00000268138	CACNA1C	NM_000719	CHD4	CCDS8552.1
C16orf9	CCDS10402.1	CACNA1E	NM_000721	CHD5	CCDS57.1
C17orf27	NM_020914	CACNA1H	NM_021098	CHD6	CCDS13317.1
C17orf31	CCDS11016.1	CACNA1I	NM_001003406	CHD9	NM_025134
C18orf25	NM_001008239	CACNA1S	CCDS1407.1	CHDH	CCDS2873.1
C18orf4	CCDS11995.1	CACNA2D3	NM_018398	CHEK1	CCDS8459.1
C19orf29	ENST00000221899	CACNB2	CCDS7125.1	ChGn	CCDS6010.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
CHKA	CCDS8178.1	CPB1	NM_001871	DDX1	CCDS1686.1
CHL1	CCDS2556.1	CPN1	CCDS7486.1	DDX31	CCDS6951.1
CHRM2	CCDS5843.1	CPNE2	CCDS10774.1	DDX54	NM_024072
CHRM5	CCDS10031.1	CPNE4	CCDS3072.1	DEFB112	NM_001037498
CHRNA3	CCDS10305.1	CPS1	CCDS2393.1	DEFB125	CCDS12989.1
CHRNA4	CCDS13517.1	CPSF4	CCDS5664.1	DELGEF	CCDS7828.1
CHRNA9	CCDS3459.1	CPT1B	CCDS14098.1	DEPDC5	NM_014662
CHST13	CCDS3039.1	CPT1C	CCDS12779.1	DFNB31	CCDS6806.1
CIDEA	CCDS11856.1	CRA	CCDS942.1	DGCR6	CCDS13753.1
CIDEC	CCDS2587.1	CRAT	CCDS6919.1	DGKD	CCDS2504.1
CIZ1	CCDS6894.1	CREB1	CCDS2374.1	DHPS	CCDS12276.1
CKLFSF5	CCDS9599.1	CRIM2	ENST00000257704	DHX29	NM_019030
CLASP1	NM_015282	CRISPLD1	CCDS6219.1	DIO3	NM_001362
CLASP2	NM_015097	CRR9	CCDS3862.1	DKFZp434I099	CCDS10787.1
CLCN1	CCDS5881.1	CRX	CCDS12706.1	DKFZp547A023	CCDS845.1
CLCN5	CCDS14328.1	CRY2	CCDS7915.1	DKFZp547B1713	CCDS1591.1
CLDN11	CCDS3213.1	CRYAA	CCDS13695.1	DKFZP564B1023	CCDS1403.1
CLEC1A	CCDS8612.1	CSK	CCDS10269.1	DKFZp564I1922	CCDS14124.1
CLEC4E	CCDS8594.1	CSMD1	NM_033225	DKFZp761L1417	CCDS5658.1
CLEC7A	CCDS8613.1	CSN3	CCDS3538.1	DKFZp761N1114	CCDS1455.1
CLIC6	CCDS13638.1	CSNK2A2	CCDS10794.1	DLD	CCDS5749.1
CLN8	CCDS5956.1	CSPG2	CCDS4060.1	DLEC1	ENST00000337335
CLSPN	CCDS396.1	CSPG5	CCDS2757.1	DLGAP2	NM_004745
CLSTN2	CCDS3112.1	CSPG6	NM_005445	DMN	NM_015286
CLTA	CCDS6600.1	CSTF1	CCDS13452.1	DMTF1	CCDS5601.1
CMIP	NM_198390	CTEN	CCDS11368.1	DNAH1	NM_015512
CMYA1	CCDS2683.1	CTNNA2	NM_004389	DNAH10	CCDS9255.1
CMYA4	CCDS11292.1	CTNNA3	CCDS7269.1	DNAH11	NM_003777
CNNM2	CCDS7543.1	CTSW	CCDS8117.1	DNAH3	CCDS10594.1
CNOT1	CCDS10799.1	CUBN	CCDS7113.1	DNAH5	CCDS3882.1
CNOT10	CCDS2655.1	CUGBP1	CCDS7938.1	DNAH8	CCDS4838.1
CNOT7	CCDS6000.1	CUGBP1	CCDS7939.1	DNAH9	CCDS11160.1
CNR2	CCDS245.1	CUL4B	NM_003588	DNAI2	CCDS11697.1
CNTN4	CCDS2558.1	CUTL1	CCDS5721.1	DNCH1	CCDS9966.1
CNTNAP2	CCDS5889.1	CX40.1	CCDS7191.1	DNCL2	CCDS10818.1
COCH	CCDS9640.1	CXCR3	CCDS14416.1	DNHD3	NM_020877
COG5	CCDS5742.1	CXorf17	CCDS14356.1	DNTTIP1	CCDS13369.1
COG5	CCDS5742.1	CXorf20	CCDS14184.1	DOCK4	NM_014705
COH1	CCDS6280.1	CXorf27	ENST00000341016	DOCK8	CCDS6440.1
COL14A1	NM_021110	CXorf37	CCDS14322.1	DOCK9	NM_015296
COL18A1	NM_030582	CXXC5	NM_016463	DOK6	NM_152721
COL23A1	CCDS4436.1	CYBB	CCDS14242.1	DONSON	CCDS13632.1
COL24A1	NM_152890	CYP26C1	CCDS7425.1	DRCTNNB1A	CCDS5377.1
COL3A1	CCDS2297.1	CYP2C19	CCDS7436.1	DRD3	CCDS2978.1
COL4A2	NM_001846	CYP2R1	CCDS7818.1	DRG1	CCDS13897.1
COL4A4	NM_000092	CYP4F12	NM_023944	DSG1	CCDS11896.1
COL4A5	CCDS14543.1	DAB2IP	CCDS6832.1	DSG2	NM_001943
COL5A3	CCDS12222.1	DCBLD2	NM_080927	DSG3	CCDS11898.1
COL6A3	NM_004369	DCC	CCDS11952.1	DSG4	CCDS11897.1
COL6A3	NM_057167	DCT	CCDS9470.1	DSPP	NM_014208
COL8A2	CCDS403.1	DCTN4	CCDS4310.1	DST	CCDS4959.1
COPB	CCDS7815.1	DDB1	NM_001923	DTX1	CCDS9164.1
COQ2	NM_015697	DDR1	CCDS4690.1	DTX4	ENST00000227451

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
DULLARD	CCDS11093.1	EPHA6	ENST00000334709	FLJ12700	CCDS5898.1
DUSP22	CCDS4468.1	EPHA8	CCDS225.1	FLJ13273	CCDS3672.1
DUSP3	CCDS11469.1	EPO	CCDS5705.1	FLJ13576	CCDS5757.1
DYRK3	NM_001004023	ERCC5	NM_000123	FLJ13725	CCDS10840.1
DZIP3	CCDS2952.1	ERF	CCDS12600.1	FLJ13841	CCDS11819.1
E2F4	NM_001950	ERN1	NM_001433	FLJ13941	CCDS40.1
EAF1	CCDS2626.1	ESCO2	NM_001017420	FLJ14397	CCDS1945.1
EBF	CCDS4343.1	ESPNP	ENST00000270691	FLJ16165	NM_001004318
EBF3	NM_001005463	ESR1	CCDS5234.1	FLJ16331	NM_001004326
ECEL1	CCDS2493.1	ESR2	CCDS9762.1	FLJ16478	NM_001004341
ECHDC2	CCDS571.1	ETV1	NM_004956	FLJ20035	NM_017631
ECOP	NM_030796	EVII	CCDS3205.1	FLJ20097	ENST00000317751
EDD1	NM_015902	EVPL	CCDS11737.1	FLJ20186	CCDS10989.1
EDG3	CCDS6680.1	EXOC6B	ENST00000272427	FLJ20232	CCDS13995.1
EDG8	CCDS12240.1	EXTL1	CCDS271.1	FLJ20272	NM_017735
EEF1A1	ENST00000331523	F13B	CCDS1388.1	FLJ20294	NM_017749
EFCBP1	NM_022351	F2RL1	CCDS4033.1	FLJ20298	CCDS14522.1
EFHC2	NM_025184	F3	CCDS750.1	FLJ21159	CCDS3792.1
EGF	CCDS3689.1	F5	CCDS1281.1	FLJ21963	CCDS9022.1
EGFR	CCDS5514.1	FAD158	CCDS725.1	FLJ22709	CCDS12351.1
EHBPI1L1	ENST00000309295	FADS1	CCDS8011.1	FLJ23049	CCDS3199.1
EIF2A	NM_032025	FAM43A	NM_153690	FLJ23447	CCDS12300.1
EIF3S12	CCDS12517.1	FAM46B	CCDS294.1	FLJ23577	ENST00000303168
EIF4G1	CCDS3259.1	FAM47A	NM_203408	FLJ23577	CCDS3910.1
EIF4G2	NM_001418	FAM48A	ENST00000360252	FLJ23790	CCDS6346.1
EME2	NM_001010865	FAM63B	NM_019092	FLJ25715	NM_182570
EML4	CCDS1807.1	FAM78B	NM_001017961	FLJ25801	CCDS3850.1
EMR4	ENST00000359590	FAM92B	NM_198491	FLJ27465	NM_001039843
EN2	CCDS5940.1	FANCA	NM_000135	FLJ30525	CCDS787.1
ENO1	CCDS97.1	FANCD2	CCDS2595.1	FLJ30655	CCDS3740.1
ENPP2	CCDS6329.1	FASN	CCDS11801.1	FLJ30707	CCDS9427.1
ENPP6	CCDS3834.1	FAT	NM_005245	FLJ31438	NM_152385
ENPP7	CCDS11763.1	FBN3	CCDS12196.1	FLJ32796	CCDS1507.1
ENSA	CCDS958.1	FBXO40	NM_016298	FLJ32934	CCDS1082.1
ENST00000294635	ENST00000294635	FBXW7	CCDS3777.1	FLJ33167	CCDS3837.1
ENST00000310882	ENST00000310882	FCGBP	CCDS12546.1	FLJ33387	CCDS9783.1
ENST00000326382	ENST00000326382	FCHSD1	NM_033449	FLJ34512	CCDS10424.1
ENST00000328067	ENST00000328067	FECH	CCDS11964.1	FLJ34658	CCDS3913.1
ENST00000331583	ENST00000331583	FEZ1	NM_005103	FLJ35709	CCDS7767.1
ENST00000334627	ENST00000334627	FGD1	CCDS14359.1	FLJ35728	CCDS1537.1
ENST00000336168	ENST00000336168	FGD4	CCDS8727.1	FLJ36004	CCDS8704.1
ENST00000355177	ENST00000355177	FGF2	NM_002006	FLJ36208	NM_145270
ENST00000355324	ENST00000355324	FGFR3	CCDS3353.1	FLJ36601	CCDS14238.1
ENST00000355607	ENST00000355607	FGIF	CCDS8300.1	FLJ37440	CCDS2095.1
ENST00000357689	ENST00000357689	FIGF	CCDS14166.1	FLJ38964	NM_173527
ENST00000358347	ENST00000358347	FLII	CCDS11192.1	FLJ38973	NM_153689
ENST00000359736	ENST00000359736	FLJ10276	CCDS363.1	FLJ39058	CCDS8489.1
EPB41L2	CCDS5141.1	FLJ10514	CCDS1311.1	FLJ39198	NM_001039769
EPB41L4B	NM_019114	FLJ11088	CCDS8716.1	FLJ39873	CCDS2980.1
EPB49	CCDS6020.1	FLJ11535	CCDS12043.1	FLJ40243	NM_173489
EPC1	CCDS7172.1	FLJ12529	CCDS8006.1	FLJ40342	CCDS11512.1
EPHA2	CCDS169.1	FLJ12644	CCDS12843.1	FLJ40869	CCDS1691.1
EPHA5	CCDS3513.1	FLJ12671	CCDS1153.1	FLJ41170	NM_001004332

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
FLJ41766	ENST00000338573	GBF1	CCDS7533.1	GPS1	CCDS11800.1
FLJ43706	NM_001039774	GCGR	NM_000160	GPS2	NM_032442
FLJ44186	CCDS5854.1	GCM1	CCDS4950.1	GPSM2	CCDS792.1
FLJ44861	CCDS11778.1	GCM2	CCDS4517.1	GPT	CCDS6430.1
FLJ45300	NM_001001681	GCNT3	CCDS10172.1	GRAP2	CCDS13999.1
FLJ45744	CCDS12424.1	GDF3	CCDS8581.1	GRASP	CCDS8817.1
FLJ45964	CCDS2530.1	GEFT	CCDS8947.1	GRCA	CCDS8563.1
FLJ45974	NM_001001707	GFI1B	CCDS6957.1	GREB1	NM_014668
FLJ46072	CCDS6410.1	GFM1	NM_024996	GRIA4	CCDS8333.1
FLJ90650	CCDS4124.1	GGA2	CCDS10611.1	GRIK4	CCDS8433.1
FLT1	CCDS9330.1	GGPS1	CCDS1604.1	GRIN2B	CCDS8662.1
FMN2	NM_020066	GHSR	CCDS3218.1	GRIN3A	CCDS6758.1
FMNL2	NM_001004417	GIMAP1	CCDS5906.1	GRINA	NM_001009184
FN1	CCDS2399.1	GIMAP5	CCDS5907.1	GRM1	CCDS5209.1
FNBP1	NM_015033	GIMAP8	NM_175571	GRM3	CCDS5600.1
FNDC1	NM_032532	GIT2	CCDS9138.1	GSR	NM_000637
FOXA2	CCDS13147.1	GJA4	NM_002060	GSTO2	CCDS7556.1
FOXB1	NM_012182	GJB4	CCDS383.1	GTF2A2	CCDS10173.1
FOXJ1	CCDS4372.1	GK	CCDS14225.1	GTF2H4	NM_020442
FOXM1	CCDS8515.1	GLRA1	CCDS4320.1	GTF3C4	CCDS6953.1
FOXR2	NM_198451	GMCLIL	CCDS4433.1	GUCY1A3	NM_000856
FRAS1	NM_025074	GMDS	CCDS4474.1	GUCY1B2	CCDS9426.1
FREM2	NM_207361	GML	CCDS6391.1	GZMH	CCDS9632.1
FRMD3	NM_174938	GNAI2	CCDS2813.1	HAMP	CCDS12454.1
FRMD4B	ENST00000264546	GNAT1	CCDS2812.1	HBB	NM_000519
FRMPD1	CCDS6612.1	GNL2	CCDS421.1	HBXAP	CCDS8253.1
FRMPD4	NM_014728	GNPTG	CCDS10436.1	HCFC2	CCDS9097.1
FSD2	NM_001007122	GNS	CCDS8970.1	HDAC2	NM_001527
FSTL1	CCDS2998.1	GOLGA3	CCDS9281.1	HDAC9	NM_178425
FSTL4	NM_015082	GOLGA4	CCDS2666.1	HDC	CCDS10134.1
FSTL5	CCDS3802.1	GORASP2	NM_015530	HECW2	NM_020760
FUBP1	CCDS683.1	GOT2	CCDS10801.1	HERC1	NM_003922
FUT2	NM_000511	GP6	NM_016363	HERC2	CCDS10021.1
FXYD6	CCDS8387.1	GPBP1	NM_022913	HGSNAT	ENST00000332689
FYCO1	CCDS2734.1	GPI7	CCDS3336.1	HHIP	CCDS3762.1
FZD10	CCDS9267.1	GPR114	CCDS10785.1	HIF3A	CCDS12681.1
FZD3	CCDS6069.1	GPR116	CCDS4919.1	HIP1	NM_005338
FZD6	CCDS6298.1	GPR132	CCDS9997.1	HIVEP1	NM_002114
FZD9	CCDS5548.1	GPR142	CCDS11698.1	HIVEP2	NM_006734
G3BP2	CCDS3571.1	GPR144	NM_182611	HIVEP3	CCDS463.1
GABPA	CCDS13575.1	GPR145	CCDS5044.1	HMG20A	CCDS10295.1
GABRA6	CCDS4356.1	GPR174	CCDS14443.1	HMGCL	CCDS243.1
GABRD	CCDS36.1	GPR37	CCDS5792.1	HMP19	CCDS4391.1
GAD2	CCDS7149.1	GPR37L1	CCDS1420.1	HNT	CCDS8491.1
GALNT13	CCDS2199.1	GPR40	CCDS12458.1	HORMAD1	CCDS967.1
GALNT3	CCDS2226.1	GPR43	CCDS12461.1	HOXA6	CCDS5407.1
GALNT7	CCDS3815.1	GPR61	CCDS801.1	HP	NM_005143
GALNTL1	NM_020692	GPR73L1	CCDS13089.1	HP1BP3	NM_016287
GANAB	CCDS8026.1	GPR74	CCDS3551.1	HPCAL4	CCDS441.1
GAPVD1	NM_015635	GPR78	CCDS3403.1	HRB	CCDS2467.1
GAS6	CCDS9540.1	GPR83	CCDS8297.1	HRBL	CCDS5697.1
GATA4	CCDS5983.1	GPR85	CCDS5758.1	HRG	CCDS3280.1
GATA6	CCDS11872.1	GPRC5C	CCDS11699.1	HS2ST1	CCDS712.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
HS2ST1	CCDS711.1	IIPR3	CCDS4783.1	KIAA0863	NM_014913
HSA9761	CCDS3981.1	IVNS1ABP	CCDS1368.1	KIAA0980	NM_025176
HSD17B2	CCDS10936.1	JMJD1A	CCDS1990.1	KIAA1024	NM_015206
HSD17B8	CCDS4769.1	JMJD1B	NM_016604	KIAA1033	NM_015275
HSPA4L	CCDS3734.1	JUNB	CCDS12280.1	KIAA1086	ENST00000262961
HSPC111	NM_016391	K0574_HUMAN	ENST00000261275	KIAA1109	ENST00000264501
HSPG2	NM_005529	KATNAL2	NM_031303	KIAA1223	NM_020337
HTR3C	CCDS3250.1	KBTBD3	CCDS8334.1	KIAA1274	NM_014431
HTR3E	CCDS3251.1	KBTBD4	CCDS7940.1	KIAA1328	NM_020776
HXMA	CCDS10586.1	KCNA4	NM_002233	KIAA1377	NM_020802
HYPB	CCDS2749.1	KCNA7	CCDS12755.1	KIAA1411	NM_020819
IBTK	NM_015525	KCNB2	CCDS6209.1	KIAA1441	CCDS992.1
ICAM3	CCDS12235.1	KCNC4	CCDS821.1	KIAA1467	NM_020853
ICEBERG	NM_021571	KCND2	CCDS5776.1	KIAA1505	NM_020879
IDE	CCDS7421.1	KCNG3	CCDS1809.1	KIAA1524	NM_020890
IDH1	CCDS2381.1	KCNH1	CCDS1496.1	KIAA1576	NM_020927
IFI44	CCDS688.1	KCNH5	CCDS9756.1	KIAA1618	CCDS11772.1
IFIT3	CCDS7402.1	KCNJ15	CCDS13656.1	KIAA1754L	NM_178495
IFNAR1	CCDS13624.1	KCNK1	CCDS1599.1	KIAA1804	CCDS1598.1
IFRD1	NM_001007245	KCNK5	CCDS4841.1	KIAA1862	NM_032534
IGF1	CCDS9091.1	KCNN1	NM_002248	KIAA1909	NM_052909
IGF2	CCDS7728.1	KCNQ3	NM_004519	KIAA1946	NM_177454
IGFBP7	CCDS3512.1	KCNQ4	CCDS456.1	KIAA1967	NM_021174
IGSF1	CCDS14629.1	KCTD7	CCDS5534.1	KIAA2022	NM_001008537
IGSF10	CCDS3160.1	KCTD8	CCDS3467.1	KIAA2026	NM_001017969
IGSF9	CCDS1190.1	KDEL2	CCDS5351.1	KIDINS220	NM_020738
IKBKE	NM_014002	KDR	CCDS3497.1	KIFC2	CCDS6427.1
IL12RB2	CCDS638.1	KEL	NM_000420	KIFC3	CCDS10789.1
IL17B	CCDS4297.1	KIAA0082	CCDS4835.1	KIRREL2	CCDS12479.1
IL17RE	CCDS2589.1	KIAA0101	CCDS10193.1	KIRREL3	NM_032531
IL1F9	CCDS2108.1	KIAA0103	CCDS6309.1	KLHDC5	NM_020782
IL1RL1	CCDS2057.1	KIAA0133	NM_014777	KLHL10	NM_152467
IL3	CCDS4149.1	KIAA0143	NM_015137	KLHL4	CCDS14456.1
ILT7	CCDS12890.1	KIAA0153	CCDS14047.1	KLK9	CCDS12816.1
IMP4	CCDS2160.1	KIAA0317	NM_001039479	KLP1	CCDS12926.1
IMPDH1	NM_183243	KIAA0329	NM_014844	KLRG1	CCDS8599.1
INDO	NM_002164	KIAA0350	NM_015226	KNTC1	NM_014708
INSIG2	CCDS2122.1	KIAA0367	NM_015225	KREMEN2	CCDS10484.1
IPO13	CCDS503.1	KIAA0404	NM_015104	KREMEN2	CCDS10483.1
IPO8	CCDS8719.1	KIAA0406	CCDS13300.1	KRT9	NM_000226
IQGAP2	NM_006633	KIAA0528	NM_014802	KRTAP12-3	NM_198697
IQWD1	CCDS1267.1	KIAA0649	CCDS6988.1	KRTAP20-2	CCDS13604.1
IRS1	CCDS2463.1	KIAA0652	CCDS7921.1	KRTHA4	CCDS11390.1
IRTA2	CCDS1165.1	KIAA0664	NM_015229	KSR1	NM_014238
IRX6	NM_024335	KIAA0672	NM_014859	L1CAM	CCDS14733.1
ISL1	NM_002202	KIAA0690	CCDS7457.1	L3MBTL2	CCDS14011.1
ITGA4	NM_000885	KIAA0701	NM_001006947	LACE1	CCDS5067.1
ITGA7	CCDS8888.1	KIAA0703	NM_014861	LACRT	CCDS8883.1
ITGAL	NM_002209	KIAA0748	ENST00000316577	LAMA1	NM_005559
ITGAX	CCDS10711.1	KIAA0759	CCDS9852.1	LAMA3	CCDS11880.1
ITIH5	NM_032817	KIAA0774	NM_001033602	LAMA4	NM_002290
ITLN1	CCDS1211.1	KIAA0802	CCDS11841.1	LAMB3	CCDS1487.1
ITPKB	CCDS1555.1	KIAA0831	NM_014924	LAMP3	CCDS3242.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
LAP1B	CCDS1335.1	LOC648272	ENST00000343945	MAN1B1	CCDS7029.1
LARGE	CCDS13912.1	LOC651746	ENST00000296657	MAN2A1	NM_002372
LARP5	NM_015155	LOC651863	ENST00000333744	MAN2B1	NM_000528
LATS1	NM_004690	LOC90379	NM_138353	MAP1B	CCDS4012.1
LATS2	CCDS9294.1	LOC90826	CCDS3771.1	MAP3K11	CCDS8107.1
LAX	CCDS1441.1	LOC92154	NM_138383	MAP3K14	NM_003954
LBP	CCDS13304.1	LOC93349	NM_138402	MAP3K8	CCDS7166.1
LCA10	NM_001039768	LPAL2	ENST00000342479	MAP3K9	NM_033141
LCT	CCDS2178.1	LPHN1	CCDS12307.1	MAP4K4	NM_004834
LDLRAD3	NM_174902	LPHN2	CCDS689.1	MAP7D3	ENST00000218318
LEMD2	CCDS4785.1	LPHN3	NM_015236	MARCO	CCDS2124.1
LENG8	CCDS12894.1	LPIN3	NM_022896	MARK3	NM_002376
LETM1	CCDS3355.1	LPL	CCDS6012.1	MARS	CCDS8942.1
LETMD1	CCDS8806.1	LRAT	CCDS3789.1	MARS2	NM_138395
LIP8	CCDS11126.1	LRCH1	NM_015116	MASS1	NM_032119
LIPM	ENST00000282673	LRFN5	CCDS9678.1	MAST4	ENST00000261569
LMNB1	CCDS4140.1	LRP1	CCDS8932.1	MATN1	CCDS336.1
LMX1A	CCDS1247.1	LRP10	CCDS9578.1	MBD1	CCDS11941.1
LNK	CCDS3492.1	LRP1B	CCDS2182.1	MBNL1	CCDS3163.1
LNK2	CCDS9323.1	LRP2	CCDS2232.1	MCCC1	CCDS3241.1
LOC113655	CCDS6431.1	LRRC16	NM_017640	MCF2L	ENST00000261963
LOC124842	CCDS11283.1	LRRC4	CCDS5799.1	MCFD2	NM_139279
LOC126248	CCDS12429.1	LRRC4B	ENST00000253728	MCM10	CCDS7095.1
LOC131368	CCDS2947.1	LRRC7	CCDS645.1	MCPH1	NM_024596
LOC131873	ENST00000358511	LRRIQ1	NM_032165	MDGA1	NM_153487
LOC134145	NM_199133	LRRK1	NM_024652	MDH2	CCDS5581.1
LOC146562	CCDS10521.1	LRRN1	NM_020873	MEA	CCDS4879.1
LOC158830	NM_001025265	LRRN3	CCDS5754.1	MED12	NM_005120
LOC200312	NM_001017981	LRRN5	CCDS1448.1	MEFV	CCDS10498.1
LOC221955	CCDS5350.1	LTB4R2	CCDS9624.1	MEN1	CCDS8083.1
LOC257106	CCDS1215.1	LTBP1	NM_000627	METTL5	NM_014168
LOC283537	CCDS9332.1	LTBP3	CCDS8103.1	MGAM	NM_004668
LOC284912	CCDS13918.1	LTBP4	NM_003573	MGC16635	CCDS14097.1
LOC284948	CCDS1976.1	LTK	CCDS10077.1	MGC19764	NM_144975
LOC339977	NM_001024611	LUC7L	CCDS10401.1	MGC20419	CCDS562.1
LOC374768	NM_199339	LY6K	CCDS6385.1	MGC20741	CCDS4861.1
LOC387755	NM_001031853	LYNX1	ENST00000317543	MGC21830	CCDS10463.1
LOC387856	NM_001013635	LYPLA1	CCDS6157.1	MGC24039	NM_144973
LOC388595	NM_001013641	LYRIC	CCDS6274.1	MGC2655	CCDS10491.1
LOC388969	NM_001013649	LYST	NM_000081	MGC26598	CCDS9036.1
LOC391123	NM_001013661	LYZL4	CCDS2697.1	MGC26818	CCDS44.1
LOC392617	ENST00000333066	LZTR2	NM_033127	MGC27016	CCDS3790.1
LOC400707	NM_001013673	M160	CCDS8577.1	MGC29814	CCDS11742.1
LOC441136	NM_001013719	MACF1	CCDS435.1	MGC29875	CCDS1493.1
LOC441233	NM_001013724	MAEA	NM_001017405	MGC33367	CCDS10738.1
LOC442213	NM_001013732	MAGEA4	CCDS14702.1	MGC33414	CCDS279.1
LOC494115	NM_001008662	MAGEB10	NM_182506	MGC33486	CCDS8133.1
LOC51058	CCDS476.1	MAGEC1	NM_005462	MGC33889	CCDS14216.1
LOC54103	NM_017439	MAGEH1	CCDS14369.1	MGC34647	CCDS10895.1
LOC54499	CCDS1251.1	MAGI-3	CCDS859.1	MGC35118	CCDS10046.1
LOC550631	NM_001017437	MAK10	CCDS6673.1	MGC35194	CCDS147.1
LOC63928	CCDS10617.1	MALT1	CCDS11967.1	MGC35366	CCDS9057.1
LOC643866	NM_001039771	MAMDC2	CCDS6631.1	MGC39581	CCDS12149.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
MGC42174	NM_152383	MYBPC3	NM_000256	NLGN2	CCDS11103.1
MGC4251	CCDS11474.1	MYBPHL	NM_001010985	NLN	CCDS3989.1
MGC4268	CCDS2152.1	MYF6	CCDS9019.1	NM_001080470.1	ENST00000271263
MGC45562	CCDS11371.1	MYH14	NM_024729	NMBR	CCDS5196.1
MGC45780	CCDS6064.1	MYH15	ENST00000273353	NMUR1	CCDS2486.1
MGC47869	CCDS8667.1	MYH3	CCDS11157.1	NNT	CCDS3949.1
MHC2TA	CCDS10544.1	MYH4	CCDS11154.1	NOD3	NM_178844
MIA3	ENST00000320831	MYO15A	NM_016239	NOR1	CCDS409.1
MICAL-L2	CCDS5324.1	MYO18B	NM_032608	NOS3	CCDS5912.1
MINK1	NM_170663	MYO1B	CCDS2311.1	NOTCH1	NM_017617
MIPEP	CCDS9303.1	MYO1D	NM_015194	NOTCH2	CCDS908.1
MIR16	CCDS10578.1	MYO1E	NM_004998	NOTCH3	CCDS12326.1
MKI67	CCDS7659.1	MYO3A	CCDS7148.1	NOTCH4	NM_004557
MLL	NM_005933	MYO3B	NM_138995	NOX4	CCDS8285.1
MLL3	CCDS5931.1	MYO5A	NM_000259	NP_001073909.1	ENST00000327928
MLL4	NM_014727	MYO5C	NM_018728	NP_001073931.1	ENST00000341689
MLLT4	CCDS5303.1	MYO9B	NM_004145	NP_001073940.1	ENST00000292357
MLLT7	NM_005938	MYOCD	CCDS11163.1	NP_001073948.1	ENST00000296794
MME	CCDS3172.1	MYOM1	NM_003803	NP_001073961.1	ENST00000219301
MMP10	CCDS8321.1	MYOM2	CCDS5957.1	NP_001073971.1	ENST00000266524
MMP16	CCDS6246.1	MYR8	NM_015011	NP_001074294.1	ENST00000342607
MOCS1	CCDS4845.1	MYRIP	CCDS2689.1	NPC1L1	CCDS5491.1
MON2	NM_015026	MYST3	CCDS6124.1	NPL	CCDS1350.1
MPDU1	CCDS11115.1	MYT1L	NM_015025	NPLOC4	NM_017921
MPDZ	NM_003829	NAGA	CCDS14030.1	NPPA	CCDS139.1
MPP1	CCDS14762.1	NALP1	NM_014922	NPR3	NM_000908
MPZ	CCDS1229.1	NALP11	CCDS12935.1	NPTXR	NM_014293
MRC2	CCDS11634.1	NALP7	CCDS12912.1	NR_002781.1	ENST00000246203
MRGX1	CCDS7846.1	NAPSB	ENST00000253720	NR2E1	CCDS5063.1
MRPL13	CCDS6332.1	NARG1L	CCDS9379.1	NRAP	CCDS7578.1
MRPL16	CCDS7976.1	NAV1	CCDS1414.1	NRBP2	NM_178564
MRPL37	ENST00000329505	NCBP1	CCDS6728.1	NRK	NM_198465
MRPL44	CCDS2459.1	NCKAP1L	NM_005337	NRP1	CCDS7177.1
MRPL46	CCDS10341.1	NCOA5	CCDS13392.1	NRP2	CCDS2364.1
MRPL55	CCDS1567.1	NCOA6	CCDS13241.1	NRXN2	CCDS8077.1
MRPS5	CCDS2010.1	NDUFA11	CCDS12155.1	NS3TP2	CCDS4136.1
MRPS7	CCDS11718.1	NDUFB2	CCDS5862.1	NT5E	CCDS5002.1
MRV11	NM_006069	NDUFS6	CCDS3866.1	NTN2L	CCDS10469.1
MS4A7	CCDS7985.1	NEB	NM_004543	NTRK3	CCDS10340.1
MSI2	CCDS11596.1	NEIL3	CCDS3828.1	NUAK1	NM_014840
MSL2L1	NM_018133	NEUROG2	CCDS3698.1	NUP160	NM_015231
MSRB3	CCDS8973.1	NF1	CCDS11264.1	NUP188	NM_015354
MTA1	NM_004689	NFATC3	CCDS10862.1	NUP205	NM_015135
MTHFD2L	NM_001004346	NFATC4	CCDS9629.1	NUP210L	NM_207308
MTNR1B	CCDS8290.1	NGEF	CCDS2500.1	NUP98	CCDS7746.1
MTP	CCDS3651.1	NHS	CCDS14181.1	NURIT	CCDS9399.1
MTR	CCDS1614.1	NIF3L1BP1	CCDS2900.1	NXF3	CCDS14503.1
MTX2	CCDS2272.1	NIN	NM_182944	NXF5	CCDS14491.1
MUC15	CCDS7859.1	NISCH	NM_007184	NXPH1	NM_152745
MUC16	NM_024690	NKG7	CCDS12830.1	OAS3	NM_006187
MUC5AC	ENST00000349637	NKRF	NM_017544	OBSCN	CCDS1570.1
MUC7	CCDS3541.1	NKX2-5	CCDS4387.1	ODZ2	ENST00000314238
MVP	CCDS10656.1	NLGN1	CCDS3222.1	OLIG2	CCDS13620.1

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
OPRD1	CCDS329.1	OR9Q2	NM_001005283	PDZD7	NM_024895
OPRL1	CCDS13556.1	OSAP	NM_032623	PEG10	ENST00000362013
OR10G3	NM_001005465	OSBPL2	CCDS13494.1	PELP1	NM_014389
OR10G4	NM_001004462	OSBPL5	NM_145638	PENK	CCDS6168.1
OR10H2	CCDS12333.1	OSBPL9	CCDS558.1	PERQ1	NM_022574
OR10P1	NM_206899	OSR2	NM_053001	PEX1	CCDS5627.1
OR10T2	NM_001004475	OSTM1	CCDS5062.1	PEX10	CCDS41.1
OR13J1	NM_001004487	OTOF	CCDS1725.1	PFAS	CCDS11136.1
OR1L8	NM_001004454	OTOG	ENST00000342528	PFKFB3	CCDS7078.1
OR2A12	NM_001004135	OTOR	CCDS13124.1	PGAP1	CCDS2318.1
OR2AG1	NM_001004489	OTUD1	ENST00000298035	PGBD5	CCDS1583.1
OR2AG2	NM_001004490	OVCH1	NM_183378	PHC3	NM_024947
OR2D2	NM_003700	OVOL1	CCDS8112.1	PHEMX	CCDS7733.1
OR2G3	NM_001001914	OXA1L	CCDS9573.1	PHF2	ENST00000298216
OR2L13	CCDS1637.1	p44S10	CCDS2901.1	PHF21A	NM_016621
OR2L2	NM_001004686	PADI2	CCDS177.1	PHIP	CCDS4987.1
OR2S2	CCDS6596.1	PAPLN	NM_173462	PHKA2	CCDS14190.1
OR2T4	NM_001004696	PAPOLG	CCDS1863.1	PHLPP	NM_194449
OR2V2	CCDS4461.1	PAPPA2	NM_020318	PHLPPL	NM_015020
OR2Y1	NM_001001657	PARC	CCDS4890.1	PHOX2B	CCDS3463.1
OR2Z1	NM_001004699	PARP11	CCDS8523.1	PIGN	NM_176787
OR3A1	CCDS11023.1	PAX9	CCDS9662.1	PIGQ	CCDS10411.1
OR4A5	NM_001005272	PCAF	CCDS2634.1	PIGR	CCDS1474.1
OR4L1	NM_001004717	PCDH11X	CCDS14463.1	PIK3C2G	NM_004570
OR4N2	NM_001004723	PCDHA10	NM_031859	PIK3CA	NM_006218
OR4P4	NM_001004124	PCDHA13	CCDS4240.1	PIK3CG	CCDS5739.1
OR52A5	NM_001005160	PCDHB7	CCDS4249.1	PIK3R1	CCDS3993.1
OR52B2	NM_001004052	PCDHGA4	NM_032053	PIK3R4	CCDS3067.1
OR52D1	NM_001005163	PCDHGA9	NM_032089	PIK3R5	CCDS11147.1
OR52E6	NM_001005167	PCDHGB7	NM_032101	PIP5K1A	CCDS990.1
OR52I1	NM_001005169	PCDHGC4	CCDS4260.1	PIP5K3	CCDS2382.1
OR52N4	NM_001005175	PCDHGC4	CCDS4261.1	PISD	CCDS13899.1
OR56A4	NM_001005179	PCDHGC4	CCDS4263.1	PITPNM1	NM_004910
OR56B1	NM_001005180	PCGF2	NM_007144	PITPNM2	CCDS9242.1
OR56B4	NM_001005181	PCNXL2	ENST00000344698	PITPNM3	CCDS11076.1
OR5A1	NM_001004728	PCSK2	CCDS13125.1	PIWIL3	NM_001008496
OR5AP2	NM_001002925	PCYOX1	CCDS1902.1	PKD1	NM_000296
OR5AU1	NM_001004731	PDCD10	CCDS3202.1	PKD1L2	NM_182740
OR5B17	ENST00000357377	PDCD11	NM_014976	PKHD1	CCDS4935.1
OR5BF1	NM_001001918	PDE1C	CCDS5437.1	PKHD1L1	NM_177531
OR5D14	NM_001004735	PDE4A	CCDS12238.1	PKIA	CCDS6222.1
OR5K4	NM_001005517	PDE4B	CCDS632.1	PLA1A	CCDS2991.1
OR5M1	ENST00000303005	PDE4C	CCDS12373.1	PLCH2	NM_014638
OR5M8	NM_001005282	PDE4D	NM_006203	PLCXD3	NM_001005473
OR5M9	NM_001004743	PDGFB	CCDS13987.1	PLD2	CCDS11057.1
OR6C74	NM_001005490	PDGFRA	CCDS3495.1	PLEC1	NM_201378
OR6K3	NM_001005327	PDGFRB	CCDS4303.1	PLEKHA4	CCDS12737.1
OR6W1P	ENST00000340373	PDHA2	CCDS3644.1	PLEKHH2	CCDS1812.1
OR7A5	CCDS12318.1	PDHB	CCDS2890.1	PLIN	CCDS10353.1
OR7D4	NM_001005191	PDIA2	NM_006849	PLSCR3	NM_020360
OR8D2	NM_001002918	PDK1	CCDS2250.1	PLXDC2	CCDS7132.1
OR8K3	NM_001005202	PDLIM4	CCDS4152.1	PLXNA3	CCDS14752.1
OR9K2	NM_001005243	PDZD2	NM_178140	PLXNB2	ENST00000359337

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
PLXNC1	CCDS9049.1	PSRC2	NM_144982	Q96CK5_HUMAN	ENST00000273582
PMS1	CCDS2302.1	PTAR1	ENST00000340434	Q96DR3_HUMAN	ENST00000324748
PMS2L4	ENST00000275546	PTCH2	CCDS516.1	Q96FF7_HUMAN	ENST00000269720
PNLIP	CCDS7594.1	PTEN	NM_000314	Q96NE0_HUMAN	ENST00000329922
PNOC	CCDS6066.1	PTGDR	CCDS9707.1	Q96NL2_HUMAN	ENST00000272907
PODXL2	CCDS3044.1	PTGFR	CCDS686.1	Q96PS2_HUMAN	ENST00000326978
POLD1	CCDS12795.1	PTGS2	CCDS1371.1	Q9H030_HUMAN	ENST00000237449
POLE	CCDS9278.1	PTPLA	CCDS7121.1	Q9H6A9_HUMAN	ENST00000309024
POLG2	NM_007215	PTPN23	CCDS2754.1	Q9H800_HUMAN	ENST00000357106
POLM	NM_013284	PTPRF	CCDS489.1	Q9H8D1_HUMAN	ENST00000360549
POLR3B	CCDS9105.1	PTPRK	CCDS5137.1	Q9HAC4_HUMAN	ENST00000206466
POLR3E	CCDS10605.1	PTPRM	CCDS11840.1	Q9P1M5_HUMAN	ENST00000303007
POPDC2	CCDS2992.1	PTPRS	CCDS12139.1	Q9ULE4_HUMAN	ENST00000265018
POR	CCDS5579.1	PTPRU	CCDS334.1	Q9Y6V0-3	ENST00000333891
PORCN	CCDS14296.1	PTX3	CCDS3180.1	QPCT	CCDS1790.1
POT1	CCDS5793.1	PUM1	CCDS338.1	QRICH2	NM_032134
POUIF1	CCDS2919.1	PYGB	CCDS13171.1	QSCN6	CCDS1337.1
POU2F1	CCDS1259.1	Q13034_HUMAN	ENST00000225928	QSER1	NM_024774
POU6F2	NM_007252	Q4VXG5_HUMAN	ENST00000327794	QTRTD1	NM_024638
PPAP2C	CCDS12023.1	Q4VXG5_HUMAN	ENST00000331811	RAB36	CCDS13805.1
PPARA	NM_001001930	Q5JX50_HUMAN	ENST00000325076	RAB3C	CCDS3976.1
PPBP	CCDS3563.1	Q5JYU7_HUMAN	ENST00000333418	RAB3GAP2	NM_012414
PPEF2	NM_006239	Q5T740_HUMAN	ENST00000343319	RAB3IL1	CCDS8014.1
PPIG	CCDS2235.1	Q5W0A0_HUMAN	ENST00000298738	RAC2	CCDS13945.1
PPL	CCDS10526.1	Q68CJ6_HUMAN	ENST00000341513	RAD23A	CCDS12289.1
PPM2C	CCDS6259.1	Q6IEE8_HUMAN	ENST00000354872	RAD51L3	CCDS11287.1
PPP1CC	CCDS9150.1	Q6PK04_HUMAN	ENST00000329214	RAD52	CCDS8507.1
PPP1R12A	NM_002480	Q6RGF6_HUMAN	ENST00000359144	RAFTLIN	NM_015150
PPP1R12C	CCDS12916.1	Q6ZRB0_HUMAN	ENST00000297487	RAI1	CCDS11188.1
PPP2CZ	CCDS855.1	Q6ZSY1_HUMAN	ENST00000320930	RALBP1	CCDS11845.1
PPP2R2C	CCDS3387.1	Q6ZT40_HUMAN	ENST00000296564	RANBP17	NM_022897
PPRC1	CCDS7529.1	Q6ZUG5_HUMAN	ENST00000344062	RANP1	ENST00000333828
PRCC	CCDS1157.1	Q6ZV46_HUMAN	ENST00000341696	RAP140	CCDS2877.1
PRDM16	NM_199454	Q76B61_HUMAN	ENST00000360022	RAPGEF4	NM_007023
PRDM5	CCDS3716.1	Q86U37_HUMAN	ENST00000335192	RAPGEF6	NM_016340
PRELP	CCDS1438.1	Q86XQ1_HUMAN	ENST00000261673	RAPGEFL1	CCDS11363.1
PRIC285	CCDS13527.1	Q86YU6_HUMAN	ENST00000330768	RAPH1	CCDS2359.1
PRKCBP1	CCDS13404.1	Q8IUR1_HUMAN	ENST00000327506	RARSL	CCDS5011.1
PRKCZ	CCDS37.1	Q8N1R6_HUMAN	ENST00000331014	RASGRF1	CCDS10309.1
PRKDC	NM_006904	Q8N646_HUMAN	ENST00000359720	RASGRF2	CCDS4052.1
PRKG2	CCDS3589.1	Q8N800_HUMAN	ENST00000322516	RASL11B	CCDS3490.1
PRKRA	CCDS2279.1	Q8N822_HUMAN	ENST00000317280	RAX	CCDS11972.1
PRO1853	CCDS1788.1	Q8N8C3_HUMAN	ENST00000319889	RB1	NM_000321
PRO1855	CCDS11566.1	Q8N8K0_HUMAN	ENST00000301807	RBM14	CCDS8147.1
PROM1	NM_006017	Q8N9H1_HUMAN	ENST00000359503	RBM19	CCDS9172.1
PROSC	CCDS6096.1	Q8NBE0_HUMAN	ENST00000297801	RBM21	CCDS8021.1
PRPF18	CCDS7100.1	Q8NDH2_HUMAN	ENST00000322527	RBM25	NM_021239
PRR12	ENST00000246798	Q8NGK8_HUMAN	ENST00000334020	RBM27	ENST00000265271
PRSS16	CCDS4623.1	Q8NGL5_HUMAN	ENST00000328673	RBM34	ENST00000362051
PRSS22	CCDS10481.1	Q8NH06_HUMAN	ENST00000324144	RBMS3	NM_001003792
PSF1	NM_021067	Q8NHB0_HUMAN	ENST00000315712	RBP3	CCDS7218.1
PSIP1	CCDS6479.1	Q8TBR1_HUMAN	ENST00000354206	RBPSUH	CCDS3436.1
PSMD8	CCDS12515.1	Q96CH6_HUMAN	ENST00000329920	RC74	NM_018250

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
RCD-8	CCDS10849.1	SARG	CCDS1475.1	SIPAIL2	NM_020808
RDHE2	CCDS6167.1	SARS	CCDS795.1	SIPAIL3	NM_015073
RDS	CCDS4871.1	SASH1	CCDS5212.1	SKIV2L	CCDS4731.1
REG1B	CCDS1963.1	SCHIP1	CCDS3186.1	SKP2	CCDS3915.1
REN	NM_000537	SCN1B	CCDS12441.1	SLC10A4	CCDS3482.1
REPS2	CCDS14180.1	SCN3A	NM_006922	SLC11A1	CCDS2415.1
RET	CCDS7200.1	SCN3B	CCDS8442.1	SLC12A1	CCDS10129.1
RFC2	CCDS5567.1	SCN5A	NM_000335	SLC12A5	CCDS13391.1
RFNG	NM_002917	SCN9A	NM_002977	SLC14A1	CCDS11925.1
RFX3	CCDS6450.1	SCRIB	CCDS6411.1	SLC14A2	CCDS11924.1
RGS22	NM_015668	SCUBE1	CCDS14048.1	SLC16A5	CCDS11713.1
RGSL1	CCDS1346.1	SDC3	NM_014654	SLC1A2	NM_004171
RHOT1	NM_001033568	SDR-O	CCDS8926.1	SLC22A11	CCDS8074.1
RICTOR	NM_152756	SEC24C	CCDS7332.1	SLC22A18	CCDS7740.1
RIMBP2	NM_015347	SELO	NM_031454	SLC22A3	CCDS5277.1
RIMS2	NM_014677	SEMA5A	CCDS3875.1	SLC24A6	NM_024959
RIMS4	CCDS13338.1	SEMA5B	CCDS3019.1	SLC25A13	CCDS5645.1
RIPK4	CCDS13675.1	SEMA7A	CCDS10262.1	SLC26A4	CCDS5746.1
RLBP1	NM_000326	SEN2L	CCDS2611.1	SLC2A1	CCDS477.1
RLTPR	NM_001013838	SENP3	NM_015670	SLC30A1	CCDS1499.1
RNASEH2A	CCDS12282.1	SEPT2	CCDS2548.1	SLC30A5	CCDS3996.1
RNF103	NM_005667	SERPINA12	CCDS9926.1	SLC30A9	CCDS3465.1
RNF127	CCDS14575.1	SERPINA9	NM_175739	SLC35B2	NM_178148
RNF128	CCDS14521.1	SERPINB3	CCDS11987.1	SLC35D3	NM_001008783
RNF19	CCDS6286.1	SERPINB7	CCDS11988.1	SLC35F2	NM_017515
RNF25	CCDS2420.1	SERPINE2	CCDS2460.1	SLC38A1	NM_030674
RNF40	CCDS10691.1	SERPING1	CCDS7962.1	SLC38A4	CCDS8750.1
RNPC2	CCDS13265.1	SET7	CCDS3748.1	SLC38A6	CCDS9751.1
ROBO3	NM_022370	SETDB2	CCDS9417.1	SLC39A2	CCDS9563.1
ROCK1	CCDS11870.1	SEZ6	NM_178860	SLC43A3	CCDS7956.1
ROM1	CCDS8024.1	SEZ6L	CCDS13833.1	SLC4A1	CCDS11481.1
ROS1	CCDS5116.1	SFII	NM_001007467	SLC4A5	CCDS1936.1
RoXaN	CCDS14013.1	SFMBT2	NM_001029880	SLC4A7	NM_003615
RPIL1	NM_178857	SFRP2	NM_003013	SLC5A5	CCDS12368.1
RPL11	CCDS238.1	SFTPB	CCDS1983.1	SLC5A7	CCDS2074.1
RPS14	CCDS4307.1	SG223_HUMAN	ENST00000330777	SLC7A10	CCDS12431.1
RPS6KA2	CCDS5294.1	SGCZ	CCDS5992.1	SLC7A13	NM_138817
RPS6KB2	NM_003952	SGK2	CCDS13320.1	SLC7A14	NM_020949
RPUSD3	CCDS2586.1	SGPP1	CCDS9760.1	SLC7A6	NM_003983
RRAGD	CCDS5022.1	SGPP2	CCDS2453.1	SLC8A1	CCDS1806.1
RSHL1	CCDS12675.1	SGSH	CCDS11770.1	SLC9A1	CCDS295.1
RSU1	CCDS7112.1	SH3BP1	CCDS13952.1	SLC9A2	CCDS2062.1
RTN1	CCDS9740.1	SH3BP2	NM_003023	SLC9A3R2	NM_004785
RTTN	NM_173630	SH3GL3	CCDS10325.1	SLC9A4	NM_001011552
RUNX1	CCDS13639.1	SHANK2	CCDS8198.1	SLCO1B1	CCDS8685.1
RUNX1T1	CCDS6256.1	SHANK3	ENST00000262795	SLCO2A1	CCDS3084.1
RWDD1	NM_001007464	SHB	NM_003028	SLCO4C1	NM_180991
RYR2	NM_001035	SHE	NM_001010846	SLCO6A1	NM_173488
RYR3	NM_001036	SHMT2	CCDS8934.1	SLIT2	CCDS3426.1
SALL3	CCDS12013.1	SIGLEC11	CCDS12790.1	SLITRK1	CCDS9464.1
SAMD11	ENST00000294573	SIGLEC5	NM_003830	SLITRK5	CCDS9465.1
SAMD9	NM_017654	SIGLEC8	NM_014442	SLITRK6	ENST00000313206
SAPS2	NM_014678	SIM2	CCDS13646.1	SMARCA2	NM_003070

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
SMARCA4	CCDS12253.1	STAP2	CCDS12128.1	TGFBRAP1	CCDS2067.1
SMARCC2	CCDS8907.1	STIM2	CCDS3440.1	TGM1	CCDS9622.1
SMC5L1	CCDS6632.1	STK33	CCDS7789.1	TGM5	NM_004245
SMCR8	CCDS11195.1	STK39	NM_013233	THAP9	CCDS3598.1
SMF_HUMAN	ENST00000261804	STRA6	CCDS10261.1	THBS1	NM_003246
SN	CCDS13060.1	STS	CCDS14127.1	THEA	CCDS592.1
SNED1	ENST00000310397	STS-1	NM_032873	THOP1	CCDS12095.1
SNRPA	CCDS12565.1	STX11	CCDS5205.1	THRAP3	ENST00000354618
SNX13	NM_015132	STX12	CCDS310.1	THSD7B	ENST00000272643
SNX27	CCDS1001.1	STXBP2	CCDS12181.1	TIMP2	CCDS11758.1
SNX4	CCDS3032.1	STXBP3	CCDS790.1	TINAG	CCDS4955.1
SOC5	CCDS1830.1	STYK1	CCDS8629.1	TJP3	NM_014428
SOHLH1	NM_001012415	SUCLA2	CCDS9406.1	TLL1	CCDS3811.1
SORCS2	NM_020777	SUCLG2	NM_003848	TLN1	NM_006289
SORCS3	CCDS7558.1	SULT6B1	NM_001032377	TLX3	NM_021025
SORL1	CCDS8436.1	SUNC1	NM_152782	TM4SF14	CCDS7369.1
SOS1	CCDS1802.1	SUSD5	ENST00000309558	TM4SF3	CCDS8999.1
SOSTDC1	CCDS5360.1	SV2B	CCDS10370.1	TM9SF4	CCDS13196.1
SOX13	NM_005686	SWAP70	NM_015055	TMED1	CCDS12249.1
SOX30	CCDS4339.1	SYDE2	ENST00000234668	TMEM131	ENST00000186436
SOX8	CCDS10428.1	SYN2	NM_133625	TMEM132C	ENST00000315208
SP100	CCDS2477.1	SYNE1	CCDS5236.1	TMEM16B	NM_020373
SPACA4	CCDS12725.1	SYNE1	CCDS5237.1	TMEM16C	NM_031418
SPAG1	NM_003114	SYNE2	CCDS9761.1	TMEM16E	NM_213599
SPAG5	NM_006461	SYT15	NM_181519	TMEM16G	NM_001001891
SPAG7	NM_004890	SYT16	NM_031914	TMEM16J	NM_001012302
SPATA1	CCDS697.1	SYT6	CCDS871.1	TMEM38A	CCDS12349.1
SPATA2	CCDS13422.1	TAAR9	ENST00000340640	TMEM46	NM_001007538
SPATC1	CCDS6413.1	TACC2	CCDS7626.1	TMEM63B	NM_018426
Spc25	CCDS2229.1	TACC3	CCDS3352.1	TMEM8	CCDS10407.1
SPEG	ENST00000265327	TAF1L	NM_153809	TMPRSS2	NM_005656
SPEN	CCDS164.1	TAF4B	ENST00000269142	TMPRSS4	NM_019894
SPG3A	CCDS9700.1	TAF6	CCDS5686.1	TNC	CCDS6811.1
SPI1	CCDS7933.1	TANC1	NM_033394	TNFAIP2	CCDS9979.1
SPIN3	NM_001010862	TAOK1	NM_020791	TNFSF18	CCDS1305.1
SPIRE2	NM_032451	TARBP2	CCDS8861.1	TNFSF4	CCDS1306.1
SPN	CCDS10650.1	TAS1R2	CCDS187.1	TNFSF9	CCDS12169.1
SPOCK3	NM_016950	TAS2R3	CCDS5867.1	TNIP1	NM_006058
SPON2	CCDS3347.1	TBC1D20	CCDS13002.1	TNIP2	CCDS3362.1
SPRED2	NM_181784	TBC1D4	NM_014832	TNK1	NM_003985
SPTB	NM_001024858	TBCD	NM_001033052	TNMD	CCDS14469.1
SPTBN1	NM_178313	TBX20	CCDS5445.1	TNN	NM_022093
SPTBN2	CCDS8150.1	TBX22	CCDS14445.1	TNPO1	CCDS4016.1
SPTBN4	CCDS12559.1	TCF7L1	CCDS1971.1	TNR	CCDS1318.1
SPTBN5	NM_016642	TCF8	CCDS7169.1	TNRC15	NM_015575
SREBF2	CCDS14023.1	TCHH	ENST00000290632	TNRC4	CCDS1002.1
SRGAP1	CCDS8967.1	TCN2	CCDS13881.1	TNRC6C	NM_018996
SRPK2	CCDS5735.1	TDRD5	CCDS1332.1	TOE1	CCDS521.1
SRRM2	NM_016333	TDRD9	CCDS9987.1	TOP2A	NM_001067
SSFA2	CCDS2284.1	TEAD2	CCDS12761.1	TOR1A	CCDS6930.1
ST14	CCDS8487.1	TEPP	CCDS10790.1	TOSO	CCDS1473.1
ST8SIA4	CCDS4091.1	TERF2IP	NM_018975	TP53	CCDS11118.1
STAB1	NM_015136	TFE3	CCDS14315.1	TPH2	NM_173353

Gene symbol	Accession ID	Gene symbol	Accession ID	Gene symbol	Accession ID
TFR	NM_003292	UNQ689	CCDS3542.1	ZAN	NM_173059
TPST2	CCDS13839.1	UPK3B	CCDS5588.1	ZBTB16	CCDS8367.1
TRAM1L1	CCDS3707.1	URB1	ENST00000270201	ZBTB24	NM_014797
TRAPPC3	CCDS404.1	USH2A	CCDS1516.1	ZBTB4	CCDS11107.1
TREML2	CCDS4853.1	USP11	CCDS14277.1	ZBTB9	NM_006772
TREML3	ENST00000332842	USP26	CCDS14635.1	ZC3H6	NM_198581
TRIM14	CCDS6734.1	USP8	CCDS10137.1	ZFPM1	NM_153813
TRIM42	CCDS3113.1	VANGL1	CCDS883.1	ZFYVE9	CCDS563.1
TRIM45	CCDS893.1	VCAM1	CCDS773.1	ZIC1	CCDS3136.1
TRIM46	CCDS1097.1	VCIP135	CCDS6192.1	ZIK1	NM_001010879
TRIM55	CCDS6186.1	VCL	CCDS7340.1	ZMAT4	NM_024645
TRIM56	NM_030961	VDP	NM_003715	ZNF10	CCDS9283.1
TRIM58	CCDS1636.1	VDR	CCDS8757.1	ZNF160	CCDS12859.1
TRIO	CCDS3883.1	VGCNL1	CCDS9498.1	ZNF17	NM_006959
TRIOBP	NM_007032	VGLL2	CCDS5115.1	ZNF18	NM_144680
TRIP12	NM_004238	VIPR2	CCDS5950.1	ZNF183L1	CCDS9486.1
TRIP6	CCDS5708.1	VMD2	NM_004183	ZNF189	CCDS6754.1
TRMT5	NM_020810	VN2RIP	ENST00000312652	ZNF25	CCDS7195.1
TRPC4AP	CCDS13246.1	VPS11	NM_021729	ZNF286	CCDS11172.1
TRPC6	CCDS8311.1	VPS13A	CCDS6655.1	ZNF294	NM_015565
TRPM2	CCDS13710.1	VPS24	NM_001005753	ZNF295	CCDS13678.1
TRPM3	CCDS6634.1	VPS41	CCDS5457.1	ZNF30	NM_194325
TRPM4	NM_017636	VPS45A	CCDS944.1	ZNF31	NM_145238
TRPM5	NM_014555	VSIG2	CCDS8452.1	ZNF313	NM_018683
TRPM6	CCDS6647.1	VWF	CCDS8539.1	ZNF318	CCDS4895.1
TRPM7	NM_017672	WBSCR17	CCDS5540.1	ZNF333	CCDS12316.1
TRPV5	CCDS5875.1	WBSCR27	CCDS5561.1	ZNF339	CCDS13132.1
TRRAP	CCDS5659.1	WDFY3	CCDS3609.1	ZNF343	CCDS13028.1
TSAP6	CCDS2125.1	WDR21	CCDS9809.1	ZNF358	NM_018083
TSC2	CCDS10458.1	WDR22	NM_003861	ZNF366	CCDS4015.1
TSCOT	CCDS6786.1	WDR24	CCDS10420.1	ZNF406	NM_001029939
TSGA10	CCDS2037.1	WDR27	NM_182552	ZNF440L	NM_001012753
TTC12	CCDS8360.1	WDR32	CCDS6613.1	ZNF473	NM_015428
TTC18	CCDS7324.1	WDR34	CCDS6906.1	ZNF487	ENST00000315429
TTC6	NM_001007795	WDR42B	ENST00000329763	ZNF496	CCDS1631.1
TTLL2	CCDS5301.1	WDR52	CCDS2972.1	ZNF497	CCDS12977.1
TTLL5	NM_015072	WDR6	CCDS2782.1	ZNF507	NM_014910
TTN	NM_133378	WDR70	NM_018034	ZNF545	CCDS12493.1
TTN	NM_133432	WDTC1	CCDS296.1	ZNF547	NM_173631
TUBGCP3	CCDS9525.1	WEE1	CCDS7800.1	ZNF558	CCDS12208.1
TUBGCP6	CCDS14087.1	WFS1	CCDS3386.1	ZNF585A	CCDS12499.1
TULP1	CCDS4807.1	WNK1	CCDS8506.1	ZNF628	NM_033113
TXNDC3	CCDS5452.1	WNK2	CCDS6704.1	ZNF67	ENST00000323012
TYR	CCDS8284.1	WNT9A	NM_003395	ZNF79	CCDS6871.1
UBAP2L	CCDS1063.1	XAB2	NM_020196	ZP2	CCDS10596.1
UBE2G2	CCDS13714.1	XDH	CCDS1775.1	ZSCAN2	CCDS10329.1
UCHL1	CCDS3462.1	XPO1	NM_003400	ZSWIM4	NM_023072
UGCGL2	CCDS9480.1	XPO7	NM_015024	ZW10	CCDS8363.1
UGDH	CCDS3455.1	XR_016172.1	ENST00000355015		
UGT1A6	CCDS2510.1	XR_017335.1	ENST00000314295		
ULK1	CCDS9274.1	YN004_HUMAN	ENST00000281581		
UNQ2446	CCDS10850.1	YTHDC2	CCDS4113.1		
UNQ3030	CCDS3319.1	YWHAH	CCDS13901.1		

Note: Gene symbols are standard symbols assigned by Entrez Gene (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene>). Accession IDs

“NM_XXXX” are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore>). Accession IDs “CCDSXXXX” are uniquely assigned to individual genes by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/CCDS/>). Accession IDs “ENSTXXXXXXXXXXXX” are uniquely assigned to individual genes by *Ensembl* (<http://www.ensembl.org/index.html>).

Table 13. Genes containing somatic mutations in pancreatic cancer adapted from the paper by Jones *et. al.* (Jones *et al.*, 2008).

Gene Symbol	Accession ID	Gene Symbol	Accession ID
7h3	CCDS12324.1	BCAN	CCDS1149.1
AARS	NM_001605	BCHE	CCDS3198.1
ABCA1	CCDS6762.1	BCL2A1	CCDS10312.1
ABCA12	NM_015657	Beta4GalNAc-T4	CCDS7694.1
ABCA7	CCDS12055.1	BMPR2	NM_001204
ABCB5	CCDS5371.1	BOC	CCDS2971.1
ABCD2	CCDS8734.1	BPIL3	CCDS13211.1
ABLIM2	NM_032432	BRCA2	CCDS9344.1
ACACB	NM_001093	BSN	CCDS2800.1
ACD	CCDS10842.1	BTBD7	NM_001002860
ACE	CCDS11637.1	C10orf113	NM_001010896
ACOT9	NM_001033583	C10orf31	NM_001012713
ACTL7B	CCDS6771.1	C10orf93	CCDS7672.1
ADA	CCDS13335.1	C10orf99	CCDS7371.1
ADAM11	CCDS11486.1	C11orf16	CCDS7794.1
ADAM12	CCDS7653.1	C13orf22	CCDS9336.1
ADAM19	CCDS4338.1	C13orf25	CCDS9467.1
ADAM21	CCDS9804.1	C14orf121	NM_138360
ADAMTS10	CCDS12206.1	C14orf124	NM_020195
ADAMTS15	CCDS8488.1	C15orf16	CCDS10026.1
ADAMTS16	NM_139056	C15orf41	NM_032499
ADAMTS18	CCDS10926.1	C17orf27	NM_020914
ADAMTS2	CCDS4444.1	C17orf38	NM_001010855
ADAMTS20	NM_175851	C19orf20	NM_033513
ADAMTS20	NM_025003	C19orf22	CCDS12048.1
ADAMTS5	CCDS13579.1	C19orf28	NM_174983
ADAMTSL3	CCDS10326.1	C19orf35	CCDS12087.1
ADCY2	CCDS3872.1	C19orf6	CCDS12052.1
ADCY4	CCDS9627.1	C1orf113	NM_024676
ADD2	CCDS1906.1	C1orf129	NM_025063
ADPRHL2	CCDS402.1	C1orf14	NM_030933
AFF3	NM_001025108	C1orf25	CCDS1366.1
AHNAK	NM_024060	C1orf45	NM_001025231
AHNAK	NM_001620	C1QL2	NM_182528
AHR	CCDS5366.1	C1RL	CCDS8573.1
AICDA	NM_020661	C2orf134	NM_001024675
AIM2	CCDS1181.1	C2orf161	CCDS13377.1
AK3	CCDS629.1	C2orf26	NM_015585
AKAP12	CCDS5229.1	C2orf42	CCDS13098.1
ALDH18A1	CCDS7443.1	C2orf77	CCDS13301.1
ALDH1A3	CCDS10389.1	C21orf29	CCDS13712.1
ALDH3A1	CCDS11212.1	C21orf63	CCDS13614.1
ALDH3B1	NM_000694	C2orf10	CCDS2291.1
ALDH8A1	CCDS5171.1	C2orf29	CCDS2050.1
ALG8	CCDS8258.1	C3	NM_000064
ALMS1	NM_015120	C3orf15	CCDS2994.1
ALOX5	CCDS7212.1	C3orf18	CCDS2829.1
AMIGO3	NM_198722	C4orf9	NM_003703
ANAPC4	CCDS3434.1	C6orf103	ENST00000326916
ANK3	CCDS7258.1	C6orf213	NM_001010852
ANKAR	ENST00000313581	C6orf54	CCDS5304.1
ANKRD27	NM_032139	C6orf60	NM_024581
ANKRD6	NM_014942	C7orf27	CCDS5334.1
ANKRD9	CCDS9973.1		
ANXA13	NM_001003954		
AOX1	NM_001159		
AP3B2	NM_004644		
APC2	CCDS12068.1		
APG4A	CCDS14538.1		
APOB	CCDS1703.1		
APRN	NM_015032		
APXL2	CCDS4161.1		
AQP8	CCDS10626.1		
ARFGAP1	CCDS13515.1		
ARHGAP10	NM_024605		
ARHGAP21	CCDS7144.1		
ARHGAP28	NM_001010000		
ARHGEF11	CCDS1162.1		
ARHGEF7	CCDS9521.1		
ARHGEF9	NM_015185		
ARID1A	CCDS285.1		
ARMC7	CCDS11714.1		
ARMCX1	CCDS14487.1		
ARNT2	NM_014862		
ARRDC2	CCDS12370.1		
ARSA	CCDS14100.1		
ARSI	NM_001012301		
ARTS-1	CCDS4085.1		
ASB2	CCDS9915.1		
ASXL2	NM_018263		
ATF2	CCDS2262.1		
ATN1	NM_001940		
ATP10A	NM_024490		
ATP10B	ENST00000327245		
ATP10D	CCDS3476.1		
ATP11B	NM_014616		
ATP1A3	CCDS12594.1		
ATP1B2	NM_001678		
ATP2A1	CCDS10643.1		
ATP2B3	CCDS14722.1		
ATP6V0A4	CCDS5849.1		
AZU1	CCDS12044.1		
B3GALT1	CCDS2227.1		
B3GNTL1	NM_001009905		
B4GALT7	CCDS4429.1		
BACH2	CCDS5026.1		
BAI1	NM_001702		
BAI3	CCDS4968.1		
BAIAP2L2	NM_025045		
BAIAP3	CCDS10434.1		
BC37295_3	NM_001005850		

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
C9orf138	CCDS6487.1	CFHR4	NM_006684	CTAG2	CCDS14759.1
C9orf39	NM_017738	CGI-09	CCDS13093.1	CTNNA2	NM_004389
C9orf45	CCDS6850.1	CGN	CCDS999.1	CTNNA3	CCDS7269.1
C9orf91	CCDS6808.1	CHD1	NM_001270	CTNND2	CCDS3881.1
C9orf98	CCDS6954.1	CHD5	CCDS57.1	CUBN	CCDS7113.1
CABLES2	NM_031215	CHD7	NM_017780	CUL4B	NM_003588
CACNA1A	NM_000068	CHI3L1	CCDS1435.1	CUTL1	CCDS5720.1
CACNA1E	NM_000721	CHMP1B	NM_020412	CX40.1	CCDS7191.1
CACNA2D1	CCDS5598.1	CHPPR	CCDS6182.1	CXorf9	CCDS14614.1
CACNG5	CCDS11666.1	CHST1	CCDS7913.1	CYFIP1	CCDS10009.1
CAD	CCDS1742.1	CHURC1	NM_145165	CYFIP2	NM_014376
CALB1	CCDS6251.1	CIAS1	CCDS1632.1	CYP1A1	CCDS10268.1
CALCR	CCDS5631.1	CILP	CCDS10203.1	DACH2	CCDS14455.1
CAMSAP1	NM_015447	CKLFSF4	CCDS10817.1	DAXX	CCDS4776.1
CAMTA1	NM_015215	CLEC4M	CCDS12187.1	DBT	CCDS767.1
CAND2	ENST00000295989	CLIPR-59	CCDS12486.1	DCC1	CCDS6330.1
CAPN12	CCDS12519.1	CLK1	CCDS2331.1	DCHS1	CCDS7771.1
CARD9	CCDS6997.1	CLSTN2	CCDS3112.1	DCHS2	CCDS3785.1
CASKIN2	CCDS11723.1	CLUAP1	NM_015041	DCT	CCDS9470.1
CASP10	CCDS2338.1	CMAS	CCDS8696.1	DDX51	NM_175066
CAT	CCDS7891.1	CMYA1	CCDS2683.1	DDX58	CCDS6526.1
CBFA2T2	CCDS13221.1	CMYA3	NM_152381	DEPDC2	CCDS6201.1
CBLN4	CCDS13448.1	CMYA5	NM_153610	DEPDC5	NM_014662
CCDC11	CCDS11940.1	CNGB1	NM_001297	DET1	NM_017996
CCDC18	NM_206886	CNGB3	CCDS6244.1	DFNB31	CCDS6806.1
CCKAR	CCDS3438.1	CNTN4	CCDS2558.1	DGKA	CCDS8896.1
CCL2	CCDS11277.1	CNTN5	NM_014361	DGKD	CCDS2504.1
CCNB3	CCDS14331.1	CNTN6	CCDS2557.1	DGKK	NM_001013742
CCNYL3	ENST00000332505	CNTNAP2	CCDS5889.1	DGKZ	CCDS7918.1
CCR1	CCDS2737.1	CNTNAP4	CCDS10924.1	DHCR24	CCDS600.1
CCT6A	CCDS5523.1	COBL1	CCDS2223.1	DHX33	CCDS11072.1
CCT6B	NM_006584	COCH	CCDS9640.1	DHX8	CCDS11464.1
CD163	CCDS8578.1	COH1	CCDS6280.1	DICER1	CCDS9931.1
CD1A	CCDS1174.1	COL11A1	CCDS778.1	DIP2B	NM_173602
CD200R1	CCDS2969.1	COL14A1	NM_021110	DKFZp313G1735	CCDS4073.1
CD44	CCDS7897.1	COL17A1	CCDS7554.1	DKFZP434B0335	NM_015395
CD6	CCDS7999.1	COL22A1	CCDS6376.1	DKFZP434G1415	CCDS8743.1
CD79A	CCDS12589.1	COL4A1	CCDS9511.1	DKFZP434L1717	CCDS3805.1
CD86	CCDS3009.1	COL4A4	NM_000092	DKFZp434O0527	CCDS2430.1
CDC42BPA	CCDS1558.1	COL5A1	CCDS6982.1	DKFZP564J0863	NM_015459
CDH1	CCDS10869.1	COL6A3	NM_004369	DKFZp566O084	CCDS11215.1
CDH10	CCDS3892.1	COLEC12	NM_130386	DKFZP586P0123	NM_015531
CDH20	CCDS11977.1	CORO2A	CCDS6735.1	DKFZp761A052	CCDS14313.1
CDH7	CCDS11993.1	CPAMD8	NM_015692	DLC1	CCDS5989.1
CDKN2A	CCDS6510.1	CPLX2	ENST00000274615	DLEC1	ENST00000337335
CDSN	NM_001264	CPN1	CCDS7486.1	DLG2	NM_001364
CEBPZ	CCDS1787.1	CPT1C	CCDS12779.1	DLG3	CCDS14403.1
CEECAM1	CCDS6901.1	CPZ	CCDS3404.1	DLGAP1	CCDS11836.1
CEL	NM_001807	CREBBP	CCDS10509.1	DMD	CCDS14228.1
CELSR1	CCDS14076.1	CSF2RB	CCDS13936.1	DMP1	CCDS3623.1
CENTD1	CCDS3441.1	CSMD1	NM_033225	DNA2L	ENST00000358410
Cep192	NM_032142	CSMD2	CCDS380.1	DNAH11	NM_003777
CEP290	NM_025114	CSS3	NM_175856	DNAH5	CCDS3882.1

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
DNAH8	CCDS4838.1	EPPK1	NM_031308	FLJ20457	CCDS6774.1
DNAH9	CCDS11160.1	EPS8L2	NM_022772	FLJ20580	CCDS576.1
DNAPTP6	NM_015535	ERCC2	NM_000400	FLJ21628	CCDS4440.1
DNHD2	NM_178504	ERCC4	NM_005236	FLJ21816	NM_024675
DNM1L	CCDS8728.1	ERCC6	CCDS7230.1	FLJ21986	NM_024913
DOCK2	CCDS4371.1	EST1B	CCDS1137.1	FLJ23420	CCDS12189.1
DOT1L	NM_032482	ETS2	CCDS13659.1	FLJ23577	ENST00000303168
DP58	NM_001004441	ETV6	CCDS8643.1	FLJ23588	CCDS14049.1
DPP6	NM_130797	EVII	CCDS3205.1	FLJ25006	CCDS11237.1
DRD2	CCDS8361.1	EVPL	CCDS11737.1	FLJ25530	CCDS8456.1
DRD3	CCDS2978.1	EXOC2	NM_018303	FLJ26175	NM_001001668
DUOX2	CCDS10117.1	EXOSC8	NM_181503	FLJ31295	CCDS8763.1
DUSP15	CCDS13193.1	FI0	CCDS9530.1	FLJ32110	CCDS5613.1
DUSP19	CCDS2289.1	FI3A1	CCDS4496.1	FLJ32112	CCDS587.1
DYSF	CCDS1918.1	F8	NM_000132	FLJ32416	CCDS12086.1
EBF	CCDS4343.1	FAD158	CCDS725.1	FLJ32685	CCDS2645.1
EBF3	NM_001005463	FADD	CCDS8196.1	FLJ34969	NM_152678
EDG8	CCDS12240.1	FADS1	CCDS8013.1	FLJ35220	NM_173627
EFEMP1	CCDS1857.1	FADS2	CCDS8012.1	FLJ35843	CCDS9151.1
EHMT1	CCDS7050.1	FAM132B	ENST00000344233	FLJ36180	CCDS3851.1
EIF2AK2	CCDS1786.1	FAM47B	ENST00000329357	FLJ36748	NM_152406
EIF5	CCDS9980.1	FAM50B	CCDS4487.1	FLJ37396	CCDS5072.1
EIF5B	NM_015904	FAM53B	CCDS7641.1	FLJ38020	NM_001039775
ELA2	CCDS12045.1	FAM54B	NM_019557	FLJ38377	CCDS2164.1
ELAVL4	CCDS553.1	FAM55C	CCDS2945.1	FLJ39155	CCDS3924.1
ELN	CCDS5562.1	FAT	NM_005245	FLJ39501	CCDS12331.1
EME2	NM_001010865	FAT3	ENST00000298047	FLJ39502	CCDS2281.1
EMILIN1	CCDS1733.1	FAT4	CCDS3732.1	FLJ40235	CCDS12827.1
EML1	NM_004434	FBN2	NM_001999	FLJ41046	NM_207479
ENC1	CCDS4021.1	FBN3	CCDS12196.1	FLJ41993	NM_001001694
ENST00000294635	ENST00000294635	FBXO15	CCDS12002.1	FLJ45231	NM_001039778
ENST00000298876	ENST00000298876	FBXO3	CCDS7887.1	FLJ45909	CCDS12522.1
ENST00000309390	ENST00000309390	FBXO41	ENST00000295133	FLJ46072	CCDS6410.1
ENST00000322493	ENST00000322493	FBXO9	NM_033481	FLJ46365	CCDS6144.1
ENST00000324303	ENST00000324303	FBXW7	CCDS3777.1	FLJ46481	CCDS3384.1
ENST00000326382	ENST00000326382	FBXW8	CCDS9182.1	FLJ46536	NM_198483
ENST00000326952	ENST00000326952	FGD2	CCDS4829.1	FLJ90805	CCDS12603.1
ENST00000332477	ENST00000332477	FGD5	NM_152536	FMN2	NM_020066
ENST00000333971	ENST00000333971	FKRP	CCDS12691.1	FMNL1	CCDS11497.1
ENST00000334548	ENST00000334548	FKSG44	CCDS8102.1	FMNL3	NM_175736
ENST00000336168	ENST00000336168	FLJ10324	NM_018059	FMR1	CCDS14682.1
ENST00000340260	ENST00000340260	FLJ10407	CCDS583.1	FMR2	CCDS14684.1
ENST00000356555	ENST00000356555	FLJ10521	CCDS182.1	FN1	CCDS2399.1
ENTH	NM_014666	FLJ10647	CCDS406.1	FOXJ1	NM_001454
EP300	CCDS14010.1	FLJ12886	NM_019108	FOXP2	CCDS5760.1
EPB41L1	CCDS13271.1	FLJ14011	CCDS12944.1	FREM1	NM_144966
EPC2	NM_015630	FLJ14299	CCDS6094.1	FREM2	NM_207361
EPHA3	CCDS2922.1	FLJ14490	CCDS446.1	FRMPD4	NM_014728
EPHA7	CCDS5031.1	FLJ14640	NM_032816	FSTL5	CCDS3802.1
EPHB1	NM_004441	FLJ20032	CCDS3666.1	FTCD	CCDS13731.1
EPHB2	CCDS229.1	FLJ20035	NM_017631	FTHL17	CCDS14227.1
EPHB6	CCDS5873.1	FLJ20244	CCDS12293.1	GABRA1	CCDS4357.1
EPM2A	CCDS5206.1	FLJ20245	CCDS7041.1	GABRR1	CCDS5019.1

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
GALNT13	CCDS2199.1	HELB	CCDS8976.1	KBTBD11	NM_014867
GALNT4	NM_003774	HELZ	NM_014877	KCNA3	CCDS828.1
GALNT8	CCDS8533.1	HIP1	NM_005338	KCNA4	NM_002233
GAS7	CCDS11152.1	HIST1H3A	CCDS4570.1	KCNB1	CCDS13418.1
GBP3	CCDS717.1	HIST1H4I	CCDS4620.1	KCNB2	CCDS6209.1
GDF6	NM_001001557	HKR2	CCDS12975.1	KCNC2	CCDS9005.1
GFAP	CCDS11491.1	HMGCLL1	NM_019036	KCNC3	CCDS12793.1
GFRA1	CCDS7593.1	HOXC10	CCDS8868.1	KCNJ3	CCDS2200.1
GH2	CCDS11648.1	HOXC9	CCDS8869.1	KCNK10	CCDS9880.1
GIMAP7	CCDS5903.1	HOXD4	CCDS2269.1	KCNMA1	CCDS7352.1
GJA3	CCDS9289.1	HPCAL1	CCDS1671.1	KCNT1	NM_020822
GLB1L3	ENST00000299136	HPS5	CCDS7836.1	KCTD15	CCDS12434.1
GLI1	CCDS8940.1	HRB2	CCDS9012.1	KEAP1	CCDS12239.1
GLI3	CCDS5465.1	HRPT2	CCDS1382.1	KIAA0082	CCDS4835.1
GLP1R	CCDS4839.1	HS3ST2	CCDS10606.1	KIAA0317	ENST00000338772
GLTSCR1	NM_015711	HS3ST5	NM_153612	KIAA0367	NM_015225
GNAT1	CCDS2812.1	HSGT1	CCDS7321.1	KIAA0372	CCDS4072.1
GOLGA3	CCDS9281.1	HTR1A	NM_000524	KIAA0590	CCDS10439.1
GPC2	CCDS5689.1	HYPC	CCDS8789.1	KIAA0774	NM_001033602
GPR	CCDS10051.1	IER5	CCDS1343.1	KIAA1024	NM_015206
GPR110	ENST00000326374	IL12RB1	NM_153701	KIAA1086	ENST00000262961
GPR133	CCDS9272.1	IL17RB	CCDS2874.1	KIAA1102	NM_014988
GPR151	NM_194251	IL17RC	CCDS2590.1	KIAA1109	ENST00000264501
GPR154	CCDS5443.1	IL18R1	CCDS2060.1	KIAA1219	CCDS13305.1
GPR158	NM_020752	IL2RG	CCDS14406.1	KIAA1543	ENST00000160298
GPR35	CCDS2541.1	ILK	CCDS7768.1	KIAA1704	CCDS9394.1
GPR54	CCDS12049.1	IMP5	NM_175882	KIAA1751	ENST00000270720
GPR73L1	CCDS13089.1	INHBB	CCDS2132.1	KIAA1755	NM_001029864
GPR82	CCDS14259.1	INO80	CCDS10071.1	KIAA1944	CCDS9266.1
GPRC5C	CCDS11699.1	INPP5D	NM_001017915	KIAA1957	ENST00000332235
GPS2	CCDS11100.1	INTS2	NM_020748	KIAA1961	NM_133372
GPX6	NM_182701	IQGAP1	CCDS10362.1	KIAA2013	ENST00000329923
GRCA	CCDS8563.1	IRGQ	NM_001007561	KIF21A	NM_017641
GRHL1	NM_198182	IRS4	CCDS14544.1	KIF25	CCDS5305.1
GRIA3	CCDS14604.1	IRX1	NM_024337	KIF3A	NM_007054
GRIK2	CCDS5048.1	ISYNA1	CCDS12379.1	KIN	CCDS7080.1
GRIN3A	CCDS6758.1	ITGA11	NM_001004439	KIRREL	CCDS1172.1
GRIP2	ENST00000273083	ITGA3	CCDS11557.1	KIT	CCDS3496.1
GRM6	CCDS4442.1	ITGA4	NM_000885	KLF5	CCDS9448.1
GRM8	CCDS5794.1	ITGA9	CCDS2669.1	KLHDC1	CCDS9692.1
GSDML	CCDS11354.1	ITGAE	NM_002208	KLHDC4	CCDS10963.1
GSR	NM_000637	ITGB4BP	CCDS13249.1	KLP1	CCDS12926.1
GTF3C1	NM_001520	ITIH2	NM_002216	KPNB1	CCDS11513.1
GTF3C3	CCDS2316.1	ITLN1	CCDS1211.1	KRAS	CCDS8702.1
GUCA2A	CCDS465.1	ITPR1	NM_002222	KRT13	CCDS11396.1
GUCY1A2	CCDS8335.1	IXL	NM_017592	KRT9	NM_000226
HIT2	CCDS8762.1	JAG1	CCDS13112.1	KRTAP11-1	CCDS13608.1
HAPLN4	CCDS12398.1	JM11	CCDS14316.1	L3MBTL4	CCDS11839.1
HAS1	CCDS12838.1	JMJD3	ENST00000254846	LAMA1	NM_005559
HBXIP	CCDS824.1	JPH3	CCDS10962.1	LAMA4	NM_002290
HCK	NM_002110	JPH4	CCDS9603.1	LAMA5	NM_005560
HECW1	CCDS5469.1	K6IRS2	CCDS8833.1	LAMC3	CCDS6938.1
HECW2	NM_020760	KAL1	CCDS14130.1	LARP	CCDS4328.1

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
LASS3	CCDS10384.1	LRRN3	CCDS5754.1	MORC	CCDS2955.1
LCT	CCDS2178.1	LRRTM4	NM_024993	MORC2	NM_014941
LENG8	CCDS12894.1	MAGEE1	CCDS14433.1	MOXD1	CCDS5152.1
LGI4	CCDS12444.1	MAMDC1	NM_182830	MPHOSPH1	CCDS7407.1
LGR6	CCDS1424.1	MAN2A1	NM_002372	MPL	CCDS483.1
LIG3	CCDS11284.1	MAP1A	NM_002373	MPN2	CCDS1563.1
LIMR	CCDS8780.1	MAP1B	CCDS4012.1	MPO	CCDS11604.1
LIPH	CCDS3272.1	MAP2	CCDS2384.1	MPZ	CCDS1229.1
LMOD1	NM_012134	MAP2K6	CCDS11686.1	MRGPRD	ENST00000309106
LMTK2	CCDS5654.1	MAP4K2	CCDS8082.1	MRGX1	CCDS7846.1
LMX1A	CCDS1247.1	MAP4K3	CCDS1803.1	MRPL38	CCDS11733.1
LOC113179	CCDS12076.1	MAP4K4	ENST00000302217	MRPS7	CCDS11718.1
LOC113386	NM_138781	MAPKBP1	NM_014994	MSLN	NM_013404
LOC123872	CCDS10943.1	MAPT	CCDS11499.1	MTF1	NM_005955
LOC126147	NM_145807	MARLIN1	CCDS3385.1	MTMR12	NM_019061
LOC128153	CCDS1519.1	MARS	CCDS8942.1	MTMR2	CCDS8305.1
LOC130951	NM_138804	MASP2	CCDS123.1	MTO1	CCDS4979.1
LOC131873	ENST00000358511	MASS1	NM_032119	MTR	CCDS1614.1
LOC163131	NM_001005851	MAST2	NM_015112	MUC1	CCDS1098.1
LOC167127	CCDS3914.1	MAT2B	CCDS4365.1	MUC15	CCDS7859.1
LOC222967	ENST00000297186	MBD3	CCDS12072.1	MUC16	NM_024690
LOC283219	NM_001029859	MCM7	CCDS5683.1	MUC2	NM_002457
LOC283398	ENST00000342823	MCTP2	NM_018349	MUF1	CCDS533.1
LOC284434	NM_001007525	MEGF11	CCDS10213.1	MUM1L1	NM_152423
LOC339768	CCDS2525.1	MEP1A	CCDS4918.1	MYBL1	ENST00000331406
LOC340578	NM_001013628	METTL3	NM_019852	MYBPHL	NM_001010985
LOC342979	ENST00000340790	MGC10731	CCDS171.1	MYCBPAP	NM_032133
LOC343521	NM_001013632	MGC13125	CCDS8374.1	MYH2	CCDS11156.1
LOC387720	NM_001013633	MGC15523	CCDS11780.1	MYH3	CCDS11157.1
LOC388135	NM_001039614	MGC15875	CCDS4434.1	MYH6	CCDS9600.1
LOC392617	ENST00000333066	MGC20806	CCDS11797.1	MYH9	CCDS13927.1
LOC399706	NM_001010910	MGC2494	CCDS10423.1	MYLIP	CCDS4536.1
LOC441136	NM_001013719	MGC26598	CCDS9036.1	MYO10	NM_012334
LOC441476	NM_001004353	MGC26988	CCDS4335.1	MYO15A	NM_016239
LOC441722	ENST00000311061	MGC29649	CCDS8033.1	MYO1G	NM_033054
LOC51334	CCDS4127.1	MGC33407	CCDS12207.1	MYO3A	CCDS7148.1
LOC63920	NM_022090	MGC34713	CCDS4070.1	MYO6	NM_004999
LOC89944	NM_138342	MGC35138	CCDS7701.1	MYO7B	ENST00000272666
LPAL2	ENST00000342479	MGC35555	CCDS6307.1	MYO9A	CCDS10239.1
LPHN3	NM_015236	MGC39581	CCDS12149.1	MYOM1	NM_003803
LPL	CCDS6012.1	MGC4266	CCDS8522.1	MYST3	CCDS6124.1
LRFN5	CCDS9678.1	MGC50721	CCDS10602.1	NAALAD2	CCDS8288.1
LRP1	CCDS8932.1	MGC5297	CCDS3873.1	NAALADL2	NM_207015
LRP1B	CCDS2182.1	MID1	CCDS14138.1	NALP10	CCDS7784.1
LRP2	CCDS2232.1	MIZF	CCDS8414.1	NALP13	NM_176810
LRP3	CCDS12430.1	MKL2	NM_014048	NALP14	CCDS7776.1
LRP5	CCDS8181.1	MLC1	CCDS14083.1	NALP4	CCDS12936.1
LRRC16	NM_017640	MLL	NM_005933	NAV2	CCDS7850.1
LRRC18	NM_001006939	MLL2	NM_003482	NAV3	NM_014903
LRRC3B	CCDS2644.1	MLL3	CCDS5931.1	NCDN	CCDS392.1
LRRC4	CCDS5799.1	MLL5	NM_182931	NCK1	CCDS3092.1
LRRC48	NM_031294	MMP9	CCDS13390.1	NCL	NM_005381
LRRK2	NM_198578	MOBKLC	CCDS539.1	NCOA2	NM_006540

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
NEB	NM_004543	OR2W3	NM_001001957	PCDHB2	CCDS4244.1
NEK8	NM_178170	OR4A16	NM_001005274	PCDHB3	CCDS4245.1
NEO1	CCDS10247.1	OR4B1	NM_001005470	PCDHGA1	NM_031993
NFATC3	CCDS10860.1	OR4E2	NM_001001912	PCDHGA11	NM_032091
NFLA	CCDS615.1	OR4L1	NM_001004717	PCDHGA8	NM_014004
NID	CCDS1608.1	OR4X1	NM_001004726	PCDHGC4	CCDS4260.1
NID2	CCDS9706.1	OR51B4	CCDS7757.1	PCNT	NM_006031
NIF3L1BP1	CCDS2900.1	OR51E1	NM_152430	PCNXL2	ENST00000344698
NIPSNAP3B	CCDS6761.1	OR51F2	NM_001004753	PCSK2	CCDS13125.1
NKX2-2	CCDS13145.1	OR52I2	NM_001005170	PCSK6	NM_138321
NLGN1	CCDS3222.1	OR52L1	ENST00000332249	PDE6A	CCDS4299.1
NMUR1	CCDS2486.1	OR5C1	NM_001001923	PDZRN3	NM_015009
NOD3	NM_178844	OR5D13	NM_001001967	PDZRN4	CCDS8739.1
NOL5A	CCDS13030.1	OR5D3P	ENST00000333984	PEG3	CCDS12948.1
NOPE	CCDS10206.1	OR5F1	NM_003697	PER3	CCDS89.1
NOR1	CCDS409.1	OR5J2	NM_001005492	PFAS	CCDS11136.1
NOS1	NM_000620	OR5T1	NM_001004745	PGM5	CCDS6622.1
NOX5	NM_024505	OR6A2	CCDS7772.1	PGR	CCDS8310.1
NP_001035826.1	ENST00000331090	OR6K2	NM_001005279	PHACTR3	CCDS13480.1
NP_001074311.1	ENST00000326096	OR8D2	NM_001002918	PHB2	NM_007273
NPD014	CCDS260.1	OR8H1	NM_001005199	PIAS4	CCDS12118.1
NPHP4	NM_015102	OR8K1	NM_001002907	PIGK	CCDS674.1
NPY1R	NM_000909	OR8K5	NM_001004058	PIGT	CCDS13353.1
NRG2	CCDS4217.1	OR9I1	NM_001005211	PIK3CG	CCDS5739.1
NRXN2	CCDS8077.1	OR9K2	NM_001005243	PIK3R2	CCDS12371.1
NRXN3	CCDS9870.1	ORC5L	CCDS5734.1	PIP5K3	CCDS2382.1
NSE1	CCDS1684.1	OSBPL6	CCDS2277.1	PITRM1	NM_014889
NTF3	CCDS8538.1	OSCAR	CCDS12873.1	PKD1L2	NM_182740
NTRK3	CCDS10340.1	OSMR	CCDS3928.1	PKHD1L1	NM_177531
NUDT5	CCDS7089.1	OSTN	CCDS3299.1	PKIA	CCDS6222.1
ENST00000318605	ENST00000318605	OTOF	CCDS1724.1	PKP2	CCDS8731.1
NUP210	NM_024923	OTP	CCDS4039.1	PLCB2	NM_004573
NURIT	CCDS9399.1	OTX1	CCDS1873.1	PLCB3	CCDS8064.1
NXN	CCDS10998.1	OVCA2	NM_001383	PLCB4	CCDS13104.1
NXPH3	CCDS11550.1	OVCH1	NM_183378	PLEC1	NM_201380
OBSCN	CCDS1570.1	P11	CCDS8754.1	PLEC1	NM_201378
OBSL1	ENST00000265318	PABPC5	CCDS14460.1	PLEK2	CCDS9782.1
OCA2	CCDS10020.1	PACS2	NM_015197	PLEKHA6	CCDS1444.1
ODZ4	ENST00000278550	PADI2	CCDS177.1	PLEKHG2	NM_022835
OGDHL	CCDS7234.1	PALMD	CCDS758.1	PLK5_HUMAN	ENST00000334770
OGFOD2	NM_024623	PAPPA	CCDS6813.1	PLXNA1	NM_032242
OGT	CCDS14414.1	PARP10	NM_032789	PLXNB1	CCDS2765.1
OR10A3	ENST00000360759	PARP14	NM_017554	PMP22CD	NM_001013743
OR10K2	NM_001004476	PARP2	NM_005484	PNPLA1	NM_001039725
OR10P1	NM_206899	PARP9	CCDS3014.1	PODN	CCDS573.1
OR10R2	NM_001004472	PAX6	NM_000280	PODXL	NM_001018111
OR10Z1	NM_001004478	PB1	CCDS2859.1	POLR2A	NM_000937
OR11L1	NM_001001959	PCDH15	CCDS7248.1	POLRMT	CCDS12036.1
OR13C3	NM_001001961	PCDH17	NM_014459	PON1	CCDS5638.1
OR13C5	NM_001004482	PCDH18	NM_019035	PPA2	CCDS3667.1
OR1J2	NM_054107	PCDH9	CCDS9443.1	PPFIA2	NM_003625
OR2AJ1	ENST00000318244	PCDHA13	NM_031864	PPP1CA	CCDS8160.1
OR2T1	NM_030904	PCDHB16	CCDS4251.1	PPP1R15B	CCDS1445.1

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
PPP1R3A	CCDS5759.1	Q96M18_HUMAN	ENST00000335239	RODH	CCDS8925.1
PPP2R1A	CCDS12849.1	Q96MJ2_HUMAN	ENST00000327832	RP1	CCDS6160.1
PPP2R3A	CCDS3087.1	Q96QE0_HUMAN	ENST00000301647	RPGRIP1	NM_020366
PPP2R4	CCDS6920.1	Q96RX8_HUMAN	ENST00000301719	RREB1	NM_001003699
PPP5C	CCDS12684.1	Q96S27_HUMAN	ENST00000301682	RTL1	ENST00000331067
PRDM10	CCDS8484.1	Q9H557_HUMAN	ENST00000237253	RTTN	NM_173630
PRDM5	CCDS3716.1	Q9H5F0_HUMAN	ENST00000360484	RUNX1T1	CCDS6256.1
PRDM9	NM_020227	Q9H8A7_HUMAN	ENST00000053084	RYR1	NM_000540
PRELP	CCDS1438.1	Q9HA39_HUMAN	ENST00000329980	RYR2	NM_001035
PREX1	CCDS13410.1	Q9HCM3_HUMAN	ENST00000242365	SACS	CCDS9300.1
PRG-3	CCDS6751.1	Q9NSI0_HUMAN	ENST00000328881	SARS2	NM_017827
PRKACG	CCDS6625.1	Q9NT86_HUMAN	ENST00000314272	SART3	CCDS9117.1
PRKCG	CCDS12867.1	Q9P169_HUMAN	ENST00000342338	SBLF	CCDS1840.1
PRKDI	CCDS9637.1	Q9P193_HUMAN	ENST00000359406	SCAP2	CCDS5400.1
ProSAP1P1	CCDS13049.1	Q9P1M5_HUMAN	ENST00000303007	SCFD2	NM_152540
PRR12	ENST00000246798	Q9Y6V0-3	ENST00000333891	SCGN	CCDS4561.1
PRSS23	CCDS8278.1	QRICH2	NM_032134	SCN11A	NM_014139
PSMD3	CCDS11356.1	RAB6B	CCDS3082.1	SCN2A2	NM_021007
PSME4	NM_014614	RAD9B	CCDS9148.1	SCN4A	NM_000334
PTCHD2	ENST00000294484	RAG1	CCDS7902.1	SCN5A	NM_000335
PTCHD3	NM_001034842	RAG2	CCDS7903.1	SCN5A	NM_198056
PTF1A	CCDS7143.1	RaLP	CCDS10130.1	SCN7A	NM_002976
PTGER3	CCDS652.1	RANBP2	CCDS2079.1	SCNMI	CCDS987.1
PTN	CCDS5844.1	RARB	CCDS2642.1	SCNN1B	CCDS10609.1
PTPN12	CCDS5592.1	RARRES2	CCDS5902.1	SCNN1G	CCDS10608.1
PTPRK	CCDS5137.1	RASEF	ENST00000330861	SCRIB	CCDS6411.1
PTPRZ1	NM_002851	RASGRP3	NM_170672	SDPR	CCDS2313.1
PUM1	CCDS338.1	RASGRP4	NM_170603	SDS	CCDS9169.1
PWP2H	NM_005049	RASIP1	CCDS12731.1	SEC14L3	CCDS13877.1
PXDN	ENST00000252804	RASSF6	CCDS3558.1	SEMA4D	CCDS6685.1
PXDNL	NM_144651	RBAF600	CCDS189.1	SEMA5B	CCDS3019.1
PYHIN1	CCDS1178.1	RBBP6	CCDS10621.1	SENP1	NM_014554
Q08AG5_HUMAN	ENST00000334213	RBM27	ENST00000265271	SESN2	CCDS321.1
Q5JX50_HUMAN	ENST00000325076	RC74	NM_018250	SEZ6L	CCDS13833.1
Q5SYT8_HUMAN	ENST00000279434	RCHY1	CCDS3567.1	SF3A1	CCDS13875.1
Q6ZMX6_HUMAN	ENST00000269197	RDH8	CCDS12223.1	SF3B1	NM_012433
Q6ZT40_HUMAN	ENST00000296564	RELN	NM_005045	SFRS12	CCDS3991.1
Q7Z2Q7_HUMAN	ENST00000334994	RENB	CCDS14738.1	SFRS16	CCDS12652.1
Q7Z7L8_HUMAN	ENST00000339446	REPIN1	NM_013400	SGEF	NM_015595
Q8N2V9_HUMAN	ENST00000324414	RFX1	CCDS12301.1	SH2D1B	NM_053282
Q8N5S4_HUMAN	ENST00000326474	RFX3	CCDS6449.1	SH3GL3	CCDS10325.1
Q8N6V7_HUMAN	ENST00000324928	RFXDC1	CCDS5113.1	SH3TC1	CCDS3399.1
Q8N800_HUMAN	ENST00000322516	RGS11	CCDS10403.1	SHANK2	CCDS8198.1
Q8N9F6_HUMAN	ENST00000317122	RGS17	CCDS5244.1	SHKBP1	CCDS12560.1
Q8N9G5_HUMAN	ENST00000313957	RHBDF1	NM_022450	SI	CCDS3196.1
Q8N9S5_HUMAN	ENST00000329388	RHOT2	CCDS10417.1	SIDT1	CCDS2974.1
Q8N9V7_HUMAN	ENST00000309765	RIC3	CCDS7788.1	SIGLEC11	CCDS12790.1
Q8N9Z1_HUMAN	ENST00000326413	RIMBP2	NM_015347	SIPA1L2	NM_020808
Q8NCK2_HUMAN	ENST00000325720	RIMS1	NM_014989	SIX2	CCDS1822.1
Q8NGP7_HUMAN	ENST00000341231	RIMS2	NM_014677	SKD3	CCDS8215.1
Q8NH06_HUMAN	ENST00000324144	RLF	CCDS448.1	SLC14A1	CCDS11925.1
Q8NH08_HUMAN	ENST00000327198	RNF175	NM_173662	SLC17A1	CCDS4565.1
Q96GK3_HUMAN	ENST00000315264	RNUT1	CCDS10281.1	SLC17A7	CCDS12764.1

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
SLC1A6	CCDS12321.1	STAC	CCDS2662.1	TM9SF4	CCDS13196.1
SLC22A15	NM_018420	STAC2	CCDS11335.1	TMCC2	NM_014858
SLC22A7	CCDS4893.1	STAMBP	CCDS1929.1	TMEFF2	CCDS2314.1
SLC25A26	CCDS2905.1	STARD13	CCDS9348.1	TMEM132B	NM_052907
SLC28A3	CCDS6670.1	STARD8	CCDS14390.1	TMEM16A	NM_018043
SLC2A1	CCDS477.1	STAT4	CCDS2310.1	TMEM16C	NM_031418
SLC2A3	CCDS8586.1	STIM1	CCDS7749.1	TMEM16G	NM_001001891
SLC2A5	CCDS99.1	STK10	NM_005990	TMEM63B	NM_018426
SLC33A1	CCDS3173.1	STK23	NM_014370	TMEM8	CCDS10407.1
SLC39A10	NM_020342	STK33	CCDS7789.1	TMEPAI	CCDS13462.1
SLC39A6	NM_012319	STMN4	CCDS6055.1	TMPO	CCDS9064.1
SLC45A1	ENST00000289877	STN2	CCDS9875.1	TMPRSS13	NM_032046
SLC4A10	NM_022058	SULF1	CCDS6204.1	TNF	CCDS4702.1
SLC4A8	CCDS8814.1	SULF2	CCDS13408.1	TNFRSF8	CCDS144.1
SLC4A9	NM_031467	SV2A	CCDS940.1	TNK1	NM_003985
SLC6A15	CCDS9026.1	SYNE1	CCDS5236.1	TNNI3	NM_000363
SLC6A17	NM_001010898	SYNE1	CCDS5237.1	TNR	CCDS1318.1
SLC6A2	CCDS10754.1	SYNE2	CCDS9761.1	TOR3A	CCDS1329.1
SLC6A3	CCDS3863.1	SYP	CCDS14321.1	TP53	CCDS11118.1
SLC9A5	NM_004594	SYT1	CCDS9017.1	TP53BP1	CCDS10096.1
SLCO1A2	CCDS8686.1	SYT6	CCDS871.1	TPO	CCDS1642.1
SLCO1B1	CCDS8685.1	SYT7	NM_004200	TREH	NM_007180
SLCO1C1	CCDS8683.1	T	CCDS5290.1	TRERF1	CCDS4867.1
SLCO4C1	NM_180991	TAF1B	NM_005680	TRIM37	NM_001005207
SLITRK2	CCDS14680.1	TAFIL	NM_153809	TRIM58	CCDS1636.1
SLITRK3	CCDS3197.1	TAF4	NM_003185	TRPM1	CCDS10024.1
SLITRK5	CCDS9465.1	TAS2R41	NM_176883	TRPM2	CCDS13710.1
SMAD3	CCDS10222.1	TATDN2	NM_014760	TRPM3	CCDS6634.1
SMAD4	CCDS11950.1	TBC1D14	CCDS3394.1	TSC2	CCDS10458.1
SMARCA4	CCDS12253.1	TBX15	NM_152380	TSP-NY	CCDS9237.1
SMOC1	CCDS9798.1	TBX18	ENST00000330469	TSTA3	CCDS6408.1
SMTN	CCDS13886.1	TBX5	CCDS9173.1	TTBK2	NM_173500
SN	CCDS13060.1	TBX6	CCDS10670.1	TTC12	CCDS8360.1
SNCAIP	CCDS4131.1	TCEB3B	CCDS11932.1	TTC21B	NM_024753
SNRPC	NM_003093	TCFL1	CCDS989.1	TTC24	ENST00000340086
SNX16	CCDS6234.1	TDRD7	CCDS6725.1	TTF1	CCDS6948.1
SNX26	CCDS12477.1	TENC1	CCDS8842.1	TTK	CCDS4993.1
SORL1	CCDS8436.1	TESSP2	NM_182702	TTN	NM_133378
SOX3	CCDS14669.1	TEX14	NM_198393	TTN	NM_133437
SP8	CCDS5372.1	TFCP2L1	CCDS2134.1	TUBB3	CCDS10988.1
SPAP1	CCDS1168.1	TFF2	CCDS13684.1	TXNDC6	CCDS3099.1
SPATA13	ENST00000360220	TFFI2	CCDS5632.1	UBE1L	CCDS2805.1
SPINLW1	CCDS13359.1	TFR2	NM_003227	UBE2M	CCDS12987.1
SPTAN1	CCDS6905.1	TFSM1_HUMAN	ENST00000314720	UBQLN4	CCDS1127.1
SPTBN2	CCDS8150.1	TG	NM_003235	UBR2	CCDS4870.1
SR140_HUMAN	ENST00000319822	TGFBR2	CCDS2648.1	UBXD7	ENST00000296328
SRCRB4D	CCDS5585.1	TGIF2	CCDS13278.1	UCP3	CCDS8229.1
SRRM2	NM_016333	THNSL1	CCDS7147.1	ULBP1	CCDS5223.1
SST	CCDS3288.1	THSD7B	ENST00000272643	UNC13C	ENST00000260323
ST6GAL2	CCDS2073.1	TIMELESS	CCDS8918.1	USP20	NM_001008563
ST6GALNAC5	CCDS673.1	TJP1	NM_175610	USP31	CCDS10607.1
ST8SIA5	CCDS11930.1	TLL2	CCDS7449.1	USP38	CCDS3758.1
STAB1	NM_015136	TM7SF4	CCDS6301.1	USP42	NM_032172

Gene Symbol	Accession ID	Gene Symbol	Accession ID
UTRN	NM_007124	ZNF423	NM_015069
VDAC2	CCDS7348.1	ZNF443	NM_005815
VGCNL1	CCDS9498.1	ZNF451	CCDS4960.1
VIM	CCDS7120.1	ZNF507	NM_014910
VIT	NM_053276	ZNF537	CCDS12421.1
VLDLR	CCDS6446.1	ZNF560	CCDS12214.1
VMD2L1	NM_017682	ZNF614	CCDS12847.1
VPS13A	CCDS6655.1	ZNF638	CCDS1917.1
VPS13D	NM_018156	ZNF645	CCDS14205.1
VPS16	CCDS13036.1	ZNF648	ENST00000339948
VPS39	CCDS10083.1	ZNF682	NM_033196
VSIG1	CCDS14535.1	ZYG11B	NM_024646
VWF	CCDS8539.1		
WASF3	CCDS9318.1		
WBSCR14	CCDS5553.1		
WBSCR17	CCDS5540.1		
WDR1	NM_005112		
WDR17	CCDS3825.1		
WDR27	NM_182552		
WDR42B	ENST00000329763		
WDR44	CCDS14572.1		
WHSC1	CCDS3357.1		
WIRE	CCDS11364.1		
WNT9A	NM_003395		
WRNIP1	CCDS4475.1		
XKR4	NM_052898		
XPNPEP1	CCDS7560.1		
XPO7	NM_015024		
XR_017918.1	ENST00000258651		
XYLT2	CCDS11563.1		
YLPM1	ENST00000238571		
YN002_HUMAN	ENST00000334389		
ZAN	NM_173059		
ZBTB24	NM_014797		
ZBTB33	CCDS14596.1		
ZBTB7	CCDS12119.1		
ZC3H12B	NM_001010888		
ZC3HDC7	CCDS10550.1		
ZDHHC4	CCDS5352.1		
ZFHX1B	CCDS2186.1		
ZFP36	CCDS12534.1		
ZHX3	CCDS13315.1		
ZIM3	NM_052882		
ZMAT4	NM_024645		
ZNF133	CCDS13134.1		
ZNF136	NM_003437		
ZNF148	CCDS3031.1		
ZNF238	CCDS1623.1		
ZNF253	ENST00000327867		
ZNF31	NM_145238		
ZNF333	CCDS12316.1		
ZNF334	NM_199441		
ZNF365	CCDS7264.1		

Note: Gene symbols are standard symbols assigned by Entrez Gene (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene>). Accession IDs "NM_XXXX" are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide>). Accession IDs "CCDSXXXX" are uniquely assigned to individual genes by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/CCDS/>). Accession IDs "ENSTXXXXXXXXXXXX" are uniquely assigned to individual genes by *Ensembl* (<http://www.ensembl.org/index.html>).

Table 14. Genes containing somatic mutations in breast cancer adapted from the paper by Wood *et. al.* (Wood *et al.*, 2007).

Gene Symbol	Accession ID	Gene Symbol	Accession ID
ABCA12	NM_173076	BLR1	NM_001716.2
ABCA3	NM_001089.1	BMP1	NM_006129.2
ABCA4	NM_000350.1	BOC	NM_033254.2
ABCB10	NM_012089.1	BRCA1	NM_007296.1
ABCB6	NM_005689.1	BRCA2	NM_000059.1
ABCB8	NM_007188.2	BSPRY	NM_017688
ABL2	NM_007314	C10orf30	NM_152751.1
ABLIM1	NM_002313.4	C10orf38	NM_001010924
ABP1	NM_001091	C10orf39	NM_194303.1
ACADM	NM_000016.2	C10orf45	NM_031453.2
ACO2	NM_001098.2	C10orf54	NM_022153
ACY1	NM_000666.1	C10orf56	NM_153367.1
ADAM12	NM_003474.2	C10orf64	NM_173524
ADAMTS16	NM_139056	C11orf37	NM_001007543
ADAMTS19	NM_133638.1	C11orf9	NM_013279
ADAR	NM_001111.2	C13orf24	NM_006346
ADH1B	NM_000668	C14orf100	NM_016475
ADHFE1	NM_144650.1	C14orf101	NM_017799.2
ADRA1A	NM_033302.1	C14orf121	NM_138360
AEGP	NM_206920.1	C14orf155	NM_032135.2
AGBL4	NM_032785	C14orf161	NM_024764
AGC1	NM_001135	C14orf21	NM_174913.1
AGRN	NM_198576	C14orf29	NM_181814.1
AHRR	NM_020731	C14orf46	NM_001024674
AHSA2	NM_152392.1	C17orf47	NM_001038704
AIM1	NM_001624	C17orf64	NM_181707
AKAP6	NM_004274.3	C18orf19	NM_152352.1
AKAP8	NM_005858.2	C19orf28	NM_174983
AKAP9	NM_005751.3	C19orf6	NM_033420.2
ALCAM	NM_001627	C1orf190	NM_001013615
ALMS1	NM_015120	C1orf2	NM_006589.2
ALS2	NM_020919	C1QB	NM_000491.2
ALS2CL	NM_147129.2	C2orf103	NM_012261.2
ALS2CR12	NM_139163.1	C2orf121	NM_024331.2
ALS2CR19	NM_152526	C2orf161	NM_033421.2
AMFR	NM_001144.3	C2orf177	NM_022106.1
AMIGO1	NM_020703	C2orf23	NM_024704.3
AMOTL1	NM_130847	C2orf44	NM_018244.3
AMPD2	NM_139156.1	C22orf19	NM_003678.3
AMPD2	NM_004037.5	C4orf14	NM_032313.2
ANAPC5	NM_016237.3	C5orf14	NM_024715.2
ANK1	NM_020476.1	C6orf102	NM_145027.3
ANK2	NM_001148.2	C6orf145	NM_183373.2
ANKRD28	NM_015199	C6orf174	NM_001012279
ANKRD29	NM_173505.1	C6orf204	NM_206921.1
ANKRD30A	NM_052997.1	C6orf21	NM_001003693
ANKRD5	NM_198798.1	C6orf213	NM_001010852
		C6orf31	NM_030651.2
		C7orf11	NM_138701.1
		C9orf126	NM_173690
		C9orf37	NM_032937
		C9orf67	NM_032728.2
		CACNA1B	NM_000718
AP1M1	NM_032493.2		
AP3B2	NM_004644		
APBB1	NM_145689		
APC2	NM_005883.1		
APCS	NM_001639.2		
APOC4	NM_001646.1		
APOL1	NM_145343.1		
APPL	NM_012096.1		
APXL	NM_001649.2		
AQP8	NM_001169.2		
ARC	NM_015193		
ARFGAP3	NM_014570.3		
ARFGEF2	NM_006420.1		
ARFRP1	NM_003224.2		
ARHGAP11A	NM_014783.2		
ARHGAP25	NM_001007231		
ARHGEF4	NM_015320.2		
ARID1B	NM_017519.1		
ARRB1	NM_020251		
ARRDC3	NM_020801		
ARV1	NM_022786.1		
ASB11	NM_080873.1		
ASGR1	NM_001671.2		
ASL	NM_000048.2		
ASTN2	NM_014010.3		
ATCAY	NM_033064		
ATF2	NM_001880.2		
ATN1	NM_001940		
ATP10A	NM_024490		
ATP12A	NM_001676		
ATP2A3	NM_174955.1		
ATP6AP1	NM_001183		
ATP6V0B	NM_004047.2		
ATP8B1	NM_005603.1		
ATP8B4	NM_024837		
ATRN	NM_139321.1		
ATXN2	NM_002973		
AVPI1	NM_021732.1		
AVPR2	NM_000054.2		
B3GALNT2	NM_152490.1		
B3GALT4	NM_003782		
BAI1	NM_001702		
BAP1	NM_004656.2		
BAT2	NM_080686.1		
BAT3	NM_080703.1		
BAZ1A	NM_013448.2		
BAZ1B	NM_032408.1		
BC002942	NM_033200.1		
BCAR1	NM_014567.2		
BCCIP	NM_016567.2		
BCL11A	NM_018014.2		
BCORL1	NM_021946.2		
BGN	NM_001711.3		

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
CACNA1F	NM_005183	COL11A1	NM_001854.2	DIP2B	NM_173602
CACNA1G	NM_198385	COL12A1	NM_004370	DKFZP564B1023	NM_031306.1
CACNA1H	NM_021098	COL19A1	NM_001858.3	DKFZP564J102	NM_001006655
CACNA1I	NM_001003406	COL4A4	NM_000092	DKFZp761I2123	NM_031449
CACNA2D3	NM_018398	COL7A1	NM_000094.2	DKFZp779B1540	NM_001010903
CAMTA1	NM_015215	COMMD7	NM_053041	DKK3	NM_015881.4
CAPN11	NM_007058	COPG	NM_016128	DLEC1	NM_007335.1
CBFB	NM_001755.2	COQ9	NM_020312	DMD	NM_004006.1
CCDC16	NM_052857	CPA3	NM_001870.1	DNAH17	NM_003727
CCDC18	NM_206886	CPAMD8	NM_015692	DNAH5	NM_001369.1
CCDC66	NM_001012506	CPEB1	NM_030594	DNAH9	NM_001372.2
CD2	NM_001767.2	CPS1	NM_001875.2	DNAJA3	NM_005147.3
CD74	NM_001025159	CPSF3	NM_016207.2	DNAJA5	NM_194283.1
CD97	NM_001784	CROCC	NM_014675	DNAJC10	NM_018981
CDC27	NM_001256.2	CRR9	NM_030782.2	DNAJC13	NM_015268
CDH10	NM_006727.2	CRSP2	NM_004229.2	DNASE1L3	NM_004944.1
CDH20	NM_031891.2	CRTC1	NM_025021	DNM2	NM_004945
CDH8	NM_001796.2	CRX	NM_000554.2	DNM3	NM_015569
CDKL2	NM_003948.2	CRYAA	NM_000394.2	DOCK1	NM_001380
CDON	NM_016952.2	CSEN	NM_013434.3	DPAGT1	NM_001382.2
CDS1	NM_001263.2	CSMD1	NM_033225	DPAGT1	NM_203316.1
CENPE	NM_001813	CSMD3	NM_198123.1	DPP10	NM_020868
CENTB1	NM_014716.2	CSNK1D	NM_001893.3	DPP6	NM_130797
CENTD3	NM_022481.4	CSPP1	NM_024790	DPYD	NM_000110
CENTG1	NM_014770.2	CST4	NM_001899.2	DRIM	NM_014503.1
CEP290	NM_025114	CTF8	NM_001039690	DSCR6	NM_018962.1
CFHL5	NM_030787.1	CTNNA1	NM_001903	DSG2	NM_001943
CFL2	NM_138638.1	CTNNA2	NM_004389	DTNA	NM_032978.4
CGI-14	NM_015944.2	CTNND1	NM_001331	DTX3L	NM_138287.2
CGI-37	NM_016101.2	CUBN	NM_001081.2	DUOX1	NM_017434
CHD1	NM_001270	CUTC	NM_015960.1	DVL3	NM_004423.3
CHD5	NM_015557.1	CUTL1	NM_001913.2	DYSF	NM_003494.2
CHD7	NM_017780	CUTL2	NM_015267	ECT2	NM_018098.4
CHD8	NM_020920	CYP1A1	NM_000499.2	EDEM1	NM_014674
CHD9	NM_025134	CYP1A2	NM_000761	EDNRA	NM_001957.1
CHRND	NM_000751.1	CYP26A1	NM_000783.2	EEF1G	NM_001404
CIC	NM_015125.2	CYP2D6	NM_000106	EGFL6	NM_015507.2
CLCA2	NM_006536.3	CYP4A22	NM_001010969	EHBP1	NM_015252.2
CLCN1	NM_000083.1	DACH1	NM_080759	EHMT1	NM_024757.3
CLCN3	NM_001829	DAZAP1	NM_018959.2	EIF4A2	NM_001967.2
CLEC6A	NM_001007033	DBN1	NM_004395.2	EIF4B	NM_001417
CLSPN	NM_022111.2	DC2	NM_021227.2	EIF5	NM_183004.3
CLUAP1	NM_015041	DDO	NM_003649.2	ELA1	NM_001971.3
CMYA1	NM_194293.2	DDX10	NM_004398.2	ELAVL3	NM_001420
CMYA4	NM_173167.1	DDX18	NM_006773.3	ENPEP	NM_001977.2
CNGA2	NM_005140.1	DDX3X	NM_024005.1	EOMES	NM_005442.2
CNGB1	NM_001297	DEFB128	NM_001037732	EP400	NM_015409
CNNM4	NM_020184.2	DENND2A	NM_015689	EPC2	NM_015630
CNTN3	NM_020872	DGKB	NM_004080	ERCC3	NM_000122.1
CNTN5	NM_014361	DGKE	NM_003647.1	ERCC6	NM_000124.1
CNTN6	NM_014461.2	DGKG	NM_001346.1	EREG	NM_001432.1
COG3	NM_031431.2	DHX32	NM_018180.2	ETV5	NM_004454
COH1	NM_017890.3	DIP	NM_015124	EVI2A	NM_001003927

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
EVI5	NM_005665	FLJ34521	NM_001039787	GOLGA7	NM_016099
EXOC2	NM_018303	FLJ36180	NM_178556.3	GOLGB1	NM_004487.1
EXOC5	NM_006544	FLJ36748	NM_152406	GOLPH4	NM_014498.2
EXOSC3	NM_016042	FLJ40342	NM_152347.3	GORASP2	NM_015530
FAAH	NM_001441.1	FLJ40869	NM_182625.2	GP5	NM_004488.1
FABP4	NM_001442.1	FLJ41821	NM_001001697	GPC1	NM_002081.1
FAM44A	NM_148894.1	FLJ45455	NM_207386	GPC2	NM_152742.1
FAM47B	NM_152631.1	FLJ46321	NM_001001670	GPMB5	NM_145171
FAM80B	NM_020734	FLJ46354	NM_198547.1	GPNMB	NM_002510.1
FANCA	NM_000135	FLJ46481	NM_207405.1	GPR115	NM_153838.1
FANCM	NM_020937	FLJ90579	NM_173591.1	GPR45	NM_007227.3
FARP1	NM_005766.1	FLNA	NM_001456	GPR7	NM_005285.1
FBXO40	NM_016298	FLNB	NM_001457.1	GPR81	NM_032554.2
FBXO8	NM_012180.1	FLNC	NM_001458	GRIK2	NM_021956.2
FBXW11	NM_012300	FMNL3	NM_175736	GRIK3	NM_000831.2
FCHO1	NM_015122	FMOD	NM_002023	GRIN2C	NM_000835
FCMD	NM_006731.1	FN1	NM_002026.2	GRIN2D	NM_000836.1
FCRH3	NM_052939.2	FNDC3B	NM_022763.2	GRIPAP1	NM_207672
FEM1C	NM_020177.2	FOLR2	NM_000803.2	GRM6	NM_000843.2
FER1L3	NM_133337	FOXP2	NM_014491.1	GSDML	NM_018530.1
FGD3	NM_033086	FOXP4	NM_138457.1	GSN	NM_000177.3
FGD6	NM_018351	FREM1	NM_144966	GTF2A1	NM_015859.2
FGFR2	NM_022970.1	FRMPD1	NM_014907.1	GTF3C1	NM_001520
FHOD1	NM_013241.1	FUCA1	NM_000147.2	GUCY2F	NM_001522.1
FHOD3	NM_025135	FUS	NM_004960.1	HADHB	NM_000183.1
FLG2	NM_001014342	FXR1	NM_005087.1	HCN3	NM_020897.1
FLJ10241	NM_018035	G3BP2	NM_203505.1	HDAC4	NM_006037.2
FLJ10292	NM_018048.2	G6PC	NM_000151.1	HDAC7A	NM_015401.1
FLJ10324	NM_018059	GA17	NM_006360.2	HDLBP	NM_203346.1
FLJ10458	NM_018096.2	GAB1	NM_002039.2	HEBP1	NM_015987
FLJ10726	NM_018195.2	GABRA4	NM_000809.2	HEL308	NM_133636.1
FLJ10874	NM_018252.1	GABRP	NM_014211.1	HIST1H4L	NM_003546.2
FLJ13089	NM_024953.2	GALK2	NM_001001556	HIST2H2AB	NM_175065.2
FLJ13231	NM_023073	GALNT17	NM_001034845	HK3	NM_002115.1
FLJ13479	NM_024706.3	GALNT5	NM_014568.1	HLCS	NM_000411.4
FLJ13868	NM_022744.1	GALNTL2	NM_054110	HM13	NM_030789.2
FLJ14503	NM_152780.2	GARNL1	NM_194301	HMG2L1	NM_001003681
FLJ14624	NM_032813.1	GDF6	NM_001001557	HOMER2	NM_199331
FLJ16331	NM_001004326	GGA1	NM_013365.2	HOOK1	NM_015888.3
FLJ20152	NM_019000	GGA3	NM_014001.2	HOOK2	NM_013312
FLJ20184	NM_017700.1	GIMAP1	NM_130759.2	HOOK3	NM_032410.2
FLJ20422	NM_017814.1	GIMAP8	NM_175571	HOXA3	NM_153631.1
FLJ20584	NM_017891.2	GIOT-1	NM_153257	HOXA4	NM_002141.2
FLJ20604	NM_017897.1	GIPC3	NM_133261	HS3ST4	NM_006040
FLJ21839	NM_021831.3	GJA8	NM_005267	HSD11B1	NM_181755.1
FLJ21945	NM_025203.1	GJB1	NM_000166.2	HSD17B8	NM_014234.3
FLJ23584	NM_024588	GKN1	NM_019617.2	HSHN1	NM_199324.1
FLJ25955	NM_178821.1	GLG1	NM_012201	HSPA14	NM_016299.1
FLJ31413	NM_152557.3	GLI1	NM_005269.1	HSPA1B	NM_005346
FLJ32115	NM_152321.1	GLT25D2	NM_015101.1	HSPC049	NM_014149
FLJ32363	NM_198566.1	GMCLIL	NM_022471.2	HTF9C	NM_182984.2
FLJ32440	NM_173685.1	GNB1L	NM_053004.1	HUMCYT2A	NM_015848.1
FLJ32830	NM_152781.1	GNPAT	NM_014236.1	HUWE1	NM_031407

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
ICAM5	NM_003259.2	KIAA1324	NM_020775.2	LOC652968	NM_001037666
IFNA2	NM_000605.2	KIAA1377	NM_020802	LOC88523	NM_033111
IFNB1	NM_002176.1	KIAA1414	NM_019024	LOC90529	NM_178122.2
IKBKAP	NM_003640.2	KIAA1632	NM_020964.1	LOC91461	NM_138370
IKBKB	NM_001556.1	KIAA1797	NM_017794	LOXL2	NM_002318
IL1RAPL2	NM_017416.1	KIAA1826	NM_032424	LPO	NM_006151
IL7R	NM_002185.2	KIAA1914	NM_001001936	LRBA	NM_006726.1
INA	NM_032727.2	KIAA1946	NM_177454	LRRRC16	NM_017640
INHBE	NM_031479.3	KIBRA	NM_015238.1	LRRRC4	NM_022143.3
IPLA2(GAMMA)	NM_015723	KIF14	NM_014875	LRRRC43	NM_152759
IPO7	NM_006391	KIR2DS4	NM_012314.2	LRRRC7	NM_020794.1
IQSEC2	NM_015075	KLHL10	NM_152467	LRRFIP1	NM_004735.1
IRF8	NM_002163.1	KLHL15	NM_030624	LUZP5	NM_017760
IRS4	NM_003604.1	KLK15	NM_017509.2	LYST	NM_000081
IRTA2	NM_031281.1	KPNA5	NM_002269.2	LYST	NM_001005736
ITGA9	NM_002207.1	KRTAP10-8	NM_198695.1	LZTS2	NM_032429.1
ITGAE	NM_002208	KRTAP20-1	NM_181615.1	MACF1	NM_012090.3
ITGAL	NM_002209	KTN1	NM_182926.1	MAGEA1	NM_004988.3
ITGB2	NM_000211.1	LAMA1	NM_005559	MAGEA4	NM_002362.3
ITPR1	NM_002222	LAMA2	NM_000426.2	MAGEB10	NM_182506
ITR	NM_180989.3	LAMA4	NM_002290	MAGEC2	NM_016249.2
JARID1B	NM_006618	LAMB4	NM_007356	MAGED2	NM_201222.1
JMJD1A	NM_018433.3	LAP1B	NM_015602.2	MAGEE1	NM_020932.1
JMJD1C	NM_004241	LDHB	NM_002300.3	MAGI1	NM_173515.1
JUP	NM_021991.1	LEPREL1	NM_018192.2	MANEA	NM_024641.2
KCNA5	NM_002234.2	LGALS2	NM_006498.1	MAOA	NM_000240.2
KCNC2	NM_139136.2	LHCGR	NM_000233.1	MAP1A	NM_002373
KCNJ1	NM_000220.2	LIP8	NM_053051.1	MAP3K6	NM_004672.3
KCNJ15	NM_170737.1	LIPE	NM_005357.2	MAPK13	NM_002754.3
KCNQ3	NM_004519	LLGL1	NM_004140	MAPKBP1	NM_014994
KEAP1	NM_203500.1	LMO6	NM_006150.3	MASP1	NM_001879
KIAA0100	NM_014680	LOC112703	NM_138411	MAZ	NM_002383
KIAA0143	NM_015137	LOC113179	NM_138422.1	MCAM	NM_006500
KIAA0256	NM_014701	LOC113828	NM_138435.1	MCART1	NM_033412.1
KIAA0284	NM_015005	LOC123876	NM_001010845	MCF2L2	NM_015078.2
KIAA0367	NM_015225	LOC126248	NM_173479.2	MCOLN1	NM_020533.1
KIAA0427	NM_014772.1	LOC200420	NM_145300	MDC1	NM_014641
KIAA0467	NM_015284	LOC220929	NM_182755.1	MED12	NM_005120
KIAA0513	NM_014732	LOC253012	NM_198151.1	MEF2C	NM_002397
KIAA0528	NM_014802	LOC255374	NM_203397	MFAP5	NM_003480.2
KIAA0664	NM_015229	LOC283849	NM_178516.2	MGC11332	NM_032718.2
KIAA0672	NM_014859	LOC339123	NM_001005920	MGC17299	NM_144626.1
KIAA0676	NM_015043.3	LOC339745	NM_001001664	MGC21688	NM_144635.3
KIAA0703	NM_014861	LOC340156	NM_001012418	MGC24047	NM_178840.2
KIAA0774	NM_001033602	LOC374955	NM_198546.1	MGC27019	NM_144705.2
KIAA0789	NM_014653	LOC388595	NM_001013641	MGC33212	NM_152773
KIAA0863	NM_014913	LOC388915	NM_001010902	MGC33370	NM_173807.2
KIAA0913	NM_015037	LOC389151	NM_001013650	MGC33657	NM_001029996
KIAA0934	NM_014974.1	LOC389549	NM_001024613	MGC34837	NM_152377.1
KIAA0999	NM_025164.3	LOC440925	NM_001013712	MGC42174	NM_152383
KIAA1012	NM_014939.2	LOC440944	NM_001013713	MGC5297	NM_024091.2
KIAA1117	NM_015018.2	LOC441070	NM_001013715	MIA2	NM_054024.3
KIAA1161	NM_020702	LOC646870	NM_001039790	MICAL1	NM_022765.2

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
MICAL-L1	NM_033386.1	NF1	NM_000267.1	OSBP2	NM_030758
MKLN1	NM_013255	NF2	NM_000268.2	OSBPL11	NM_022776.3
MLL4	NM_014727	NFASC	NM_015090	OTC	NM_000531.3
MLLT2	NM_005935.1	NFIX	NM_002501	OTOF	NM_194323.1
MMP10	NM_002425.1	NFKB1	NM_003998.2	P15RS	NM_018170.2
MMP15	NM_002428.2	NFKBIA	NM_020529.1	PADI3	NM_016233.1
MOGAT1	NM_058165	NFKBIE	NM_004556	PADI6	NM_207421
MOSPD1	NM_019556.1	NFYC	NM_014223.2	PANX2	NM_052839.2
MPFL	NM_001025190	NGLY1	NM_018297	PAPPA2	NM_020318
MRE11A	NM_005590.2	NHS	NM_198270.2	PARP1	NM_001618.2
MSI1	NM_002442.2	NID2	NM_007361.2	PCDH19	NM_020766
MTA1	NM_004689	NIPBL	NM_133433.2	PCDH20	NM_022843.2
MTAC2D1	NM_152332.2	NOD27	NM_032206.2	PCDH8	NM_002590.2
MTL5	NM_004923.2	NOS2A	NM_000625.3	PCDHA10	NM_031859
MTMR3	NM_021090.2	NOTCH1	NM_017617	PCDHA11	NM_031861
MTMR8	NM_017677.2	NOTCH4	NM_004557	PCDHA5	NM_031501
MUC16	NM_024690	NOX5	NM_024505	PCDHB15	NM_018935.2
MUC2	NM_002457	NRCAM	NM_005010.2	PCDHGA1	NM_031993
MUF1	NM_006369.3	NRK	NM_198465	PCDHGA3	NM_032011
MULK	NM_018238.2	NRXN3	NM_004796.3	PCDHGA6	NM_032086
MYBPC2	NM_004533	NUFIP2	NM_020772	PCDHGB1	NM_032095
MYCBP2	NM_015057	NUP133	NM_018230.2	PCDHGB5	NM_032099
MYH1	NM_005963.2	NUP188	NM_015354	PCM1	NM_006197
MYH7B	NM_020884	NUP205	NM_015135	PCNT	NM_006031
MYH9	NM_002473.2	NUP214	NM_005085.2	PDCD11	NM_014976
MYLC2PL	NM_138403	NUP98	NM_016320.2	PDCD4	NM_014456.3
MYO15A	NM_016239	NXN	NM_022463.3	PDCD6	NM_013232.2
MYO18B	NM_032608	NYD-SP21	NM_032597	PDE2A	NM_002599.1
MYO1G	NM_033054	OATL1	NM_002536	PDLIM7	NM_005451.3
MYO7A	NM_000260	OBSCN	NM_052843.1	PDPR	NM_017990
MYO9B	NM_004145	OCA2	NM_000275.1	PDZD7	NM_024895
MYOD1	NM_002478.3	ODZ1	NM_014253.1	PDZK2	NM_024791.2
MYR8	NM_015011	OR10A2	NM_001004460	PDZK4	NM_032512.2
MYST4	NM_012330.1	OR10H4	NM_001004465	PEBP4	NM_144962
N4BP2	NM_018177.2	OR12D3	NM_030959.2	PER1	NM_002616.1
NAG6	NM_022742	OR1J2	NM_054107	PER2	NM_022817.1
NALP1	NM_014922	OR1N1	NM_012363.1	PEX14	NM_004565
NALP14	NM_176822.2	OR1S1	NM_001004458	PFC	NM_002621.1
NALP8	NM_176811.2	OR2AK2	NM_001004491	PFKFB4	NM_004567.2
NALP9	NM_176820.2	OR2M4	NM_017504	PGBD3	NM_170753.1
NAV3	NM_014903	OR2W3	NM_001001957	PHACS	NM_032592.1
NCAM1	NM_000615	OR2W5	NM_001004698	PHC1	NM_004426.1
NCB5OR	NM_016230.2	OR4D2	NM_001004707	PHF19	NM_015651
NCOA6	NM_014071.2	OR52A1	NM_012375	PHF7	NM_016483.4
NDRG2	NM_201541.1	OR52H1	NM_001005289	PHKB	NM_000293.1
NDST1	NM_001543	OR56A1	NM_001001917	PIGN	NM_176787
NDUFA2	NM_002488.2	OR5H1	NM_001005338	PIGS	NM_033198.2
NDUFA3	NM_004542.1	OR5J2	NM_001005492	PIK3C2G	NM_004570
NDUFA8	NM_014222.2	OR5M11	NM_001005245	PIK3CA	NM_006218
NEB	NM_004543	OR8B12	NM_001005195	PIK3R1	NM_181523.1
NEDD4	NM_198400.1	OR8D2	NM_001002918	PIK3R4	NM_014602.1
NEF3	NM_005382.1	OR8I2	NM_001003750	PKD1L1	NM_138295
NET1	NM_005863.2	OR9Q2	NM_001005283	PKD1L2	NM_052892

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
PKDREJ	NM_006071.1	PTRF	NM_012232.2	SAPS1	NM_014931
PKHD1L1	NM_177531	PURG	NM_013357.2	SATL1	NM_001012980
PKN1	NM_213560	PUS1	NM_025215.3	SBNO1	NM_018183.2
PLA2G4A	NM_024420.1	PUS7	NM_019042	SCARF2	NM_153334.3
PLB1	NM_153021	RAB41	NM_001032726	SCGB3A2	NM_054023.2
PLCB1	NM_015192.2	RABEP2	NM_024816	SCML1	NM_006746.2
PLCB2	NM_004573	RAC2	NM_002872.3	SCN2A2	NM_021007
PLCD3	NM_133373	RAI17	NM_020338.1	SCN3A	NM_006922
PLCG1	NM_002660.2	RANBP1	NM_002882.2	SCNN1B	NM_000336.1
PLD2	NM_002663.2	RANBP3	NM_007321	SCP2	NM_002979.2
PLEKHA8	NM_032639.2	RANBP3	NM_007322	SEC31L1	NM_014933.2
PLEKHG2	NM_022835	RAP1GA1	NM_002885.1	SEMA3A	NM_006080.1
PLOD1	NM_000302.2	RAPH1	NM_213589.1	SEMA4B	NM_198925
PLS3	NM_005032.3	RARG	NM_000966.3	SEMA4G	NM_017893.2
PLXNB1	NM_002673.3	RASAL2	NM_170692.1	SEMA5B	NM_018987.1
PNCK	NM_198452.1	RASGRF2	NM_006909.1	SEMA6D	NM_153616
PNLIPRP1	NM_006229.1	RASL10B	NM_033315.2	SEMA7A	NM_003612.1
PNPLA1	NM_001039725	RBAF600	NM_020765.1	SEPHS2	NM_012248
PODXL	NM_001018111	RBM25	NM_021239	SERPINB1	NM_030666.2
POLH	NM_006502.1	RCE1	NM_005133.1	SERPINB11	NM_080475
POLR2F	NM_021974.2	RFC4	NM_181573.1	SERPINE2	NM_006216.2
POP1	NM_015029.1	RFX2	NM_000635.2	SF3B1	NM_012433
POU2F1	NM_002697.2	RG9MTD2	NM_152292.2	SF3B2	NM_006842
POU4F2	NM_004575	RGL1	NM_015149.2	SFRS1	NM_006924.3
PP	NM_021129.2	RGS22	NM_015668	SFRS16	NM_007056.1
PPAPDC1A	NM_001030059	RHAG	NM_000324.1	SGKL	NM_013257.3
PPFIBP2	NM_003621	RHD	NM_016124.2	SH2D3A	NM_005490.1
PPHLN1	NM_201439.1	RIF1	NM_018151.1	SH3RF1	NM_020870
PPM1E	NM_014906.3	RIMS1	NM_014989	SHCBP1	NM_024745.2
PPM1F	NM_014634.2	RIMS2	NM_014677	SIGLEC5	NM_003830
PPP1R12A	NM_002480	RLTPR	NM_001013838	SIPA1L1	NM_015556.1
PPP1R3A	NM_002711.2	RNF123	NM_022064	SIX4	NM_017420.1
PRDM13	NM_021620	RNF127	NM_024778.3	SKIP	NM_016532.2
PRDM4	NM_012406.3	RNF149	NM_173647.2	SKIV2L	NM_006929.3
PRDX5	NM_012094.3	RNU3IP2	NM_004704.2	SLAMF1	NM_003037.1
PRKAA1	NM_006251.4	ROBO3	NM_022370	SLC12A3	NM_000339.1
PRKAA2	NM_006252.2	ROR1	NM_005012.1	SLC16A2	NM_006517.1
PRODH	NM_016335.2	RP1L1	NM_178857	SLC17A6	NM_020346.1
PRPF39	NM_017922.2	RPGRIP1	NM_020366	SLC22A2	NM_003058.2
PRPF4B	NM_176800.1	RPL3	NM_000967.2	SLC22A9	NM_080866.2
PRPS1	NM_002764.2	RPRC1	NM_018067	SLC25A30	NM_001010875
PRPS1L1	NM_175886	RPS26	NM_001029	SLC35A2	NM_005660.1
PRRG1	NM_000950.1	RPS6KA3	NM_004586.1	SLC35F1	NM_001029858
PRSS7	NM_002772.1	RPS9	NM_001013.2	SLC38A3	NM_006841
PSD	NM_002779	RPUSD4	NM_032795.1	SLC39A12	NM_152725.1
PSME4	NM_014614	RREB1	NM_001003699	SLC4A3	NM_005070.1
PSPC1	NM_018282	RSN	NM_002956.2	SLC6A3	NM_001044.2
PSRC2	NM_144982	RTP1	NM_153708.1	SLC6A5	NM_004211.1
PTD004	NM_013341.2	RTTN	NM_173630	SLC7A7	NM_003982.2
PTH1H	NM_198964.1	RUFY1	NM_025158.2	SLC8A3	NM_033262.3
PTPN14	NM_005401.3	RYR1	NM_000540	SLC8A3	NM_182932.1
PTPN6	NM_080548	RYR2	NM_001035	SLC9A10	NM_183061
PTPRC	NM_002838.2	SAMD9	NM_017654	SLC9A2	NM_003048.3

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
SLCO2B1	NM_007256.2	TACC2	NM_206862.1	TREML1	NM_178174.2
SLFN13	NM_144682	TAF1	NM_004606.2	TREML4	NM_198153
SLICK	NM_198503.2	TAF1B	NM_005680	TRIAD3	NM_207116
SMARCAL1	NM_014140.2	TA-KRP	NM_032505.1	TRIF	NM_182919.1
SMC4L1	NM_005496.2	TAS2R13	NM_023920.1	TRIM25	NM_005082.3
SMC6L1	NM_024624.2	TAX1BP1	NM_006024.4	TRIM29	NM_012101.2
SMOX	NM_175839.1	TBC1D19	NM_018317.1	TRIM36	NM_018700.2
SN	NM_023068.2	TBC1D2B	NM_015079	TRIOBP	NM_001039141
SNTG2	NM_018968	TBX1	NM_005992.1	TRIP12	NM_004238
SNX25	NM_031953	TBXAS1	NM_001061.2	TRPC4	NM_016179.1
SOHLH1	NM_001012415	TCEAL5	NM_001012979	TRPM5	NM_014555
SORBS1	NM_015385.1	TCF1	NM_000545.3	TSN	NM_004622
SORCS1	NM_052918.2	TCF7L1	NM_031283.1	TTC15	NM_016030.5
SORL1	NM_003105.3	TCFL1	NM_005997.1	TTC21B	NM_024753
SOX13	NM_005686	TCPI	NM_030752.1	TTC3	NM_003316.2
SOX15	NM_006942	TCPI10	NM_004610	TTC7A	NM_020458
SP110	NM_004509.2	TDRD6	NM_001010870	TTN	NM_133378
SPAG6	NM_012443.2	TECTA	NM_005422.1	TXNDC3	NM_016616.2
SPATS2	NM_023071	TEK	NM_000459.1	UBE2I	NM_194261.1
SPCS2	NM_014752	TESK1	NM_006285.1	UBE2O	NM_022066
SPEN	NM_015001.2	TESK2	NM_007170	UGT1A9	NM_021027.2
SPG4	NM_014946.3	TEX11	NM_031276	UNQ9356	NM_207410.1
SPINK5	NM_006846	TFAP2D	NM_172238.1	UQCR	NM_006830.2
SPO11	NM_012444.2	TG	NM_003235	USP29	NM_020903
SPOCD1	NM_144569.3	TGM3	NM_003245	USP34	NM_014709
SPTA1	NM_003126	THBS3	NM_007112.3	USP54	NM_152586.2
SPTAN1	NM_003127.1	THG-1	NM_030935.3	UTP14C	NM_021645
SPTBN1	NM_178313	TIAM2	NM_001010927	UTS2R	NM_018949.1
SPTLC1	NM_006415.2	TIFA	NM_052864	VAV3	NM_006113.3
SPTY2D1	NM_194285	TIMELESS	NM_003920.1	VEPH1	NM_024621.1
SREBF2	NM_004599.2	TLL1	NM_012464.3	VGCNL1	NM_052867.1
SRGAP3	NM_014850.1	TLN1	NM_006289	VWF	NM_000552.2
SSFA2	NM_006751.3	TLN2	NM_015059	WARS	NM_173701.1
SSNA1	NM_003731.1	TM4SF7	NM_003271.3	WBP4	NM_007187.3
ST8SIA3	NM_015879	TMED1	NM_006858.2	WBSCR28	NM_182504
STAB1	NM_015136	TMEM123	NM_052932	WDR48	NM_020839
STARD8	NM_014725.2	TMEM132B	NM_052907	WDR53	NM_182627.1
STAT1	NM_007315.2	TMEM28	NM_015686	WDR60	NM_018051
STAT4	NM_003151.2	TMEM37	NM_183240	WDSOF1	NM_015420
STATIP1	NM_018255.1	TMEM39A	NM_018266.1	WFDC1	NM_021197.2
STRBP	NM_018387.2	TMEM62	NM_024956	WNK1	NM_018979.1
STX12	NM_177424.1	TMEM63A	NM_014698	WNT2	NM_003391.1
STX5A	NM_003164.2	TMPRSS3	NM_024022.1	XAB2	NM_020196
SULF2	NM_018837.2	TMPRSS6	NM_153609.1	XBP1	NM_005080.2
SULT6B1	NM_001032377	TNFRSF25	NM_003790.2	XDH	NM_000379.2
SUPT3H	NM_181356	TNS	NM_022648.2	XKR7	NM_001011718
SURF1	NM_003172.2	TOP1	NM_003286.2	XPO5	NM_020750
SUSD3	NM_145006.2	TOP2B	NM_001068	XPO7	NM_015024
SUV39H2	NM_024670.3	TP53	NM_000546.2	YY2	NM_206923.1
SYNE2	NM_182914.1	TPM4	NM_003290.1	ZBTB3	NM_024784.2
SYT3	NM_032298.1	TPTE	NM_199261.1	ZBTB39	NM_014830
SYTL2	NM_032943	TRAD	NM_007064.1	ZCCHC14	NM_015144.1
TAC4	NM_170685	TREM1	NM_018643.2	ZCSL3	NM_181706.3

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
ZDHHC4	NM_018106.2	ZNF142	NM_005081	ZNF281	NM_012482.3
ZFHX4	NM_024721	ZNF161	NM_007146	ZNF318	NM_014345.1
ZFP64	NM_199427.1	ZNF183	NM_006978.1	ZNF37A	NM_001007094
ZFYVE26	NM_015346.2	ZNF22	NM_006963.2	ZNF425	NM_001001661
ZIC3	NM_003413.2	ZNF25	NM_145011.2	ZNF432	NM_014650.2
ZNF10	NM_015394.4	ZNF267	NM_003414	ZNF436	NM_030634.1
ZNF124	NM_003431	ZNF277	NM_021994.1	ZNF529	NM_020951
ZNF532	NM_018181.3				
ZNF541	NM_032255.1	ZNF674	NM_001039891		
ZNF546	NM_178544.2	ZNF694	NM_001012981		
ZNF548	NM_152909	ZNF707	NM_173831		
ZNF569	NM_152484.2	ZNF75A	NM_153028.1		
ZNF644	NM_201269.1	ZNHIT2	NM_014205.2		
ZNF646	NM_014699.2				

Note: Gene symbols are standard symbols assigned by Entrez Gene (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene>). Accession IDs "NM_XXXX" are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide>)

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
CIR	NM_004882.3	DMD	NM_004021.1	FBXL2	NM_012157.2
CLIC2	NM_001289.3	DMD	NM_004006.1	FBXO30	NM_032145.3
CLSTN2	NM_022131.1	DMRTA1	NM_022160.1	FBXW7	NM_033632.1
CLSTN3	NM_014718.2	DNAH1	NM_015512	FCN1	NM_002003.2
CMKOR1	NM_020311.1	DNAH11	NM_003777	FCN2	NM_004108.1
CNKSR2	NM_014927.2	DNAH3	NM_017539.1	FERD3L	NM_152898.2
CNOT6L	NM_144571	DNAH8	NM_001371.1	FGF13	NM_033642.1
CNTN1	NM_001843.2	DNAJC10	NM_018981	FGF14	NM_175929.1
CNTN4	NM_175613.1	DNAJC6	NM_014787	FHOD3	NM_025135
COL12A1	NM_004370	DNALI1	NM_003462.3	FIGN	NM_018086.1
COL3A1	NM_000090.2	DNAPTP6	NM_015535	FLJ10241	NM_018035
COL4A6	NM_001847.1	DNASE1L3	NM_004944.1	FLJ10404	NM_019057
CORO1B	NM_020441.1	DPEP1	NM_004413.1	FLJ10490	NM_018111
CORO2B	NM_006091.1	DPP10	NM_020868	FLJ10521	NM_018125.2
CPAMD8	NM_015692	DPYSL2	NM_001386.3	FLJ10560	NM_018138.1
CPE	NM_001873.1	DSCAML1	NM_020693.2	FLJ10665	NM_018173.1
CPO	NM_173077.1	DSTN	NM_006870.2	FLJ10996	NM_019044.2
CRB1	NM_201253.1	DTNB	NM_183361	FLJ11000	NM_018295.1
CRNKL1	NM_016652	DUSP21	NM_022076.2	FLJ12770	NM_032174.3
CSDA	NM_003651.3	DUX4C	NM_001023569	FLJ13305	NM_032180
CSE1L	NM_001316.2	EDA	NM_001399.3	FLJ14803	NM_032842
CSMD1	NM_033225	EDD1	NM_015902	FLJ16171	NM_001004348
CSMD3	NM_198123.1	EFS	NM_005864.2	FLJ16542	NM_001004301
CSNK1A1L	NM_145203.2	EIF2S2	NM_003908.2	FLJ20294	NM_017749
CTCFL	NM_080618.2	EIF4G1	NM_198241.1	FLJ20729	NM_017953.2
CTEN	NM_032865.3	EML1	NM_004434	FLJ21019	NM_024927.3
CTNNA1	NM_001903	EML2	NM_012155.1	FLJ21986	NM_024913
CTNND2	NM_001332.2	EN1	NM_001426.2	FLJ22679	NM_032227.1
CTSH	NM_004390.2	ENPP2	NM_006209.2	FLJ25477	NM_199138.1
CUBN	NM_001081.2	EPHA3	NM_005233.3	FLJ32252	NM_182510
CUTL1	NM_001913.2	EPHA4	NM_004438.3	FLJ32312	NM_144709.1
CX40.1	NM_153368.1	EPHA7	NM_004440.2	FLJ33534	NM_182586.1
CXorf53	NM_024332	EPHB1	NM_004441	FLJ34633	NM_152365.1
CYP4F8	NM_007253	EPHB6	NM_004445.1	FLJ34922	NM_152270.2
DACT1	NM_016651.4	ERCC6	NM_000124.1	FLJ35834	NM_178827.3
DBC1	NM_014618.1	ESSPL	NM_183375	FLJ36119	NM_153254.1
DCC	NM_005215.1	ETAA16	NM_019002.2	FLJ38964	NM_173527
DCHS1	NM_003737.1	ETFDH	NM_004453.1	FLJ40142	NM_207435.1
DDEFL1	NM_017707.2	EVC2	NM_147127.2	FLJ42418	NM_001001695
DDHD2	NM_015214	EVL	NM_016337.1	FLJ43339	NM_207380.1
DDI1	NM_001001711	EYA4	NM_004100.2	FLJ43980	NM_001004299
DDIT3	NM_004083.3	EZH2	NM_004456.3	FLJ44653	NM_001001678
DDN	NM_015086	F5	NM_000130.2	FLJ45273	NM_198461.1
DDX53	NM_182699	F8	NM_000132	FLJ46082	NM_207417.1
DEFA4	NM_001925.1	FAM102B	NM_001010883	FLJ46154	NM_198462.1
DEFB111	NM_001037497	FAM19A5	NM_015381	FLNC	NM_001458
DENND1C	NM_024898	FAM26A	NM_182494	FMN2	NM_020066
DEPDC2	NM_024870.2	FAM3A	NM_021806	FN1	NM_002026.2
DGCR2	NM_005137	FAM40A	NM_033088	FNDC1	NM_032532
DHRS2	NM_005794.2	FANCG	NM_004629.1	FOLH1	NM_004476.1
DJ167A19.1	NM_018982.3	FAT	NM_005245	FRAS1	NM_025074
DKFZp761I2123	NM_031449	FBN1	NM_000138	FRAS1	NM_032863
DLG3	NM_021120.1	FBN2	NM_001999	FRMPD2	NM_152428.2

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
FRMPD4	NM_014728	HS3ST4	NM_006040	KRTAP10-8	NM_198695.1
FRY	NM_023037	HSPG2	NM_005529	KSR2	NM_173598
FSTL5	NM_020116.2	HTR3C	NM_130770.2	LAMA1	NM_005559
FZD4	NM_012193.2	HTR5A	NM_024012.1	LAMA4	NM_002290
GAB4	NM_001037814	HUWE1	NM_031407	LAMB3	NM_000228.1
GABPB2	NM_016654.2	IDH1	NM_005896.2	LAMB4	NM_007356
GABRA6	NM_000811.1	IGFBP3	NM_000598.2	LAMC1	NM_002293.2
GALGT2	NM_153446.1	IGSF22	NM_173588	LAS1L	NM_031206.2
GALNS	NM_000512.2	IGSF9	NM_020789.2	LCN10	NM_001001712
GDAP1L1	NM_024034.3	IK	NM_006083	LCN9	NM_001001676
GFI1	NM_005263	IL6ST	NM_002184.2	LDB1	NM_003893.3
GFI1B	NM_004188.2	IQSEC3	NM_015232	LDLRAD1	NM_001010978
GHRHR	NM_000823.1	IREM2	NM_181449.1	LEF1	NM_016269.2
GJA8	NM_005267	IRS2	NM_003749.2	LGR6	NM_021636.1
GLB1	NM_000404	IRS4	NM_003604.1	LIFR	NM_002310.2
GLI3	NM_000168.2	ISLR	NM_201526.1	LIG1	NM_000234.1
GLIPR1	NM_006851.1	ITGAE	NM_002208	LIG3	NM_013975.1
GMCL1L	NM_022471.2	ITGB3	NM_000212.2	LILRB1	NM_006669
GNAS	NM_000516.3	ITPR1	NM_002222	LMNB2	NM_032737.2
GNRH1	NM_000825	K6IRS3	NM_175068.2	LMO7	NM_005358.3
GPBP1	NM_022913	KCNA10	NM_005549.2	LOC122258	NM_145248.2
GPR112	NM_153834	KCNB2	NM_004770.2	LOC126147	NM_145807
GPR124	NM_032777.6	KCNC4	NM_004978.2	LOC129531	NM_138798.1
GPR158	NM_020752	KCND3	NM_004980.3	LOC157697	NM_207332.1
GPR50	NM_004224	KCNH4	NM_012285.1	LOC167127	NM_174914.2
GPR8	NM_005286.2	KCNQ5	NM_019842.2	LOC223075	NM_194300.1
GPR87	NM_023915.2	KCNT1	NM_020822	LOC388199	NM_001013638
GPX1	NM_000581	KCTD16	NM_020768	LOC91807	NM_182493.1
GRID1	NM_017551	KDR	NM_002253.1	LPIN1	NM_145693.1
GRID2	NM_001510.1	KIAA0182	NM_014615.1	LPPR2	NM_022737.1
GRIK1	NM_175611	KIAA0367	NM_015225	LRCH4	NM_002319
GRIK3	NM_000831.2	KIAA0415	NM_014855	LRP1	NM_002332.1
GRM1	NM_000838.2	KIAA0528	NM_014802	LRP2	NM_004525.1
GTF2B	NM_001514.2	KIAA0555	NM_014790.3	LRRC4	NM_022143.3
GUCY1A2	NM_000855.1	KIAA0556	NM_015202	LRRN6D	NM_001004432
HAPIP	NM_003947.1	KIAA0789	NM_014653	LRTM2	NM_001039029
HAPLN1	NM_001884.2	KIAA0934	NM_014974.1	LSP1	NM_001013253
HAT1	NM_003642.1	KIAA1078	NM_203459.1	LZTS2	NM_032429.1
HBXIP	NM_006402.2	KIAA1185	NM_020710.1	MAMDC1	NM_182830
HCAP-G	NM_022346.2	KIAA1285	NM_015694	MAN2A2	NM_006122
HDC	NM_002112.1	KIAA1409	NM_020818.1	MAP1B	NM_005909.2
HECTD1	NM_015382	KIAA1468	NM_020854.2	MAP2	NM_002374.2
HIC1	NM_006497	KIAA1529	NM_020893	MAP2K7	NM_145185
HIST1H1B	NM_005322.2	KIAA1727	NM_033393	MAPK8IP2	NM_012324
HIST1H1E	NM_005321.2	KIAA1875	NM_032529	MARLIN1	NM_144720.2
HIST1H2BM	NM_003521.2	KIAA2022	NM_001008537	MAST1	NM_014975
HIVEP1	NM_002114	KIF13A	NM_022113	MCF2L2	NM_015078.2
HIVEP3	NM_024503.1	KL	NM_004795.2	MCM3AP	NM_003906.3
HK3	NM_002115.1	KLF5	NM_001730.2	MCP	NM_172350.1
HOXC9	NM_006897.1	KLRF1	NM_016523	MCRS1	NM_006337.3
HPS3	NM_032383.3	KRAS	NM_004985.3	MED12L	NM_053002
HR	NM_005144.2	KRT20	NM_019010.1	MEF2C	NM_002397
HRH1	NM_000861.2	KRTAP10-2	NM_198693	MEGF6	NM_001409

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
MET	NM_000245	NID	NM_002508.1	PDZD2	NM_178140
MFN1	NM_033540.2	NLGN4X	NM_181332.1	PDZRN3	NM_015009
MGC13125	NM_032725.2	NODAL	NM_018055.3	PDZRN4	NM_013377.2
MGC15730	NM_032880.2	NOS3	NM_000603.2	PEBP4	NM_144962
MGC16943	NM_080663.1	NR3C2	NM_000901.1	PEG3	NM_006210.1
MGC20470	NM_145053	NTNG1	NM_014917	PER1	NM_002616.1
MGC26733	NM_144992	NUP210	NM_024923	PERQ1	NM_022574
MGC29671	NM_182538.3	NUP210L	NM_207308	PEX5L	NM_016559.1
MGC32124	NM_144611.2	OBSCN	NM_052843.1	PF6	NM_206996.1
MGC33407	NM_178525.2	ODZ1	NM_014253.1	PHIP	NM_017934.4
MGC33846	NM_175885	OLFM2	NM_058164.1	PHKB	NM_000293.1
MGC39325	NM_147189.1	OMA1	NM_145243.2	PIGO	NM_032634.2
MGC39545	NM_203452.1	OR10G3	NM_001005465	PIK3CA	NM_006218
MGC48628	NM_207491	OR13F1	NM_001004485	PIK3R5	NM_014308.1
MGC52022	NM_198563.1	OR1E2	NM_003554.1	PKHD1	NM_138694.2
MGC52282	NM_178453.2	OR2T33	NM_001004695	PKHD1L1	NM_177531
MGC5242	NM_024033.1	OR2T34	NM_001001821	PKNOX1	NM_004571.3
MGC8685	NM_178012.3	OR4A16	NM_001005274	PLA2G4B	NM_005090
MKRN3	NM_005664.1	OR4K14	NM_001004712	PLA2G4D	NM_178034
MLF2	NM_005439.1	OR51E1	NM_152430	PLB1	NM_153021
MLL3	NM_170606.1	OR51T1	NM_001004759	PLCG2	NM_002661
MMP11	NM_005940.2	OR5H6	NM_001005479	PLEC1	NM_201378
MMP2	NM_004530.1	OR5J2	NM_001005492	PLXND1	NM_015103
MMRN2	NM_024756.1	OR5K1	NM_001004736	PNLIPRP2	NM_005396
MN1	NM_002430	OR6C1	NM_001005182	PNMA3	NM_013364
MPO	NM_000250.1	OR6C6	NM_001005493	PNPLA1	NM_001039725
MPP3	NM_001932	OR6C75	NM_001005497	PPM1F	NM_014634.2
MRGPRE	NM_001039165	OR8K3	NM_001005202	PPP1R12A	NM_002480
MRPL23	NM_021134	OSBP	NM_002556.2	PQBP1	NM_005710.1
MS4A5	NM_023945.2	OSBPL5	NM_020896	PQLC1	NM_025078.3
MTHFD1L	NM_015440.3	OSBPL5	NM_145638	PRDM9	NM_020227
MUC1	NM_002456.3	OTOP2	NM_178160.1	PRF1	NM_005041.3
MUC16	NM_024690	OVCH1	NM_183378	PRG2	NM_002728.4
MYADML	NM_207329.1	OVGP1	NM_002557.2	PRIMA1	NM_178013.1
MYO18B	NM_032608	OXCT1	NM_000436.2	PRKCE	NM_005400.2
MYO1B	NM_012223.2	P2RX7	NM_002562.4	PRKCZ	NM_002744.2
MYO1D	NM_015194	P2RY14	NM_014879.2	PRKD1	NM_002742.1
MYO5C	NM_018728	PAK6	NM_020168.3	PRKDC	NM_006904
MYOHD1	NM_001033579	PANK4	NM_018216.1	PRNPIP	NM_024066
MYR8	NM_015011	PAOX	NM_207128.1	PRO0149	NM_014117.2
NALP7	NM_139176.2	PARP8	NM_024615.2	PROL1	NM_021225
NALP8	NM_176811.2	PBEF1	NM_005746.1	PROS1	NM_000313.1
NAV3	NM_014903	PBX4	NM_025245.1	PRPS1	NM_002764.2
NBEA	NM_015678	PBXIP1	NM_020524.2	PRSS1	NM_002769.2
NCDN	NM_014284.1	PCDH11X	NM_032968.2	PRTG	NM_173814
NCR1	NM_004829.3	PCDHA9	NM_014005	PSMA2	NM_002787.3
NDST3	NM_004784.1	PCDHGA7	NM_032087	PSMC5	NM_002805.4
NDUFA1	NM_004541.2	PCDHGB4	NM_032098	PTEN	NM_000314
NEB	NM_004543	PCP4	NM_006198	PTPRD	NM_130391.1
NELL1	NM_006157.2	PCSK2	NM_002594.2	PTPRH	NM_002842
NEUGRIN	NM_016645.1	PDE11A	NM_016953	PTPRN2	NM_002847.2
NF1	NM_000267.1	PDGFD	NM_033135.2	PTPRS	NM_130853.1
NFATC1	NM_006162.3	PDILT	NM_174924.1	PTPRU	NM_005704.2

Gene Symbol	Accession ID	Gene Symbol	Accession ID	Gene Symbol	Accession ID
PTPRZ1	NM_002851	SDCBP2	NM_080489.2	SUHW4	NM_001002843
PZP	NM_002864.1	SDK1	NM_152744	SYNE1	NM_182961.1
QKI	NM_006775.1	SEC24B	NM_006323	SYNPO	NM_007286.3
RAB38	NM_022337.1	SEC8L1	NM_021807.2	SYT9	NM_175733.2
RAB5C	NM_201434.1	SEMA3D	NM_152754	SYTL2	NM_206927
RABEP1	NM_004703	SERPINA3	NM_001085	T3JAM	NM_025228.1
RALGDS	NM_006266.2	SETBP1	NM_015559.1	TAF1L	NM_153809
RAPGEF4	NM_007023	SEZ6	NM_178860	TAF2	NM_003184
RARB	NM_000965.2	SF3A1	NM_005877.3	TAIP-2	NM_024969.2
RASAL2	NM_170692.1	SFMBT2	NM_001029880	TA-KRP	NM_032505.1
RASGRF2	NM_006909.1	SFRS6	NM_006275.4	TBC1D2B	NM_015079
RASGRP1	NM_005739	SGEF	NM_015595	TBX1	NM_005992.1
RASSF2	NM_170774.1	SH3TC1	NM_018986.2	TBX15	NM_152380
RASSF4	NM_032023.3	SHANK1	NM_016148.1	TBX22	NM_016954.2
RAVER2	NM_018211	SHQ1	NM_018130	TCEB3B	NM_016427.2
RB1CC1	NM_014781	SIGLEC7	NM_014385.1	TCERG1L	NM_174937.1
RBM10	NM_005676.3	SKIP	NM_030623	TCF3	NM_003200.1
RBP3	NM_002900.1	SKIV2L	NM_006929.3	TCF7L2	NM_030756.1
RCN1	NM_002901.1	SLB	NM_015662.1	TCFL5	NM_006602.2
RDH13	NM_138412	SLC11A2	NM_000617.1	TCOF1	NM_000356.1
RELN	NM_005045	SLC12A5	NM_020708.3	TFEC	NM_012252.1
RET	NM_020975.2	SLC12A7	NM_006598	TFG	NM_006070.3
REV3L	NM_002912.1	SLC1A7	NM_006671.3	TGFBR2	NM_003242.3
RFC4	NM_181573.1	SLC22A15	NM_018420	TGM2	NM_004613.2
RHEB	NM_005614.2	SLC22A9	NM_080866.2	TGM3	NM_003245
RHPN1	NM_052924	SLC26A10	NM_133489.1	THAP9	NM_024672.2
RIC3	NM_024557.2	SLC29A1	NM_004955.1	THRAP1	NM_005121
RIMBP2	NM_015347	SLC33A1	NM_004733.2	TIAM1	NM_003253.1
RIMS2	NM_014677	SLC37A4	NM_001467	TLR8	NM_138636.2
RNF182	NM_152737.1	SLC39A7	NM_006979	TLR9	NM_017442.2
RNF31	NM_017999	SLC4A9	NM_031467	TM7SF4	NM_030788.2
RNPEPL1	NM_018226.2	SLCO1A2	NM_134431.1	TMEM132B	NM_052907
ROBO1	NM_002941	SLCO1B3	NM_019844.1	TMEM16B	NM_020373
ROBO2	NM_002942	SLITRK4	NM_173078.2	TMPRSS4	NM_019894
RORA	NM_002943.2	SLITRK6	NM_032229	TNFRSF9	NM_001561.4
RPA3	NM_002947.2	SMAD2	NM_005901.2	TNN	NM_022093
RPAP1	NM_015540.2	SMAD3	NM_005902.2	TNNI3K	NM_015978.1
RPL6	NM_000970.2	SMAD4	NM_005359.3	TOP2A	NM_001067
RPS6KB1	NM_003161.1	SMTN	NM_006932.3	TP53	NM_000546.2
RREB1	NM_001003699	SNRNP2	NM_198220.1	TP53BP1	NM_005657.1
RTN4	NM_207521.1	SNTG2	NM_018968	TPX2	NM_012112.4
RUNX1T1	NM_175634.1	SNX5	NM_152227.1	TREX2	NM_080701
RYR2	NM_001035	SNX8	NM_013321.1	TRIM3	NM_033278.2
SACS	NM_014363.3	SOCS6	NM_004232.2	TRIM71	NM_001039111
SALL2	NM_005407	SORL1	NM_003105.3	TRMT5	NM_020810
SALL3	NM_171999.1	SPOCK3	NM_016950	TSKS	NM_021733.1
SCN10A	NM_006514	SPTBN2	NM_006946.1	TSN	NM_004622
SCN1A	NM_006920	ST8SIA4	NM_005668.3	TSP-NY	NM_032573.3
SCN3B	NM_018400.2	STAB1	NM_015136	TSPYL5	NM_033512
SCN7A	NM_002976	STAM	NM_003473.2	TTID	NM_006790.1
SCNN1B	NM_000336.1	STK32C	NM_173575.2	TTLL3	NM_015644.1
SCNN1G	NM_001039.2	STMN4	NM_030795.2	TTN	NM_133378
SDBCAG84	NM_015966.2	STX17	NM_017919.1	TTYH2	NM_032646

Gene Symbol	Accession ID	Gene Symbol	Accession ID
TXLNB	NM_153235	ZNF624	NM_020787.1
TYSND1	NM_173555	ZNF659	NM_024697.1
UBE3C	NM_014671	ZNF714	NM_182515
UGDH	NM_003359.1	ZNHIT1	NM_006349.2
UHRF2	NM_152896.1	ZNRF4	NM_181710
UNC13B	NM_006377.2	ZSCAN5	NM_024303.1
UNC84B	NM_015374.1	ZZZ3	NM_015534.3
UNQ689	NM_212557.1		
UQCRC2	NM_003366.1		
USP28	NM_020886		
USP32	NM_032582		
USP52	NM_014871.2		
UTP14C	NM_021645		
UTX	NM_021140.1		
VEST1	NM_052958.1		
VIM	NM_003380.1		
VPS13A	NM_033305.1		
WAC	NM_016628.2		
WDR19	NM_025132		
WDR49	NM_178824.3		
WNK1	NM_018979.1		
WNT16	NM_016087.2		
WNT8B	NM_003393.2		
WRN	NM_000553.2		
XKR3	NM_175878		
XPO4	NM_022459		
XRCC1	NM_006297.1		
YEATS2	NM_018023		
ZAN	NM_173059		
ZBTB8	NM_144621.2		
ZD52F10	NM_033317.2		
ZDHHC7	NM_017740.1		
ZFHX1B	NM_014795.2		
ZFHX4	NM_024721		
ZFPM2	NM_012082		
ZNF155	NM_198089.1		
ZNF217	NM_006526.2		
ZNF232	NM_014519.2		
ZNF235	NM_004234		
ZNF262	NM_005095.2		
ZNF291	NM_020843		
ZNF43	NM_003423.1		
ZNF435	NM_025231.1		
ZNF442	NM_030824.1		
ZNF471	NM_020813.1		
ZNF480	NM_144684.1		
ZNF521	NM_015461		
ZNF536	NM_014717		
ZNF540	NM_152606.2		
ZNF560	NM_152476.1		
ZNF568	NM_198539		
ZNF572	NM_152412.1		
ZNF582	NM_144690		

Note: Gene symbols are standard symbols assigned by Entrez Gene (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene>). Accession IDs "NM_XXXX" are uniquely assigned to each gene by National Center for Biotechnology Information (NCBI) (<http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucore>).

We claim:

1. A diagnostic method, wherein said method aids in the detection of a disease or other medical condition in a subject, the method comprising the steps of:
 - (a) isolating a microvesicle fraction from a biological sample from the subject;
 - (b) detecting the presence or absence of a biomarker within the microvesicle fraction, wherein the biomarker is associated with the disease or other medical condition.
2. A monitoring method, wherein said method aids in monitoring the status of a disease or other medical condition in a subject, the method comprising the steps of:
 - (a) isolating a microvesicle fraction from a biological sample from the subject;
 - (b) detecting the presence or absence of a biomarker within the microvesicle fraction, wherein the biomarker is associated with the disease or other medical condition.
3. An evaluation method, wherein said method aids in evaluating treatment efficacy in a subject having a disease or other medical condition, the method comprising the steps of:
 - (a) isolating a microvesicle fraction from a biological sample from the subject;
 - (b) detecting the presence or absence of a biomarker within the microvesicle fraction, wherein the biomarker is associated with treatment efficacy for the disease or other medical condition.
4. The method of any of claims 1-3, wherein the biological sample is a sample of bodily fluid.
5. The method of any of claims 1-4, wherein the biomarker is:
 - (i) a species of nucleic acid;
 - (ii) the level of expression of a nucleic acid;
 - (iii) a nucleic acid variant; or
 - (iv) a combination thereof.
6. The method of any of claims 1-5, wherein the biomarker is messenger RNA, microRNA, siRNA or shRNA.
7. The method of any of claims 1-5, wherein the biomarker is DNA, single stranded DNA, complementary DNA, or noncoding DNA.

8. The method of any of claims 1-7, wherein the disease or other medical condition is a neoplastic disease or condition.
9. The method of claim 8, wherein the biomarker is a nucleic acid listed in any of Tables 3-15, or a variant thereof.
10. The method of claim 9, wherein the disease or other medical condition is glioblastoma.
11. The method of claim 10, wherein the biomarker is a nucleic acid listed in any of Tables 8-12, or a variant thereof.
12. The method of claim any of claims 8-11, wherein the biomarker is microRNA-21.
13. The method of claim 8, wherein the biomarker is associated with a clinically distinct type or subtype of tumor.
14. The method of any of claims 1-13, wherein the biomarker is a variant in the EGFR gene.
15. The method of claim 14, wherein the biomarker is the EGFRvIII mutation.
16. The method of claim 8, wherein the biomarker is associated with prostate cancer.
17. The method of claim 16, wherein the biomarker is TMPRSS2-ERG, PCA-3, PSA, or variants thereof.
18. The method of claim 8, wherein the biomarker is associated with melanoma.
19. The method of claim 18, wherein the biomarker is a BRAF variant.
20. The method of any of claims 1-3, wherein the biomarker is the expression level of one or more nucleic acids selected from the group consisting of let-7a; miR-15b; miR-16; miR-19b; miR-21; miR-26a; miR-27a; miR-92; miR-93; miR-320 and miR-20.
21. The method of any of claims 1-7, wherein the disease or other medical condition is a metabolic disease or condition.
22. The method of claim 21, wherein the metabolic disease or condition is diabetes, inflammation, or a perinatal condition.

23. The method of claim 21, wherein the metabolic disease or condition is associated with iron metabolism.
24. The method of claim 21, wherein the biomarker is a nucleic acid encoding hepcidin, or a fragment or variant thereof.
25. The method of any of claims 1-7, wherein the medical condition is a post transplantation condition.
26. The method of any of claims 1-7, wherein the biomarker is mRNA encoding a member of the family of matrix metalloproteinases.
27. The method of any of claims 1-7, wherein the biomarker is a nucleic acid listed in Table 10.
28. The method of any of claims 1-7, wherein the disease or other medical condition is cancer and the biomarker is a nucleic acid variant of the Kras gene.
29. The method of any of claims 1-28, wherein the microvesicles in the microvesicle fraction have a diameter in the range of about 30 nm to about 800 nm.
30. The method of claim 29, wherein the range is about 30 nm to about 200 nm.
31. The method of any of claims 1-30, wherein step (a) is performed by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
32. The method of any of claims 1-31, wherein the biomarker is a nucleic acid and the method further comprises amplification of the nucleic acid.
33. The method of any of claims 1-32, wherein the detecting step b) is performed by microarray analysis, PCR, hybridization with allele-specific probes, enzymatic mutation detection, ligation chain reaction (LCR), oligonucleotide ligation assay (OLA), flow-cytometric heteroduplex analysis, chemical cleavage of mismatches, mass spectrometry, nucleic acid sequencing, single strand conformation polymorphism (SSCP), denaturing gradient gel electrophoresis (DGGE), temperature gradient gel electrophoresis (TGGE),

restriction fragment polymorphisms, serial analysis of gene expression (SAGE), or combinations thereof.

34. The method of any of claims 1-33, further comprising the isolation of a selective microvesicle fraction derived from cells of a specific type.
35. The method of claim 34, wherein the cells are tumor cells.
36. The method of claim 34, wherein the microvesicle fraction is derived from lung, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colorectal, breast, prostate, brain, esophagus, liver, placenta, fetus cells, or combinations thereof.
37. The method of claim 34, wherein the selective microvesicle fraction consists essentially of urinary microvesicles.
38. A diagnostic method, wherein said method aids in the detection of a disease or other medical condition in a subject, the method comprising the steps of:
 - (a) obtaining a biological sample from the subject; and
 - (b) determining the concentration of microvesicles within the biological sample.
39. A monitoring method, wherein said method aids in monitoring the status of a disease or other medical condition in a subject, the method comprising the steps of:
 - (a) obtaining a biological sample from the subject; and
 - (b) determining the concentration of microvesicles within the biological sample.
40. The method of claim 38 or 39, further comprising the step of isolating a microvesicle fraction from the biological sample prior to determining the concentration.
41. The method of claim 40, wherein the isolation step is performed by size exclusion chromatography, density gradient centrifugation, differential centrifugation, nanomembrane ultrafiltration, immunoabsorbent capture, affinity purification, microfluidic separation, or combinations thereof.
42. The method of claim 40 or 41, wherein the microvesicle fraction is derived from cells of a specific type.

43. The method of claim 42, wherein the cells are tumor cells.
44. The method of claim 42, wherein the microvesicle fraction is derived from lung, pancreas, stomach, intestine, bladder, kidney, ovary, testis, skin, colorectal, breast, prostate, brain, esophagus, liver, placenta, fetus cells, or combinations thereof.
45. The method of claim 42, wherein the selective microvesicle fraction consists essentially of urinary microvesicles.
46. The method of any of claims 38-45, wherein the microvesicles have a diameter in the range of about 30 nm to about 800 nm.
47. The method of claim 46, wherein the range is about 30 nm to about 200 nm.
48. A method for delivering a nucleic acid or protein to a target cell in an individual comprising, administering one or more microvesicles that contain the nucleic acid or protein, or one or more cells that produce such microvesicles, to the individual such that the microvesicles enter the target cell of the individual.
49. The method of claim 48, wherein microvesicles are delivered to a brain cell.
50. The method of claim 48 or 49, wherein the nucleic acid delivered is siRNA, shRNA, mRNA, microRNA, DNA, or combinations thereof.
51. A method for performing a body fluid transfusion, comprising the steps of obtaining a fraction of donor body fluid free of all or substantially all microvesicles, or free of all or substantially all microvesicles from a particular cell type, and introducing the microvesicle-free fraction to a patient.
52. The method of claim 51, wherein the cell type is a tumor cell type.
53. The method of 51 or 52, wherein the body fluid is blood, serum or plasma.
54. A composition of matter comprising a sample of body fluid free of all or substantially all microvesicles, or free of all or substantially all microvesicles from a particular cell type.
55. The composition of claim 54, wherein the body fluid is blood, serum or plasma.

56. A method for performing body fluid transfusion, comprising the steps of obtaining a microvesicle-enriched fraction of donor body fluid and introducing the microvesicle-enriched fraction to a patient.
57. The method of claim 56, wherein the fraction is enriched with microvesicles derived from a particular cell type.
58. The method of claim 56 or 57, wherein the body fluid is blood, serum or plasma
59. A composition of matter comprising a sample of body fluid enriched with microvesicles.
60. The composition of claim 59, wherein the microvesicles are derived from a particular cell type.
61. The composition of claim 59 or 60, wherein the bodily fluid is blood, serum or plasma.





FIG. 1 a-e



08-197.007.tif
08-197
EXO's in Fix 17/7
Print Mag: 93500x @ 7.0 in
10:43 08/29/08
Microscopist: HLM

100 nm
HV=60.0kV
Direct Mag: 50000x

FIG. 1 f




FIG. 2

Fig. 3a




Fig. 3b




Fig. 3c




Fig. 3d




Fig. 3e




Fig. 3f




Fig. 3g




Fig. 3h




Fig. 3i







Fig. 4






FIG. 5




FIG. 6




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13






FIG. 14a-d

Fig. 14e




Fig. 14f




Fig. 14g






Fig. 14h





c

No.	Stage			prostate cancer biomarkers	
	Grade	Gleason	PSA	TMERG	PCA-3
P1	T3NxM0	9	25	+	+
P2	T2cNxM0	7	24	+	+
P3	T2	6	7.4	-	+
P4	T2	6	3.6	-	+

FIG. 15




FIG. 16








FIG. 17

a



b



c




FIG. 18





FIG. 19

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/032881

A. CLASSIFICATION OF SUBJECT MATTER INV. C12Q1/68				
According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED				
Minimum documentation searched (classification system followed by classification symbols) C12Q				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, BIOSIS, EMBASE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X Y	WO 2005/121369 A (SOURCEPHARM INC [US]; PIETRZKOWSKI ZBIGNIEW [US]) 22 December 2005 (2005-12-22) the whole document page 2 - page 5 page 15, line 15 - page 23, line 17 claims 8,33-37	1-50 51-61		
X Y	WO 01/36601 A (CHIRON SPA [IT]; ABRIGNANI SERGIO [IT]; PILERI PIERO [IT]) 25 May 2001 (2001-05-25) the whole document page 2, line 14 - page 3, line 30 example 3 claims 12-16	1-37 38-61		
----- -/--				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C.				
<input checked="" type="checkbox"/> See patent family annex.				
* Special categories of cited documents :				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; border: none; vertical-align: top;"> <ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family </td> </tr> </table>			<ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family
<ul style="list-style-type: none"> *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed 	<ul style="list-style-type: none"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family 			
Date of the actual completion of the international search <p style="text-align: center; font-size: 1.2em;">30 April 2009</p>	Date of mailing of the international search report <p style="text-align: center; font-size: 1.2em;">02/06/2009</p>			
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer <p style="text-align: center; font-size: 1.2em;">Sauer, Tincuta</p>			

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/032881

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X Y	WO 94/22018 A (HOLMES MICHAEL JOHN [GB]; NYCOMED PHARMA AS [NO]; SOLUM NILS OLAV [NO]) 29 September 1994 (1994-09-29) the whole document page 3, last paragraph page 4 page 5, last paragraph claims 1-15	38-47, 54,55, 59-61 1-37, 48-53, 56-58
X Y	CA 2 453 198 A1 (ICHIM THOMAS EMANUEL [CA]; MIN WEI-PING [CA]) 7 July 2005 (2005-07-07) the whole document page 3 - page 6 claims 1-29	38-47 1-37, 48-61
X Y	WO 2007/126386 A (LOETVALL JAN OLOF [SE]; VALADI HADI [SE]) 8 November 2007 (2007-11-08) the whole document. page 3, lines 16-33 page 8, line 31 - page 10, line 6 page 14, lines 5-13 claims 1,2,12-17	48-50 1-47, 51-61
X Y	US 2007/104738 A1 (TATISCHEFF IRENE [FR] ET AL) 10 May 2007 (2007-05-10) the whole document paragraphs [0031] - [0034] claims 15-19	48-50 1-47, 51-61
X Y	WO 03/076603 A (ANOSYS INC [US]; HOU YAFEI [US]; HSU DI-HWEI [US]; MEHTA-DAMANI ANITA) 18 September 2003 (2003-09-18) the whole document page 3, line 10 - page 4, line 3 page 8, lines 22-27 claims 1,12,28,30	48-50, 59-61 1-47, 51-58

-/--

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2009/032881

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2007/103572 A (AETHLON MEDICAL INC [US]; ICHIM THOMAS [US]; TULLIS RICHARD H [US]) 13 September 2007 (2007-09-13)	51-55
Y	the whole document paragraphs [0008], [0016] - [0027], [0029], [0032], [0036], [0039], [0040] paragraphs [0045], [0060]	1-50, 56-61
X	US 2006/116321 A1 (ROBBINS PAUL D [US] ET AL) 1 June 2006 (2006-06-01)	56-61
Y	the whole document paragraphs [0015], [0075], [0081] - [0088], [0090] claims 1-46	1-55
X	MONIKA BAJ-KRZYWORZEKA ET AL: "Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes" CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 7, 1 July 2006 (2006-07-01), pages 808-818, XP019333260 ISSN: 1432-0851	36-47
Y	the whole document page 808, column 2	1-35, 48-61
P,X	SKOG JOHAN ET AL: "Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers." NATURE CELL BIOLOGY DEC 2008, vol. 10, no. 12, December 2008 (2008-12), pages 1470-1476, XP002526160 ISSN: 1476-4679 the whole document	1-61
P,Y	AL-NEDAWI KHALID ET AL: "Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells." NATURE CELL BIOLOGY MAY 2008, vol. 10, no. 5, May 2008 (2008-05), pages 619-624, XP002526161 ISSN: 1476-4679 the whole document	1-61

-/--

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2009/032881

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 2009/015357 A (UNIV LOUISVILLE RES FOUND [US]; TAYLOR DOUGLAS D [US]; GERCEL-TAYLOR C) 29 January 2009 (2009-01-29)	1-37
P, Y	the whole document page 3 - page 6 page 14 tables 1,2	38-61
E	----- WO 2009/036236 A (UNIV OHIO STATE RES FOUND [US]; MARSH CLAY B [US]; HUNTER MELISSA G [U] 19 March 2009 (2009-03-19) the whole document paragraphs [0008] - [0022], [0034] - [0052] page 32 - page 38 claims 1-50	1-37
E	----- WO 2009/021322 A (UNIV MCGILL [CA]; RAK JANUSZ [CA]; AL-NEDAWI KHALID [CA]; MEEHAN BRIAN) 19 February 2009 (2009-02-19) the whole document page 6 - page 10 page 13 - page 19 claims 1-40 -----	1-37

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2009/032881

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
- a. type of material
- a sequence listing
- table(s) related to the sequence listing
- b. format of material
- on paper
- in electronic form
- c. time of filing/furnishing
- contained in the International application as filed
- filed together with the international application in electronic form
- furnished subsequently to this Authority for the purpose of search
2. In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2009/032881

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2005121369	A	22-12-2005	CA 2609260 A1	22-12-2005
			EP 1766053 A2	28-03-2007
			JP 2008501336 T	24-01-2008
			US 2008268429 A1	30-10-2008
WO 0136601	A	25-05-2001	AT 373084 T	15-09-2007
			AU 1721801 A	30-05-2001
			CA 2392075 A1	25-05-2001
			DE 60036403 T2	12-06-2008
			DK 1230347 T3	05-11-2007
			EP 1230347 A1	14-08-2002
			ES 2292489 T3	16-03-2008
			JP 2003514523 T	22-04-2003
			PT 1230347 E	20-12-2007
			US 7198923 B1	03-04-2007
			US 2007254351 A1	01-11-2007
			WO 9422018	A
AU 691489 B2	21-05-1998			
AU 6262794 A	11-10-1994			
CA 2158363 A1	29-09-1994			
DE 69403961 D1	31-07-1997			
DE 69403961 T2	02-01-1998			
DK 694168 T3	21-07-1997			
EP 0694168 A1	31-01-1996			
ES 2103582 T3	16-09-1997			
FI 954499 A	22-09-1995			
JP 3422491 B2	30-06-2003			
JP 8509806 T	15-10-1996			
NO 953770 A	22-09-1995			
US 5811250 A	22-09-1998			
CA 2453198	A1	07-07-2005	NONE	
WO 2007126386	A	08-11-2007	EP 2010663 A1	07-01-2009
			US 2007298118 A1	27-12-2007
US 2007104738	A1	10-05-2007	CA 2531865 A1	20-01-2005
			EP 1498144 A1	19-01-2005
			WO 2005004925 A1	20-01-2005
WO 03076603	A	18-09-2003	AU 2003214566 A1	22-09-2003
			CA 2479021 A1	18-09-2003
			CN 1639323 A	13-07-2005
			EP 1483372 A2	08-12-2004
			JP 2005528091 T	22-09-2005
WO 2007103572	A	13-09-2007	CA 2644855 A1	13-09-2007
			EP 1993600 A2	26-11-2008
US 2006116321	A1	01-06-2006	AU 2005262319 A1	19-01-2006
			BR PI0512814 A	08-04-2008
			CA 2572065 A1	19-01-2006
			CN 101022824 A	22-08-2007
			EP 1773381 A2	18-04-2007
			JP 2008505104 T	21-02-2008
			KR 20070058441 A	08-06-2007
			WO 2006007529 A2	19-01-2006

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2009/032881

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 2009015357	A	29-01-2009	NONE	
WO 2009036236	A	19-03-2009	NONE	
WO 2009021322	A	19-02-2009	NONE	